Panel Disdussion
Panel Disdussion
Panel Disdussion
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
3rd International Congress of Nuclear Medicine & 15th Iranian Annual<br />
Congress of Nuclear Medicine<br />
Shahid Beheshti University of Medical Sciences 19-21 May 2011
3rd International Congress of Nuclear Medicine & 15th Iranian Annual<br />
Congress of Nuclear Medicine<br />
Shahid Beheshti University of Medical Sciences 19-21 May 2011
3rd International Congress of Nuclear Medicine & 15th Iranian Annual<br />
Congress of Nuclear Medicine<br />
Shahid Beheshti University of Medical Sciences 19-21 May 2011<br />
3rd International Congress of<br />
Nuclear Medicine<br />
&<br />
15th Iranian Annual Meeting of<br />
Nuclear Medicine<br />
Shahid Beheshti University of Medical<br />
Sciences<br />
19-21 May<br />
2011
3rd International Congress of Nuclear Medicine & 15th Iranian Annual<br />
Congress of Nuclear Medicine<br />
Shahid Beheshti University of Medical Sciences 19-21 May 2011
3rd International Congress of Nuclear Medicine & 15th Iranian Annual<br />
Congress of Nuclear Medicine<br />
Shahid Beheshti University of Medical Sciences 19-21 May 2011<br />
Content<br />
Congress Overview and Executive Secretary’s Message....7<br />
Welcome Message of Congress President........................9<br />
Welcome Message of President of Iranian Society of<br />
Nuclear Medicine........................................................10<br />
Message of Scientific Secretary....................................11<br />
Welcome Message of Scientific Secretary of Seminar of<br />
Nuclear Medicine Technology.......................................13<br />
Outline Scientific Program...........................................14<br />
Committees..............................................................17<br />
Awards.....................................................................20<br />
Continuing Medical Education, panels & Workshops........21<br />
CME Lectures............................................................34<br />
Oral Presentations.....................................................48<br />
Poster Presentations.................................................119<br />
Index.....................................................................193
3rd International Congress of Nuclear Medicine & 15th Iranian Annual<br />
Congress of Nuclear Medicine<br />
Shahid Beheshti University of Medical Sciences 19-21 May 2011
3rd International Congress of of Nuclear Medicine & & 15th 15th Iranian Annual Annual Congress of<br />
Congress of Nuclear Medicine<br />
Shahid Beheshti Shahid Beheshti University University of Medical of Medical Sciences Sciences 19-21 19-21 May May 2011<br />
Congress Overview and Executive Secretary’s<br />
Message<br />
It is of a great honor that only after 6 months since the<br />
last congress of nuclear medicine which was held in<br />
Mashhad, we are to be host of the 3rd International<br />
Congress of Nuclear Medicine and the 15th Iranian<br />
Annual Meeting of Nuclear Medicine in Shahid Beheshti<br />
University of Medical Sciences. The scientific committee<br />
has organized the most worthy and useful plans for this<br />
event, which includes the major of the main and<br />
practical topics of this field. It is hoped that it become<br />
satisfactory and pleasant for you, dearest participants.<br />
In the 3rd International Congress of Nuclear Medicine<br />
and the 15th Iranian Annual Meeting of Nuclear<br />
Medicine some efforts has been done to put the<br />
practical subjects in the form of general CMEs and<br />
<strong>Panel</strong>s with the participation of local and foreign<br />
prominent professors and researchers with different<br />
expertise, that can be included to the conference to<br />
foster scientific richness and to consolidate the<br />
scientific communication of the various medical<br />
specialty groups. Also in the scientific plan of the<br />
congress several workshops will be run.<br />
In the other hand, to be more familiar with the<br />
application of related Basic Sciences,<br />
radiopharmaceutical meeting among all the other<br />
meetings such as imaging equipments and radiation<br />
protection and radiobiology while separated, will take<br />
place at the same time.<br />
Also independent retraining courses for the experts and<br />
employed technicians in nuclear medicine centers as “<br />
two-day seminar of nuclear medicine technology” is<br />
provided at the same time of the congress.<br />
It is to say that all the programs and plans of this<br />
congress were confirmed by EANM (European<br />
Association of Nuclear Medicine) and this Forum has<br />
even dedicated its logo to the secretariat.<br />
7
3rd International Congress 3rd International of Nuclear Congress Medicine of Nuclear & 15th Medicine Iranian Annual & 15th Congress Iranian Annual of<br />
Nuclear Congress Medicine of Nuclear Medicine<br />
Shahid Beheshti Shahid Beheshti University of University Medical Sciences of Medical 19-21 Sciences May 201119-21 May 2011<br />
Due to this important fact that the success of each<br />
congress depends on its articles and research<br />
achievements ,all dear colleagues including members of<br />
the board ,researchers, experts , assistants and<br />
students are invited to provide their valuable articles to<br />
this congress and make this an effective step in<br />
flourishing the medical knowledge and promoting the<br />
health of our beloved homeland. Your active presence<br />
and participation will be our pride and joy.<br />
We welcome you in the 15 th Congress of Nuclear<br />
Medicine to be held in Shahid Beheshti University of<br />
Medical Sciences.<br />
Mojtaba Ansari, M.D.<br />
Executive Secretary<br />
8
3rd International Congress of Nuclear Medicine & & 15th 15th Iranian Annual Annual Congress of<br />
Congress of Nuclear Medicine<br />
Shahid Beheshti Shahid University Beheshti University of Medical of Medical Sciences Sciences 19-21 19-21 May May 2011<br />
Welcome Message of Congress President<br />
Nuclear Medicine Department of Shahid Beheshti<br />
University of Medical Sciences is honored to host the<br />
"3 rd International Nuclear Medicine Congress<br />
accompanied with 15 th Annual Meeting of Iranian<br />
Society of Nuclear Meeting" on 19 th -21 st may 2011.<br />
I give my best praise to all nuclear physicians,<br />
physicists, radiopharmacists, technologists and other<br />
scientist colleagues in this international meeting.<br />
This meeting is under cooperation AEOI, Tehran<br />
municipality, NMRC, AOFNMB, EANM and Shahid<br />
Beheshti University of Medical Sciences.<br />
In this congress we will be informed and will discuss<br />
about any new development in all fields of nuclear<br />
medicine and technology.<br />
We are honored to provide a friendly scientific<br />
environment for sharing the research findings and<br />
nuclear medicine progressions with others.<br />
I attract you for your scientific contribution and<br />
abstracts in this international meeting.<br />
Isa Neshandar Asli, M.D.<br />
Congress President<br />
9
3rd International Congress 3rd International of Nuclear Congress Medicine of Nuclear & 15th Medicine Iranian Annual & 15th Iranian Congress Annual of<br />
Nuclear Congress Medicine of Nuclear Medicine<br />
Shahid Beheshti Shahid Beheshti University University of Medical Sciences of Medical 19-21 Sciences May 201119-21 May 2011<br />
Welcome Message of President of Iranian Society<br />
of Nuclear Medicine<br />
In God we Trust<br />
Endless praise and thanks to God for providing us the<br />
success of holding the 15 th annual conference of<br />
nuclear medicine .Fortunately ,after three decades of<br />
revolution , despite the problems and many ups and<br />
downs , nuclear medicine in the country has enjoyed<br />
significant growth. The result is one hundred people<br />
trained professionals and established the same number<br />
of nuclear medicine centers and teaching hundreds of<br />
students in grade Associate, Bachelor, Master and PhD<br />
degrees and other medical assistance, a parallel service<br />
to millions of our compatriots and outstanding research<br />
work that has been symbolized in the Iranian Journal of<br />
nuclear medicine which quarterly is published in<br />
English.<br />
From other successes ranked first in the 10 th World<br />
Congress of Nuclear Medicine in the Year 2010 in the<br />
number of articles and being selected as the Host of the<br />
10 th Asia Oceania Congress of Nuclear Medicine and<br />
Biology in 2012. The arrangements of holding such<br />
congress have been provided and we expect that our<br />
venerable colleagues cooperate and assist us in this<br />
event.<br />
At the end I wanted to thank Dr. Amouei the scientific<br />
secretary and Dr. Mojtaba Ansari the executive<br />
secretary for their unsparing efforts in holding this<br />
conference magnificently.<br />
Mohsen Saghari, M.D.<br />
President of Iranian Society of Nuclear Medicine<br />
10
3rd International Congress of of Nuclear Medicine & & 15th 15th Iranian Annual Annual Congress of<br />
Congress of Nuclear Medicine<br />
Shahid Beheshti Shahid Beheshti University University of Medical of Medical Sciences Sciences 19-21 19-21 May May 2011<br />
Message of Scientific Secretary<br />
In the name of GOD<br />
It is my great pleasure and honor to inform that the 3 rd<br />
International congress of nuclear medicine and 15th<br />
Annual meeting of nuclear meeting will be held under<br />
auspices of EANM and AOFNM in 29-31 th of Ordibehesht<br />
1390 (19-21 th of May 2011) in Shahid Beheshti<br />
University of Medical Sciences.<br />
In addition to multiple CMEs and research articles, 8<br />
panel discussions, 8 workshops and one seminar are<br />
proposed for ICNM program in assistance with 10<br />
invited lecturers and local experts. It would be<br />
appreciated Dr. Zakavi and his colleagues in Mashad<br />
Nuclear Medicine Research Center for great efforts in<br />
programming and executing the congress.<br />
Basic science section will be held accompanied with<br />
clinical nuclear medicine section as a new policy in<br />
assistance with Drs. Shahhossani, Dr. Jalilian, Dr.<br />
Monfared, Dr. Ay, and Dr. Tabaei and experts in<br />
radiopharmacy, instrumentation/software and radiation<br />
protection/radiobiology.<br />
Two-day precongress course of PET/CT is conducted in<br />
25-26 th Ordibehesht (15-16 th of May) by Dr. Bijan<br />
(USA) in executive support of Dr. Baharfar, Dr.<br />
Pirayesh and Dr. Shafiei. It includes cross-sectional CT<br />
and clinical applications of PET/CT.<br />
Two-day seminar of nuclear medicine technology will be<br />
held under auspices of ICNM for radiation workers in<br />
nuclear medicine departments. I thank Dr. Amiri as<br />
scientific secretary and Dr. Raziei as executive<br />
secretary of the seminar.<br />
You will find some interesting and helpful information<br />
about nuclear medicine in Iran in the Congress<br />
newspaper, published for the first time by help of my<br />
young colleagues in support of Mrs. Rezaian.<br />
11
3rd International Congress 3rd International of Nuclear Congress Medicine of Nuclear & 15th Medicine Iranian Annual & 15th Iranian Congress Annual of<br />
Nuclear Congress Medicine of Nuclear Medicine<br />
Shahid Beheshti Shahid Beheshti University University of Medical Sciences of Medical 19-21 Sciences May 201119-21 May 2011<br />
We are waiting for effective presence of our colleagues<br />
to update knowledge, share invaluable experiences and<br />
improve our speciality.<br />
Mahasti Amoui, M.D.<br />
Scientific Secretary<br />
12
3rd International Congress of of Nuclear Medicine & & 15th 15th Iranian Annual Annual Congress of<br />
Congress of Nuclear Medicine<br />
Shahid Beheshti Shahid Beheshti University University of Medical of Medical Sciences Sciences 19-21 19-21 May May 2011<br />
Welcome Message of Scientific Secretary of<br />
“Seminar of Nuclear Medicine Technology”<br />
Nuclear Medicine has developed and progressed very<br />
rapidly in recent years. Higher sensitivity for detecting<br />
normal as well as pathologic tissues, quantitative<br />
analysis of diagnostic data and lower doses of ionizing<br />
radiation has made it as one of the most important<br />
imaging modalities in the medicine. Improvement of<br />
image quality, fast imaging techniques and early<br />
detection of diseases are unique criteria of nuclear<br />
imaging. The higher the technology, the more need to<br />
update the knowledge and skills. Fortunately, nuclear<br />
medicine technology has established as an academic<br />
course in some universities in Iran in recent years.<br />
Providing a two days seminar for nuclear medicine<br />
technology parallel with international congress of<br />
nuclear medicine is an excellent opportunity to<br />
promotion of knowledge and practice of nuclear<br />
medicine technologist. I hope our technologist<br />
colleagues find the seminar helpful and fruitful.<br />
M. Amiri, M.D.<br />
Seminar Scientific Secretary<br />
13
3rd International Congress 3rd International of Nuclear Congress Medicine of Nuclear & 15th Iranian Medicine Annual & 15th Congress Iranian Annual of<br />
Nuclear Congress Medicine of Nuclear Medicine<br />
Shahid Beheshti Shahid University Beheshti of University Medical Sciences of Medical 19-21 Sciences May 201119-21 May 2011<br />
Thursday, May 19, 2011<br />
Outline Scientific Program<br />
Hall SA’DI Hall 4 Hall 1<br />
8:00<br />
Opening Ceremony<br />
9:00<br />
10:00<br />
CME 1<br />
Molecular Imaging & Nuclear Oncology<br />
break<br />
11:00<br />
<strong>Panel</strong> 1<br />
Management of Breast<br />
Cancer<br />
12:00<br />
CME 2<br />
Sentinel Lymph Node<br />
Biopsy<br />
CME 4<br />
Radiopharmacy<br />
Development 1<br />
13:00<br />
14:00 Oral<br />
Presentation<br />
Molecular Imaging &<br />
Nuclear Oncology<br />
15:00<br />
16:00<br />
17:00<br />
CME 3<br />
Nuclear Genitourinary<br />
<strong>Panel</strong> 2<br />
Hydronephrosis<br />
Pray & Lunch<br />
CME 5<br />
Instrumentation &<br />
Imaging 1<br />
Oral<br />
Presentation<br />
Workshop 1<br />
SNLB in Breast Cancer<br />
Seminar<br />
Clinical applications of<br />
PET in today oncologic<br />
practice<br />
CME 6<br />
Radiation Protection &<br />
Radiobiology 1<br />
Workshop 2<br />
Quantitative Renal<br />
Scan<br />
14
3rd International Congress of of Nuclear Medicine & 15th & 15th Iranian Iranian Annual Annual Congress of<br />
Congress of Nuclear Medicine Medicine<br />
Shahid Beheshti Shahid Beheshti University University of Medical of Medical Sciences 19-21 May 2011<br />
Friday, May 20, 2011<br />
Outline Scientific Program<br />
Hall SA’DI Hall 4 Hall 1 Hall 5<br />
8:00<br />
9:00<br />
10:00<br />
CME 7<br />
Nuclear<br />
Endocrinology<br />
<strong>Panel</strong> 3<br />
Management of<br />
DTC<br />
CME 9<br />
Instrumentation &<br />
Imaging 2<br />
Oral<br />
Presentation<br />
break<br />
Opening<br />
Ceremony<br />
Lectures<br />
11:00 Oral<br />
Presentation<br />
Nuclear<br />
Endocrinology<br />
12:00<br />
CME 8<br />
Nuclear Cardiology<br />
13:00<br />
CME 10<br />
Radiation<br />
Protection &<br />
Radiobiology 2<br />
Oral<br />
Presentation<br />
Lunch & Pray<br />
Workshop4<br />
Bone<br />
Densitometry<br />
Workshop5<br />
QC of Gamma<br />
Camera<br />
14:00<br />
15:00<br />
<strong>Panel</strong> 4<br />
Radiation Protection in Nuclear Medicine<br />
16:00<br />
CME 8<br />
Nuclear Cardiology<br />
<strong>Panel</strong> 5<br />
Coronary Artery<br />
Disease<br />
Oral<br />
Presentation<br />
CME 11<br />
Radiopharmacy<br />
Development 2<br />
Lectures<br />
17:00 Oral<br />
Presentation<br />
Nuclear Cardiology<br />
Oral<br />
Presentation<br />
Workshop3<br />
Gated SPECT<br />
15
3rd International Congress 3rd International of Nuclear Congress Medicine of & Nuclear 15th Iranian Medicine Annual & 15th Congress Iranian Annual of<br />
Nuclear Congress Medicineof Nuclear Medicine<br />
Shahid Beheshti Shahid University Beheshti of Medical University Sciences of Medical 19-21 May Sciences 2011 19-21 May 2011<br />
Saturday, May 21, 2011<br />
Outline Scientific Program<br />
Hall SA’DI Hall 4 Hall 1 Hall 5<br />
8:00<br />
9:00<br />
10:00<br />
Nuclear<br />
Medicine in<br />
Practice<br />
Forensic & Ethics<br />
CME 12<br />
Nuclear Neurology<br />
<strong>Panel</strong> 7<br />
Radiation Protection<br />
CME 13<br />
Disimetry & Radiation<br />
Protection<br />
Oral<br />
Presentation<br />
break<br />
Workshop7<br />
QC of<br />
Raiopharmaceuticals<br />
Lectures<br />
11:00<br />
12:00<br />
CME 12<br />
Nuclear Neurology<br />
<strong>Panel</strong> 6<br />
Nuclear Neurology<br />
<strong>Panel</strong> 8<br />
Radiopharmacy in<br />
Iran<br />
CME 14<br />
Radiopharmaceuticals<br />
& Radioprotection<br />
Lectures<br />
Workshop8<br />
Dosimeters /<br />
Decontamination<br />
13:00<br />
Lunch & Pray<br />
14:00<br />
15:00<br />
16:00<br />
Oral<br />
Presentation<br />
Nuclear Neurology<br />
Oral<br />
Presentation<br />
Miscellaneous<br />
CME 15<br />
Physics/Cyclotron<br />
Oral<br />
Presentation<br />
Workshop6<br />
Brain Scan<br />
Interpretation<br />
Lectures<br />
17:00<br />
Awards & Ending Ceremony<br />
16
3rd International Congress of of Nuclear Medicine & & 15th 15th Iranian Annual Annual Congress of<br />
Congress of Nuclear Medicine<br />
Shahid Beheshti Shahid Beheshti University University of Medical of Medical Sciences Sciences 19-21 19-21 May May 2011<br />
Committees<br />
Planning Committee<br />
I. Neshandar (President)<br />
M. Amiri<br />
M. Amoui<br />
M. Ansari<br />
M.R. Ay<br />
A.R. Jalilian<br />
Gh. Razi’ei<br />
A. Shabestani Monfared<br />
S. Shah’hosseini<br />
R. Zakavi<br />
Executive Committee<br />
Chair:<br />
M. Ansari<br />
Members:<br />
M. Akbari<br />
M. Amoui<br />
A. Ansari<br />
N. Baharfar<br />
M.B. Ghalibaf<br />
A. Hooman<br />
M. S. Malekzadeh<br />
E. Pirayesh<br />
Gh. Razi’ei<br />
S. Shah’hoseini<br />
B. Shaf’iei<br />
F. Tabe’ie<br />
A.R. Zakani<br />
M. Bagherzadeh<br />
S. Sedaghat<br />
Executive Managers<br />
N. Baharfar<br />
E. Pirayesh<br />
17
3rd International Congress 3rd International of Nuclear Congress Medicine of Nuclear & 15th Medicine Iranian Annual & 15th Iranian Congress Annual of<br />
Nuclear Congress Medicine of Nuclear Medicine<br />
Shahid Beheshti Shahid Beheshti University University of Medical Sciences of Medical 19-21 Sciences May 201119-21 May 2011<br />
Scientific Committee<br />
Chair:<br />
M. Amoui<br />
Members:<br />
F. Abbasi<br />
K. Abbasi<br />
A.H. Abedi’yekta<br />
M. Agha’miri<br />
M.E. Akbari<br />
Sh. Akhlaghpoor<br />
F. Akhzari<br />
A. Alavi<br />
M. Alavi<br />
M. Amiri<br />
A. Amirpoor<br />
M. Ansari<br />
A. Arjmand Shabestari<br />
K. Aryana<br />
M. Assadi<br />
M.R. Ay<br />
P. Azadeh<br />
H. Azarnik<br />
F. Azizi<br />
M.H. Baba’ee<br />
G. Bakhshanehpour<br />
M. Beheshti<br />
D. Beyki<br />
B. Bijan<br />
E. Bombardieri<br />
V.R. Dabbagh Kakhki<br />
Sh. Dabiri<br />
S. Dadparvar<br />
Y. Davari<br />
B. Davarpanah<br />
S. Derakhshan<br />
M. Eftekhari<br />
M. Erfani<br />
D. Fahimi<br />
J. Farahati<br />
B. Fallahi<br />
A. Fard<br />
M. Farsad<br />
H. Firrozabadi<br />
F. Fotouhi<br />
M. Ghannadi Maragheh<br />
H. Ghadiri<br />
Ch. Giannopoulou<br />
R. Hashemi<br />
S. Hekmat<br />
A. Hooman<br />
S.J Hosseini<br />
R. Hosseini<br />
J. Hosseinimehr<br />
H. Jadvar<br />
M. Jalili<br />
A.R. Jalilian<br />
H.R. Javadi<br />
M.R. Kardan<br />
D. Kamal’hedayat<br />
M. Khosh’niyat<br />
H. Khosravi<br />
V. Langesteger<br />
M. Lesan’pezeshki<br />
B. Mahmoodian<br />
H. Malek<br />
H. Mandegar<br />
B. Mansouri<br />
H.R. Mirza’ee<br />
K.P. Mishra<br />
M.M. Modarresi<br />
M. Momen’nejhad<br />
A. Moosavizadeh<br />
18
3rd International Congress of Nuclear Medicine & & 15th 15th Iranian Annual Annual Congress of<br />
Congress of Nuclear Medicine<br />
Shahid Beheshti Shahid University Beheshti University of Medical of Medical Sciences Sciences 19-21 19-21 May May 2011<br />
M. Movahed<br />
H. Mozdarani<br />
M. Mozzafar<br />
R. Najafi<br />
A.R. Nasrollahi<br />
I. Neshandar Asli<br />
M. Noroozian<br />
M.A. Oghabian<br />
H.R. Pouraliakbar<br />
A. Rahmim<br />
H. Rajabi<br />
A. Rakhsha<br />
B. Rashidi<br />
M. Raygani<br />
M.R. Razzaghi<br />
S. Saber<br />
R. Sadeghi<br />
M. Safavi<br />
M. Saghari<br />
N. Salehi<br />
Sh. Samangou’ee<br />
F. Sami’ee<br />
H.R. San’ti<br />
F. Sarvghadi<br />
F. Sedaghat<br />
Sh. Seifollahi<br />
Gh.A. Shabani<br />
A. Monfared<br />
B. Shafi’ei<br />
S. Shah’hosseini<br />
N. Simforoosh<br />
B. Singh<br />
K. Soltani<br />
P.S. Soni<br />
H. Tabataba’ee<br />
F. Tabe’ie<br />
M. Taghavi<br />
A. Takavar<br />
A. Vakili<br />
N. Yaghoobi<br />
S.R. Zakavi<br />
Technologist Programme Committee<br />
Chair:<br />
M. Amiri<br />
Members:<br />
M.R. Ay<br />
V.R. Dabbagh<br />
S. Derakhshan<br />
H. Ghadiri<br />
A.R. Gholami<br />
M. Jalili<br />
A.R. Jalilian<br />
M. Khorrami<br />
H. Khosravi<br />
M. Momen’nejhad<br />
H. Mozdarani<br />
R. Sadeghi<br />
A. Monfared<br />
B. Shafi’ei<br />
F. Tabe’ie<br />
R. Zakavi<br />
19
3rd International Congress 3rd International of Nuclear Congress Medicine of Nuclear & 15th Medicine Iranian Annual & 15th Iranian Congress Annual of<br />
Nuclear Congress Medicine of Nuclear Medicine<br />
Shahid Beheshti Shahid Beheshti University University of Medical Sciences of Medical 19-21 Sciences May 201119-21 May 2011<br />
Awards<br />
As in the past years, Dr. Shahram Dabiri is offering<br />
awards to authors of good quality abstracts accepted<br />
for presentation at the congress. The purpose of these<br />
awards is to encourage nuclear medicine investigators<br />
and to highlight scientific excellence.<br />
Six selected papers submitted to the congress are<br />
bestowed with valuable prize money:<br />
<br />
<br />
<br />
<br />
<br />
<br />
Best Presented Paper by Young Resercher<br />
Best Clinical Nuclear Medicine Paper<br />
Best Scientific Paper in Radiation Protection and<br />
Radiobiology<br />
Best Scientific paper in Instrumentation and<br />
Software<br />
Best Scientific paper in Radiopharmacy<br />
Best Presented Poster<br />
In addition, 3 invaluable prizes will be awarded to the<br />
best accepted papers in Seminar of Nuclear<br />
Medicine Technology by the seminar scientific<br />
secretary to promote the exchange and expansion of<br />
knowledge among technicians who have demonstrated<br />
an interest and involvement in research experience in<br />
nuclear medicine and related fields.<br />
20
3rd International Congress of of Nuclear Medicine & & 15th 15th Iranian Annual Annual Congress of<br />
Congress of Nuclear Medicine<br />
Shahid Beheshti Shahid Beheshti University University of Medical of Medical Sciences Sciences 19-21 19-21 May May 2011<br />
Continuing Medical Education, <strong>Panel</strong>s &<br />
Workshops<br />
Continuing medical education sessions as well as<br />
multiple panels and workshops will span all 3 days of<br />
the Congress of Nuclear Medicine and dive attention on<br />
the newest practical developments. In order to provide<br />
the CME program with a thematic focus and clinical<br />
input while maintaining a board spectrum of education,<br />
there will be multiple categorized CME sessions in<br />
Diagnostic, Therapy, Radiopharmacy Development,<br />
Physics, Instrumentation, and Radiation Protection<br />
topics.<br />
CME 1: Molecular Imaging & Nuclear Oncology<br />
The Achievement and Future of Molecular<br />
Iimaging in Oncology, E. Bombardieri (Italy)<br />
Era of Hybrid Imaging, B. Bijan (USA)<br />
Quantitative PET Imaging, A. Rahmim (USA)<br />
Non-FDG PET Tracers, M. Farsad (Italy)<br />
Thursday, May 19, 2011, 9:00-10:30, Hall Sa’di & 4<br />
CME 2: Sentinel Lymph Node Biopsy<br />
Accuracy of SLNB in Breast Cancer after<br />
Incisional Biopsy, R. Sadeghi (Iran)<br />
SLNB in Cervical Cancer, E. Bombardieri<br />
(Italy)<br />
Review of SLNB in Prostate Cancer, R. Sadeghi<br />
(Iran)<br />
Thursday, May 19, 2011, 12:00-13:00, Hall Sa’di<br />
21
3rd International Congress 3rd International of Nuclear Congress Medicine of Nuclear & 15th Medicine Iranian Annual & 15th Iranian Congress Annual of<br />
Nuclear Congress Medicine of Nuclear Medicine<br />
Shahid Beheshti Shahid Beheshti University University of Medical Sciences of Medical 19-21 Sciences May 201119-21 May 2011<br />
CME 3: Genitiurinary<br />
Renal Transplant Rejection, A. Nasrollahi<br />
(Iran)<br />
Renal Transplant Rejection and Nuclear<br />
Medicine, M. Movahed (Iran)<br />
Diagnosis & Management of UTI,<br />
N. Rahimzadeh (Iran)<br />
Patterns of Infection in Renal Scan,<br />
S. Hekmat (Iran)<br />
Thursday, May 19, 2011, 15:00-16:15, Hall Sa’di<br />
CME 4: Radiopharmacy Development 1<br />
Development of Non FDG PET Tracers in Iran,<br />
A.R. Jalilian (Iran)<br />
Production Problems Concerning Anti-CD20<br />
Radiopharmaceuticals, M.H. Babaei (Iran)<br />
Cancer Therapy by Alpha-emitters Labeled<br />
Peptides, F. Johari Daha (Iran)<br />
Radiopharmaceuticals for Bone Pain Palliation,<br />
D. Beiki (Iran)<br />
Peptide Based Radiopharmaceuticals for<br />
Diagnosis & Therapy, M. Erfani (Iran)<br />
Thursday, May 19, 2011, 11:00-13:00, Hall 4<br />
CME 5: Instrumentation & Imaging 1<br />
Recent Advances and Technological<br />
Innovations in Nuclear Medicine<br />
Instrumentations, P.S. Soni (India)<br />
State of the Art Image Reconstruction<br />
Algorithms in Emission Computed<br />
Tomography, A. Rahmim (USA)<br />
Preclinical Imaging & Imaging Technologies,<br />
M.R. Ay (Iran)<br />
Thursday, May 19, 2011, 14:00-15:30, Hall 4<br />
22
3rd International Congress of Nuclear Medicine & & 15th 15th Iranian Annual Annual Congress of<br />
Congress of Nuclear Medicine<br />
Shahid Beheshti Shahid University Beheshti University of Medical of Medical Sciences Sciences 19-21 19-21 May May 2011<br />
CME 6: Radiation Protection & Radiobiology 1<br />
Approach to Protection Against Low Doses of<br />
Ionizing Radiation, K.P. Mishra (India)<br />
New Concepts in Radiation Biolog,<br />
H. Mozdarani (Iran)<br />
Low Dose Medical Exposure and Its Health<br />
Impacts, B. Singh (India)<br />
Thursday, May 19, 2011, 16:15-18:00, Hall 4<br />
CME 7: Endocrinology<br />
Neuroendocine Tumors, M. Malekzadeh (Iran)<br />
SPECT & PET in Neuroendocine Tumors,<br />
M. Farsad (Italy)<br />
Radionuclide Therapy in Neuroendocine<br />
Tumors, E. Bombardieri (Italy)<br />
Updates in Follow-up of Differentiated Thyroid<br />
Carcinoma, M. Eftekhari (Iran)<br />
Friday, May 20, 2011, 8:00-9:30, Hall Sa’di<br />
CME 8: Cardiology<br />
Where We Need to Study Viability,<br />
N. Salehi (Iran)<br />
Myocardial Viability and Case Selection for<br />
CABG, K. Abbasi (Iran)<br />
Nuclear Medicine in Myocardial Viability<br />
Assessment, Ch. Giannopoulou (Greece)<br />
Quantitative Myocardial Perfusion Scan &<br />
Prognosis of CAD, R. Zakavi (Iran)<br />
Friday, May 20, 2011, 12:00-13:00 & 15:30-16:00,<br />
Hall Sa’di<br />
23
3rd International Congress 3rd International of Nuclear Congress Medicine of Nuclear & 15th Medicine Iranian Annual & 15th Iranian Congress Annual of<br />
Nuclear Congress Medicine of Nuclear Medicine<br />
Shahid Beheshti Shahid Beheshti University University of Medical Sciences of Medical 19-21 Sciences May 201119-21 May 2011<br />
CME 9: Instrumentation & Imaging 2<br />
PET/CT Instrumentation and QC,<br />
P.S. Soni (India)<br />
Direct 4D Parametric Imaging in PET,<br />
A. Rahmim (USA)<br />
Role of Physicist in NM/PET Departments,<br />
P.S. Soni (India) / A. Rahmim (USA)<br />
Friday, May 20, 2011, 8:00-9:40, Hall 4<br />
CME 10: Radiation Protection & Radiobiology 2<br />
Radio-Iodine Therapy (Discharge Criteria),<br />
F. Tabe’ie (Iran)<br />
Personnel Dosimetry in Nuclear Medicine,<br />
H. Moosavi (Iran)<br />
Radiophobia, Is Radiation All Bad?,<br />
A. Shabestani Monfared (Iran)<br />
Friday, May 20, 2011, 11:00-12:30, Hall 4<br />
CME 11: Radiopharmacy Development 2<br />
Is cyclotron produced 99m Tc a realistic<br />
alternative during 99 Mo shortage?<br />
D. Beiki (Iran)<br />
Radiopharmaceuticals for Synovectomy,<br />
A.R. Jalilian (Iran)<br />
Non Peptide Radiopharmaceuticals for Tumor<br />
Imaging, M.H. Babaei (Iran)<br />
Friday, May 20, 2011, 16:00-17:00, Hall 4<br />
24
3rd International Congress of of Nuclear Medicine & & 15th 15th Iranian Annual Annual Congress of<br />
Congress of Nuclear Medicine<br />
Shahid Beheshti Shahid Beheshti University University of Medical of Medical Sciences Sciences 19-21 19-21 May May 2011<br />
CME 12: Neurology<br />
Dopamine Terminal Function in Central<br />
Movement Disorder, F. Sedaghat (Greece)<br />
Clinical Aspects of MCI & Dementia,<br />
M. Nouroozian (Iran)<br />
Applications of Emmision Tomography in<br />
Dementia, F. Sedaghat (Greece)<br />
Saturday, May 21, 2011, 10:00-10:30 &<br />
11:00-12:00, Hall Sa’di<br />
CME 13: Disimetry & Radiation Protection<br />
Dose Estimation and RP in Multi-modality<br />
Imaging, F. Bouzarjomehri (Iran)<br />
Internal Dosimetry, H. Rajabi (Iran)<br />
Radiation Protection in Special Cases,<br />
R. Mahdavi (Iran)<br />
Saturday, May 21, 2011, 9:00-10:00, Hall 4<br />
CME 14: Radiopharmaceuticals & Radioprotection<br />
Radiopharmaceuticals for Infection Diagnosis<br />
in Iran, M. Erfani (Iran)<br />
The Importance of Natural Products as<br />
Radioprotective Agents in Nuclear Medicine, J.<br />
Hosseinimehr (Iran)<br />
Saturday, May 21, 2011, 11:30-12:10, Hall 4<br />
CME 15: Physics/Cyclotron<br />
Medical Cyclotron: Physics & Instrumentation,<br />
M.R. Ay (Iran)<br />
Operational Aspects of Medical Cyclotron<br />
Facility, P.S. Soni (India)<br />
Saturday, May 21, 2011, 14:00-15:00, Hall 4<br />
25
3rd International Congress 3rd International of Nuclear Congress Medicine of Nuclear & 15th Medicine Iranian Annual & 15th Iranian Congress Annual of<br />
Nuclear Congress Medicine of Nuclear Medicine<br />
Shahid Beheshti Shahid Beheshti University University of Medical Sciences of Medical 19-21 Sciences May 201119-21 May 2011<br />
<strong>Panel</strong> 1: Management of Breast cancer<br />
Thursday, May 19, 2011, 11:00-12:00, Hall Sa’di<br />
Moderator: R. Sadeghi (Iran)<br />
Members: E. Bombardieri<br />
M. Akbari<br />
F. Samiee<br />
F. Elahi<br />
A. Jangjoo<br />
B. Bijan<br />
M. Amoui<br />
Educational objectives:<br />
Interactive presentations of breast cancer patients<br />
referred to Nuclear Medicine Department for various<br />
reasons. The objectives of the panel are:<br />
To provide an overview of sentinel node biopsy<br />
applications in breast cancer patients with<br />
especial focus on the controversial issues in this<br />
regard.<br />
To provide an overview of radiotherapy and<br />
chemotherapy in breast cancer patients with<br />
special attention to nuclear physician<br />
involvement.<br />
To provide an overview of staging , follow-up<br />
and metastatic work-up in breast cancer patients<br />
To provide an overview of PET/CT applications in<br />
breast cancer patients.<br />
Summary:<br />
In this interactive panel, various aspects of<br />
conventional nuclear medicine applications in breast<br />
cancer patients are reviewed including bone<br />
scintigraphy, sentinel node biopsy, PET/CT, etc.<br />
Several controversial issues in sentinel node biopsy<br />
as well as radiotherapy and chemotherapy will be<br />
discussed.<br />
Key words: Breast cancer, Bone scintigraphy,<br />
Lymphoscintigraphy, Sentinel lymph node biopsy,<br />
PET/CT<br />
26
3rd International Congress of of Nuclear Medicine & & 15th 15th Iranian Annual Annual Congress of<br />
Congress of Nuclear Medicine<br />
Shahid Beheshti Shahid Beheshti University University of Medical of Medical Sciences Sciences 19-21 19-21 May May 2011<br />
<strong>Panel</strong> 2: Hydronephrosis<br />
Thursday, May 19, 2011, 16:15-17:00, Hall Sa’di<br />
Moderator: S. Hekmat (Iran)<br />
Members: M. Bagheri<br />
R. Hosseini<br />
R. Maghsoodi<br />
H. Salimi<br />
B. Shafiei<br />
Educational objectives:<br />
General review on the neonatal hydronephrosis<br />
and medical management<br />
Adult hydronephrosis<br />
Surgical approach to neonatal hydronephrosis<br />
Radiologic imaging<br />
Indications and diagnostic value of nuclear<br />
medicine in hydronephrosis<br />
Summary:<br />
Hydronephrosis is a relatively common finding in<br />
the evaluation of patients, including those with<br />
symptoms related to the urinary tract, as an<br />
incidental finding during imaging of the abdomen<br />
and also in the routine prenatal sonographic studies<br />
Diagnosis of the underlying causes, medical<br />
treatment, defining the time and plan of surgical<br />
interventions, particularly during the neonatal<br />
period are considered vital issues.<br />
This session is directed toward a general review of<br />
the subject and the most recent diagnostic and<br />
therapeutic guidelines with more emphasis on the<br />
nuclear medicine values and beneficial findings.<br />
27
3rd International Congress 3rd International of Nuclear Congress Medicine of Nuclear & 15th Medicine Iranian Annual & 15th Iranian Congress Annual of<br />
Nuclear Congress Medicine of Nuclear Medicine<br />
Shahid Beheshti Shahid Beheshti University University of Medical Sciences of Medical 19-21 Sciences May 201119-21 May 2011<br />
<strong>Panel</strong> 3: Management of Differentiated Thyroid<br />
carcinoma<br />
Friday, May 20, 2011, 9:30-10:30, Hall Sa’di<br />
Moderator: A. Fard (Iran)<br />
Members: A. Hedayati<br />
E. Bombardieri<br />
M. Farsad<br />
M.R. Mohajeri<br />
F. Sarvghadi<br />
M. Alavi<br />
B. Shafi’ei<br />
Educational objectives:<br />
Preoperative evaluation of DTC<br />
Surgical approaches and second surgery in DTC<br />
Management of hypocalcemia in DTC<br />
Value of Thyroglobulin in follow-up of DTC<br />
Value of exogenous TSH in follow-up of DTC<br />
<strong>Panel</strong> 4: Radiation Protection in Nuclear Medicine:<br />
Personnel Exposure, Medical Exposure,<br />
Low Dose Radiation<br />
Friday, May 20, 2011, 14:00-15:30, Hall Sa’di, 4 & 5<br />
Moderator: R. Zakavi (Iran)<br />
Members: M. Momen’nejhad<br />
A. Monfared<br />
K.P. Mishra<br />
M. Kardan<br />
H. Mozdarani<br />
A. Arjmand Shabestari<br />
Educational objectives:<br />
Radiation to patients from CT scan in<br />
multimodality imaging to patients<br />
Radiation to patients from nuclear medicine<br />
procedures and comparison with other risks<br />
Radiation to staff in nuclear medicine procedures<br />
Recommendations and ways to protect staff<br />
Low dose radiation; hazards vs benefits<br />
28
3rd International Congress of of Nuclear Medicine & & 15th 15th Iranian Annual Annual Congress of<br />
Congress of Nuclear Medicine<br />
Shahid Beheshti Shahid Beheshti University University of Medical of Medical Sciences Sciences 19-21 19-21 May May 2011<br />
<strong>Panel</strong> 5: Coronary Artery Disease<br />
Friday, May 20, 2011, 16:00-17:00, Hall Sa’di<br />
Moderator: H. Malek (Iran)<br />
Members: Ch. Giannopoulou<br />
V.R. Dabbagh<br />
H.R. San’ati<br />
H.R. Pouraliakbar<br />
A. Arjmand Shabestari<br />
Educational objectives:<br />
Provide a brief review on the approach to a<br />
patient with chest pain.<br />
Provide an overview on the assessment of CAD,<br />
using radionuclide myocardial perfusion imaging,<br />
Coronary CT angiography and conventional<br />
angiography.<br />
Provide and overview on the risk assessment of<br />
hard cardiac events, using different diagnostic<br />
modalities.<br />
Provide and overview on the therapeutic<br />
strategies on the basis of the imaging techniques.<br />
Summery:<br />
This continuing education session is directed toward<br />
physicians, trainees and technologist interested in<br />
the practice of nuclear cardiology. It will cover<br />
state-of-the art protocols and technology of SPECT,<br />
Coronary CT Angiography, cardiac MR and<br />
conventional angiography in patients with ischemic<br />
heart disease (IHD). By providing an overview on<br />
relevant practical aspects of the different imaging<br />
modalities, this session will provide the audience<br />
the basis for approaching to patients with IHD and<br />
the application of different imaging modalities.<br />
Key Words: Myocardial Perfusion Imaging, SPECT,<br />
Coronary CT Angiography, Ischemic Heart Disease<br />
29
3rd International Congress 3rd International of Nuclear Congress Medicine of Nuclear & 15th Medicine Iranian Annual & 15th Iranian Congress Annual of<br />
Nuclear Congress Medicine of Nuclear Medicine<br />
Shahid Beheshti Shahid Beheshti University University of Medical Sciences of Medical 19-21 Sciences May 201119-21 May 2011<br />
<strong>Panel</strong> 6: Minimal Cognetive Impairment &<br />
Alzheimer Disease<br />
Saturday, May 21, 2011, 12:00-13:00, Hall Sa’di<br />
Moderator: Sh. Seifollahi (Iran)<br />
Members: M. Nouroozian<br />
A. Shoja’ee<br />
M. Arbabi<br />
F. Sedaghat<br />
G. Bakhshandehpour<br />
Educational objectives:<br />
Definition of MCI & dementia<br />
Diagnostic problems in MCI & dementia<br />
Psychiatric aspects of MCI & dementia<br />
Management & outcomes of MCI & dementia<br />
Role of structural imaging in diagnosis &<br />
management of dementias<br />
Role of neuronuclear imaging in diagnosis &<br />
management of MCI & dementia<br />
Quantitative aspect of neuronuclear imaging<br />
Summery:<br />
Minimal cognitive impairment (MCI) is a precursor<br />
of dementia proposed to proceed to Alzheimer's<br />
disease (AD) and its progression could be controlled<br />
by drugs producing in advanced promising<br />
researches. This panel discussion is held to<br />
overview different aspects of MCI from standpoint<br />
of neurologists, psychiatrists, radiologists,<br />
neurosurgeons & nuclear physicians for better<br />
diagnosis & management of MCI & dementia and<br />
impression of novel software to quantify regional<br />
cerebral blood flow & metabolism.<br />
30
3rd International Congress of of Nuclear Medicine & & 15th 15th Iranian Annual Annual Congress of<br />
Congress of Nuclear Medicine<br />
Shahid Beheshti Shahid Beheshti University University of Medical of Medical Sciences Sciences 19-21 19-21 May May 2011<br />
<strong>Panel</strong> 7: Structure, Policies & Prospective of<br />
Radiation Protection<br />
Saturday, May 21, 2011, 8:00-9:00, Hall 4<br />
Moderator: A. Shabestani Monfared (Iran)<br />
Members: H. Khosravi<br />
B. Singh<br />
K.P. Mishra<br />
M. Momen’nejhad<br />
Educational objectives:<br />
A closer and feasible look to radiation protection<br />
guidelines in nuclear medicine in Iran<br />
Protection or over protection against ionizing<br />
radiation in nuclear medicine<br />
The radiation protection guidelines on the basis of<br />
other radiobiological models<br />
<strong>Panel</strong> 8: Radiopharmacy in Iran<br />
Saturday, May 21, 2011, 11:00-11:30, Hall 4<br />
Moderator: A.R. Jalilian<br />
Members: R. Najafi<br />
S. Shah’hosseini<br />
D. Beiki<br />
M.H. Babaie<br />
J. Hoseinimehr<br />
Educational objectives:<br />
PhD of radiopharmacy in Iran<br />
Current status of radiopharmaceuticals in Iran<br />
(production and quality control)<br />
Clinical studies of new radiopharmaceuticals<br />
New added radiopharmceuticals to the list of<br />
Ministry of health and Iranian Pharmacopeia<br />
The current status of research in radiopharmcy<br />
Role of Radiopharmacist as a member of Nuclear<br />
Medicine Department<br />
Summary<br />
This session will highlight and give an update of<br />
radiopharmacy in Iran, that have attracted lots of<br />
attention in recent years and have large potential<br />
31
3rd International Congress 3rd International of Nuclear Congress Medicine of Nuclear & 15th Medicine Iranian Annual & 15th Iranian Congress Annual of<br />
Nuclear Congress Medicine of Nuclear Medicine<br />
Shahid Beheshti Shahid Beheshti University University of Medical Sciences of Medical 19-21 Sciences May 201119-21 May 2011<br />
for further development of new<br />
radiopharmaceuticals. It will cover a review of<br />
current status of radiopharmaceuticals in Iran as<br />
well as insights into the clinical studies of new<br />
radiopharmaceuticals. It will also discuss the<br />
limitations and problems with production and<br />
research in the field of radiopharmacy in Iran.<br />
Workshop 1: Sentinel Lymph Node Biopsy in<br />
Breast Cancer<br />
Speaker: R. Sadeghi (Iran)<br />
Thursday, May 19, 2011, 14:00-15:00, Hall 1<br />
Workshop 2: Quantitative Renal Scan<br />
Speakers: H. Rajabi (Iran) / B. Shafi’ei<br />
(Iran)<br />
Thursday, May 19, 2011, 17:00-18:00, Hall 1<br />
Workshop 3: Gated SPECT<br />
Speaker: V.R. Dabbagh (Iran)<br />
Friday, May 20, 2011, 17:00-18:00, Hall 1<br />
Workshop 4: Bone Densitometry<br />
Speakers: H. Ghadiri / S. Derakhshan<br />
(Iran)<br />
Friday, May 20, 2011, 1100-1200, Hall 5<br />
32
3rd International Congress of of Nuclear Medicine & & 15th 15th Iranian Annual Annual Congress of<br />
Congress of Nuclear Medicine<br />
Shahid Beheshti Shahid Beheshti University University of Medical of Medical Sciences Sciences 19-21 19-21 May May 2011<br />
Workshop 5: QC of γ Camera<br />
Speakers: M.R. Ay / F. Tabe’ie (Iran)<br />
Friday, May 20, 2011, 12:30-13:00, Hall 5<br />
Workshop 6: Interpretation of Brain Perfusion<br />
Scan<br />
Speaker: F. Sedaghat (Greece)<br />
Saturday, May 21, 2011, 15:15-16:30, Hall 1<br />
Workshop 7: QC of Raiopharmaceuticals<br />
Speakers: A.R. Jalilian (Iran)<br />
Saturday, May 21, 2011, 8:30-9:00, Hall 5<br />
Workshop 8: Dosimeters & Decontamination<br />
Speakers: H. Khosravi (Iran) &<br />
A. Monfared (Iran)<br />
Saturday, May 21, 2011, 12:00-13:00, Hall 5<br />
33
3rd International Congress 3rd International of Nuclear Congress Medicine of Nuclear & 15th Medicine Iranian Annual & 15th Iranian Congress Annual of<br />
Nuclear Congress Medicine of Nuclear Medicine<br />
Shahid Beheshti Shahid Beheshti University University of Medical Sciences of Medical 19-21 Sciences May 201119-21 May 2011<br />
CME Lectures<br />
34
3rd International Congress of of Nuclear Medicine & & 15th 15th Iranian Annual Annual Congress of<br />
Congress of Nuclear Medicine<br />
Shahid Beheshti Shahid Beheshti University University of Medical of Medical Sciences Sciences 19-21 19-21 May May 2011<br />
NON-FDG PET TRACERS IN ONCOLOGY<br />
Mohsen Farsad (Italy)<br />
Nuclear Medicine Department, PET Unit, Policlinico S. Orsola-Malpighi, Bologna<br />
Educational Objectives:<br />
To delineate the appropriate clinical indications<br />
To help the imaging specialists to interpret correctly the images,<br />
avoiding pitfalls<br />
To get an insight on current status and future perspectives of NON<br />
FDG PET tracers<br />
Summery:<br />
[(18)F]-fluoro-2-deoxy-D-glucose (FDG) is the most frequently used<br />
radiopharmaceutical for clinical positron emission tomography (PET).<br />
However, FDG cannot be used for all cancer types, either because the<br />
abnormal tissue does not concentrate it, or because the tissues under<br />
investigation demonstrate high physiological glucose uptake.<br />
Consequently, alternative PET tracers have been produced and<br />
introduced into clinical practice. The most important NON FDG<br />
compounds in routine practice are 11 C-choline and 18 F-choline, mainly<br />
for the evaluation of prostate cancer; 11 C-methionine and 18 F-FET for<br />
brain tumours;<br />
18 F-DOPA and<br />
68 Ga-DOTA-PEPTIDES for<br />
neuroendocrine tumours. The lecture will highlight the major clinical<br />
applications of the above mentioned PET tracers in Oncology.<br />
Key Words: 11 C-choline; 18 F-choline; 18 F-DOPA; 11 C-methionine;<br />
18 F-FET; 68 Ga-DOTA-NOC; 68 Ga-DOTA-TOC; PET-CT Imaging<br />
35
3rd International Congress 3rd International of Nuclear Congress Medicine of Nuclear & 15th Medicine Iranian Annual & 15th Iranian Congress Annual of<br />
Nuclear Congress Medicine of Nuclear Medicine<br />
Shahid Beheshti Shahid Beheshti University University of Medical Sciences of Medical 19-21 Sciences May 201119-21 May 2011<br />
Diagnostic value of nuclear medicine in urinary trace infection<br />
Sepideh Hekmat (Iran)<br />
Hasheminejad Hospital<br />
Urinary tract infection (UTI) is a general term for a group of<br />
conditions in which bacteria grow in the urinary tract. It could be<br />
symptomatic or asymptomatic and is classified as acute<br />
pyelonephritis (that is renal parenchymal involvement and its main<br />
symptom is fever) and acute cystitis. It is of major importance to<br />
differentiate these two conditions in order to define the treatment<br />
schedule and plan for long trm follow up of the patients. We will<br />
shortly review the diagnostic value of the imaging procedures and the<br />
best recommended protocols pertinent to this issue.<br />
Keywords: UTI, DMSA renal scan, SPECT, planar<br />
Production Problems Concerning Anti-CD20<br />
Radiopharmaceuticals<br />
Mohammadhossein Babaei (Iran)<br />
PadtanGostar Co., Zarandieh<br />
Cancer treatment using radioimmunotherapy has been focus of much<br />
research in the last two decades. In radioimmunotherapy, a<br />
radioisotope is coupled to a monoclonal antibody to form a tumorspecific<br />
target agent. Radioimmunotherapy (RIT) is new therapy for<br />
the treatment of B-Cell non-Hodgkin’s lymphoma (NHL). Iodine-131,<br />
Yetterium-90 and Lutetium-177 are frequently used nuclides in<br />
clinical RIT, but their usefulness had been limited by several<br />
problems in their production.<br />
There are many methods that could have been used to label the<br />
radionuclide to the monoclonal antibody. However, in antibody<br />
labeling the aim is to produce a stable complex in an easy, fast and<br />
inexpensive procedure while preserving the immunoreactivity of the<br />
antibody. It has been investigated many conditions such as pH,<br />
temperature, antibody/chelator ratio and labeling time to optimize<br />
the method.<br />
In this lecture, the labeling efficiency, immunoreactivity, in vitro and<br />
in vivo stability of the produced complexes were considered.<br />
36
3rd International Congress of of Nuclear Medicine & & 15th 15th Iranian Annual Annual Congress of<br />
Congress of Nuclear Medicine<br />
Shahid Beheshti Shahid Beheshti University University of Medical of Medical Sciences Sciences 19-21 19-21 May May 2011<br />
Development of Non-FDG PET tracers in Iran<br />
A.R. Jalilian (Iran)<br />
Radiopharmaceutical Research & Development Laboratory (RRDL), Nuclear<br />
Science and Technology Research Institute (NSTRI)<br />
Apart from FDG, which is the most widely used tracer in PET nuclear<br />
medicine, research has been continued for the creation and<br />
introduction of other PET radioisotopes and radiopharmaceuticals<br />
around the world as well as in our country. The development of first<br />
Iranian 68 Ge/ 68 Ga prototype generator, with great performance of 5-<br />
10 mCi per milking is a breakthrough in the development of<br />
radiopharmaceuticals in the country at NSTRI, which a progressive<br />
expanding program is underway for high scale production for<br />
upcoming country’s need.<br />
Production and preclinical studies of<br />
64 Cu-ATSM has also been<br />
recently performed at NSTRI and is ready for clinical studies in<br />
National Radiopharmaceutical Project having interesting<br />
PET/therapeutic properties yielding few hundred-millicurie amounts.<br />
Also great efforts are now being performed on the development of<br />
other molecular imaging probes such as 64 Cu-monoclonal antibodies<br />
and pepties such as trastuzumab, cetuximab and octreotide. In other<br />
research works 61 Cu, 89 Zr, 66 Ga and 82m Rb production have been<br />
performed while feasibility studies for high performance 62 Zn/ 62 Cu<br />
generator is finalized in collaboration with IAEA a CRP work on the<br />
production of 18 F-FLT, 18 F-FAZA and 18 F-Flumazenil is in process.<br />
37
3rd International Congress 3rd International of Nuclear Congress Medicine of Nuclear & 15th Medicine Iranian Annual & 15th Iranian Congress Annual of<br />
Nuclear Congress Medicine of Nuclear Medicine<br />
Shahid Beheshti Shahid Beheshti University University of Medical Sciences of Medical 19-21 Sciences May 201119-21 May 2011<br />
APPROACHES FOR DEVELOPING RADIOPROTECTORS AGAINST<br />
LOW DOSE IRRADIATION<br />
K.P. Mishra (India)<br />
Nehru Gram Bharati University, George Town, Allahabad 211 002 INDIA &<br />
Ex Radiation Biology and Health Sciences Division, Bhabha Atomic Research<br />
Center, Mumbai<br />
Adverse effects of ionizing radiation became known soon after the<br />
discoveries of X ray and radioactivity at the end of 20 th century. With<br />
the increasing advances in radiation technology, growing concerns<br />
were expressed for likely exposure of humans to radiation with<br />
possible harmful effects. Radiation exposures could arise from<br />
planned, unplanned and natural environmental sources. The planned<br />
sources include diagnostic, therapeutic and industrial sources<br />
whereas unplanned exposures comprise of strategic explosions,<br />
reactor accidents, fall outs, dirty bombs and terrorist attacks. It is<br />
fairly well understood that ionizing radiations affect vital biological<br />
molecules through direct action or through indirect deposition of<br />
energy in abundant water generating reactive oxygen species (ROS).<br />
These ROS, in turn, react with critical biomolecules, namely, lipid,<br />
DNA and proteins leading to deleterious oxidative damage. To protect<br />
living organisms against high and low doses of radiation exposure it<br />
requires developing strategies depending upon the nature of radiation<br />
and severity of exposure. Over the years, a large chain of chemically<br />
synthesized compounds, vitamins, amino acids, nucleic acid<br />
derivatives were investigated for their radioprotective potential but<br />
these results were found not translatable into practical applications<br />
either due to poor efficacy or unacceptable associated toxicity. The<br />
available radioprotectors are either inefficient or unsafe for<br />
applications to humans. The effective radioprotector should be nontoxic,<br />
stable, prolonged activity, low cost and easy availability.<br />
Interestingly, past years have witnessed extensive screening of<br />
various plants for their radioprotective properties. Considering<br />
toxicity as the major constraint for the use of synthetic compounds,<br />
numerous plants have been screened for radioprotective efficacy<br />
against the deleterious effects of ionizing radiation. Herbal<br />
compounds rich in antioxidants may be a potential radioprotector.<br />
Compounds with efficient abilities to neutralize ROS produced by<br />
radiation may form potentially useful radioprotectors for practical<br />
applications. Also, compounds or formulations that can stimulate<br />
immunological responses may be another approach to develop<br />
effective radioprotection. This talk will present a highlight of<br />
developing new approaches for developing radioprotectors against<br />
radiation exposures especially low doses of radiation exposures.<br />
38
3rd International Congress of of Nuclear Medicine & & 15th 15th Iranian Annual Annual Congress of<br />
Congress of Nuclear Medicine<br />
Shahid Beheshti Shahid Beheshti University University of Medical of Medical Sciences Sciences 19-21 19-21 May May 2011<br />
Radiopharmaceuticals for bone pain palliation therapy<br />
Davood Beiki (Iran)<br />
Research Institute for Nuclear Medicine, Tehran University of Medical Sciences<br />
The incidence of cancer in the United States is over a million new<br />
cases a year (excluding cancers of the skin), of which over 100,000,<br />
perhaps up to 150,000 patients a year, develop bone metastases.<br />
The frequently occurring tumors that spread to the bone are prostate,<br />
breast, and lung cancer. The prevalence of pain in all patients with<br />
metastatic bone cancer has been estimated at 60% to 90%. Besides<br />
analgesics, treatment options include external beam radiotherapy,<br />
bisphosphonates, chemotherapy, surgery and bone seeking<br />
radiopharmaceuticals. Particle-emitting bone-seeking<br />
radiopharmaceuticals have attracted the attention of the nuclear<br />
medicine community over the last three decades for the treatment of<br />
the pain of osteoblastic metastases. For the eight<br />
radiopharmaceuticals including<br />
188 Re(Sn)HEDP, 153 Sm-EDTMP, 90 Y-<br />
citrate, 186 Re(Sn)HEDP, 117m Sn-DTPA, 32 P-phosphate, 89 Sr-chloride<br />
and 85 Sr-chloride, there are published data on clinical trials in<br />
humans. Of these eight, only phosphorus-32 (P-32) as sodium<br />
phosphate, Sm-153 lexidronam (EDTMP), and Sr-89 chloride are<br />
commercially available in the United States, although rhenium-186<br />
(Re-186) etidronate (HEDP) is widely employed in Europe. This talk<br />
will discuss the role of bone seeking radiopharmaceuticals in pain<br />
control of these painful osseous metastases.<br />
39
3rd International Congress 3rd International of Nuclear Congress Medicine of Nuclear & 15th Medicine Iranian Annual & 15th Iranian Congress Annual of<br />
Nuclear Congress Medicine of Nuclear Medicine<br />
Shahid Beheshti Shahid Beheshti University University of Medical Sciences of Medical 19-21 Sciences May 201119-21 May 2011<br />
Peptides based radiopharmaceuticals for Tumor Diagnosis and<br />
Therapy<br />
Mostafa Erfani (Iran)<br />
Nuclear Science Research School, Nuclear Science & Technology Research<br />
Institute (NSTRI), Atomic Energy Organization of Iran<br />
The specific binding of peptides to their receptors can be used to<br />
meet the key requirement in tumor targeting. Because of their small<br />
size, peptides exhibit faster blood clearance and higher target-tobackground<br />
ratios compared to macromolecular compounds.<br />
Although the use of an 111 In peptide was first explored for the use in<br />
nuclear medicine in 1981, it was not until a decade later that a 123 I<br />
labelled peptide was injected to tumor bearing animals. To date,<br />
radiolabelled receptor-binding peptides have emerged as a new class<br />
of radiopharmaceuticals. There is a tremendous amount of peptides<br />
that are potential candidates for being used as tumor imaging<br />
radiopharmaceuticals. For example octereotide, bombesin, gastrins,<br />
angiotansin, RGD, substance p, NPY are examples that are currently<br />
being tested, and many more have been suggested.<br />
There are several prerequisites for peptides used for scintigraphy or<br />
even radio-therapy. First of all, the corresponding receptors have to<br />
be expressed on the target in suitable amounts, over expression is<br />
desirable. There is no sense in developing a radioligand for a clinically<br />
important disease if the receptor is not concentrated in the target<br />
tissue in such an amount that an external image can be obtained.<br />
Natural peptide ligands exhibit high affinity to the receptor, usually in<br />
the nano molar range. It is crucial that the radiolabeled analog<br />
retains its high affinity. Because of the small size of peptides, the<br />
attachment of a bulky chelator and a radionuclide has a significant<br />
contribution the overall molecular weight, which may lead to<br />
conformational changes in the binding sequence. Thus, the<br />
attachment of the radiolabel should be made far from the receptor<br />
binding sequence, or a spacer should be introduced. Specificity is also<br />
a prerequisite. Whereas the natural ligand usually binds with similar<br />
affinities to receptor subtypes, chemically modified synthetic<br />
analogues often display pronounced subtype selectivity for only one<br />
or few receptor subtypes. Thus, receptor subtype expression on the<br />
targeted tumor tissue has to be considered. Receptor-agonists are<br />
preferred, since they usually exhibit receptor-mediated<br />
internalization. This results in accumulation of the radioligand in the<br />
target, providing an increased signal for scintigraphy. For therapeutic<br />
applications, internalization is an absolute precondition, as the<br />
cytotoxic moiety has to reach its target within the cell. A further<br />
prerequisite for radiopeptides is that the complexing of the chelatorpeptide<br />
with the radiometal is achieved in high yields. Last, but not<br />
least, a main concern of radiolabelled peptides is their stability under<br />
physiological conditions, i.e. peptide fragmentation by peptidases and<br />
the stability of the radiometal-chelator complex.<br />
40
3rd International Congress of of Nuclear Medicine & & 15th 15th Iranian Annual Annual Congress of<br />
Congress of Nuclear Medicine<br />
Shahid Beheshti Shahid Beheshti University University of Medical of Medical Sciences Sciences 19-21 19-21 May May 2011<br />
Myocardial viability<br />
Role of myocardial viability in patient management<br />
N. Salehi (Iran)<br />
The role of Nuclear Medicine imaging in Myocardial Viability<br />
assessment<br />
Ch. Giannopoulou (Greece)<br />
Educational Objectives:<br />
Provide an overview on the proposed pathophysiological<br />
mechanisms underlying stunned and hibernating myocardium, such<br />
as adoptive downregulation and structural alterations, in patients<br />
with ischemic left ventricular dysfunction.<br />
Provide an update on the use of radionuclide methods, both SPECT<br />
and PET, in the assessment of the presence and extent of<br />
hibernating myocardium, as well as on their prognostic and<br />
diagnostic value.<br />
Adopt knowledge on PET imaging principles, radiotracers’<br />
mechanisms of uptake and imaging protocols in myocardial PET<br />
(perfusion/metabolism) and SPECT viability studies.<br />
Compare radionuclide techniques to other viability imaging<br />
modalities.<br />
Provide a brief overview of recent clinical trials on the utility of<br />
myocardial viability assessment in patient revascularization<br />
selection.<br />
Summary:<br />
This continuing education session is directed toward physicians,<br />
trainees and technologists interested in the practice of nuclear<br />
cardiology. It will cover the topic of cardiac radionuclide imaging<br />
techniques and their applications in ischaemic left ventricular<br />
dysfunction and especially in assessing myocardial viability. Evidence<br />
for the role of these techniques will be summarized with particular<br />
reference to current guidelines. Knowledge on PET technology and<br />
acquisition protocols, as well as the importance of these imaging<br />
techniques in the clinical decision-making process and their present<br />
limitations will be discussed. An overview of the combination of<br />
various tests, to make it possible to establish correlations between<br />
coronary anatomy and functional imaging, further improving the noninvasive<br />
assessment of patients with ischaemic heart failure will be<br />
presented.<br />
Key Words: Cardiac PET, SPECT, metabolism, myocardial perfusion,<br />
viability, hibernation, stunning, FDG<br />
41
3rd International Congress 3rd International of Nuclear Congress Medicine of Nuclear & 15th Medicine Iranian Annual & 15th Iranian Congress Annual of<br />
Nuclear Congress Medicine of Nuclear Medicine<br />
Shahid Beheshti Shahid Beheshti University University of Medical Sciences of Medical 19-21 Sciences May 201119-21 May 2011<br />
Is cyclotron-produced Tc-99m a realistic alternative during<br />
Mo-99 shortage?<br />
Davood Beiki (Iran)<br />
Research Institute for Nuclear Medicine, Tehran University of Medical Sciences<br />
The radioisotope Technetium-99m ( 99m Tc) is the most commonly<br />
used radionuclide in nuclear medicine imaging and accounts for<br />
around 80% of all such imaging procedures<br />
being performed. In 2009 it is estimated that globally a total of<br />
almost 40 million procedures per year were performed in nuclear<br />
medicine and this equates to around 120,000 patient injections using<br />
99m Tc each day. The short supply in radiopharmaceuticals during the<br />
past three years is mainly caused by technical problems in research<br />
reactors producing medical radioisotopes on an industrial scale. On<br />
the other hand, the cyclotron technologies for manufacturing<br />
Molybdenum-99 or Technetium-99m have been described several<br />
times in the literature and a complete report on the topic was<br />
generated as early as 1999. Most of these publications extensively<br />
describe the technical feasibility of this approach at small scale, but<br />
never addressed the technical and economical impact associated with<br />
the scaling up. These issues including impurity profile control,<br />
regulatory constraints, pharmaceutical aspect, logistics and<br />
customers interest will be described here. Briefly, the conclusion<br />
leads that the cyclotron generated 99m Tc is not an economically viable<br />
alternative to the well-established 99 Mo/ 99m Tc generator. Even from a<br />
technical point of view the development of a cyclotron for large scale<br />
production of 99m Tc will be difficult to concretize. Therefore, despite<br />
its huge initial investment, the best option from an economical point<br />
of view will definitely remain the reactor route. Also, the decision to<br />
set up an alternative method will be based not just on the technology<br />
or capacity criteria but on a full economic and comprehensive<br />
business evaluation.<br />
42
3rd International Congress of of Nuclear Medicine & & 15th 15th Iranian Annual Annual Congress of<br />
Congress of Nuclear Medicine<br />
Shahid Beheshti Shahid Beheshti University University of Medical of Medical Sciences Sciences 19-21 19-21 May May 2011<br />
Radiopharmaceuticals for Synovectomy<br />
A.R Jalilian (Iran)<br />
Radiopharmaceutical Research and Development Lab (RRDL), Nuclear Science<br />
and Technology Research Institute (NSTRI)<br />
As the aging of the human population around the world, the need for<br />
the management of elderly-diseases such as rheumatoid arthritis and<br />
other joint problems has emerged. Also a majority of diseases can<br />
cause arthropathy leading to the pain, inflammation and also<br />
immobility of the patients such as spondylarthropathy, Lyme disease,<br />
Behcet´s disease, persistent synovial effusion, haemophilic arthritis,<br />
calcium pyrophosphate dihydrate (CPPD) arthritis, pigmented<br />
villonodular synovitis (PVNS), persistent effusion after joint<br />
prosthesis, undifferentiated arthritis, etc. among the most used<br />
radiopharmaceuticals used according to EANM protocols, three agents<br />
are of the great importance including,<br />
90 Y silicate/citrate,<br />
186 Re<br />
sulphide and 169 Er citrate.<br />
90 Y emits a beta particle with maximum energy 2.27 MeV with mean<br />
energy 0.935 MeV and average soft tissue range 3.6 mm and<br />
physical half life of 2.7 days suitable for the knee joint (5 – 6 mCi per<br />
joint).<br />
On the other hand, 186 Re emits a beta particle with maximum energy<br />
1.07 MeV, mean energy 0.349 MeV, average soft-tissue range 1.1<br />
mm and a 9% abundant gamma emission with a photopeak of 0.137<br />
MeV The physical half life is 3.7 days suitable for hip, shoulder,<br />
elbow, wrist, ankle and subtalar joints.<br />
Finally 169 Er emits a beta particle with maximum energy 0.34 MeV,<br />
mean energy 0.099 MeV and average soft tissue range 0.3 mm. and<br />
physical half life of 9.4 days used for metacarpophalangeal,<br />
metatarsophalangeal and digital interphalangeal joints.<br />
The production, quality control and clinical trials for above mentioned<br />
agents are in process by NSTRI and Iranian medical societies<br />
according to National Radiopharmaceutical Production Project started<br />
in Jan. 2010.<br />
43
3rd International Congress 3rd International of Nuclear Congress Medicine of Nuclear & 15th Medicine Iranian Annual & 15th Iranian Congress Annual of<br />
Nuclear Congress Medicine of Nuclear Medicine<br />
Shahid Beheshti Shahid Beheshti University University of Medical Sciences of Medical 19-21 Sciences May 201119-21 May 2011<br />
Cancer therapy with alpha-emitters labeled peptides<br />
Fariba Johari Daha (Iran)<br />
School of Nuclear Science, Nuclear Science and Technology Research Institute<br />
(NSTRI)<br />
Alpha particles are of considerable interest for radioimmunotherapy<br />
applications. Due to their short range in tissue(a few cell diameters),<br />
and high linear- energy- transfer (LET),they are specially suited for<br />
targeting micrometastases and single tumor cells such as leukemia<br />
and other blood-borne diseases. Actively targeted α-particles offer<br />
specific tumor cell killing action with less collateral damage to<br />
surrounding normal tissues than β-emitters. During the last decade,<br />
radiolabeled peptides that bind to different receptors on the tumors<br />
have been investigated as potential therapeutic agents both in the<br />
preclinical and clinical settings. Advantages of radiolabeled peptides<br />
over antibodies include relatively straightforward chemical synthesis,<br />
versatility, easier radiolabeling, rapid clearance from the circulation,<br />
faster penetration and more uniform distribution into tissues, and less<br />
immunogenicity. Rapid internalization of the radiolabeled peptides<br />
with equally rapid re-expression of the cell surface target is a highly<br />
desirable property that enhances the total delivery of these<br />
radionuclides into malignant sites. 211 At(t 1/2 =7.2 h), 212 Bi(t 1/2 =60.6<br />
h), 213 Bi(t 1/2 =45.6 h), 233 Ra(t 1/2 =11d) are potential radionuclides for<br />
these applications. Peptides, such as octreotide, α-melanocytestimulating<br />
hormone analogues, arginine-glycine-aspartic acidcontaining<br />
peptides, bombesin derivatives, and others may all be<br />
feasible for use with α-emitters. The on-going preclinical work has<br />
primarily concentrated on octreotide and octreotate analogues<br />
labeled with Bismuth-213 and Astatine-211.<br />
44
3rd International Congress of of Nuclear Medicine & & 15th 15th Iranian Annual Annual Congress of<br />
Congress of Nuclear Medicine<br />
Shahid Beheshti Shahid Beheshti University University of Medical of Medical Sciences Sciences 19-21 19-21 May May 2011<br />
Imaging of Dopamine-Terminal Function in Central Movement<br />
Disorders Using Emission Tomography<br />
F. Sedaghat (Greece)<br />
Aristotle University of Thessaloniki, Thessaloniki<br />
Educational Objectives:<br />
The importance of dopamine transporters and receptors imaging<br />
using SPECT in early differential diagnosis of parkinsonism,<br />
Its potential as a screening tool for subjects at risk of developing<br />
PD,<br />
Issues around the assessment of disease progression,<br />
The importance of semiquantitative analysis of the images.<br />
Summery:<br />
Patients suffering from central movement disorders share the<br />
common clinical symptom of parkinsonism. Differentiating between<br />
these pathologies and essential tremor (ET) is a difficult and<br />
important task as they demand different therapeutic strategies and<br />
have different prognoses. Studies suggest that almost one third of<br />
patients are incorrectly diagnosed with PD by primary care physicians<br />
initially. Even among movement disorder specialists, the rate of<br />
misdiagnosis of PD is reported to be 10% to 12%. The development<br />
of PET and SPECT imaging in movement disorders has been<br />
accelerated by the early descriptions of the loss of dopamine neurons<br />
of substantia nigra. The application of emission tomography using<br />
dopamine-transporters and receptors radiopharmaceuticals in<br />
investigation of movement disorders will be discussed.<br />
Keywords: SPECT, DaT Scan, Parkinsonism, IBZM, Parkinson,<br />
Dopamine receptors, Presynaptic dopamine transporters<br />
45
3rd International Congress 3rd International of Nuclear Congress Medicine of Nuclear & 15th Medicine Iranian Annual & 15th Iranian Congress Annual of<br />
Nuclear Congress Medicine of Nuclear Medicine<br />
Shahid Beheshti Shahid Beheshti University University of Medical Sciences of Medical 19-21 Sciences May 201119-21 May 2011<br />
The Application of Emission Tomography in Dementia<br />
F. Sedaghat (Greece)<br />
Aristotle University of Thessaloniki, Thessaloniki<br />
Educational Objectives:<br />
The value of PET and SPECT in differential diagnosis of dementias,<br />
Their potential role as screening tools for cases with Mild Cognitive<br />
impairment and thus early diagnosis of Alzheimer’s disease,<br />
Monitoring of disease progression and therapy.<br />
Summery:<br />
Alzheimer’s disease (AD) is a progressive impairment of intellect,<br />
memory and personality with enormous impact on health care<br />
provision. Single photon emission computed tomography (SPECT)<br />
and positron emission tomography (ΡΕΤ) are imaging modalities<br />
which help the clinician to investigate the functional and<br />
neurochemical changes of the brain, in patients with dementia and in<br />
those at risk οf subsequent cognitive decline. AD with several<br />
pathophysiological characteristic features (amyloid plaques,<br />
neurofibrillary tangles, several neurotransmitter deficits) is a common<br />
cause of dementia in elderly. AD is characterized by biIateral<br />
posterior temporoparietal hypoperfusion on SPECΤ and<br />
hypometabolism on ΡΕΤ which may precede the onset of dementia,<br />
as similar perfusion changes can be demonstrated in prodromal stage<br />
of AD and in those who carry susceptibility genes.<br />
Multi-infarct dementia is associated with multiple asymmetric<br />
perfusion deficits. Fronto-temporaI dementia is characterized by both<br />
hypometabolism and hypoperfusion in fronto-temporal regions. In<br />
dementia with Lewy bodies temporoparietal and occipital perfusion<br />
deficits are seen together with a reduction in the striatal presynaptic<br />
dopamine transporter which can be visualized in 123 I-FP-CIT (DaT<br />
Scan).<br />
Several studies of therapy response in AD with cholinergic drugs,<br />
using specific ligands, have found changes in regional blood flow and<br />
nicotinic and muscarinic receptor function in the patients who<br />
respond to therapy.<br />
PET ligands are developed for demonstration of amyloid plaques.<br />
Emission tomography, with highly specific new ligands will have more<br />
increasing application in both, dementia research and patient<br />
management in the future.<br />
Disease-modifying therapies would be most important to initiate<br />
during the earliest phases of the disease, making it especially<br />
important to have an early clinical diagnosis of AD, when treatment<br />
could potentially delay the degenerative process at a time when<br />
damage to brain tissue is minimal.<br />
Key words: Dementia, Alzheimer’s disease, SPECT, PET, MCI,<br />
Amyloid Plaque imaging, Lewy Body, DaT scan, Frontotemporal<br />
dementia, Vascular dementia.<br />
46
3rd International Congress of of Nuclear Medicine & & 15th 15th Iranian Annual Annual Congress of<br />
Congress of Nuclear Medicine<br />
Shahid Beheshti Shahid Beheshti University University of Medical of Medical Sciences Sciences 19-21 19-21 May May 2011<br />
Radiopharmaceuticals for infection diagnosis in Iran<br />
Mostafa Erfani (Iran)<br />
Nuclear Science Research School, Nuclear Science & Technology Research<br />
Institute (NSTRI), Atomic Energy Organization of Iran<br />
Infectious diseases remain a major health problem and cause of<br />
death worldwide, particularly in developing countries. Nuclear<br />
medicine imaging, because of its sensitivity, offers an attractive<br />
option for diagnosis of focal. This needs a reliable<br />
radiopharmaceutical that can selectively concentrate in sites of<br />
infection. Radiopharmaceuticals for imaging infection have generally<br />
been divided into two types ‘specific’ and ‘non-specific’. The<br />
distinction between them relates to the mechanism of their action.<br />
‘Non-specific’ agents work solely by their ability to localize at the site<br />
of inflammation that is often accompanied with infection. ‘Specific’<br />
agents, while also exhibiting some degree of non-specific localization<br />
show an additional interaction with either the host immune system or<br />
the agent causing the inflammation that increases the efficiency of<br />
delivery. Both ‘specific’ and ‘non-specific’ radiopharmaceuticals may,<br />
depending on the nature of the condition under study is equally<br />
effective. For example, a ‘non-specific’ agent, 111In-hIgG has shown<br />
high accuracy in diagnosis of number of infections by localizing in<br />
associated inflammations. However, in some cases, particularly with<br />
regard to identifying the cause of an inflammation, a ‘specific’ product<br />
may be more appropriate.<br />
The most well established ‘specific’ agent that is still regarded as the<br />
‘gold-standard’ for infection imaging is 111In labelled WBCs. In view<br />
of the cost, limited availability, and not so favorable nuclear<br />
properties for imaging of 111In, techniques for 99mTc labelling of<br />
WBCs have also been developed and used. However, both these<br />
products have a number of drawbacks, in particular: the need for<br />
labelling individual patient’s blood sample and reinjection; need for<br />
well-trained staff and suitable facilities; the risk of infection and<br />
cross-contamination; and the considerable cost of the materials<br />
required for cell labelling. Because of these, WBC labelling procedure<br />
has not become so extensively used commensurate with its potential<br />
and considerable efforts have gone towards developing convenient<br />
replacements. They include 99mTc labelled anti neutrophil antibodies,<br />
chemotactic peptides, and platelet factor. However, these<br />
radiopharmaceuticals retain many disadvantages related to either<br />
their cost and availability or their performance. To achieve a more<br />
desirable 99mTc radiopharmaceutical for infection imaging, one<br />
displaying a faster blood clearance, less non- target uptake and<br />
better concentration in infection sites, it will be necessary to exploit<br />
alternate biochemical pathways. Some of these pathways like binding<br />
of antimicrobial peptides for example ubiquicidine, have been<br />
recently explored with promising results.<br />
47
3rd International Congress 3rd International of Nuclear Congress Medicine of Nuclear & 15th Medicine Iranian Annual & 15th Iranian Congress Annual of<br />
Nuclear Congress Medicine of Nuclear Medicine<br />
Shahid Beheshti Shahid Beheshti University University of Medical Sciences of Medical 19-21 Sciences May 201119-21 May 2011<br />
Oral Presentations<br />
48
3rd International Congress of of Nuclear Medicine & & 15th 15th Iranian Annual Annual Congress of<br />
Congress of Nuclear Medicine<br />
Shahid Beheshti Shahid Beheshti University University of Medical of Medical Sciences Sciences 19-21 19-21 May May 2011<br />
Comparison of pediatric thyroid cancer with adult thyroid<br />
cancer in a single thyroid cancer clinic<br />
Seyed Rasoul Zakavi 1 , Zohre Mousavi 2 , Vahidreza Dabbagh Kakhki 1 ,<br />
Ramin Sadeghi 1<br />
1 Mash’had University of Medical Science, Nuclear Medicine Research Center<br />
2 Mash’had University of Medical Science, Endocrinology and metabolism<br />
research Center<br />
Aim: To find differences in general characteristics of thyroid cancer in<br />
pediatric patients compared to adults.<br />
Methods and patients: All thyroid cancer files in the main thyroid<br />
cancer clinic in Khorasan were reviewed retrospectively. Different<br />
variables were compared between pediatric (age of ≤16 years at the<br />
time of diagnosis) and adult patients.<br />
Results: 785 patients with thyroid cancer referred for thyroid cancer<br />
clinic from 1995-2009. Thirty patients (20 female, 10 male) had<br />
age≤16 years old at the time of diagnosis with mean age of 13.08<br />
years. At the same period, 755 adult patients with mean age of<br />
42.5±15.7 years also recorded in the center. The sex ratio was not<br />
statistically significant comparing pediatric group with adult patients<br />
(p=0.2). 3% of adults and 0% of pediatric group had family history<br />
of thyroid cancer in first relatives (p=0.6) while 9.5% versus 5.9%<br />
had family history of other cancers respectively (P=0.5). Distant<br />
metastasis was the first presentation in 13.6% of pediatric and 9.4%<br />
of adult patients (P=0.6). No pediatric patient and 6.1% of adults had<br />
previous history of radiotherapy to head and neck region as a<br />
predisposing factor (P=0.2). Papillary carcinoma was seen in 93.3%<br />
of pediatric patients and 88.6% of adult patients (P=0.004).<br />
Extrathyroid invasion was seen in 39.3% of adult and 35.7% of<br />
pediatric group (P=0.8). Multifocal cancer was seen in 60.7% of<br />
pediatric group and 39% of adult patients (P=0.02) Distant<br />
metastasis was noted in 20% of pediatric and 8.9% of adult patients.<br />
T staging analysis showed that T1 was less prevalent and T4 was<br />
more prevalent in pediatric patients compared to adults(P=0.04). N<br />
staging analysis showed that 88.6% of pediatric and 52.7% of adults<br />
patients had N1(P=0.009).The mean number of involved lymph<br />
nodes was 6.06±3.8 in pediatrics and 3.52±3.4 in adults(0.005).<br />
There was no significant difference between adults and pediatrics in<br />
tumor size either in preoperative sonography or in pathology, mean<br />
first Tg level and mean first anti-Tg levels(P>0.2).<br />
Conclusion: 3.8% of all thyroid cancer patients in our center<br />
was
3rd International Congress 3rd International of Nuclear Congress Medicine of Nuclear & 15th Medicine Iranian Annual & 15th Iranian Congress Annual of<br />
Nuclear Congress Medicine of Nuclear Medicine<br />
Shahid Beheshti Shahid Beheshti University University of Medical Sciences of Medical 19-21 Sciences May 201119-21 May 2011<br />
Keywords: Thyroid Cancer, Pediatrics<br />
50
3rd International Congress of of Nuclear Medicine & & 15th 15th Iranian Annual Annual Congress of<br />
Congress of Nuclear Medicine<br />
Shahid Beheshti Shahid Beheshti University University of Medical of Medical Sciences Sciences 19-21 19-21 May May 2011<br />
The role of 99mTc-EDDA/HYNIC-TATE(Octreotate) in the<br />
evaluation of solitary pulmonary nodule (SPN)<br />
Kamran Aryana<br />
Mashhad University of Medical Sciences<br />
Introduction: Solitary pulmonary nodule (SPN) radiologically<br />
defined as a single lesion that is less than 3cm in diameter, surround<br />
by lung parenchyma and not associated with adenopathy or<br />
atelectasis. Those SPNs that do not meet specific benign criteria are<br />
considered indeterminate and need to further evaluation. Tc99m-<br />
Octreotate is a somatostatin analogue that binds with high affinity to<br />
somatostatin receptors.<br />
Objective: Initial experience to assess the usefulness of 99mTc-<br />
Octreotate in the differential diagnosis of incidentally discovered SPN<br />
and to determinate the cut off value that would discriminate between<br />
benign and malignant nodules.<br />
Methods: 15 pulmonary nodules, with sized 1.2-3cm, were<br />
evaluated in 14 patients (8 male and 6 female) aged 22-70yrs (mean<br />
47 yrs). An activity of 740MBq of the Tc99m-Octreotate was injected<br />
intravenously in each patient. Imaging was started 2 h post injection,<br />
a static image (500 counts) and a SPECT acquisition was obtained<br />
from the chest.<br />
Results: The SPECT was true positive in 7/8 malignant SPNs.<br />
Negative scintigraphic results were found in 4 Pt’s with benign SPN.<br />
Two Pt’s with positive scan have infectious process (false positive).<br />
Definitive diagnosis was obtained in all of patients by<br />
histopathologiocal result or clinical and CT follow up.<br />
Conclusion: Our study demonstrated that Tc99m-Octreotate is a<br />
sensitive imaging modality with significant specificity and negative<br />
predictive value when compared with CT. We recommend this scan<br />
for the evaluation of SPNs, especially when PET is not available<br />
before biopsy.<br />
Keywords: Octreotate, Solitaire pulmonary nodule<br />
51
3rd International Congress 3rd International of Nuclear Congress Medicine of Nuclear & 15th Medicine Iranian Annual & 15th Iranian Congress Annual of<br />
Nuclear Congress Medicine of Nuclear Medicine<br />
Shahid Beheshti Shahid Beheshti University University of Medical Sciences of Medical 19-21 Sciences May 201119-21 May 2011<br />
Accuracy of sentinel lymph node biopsy for axillary staging of<br />
breast cancer patients undergone prior surgical biopsy: metaanalysis<br />
of the literature.<br />
Ramin Sadeghi 1 , Hassan Gholami 2 , Hadi Javan 3 , Azar Fani Pakdel 4 ,<br />
Mehdi Asadi 5<br />
1 Mash’had University of Medical Science, Nuclear Medicine Research Center<br />
2 Mash’had University of Medical Science, Evidence Based Medicine Committee<br />
3 Mashhad University of Medical Sciences<br />
4 Mash’had University of Medical Science, Cancer Research Center<br />
5 Mash’had University of Medical Science, Surgical Oncology Research Center<br />
Introduction: Sentinel lymph node biopsy is the standard method of<br />
axillary staging in early stage breast cancer patients. An important<br />
issue is the eligibility of patients undergone prior surgical biopsy of<br />
the primary breast lesion. In this meta-analysis we comprehensively<br />
searched the literature regarding this issue and summarized the<br />
results accordingly.<br />
Materials and methods: We systematically searched Medline,<br />
SCOPUS, and Google Scholar for studies with head to head<br />
comparison of sentinel lymph node biopsy method in patients with<br />
and without prior surgical biopsy. No language or date restriction was<br />
imposed. Studies with enough information to calculate detection rate<br />
as well as false negative rate for both groups were included. For<br />
pooling of the results random effects model was used (Der-Simonian<br />
and Laird method). Q statistics and I2 index were used for<br />
heterogeneity evaluation.<br />
Results: 68 studies for detection rate and 16 for false negative rate<br />
were located with the required information. Pooled detection rates for<br />
patients with and without history of prior surgical biopsy were<br />
91.33% [89.1-93%] and 92.7% [90.9-94.1%] respectively. OR of<br />
unsuccessful mapping was 1.14 [0.955-1.362] and risk difference<br />
was 0.00018 [-0.00844-0.00881] (Q value=104.730 p=0.001 and<br />
I2=38.89). Pooled false negative rates for patients with and without<br />
history of prior surgical biopsy were 13% [9.6%-17.4%] and 10%<br />
[7.6%-12.8%] respectively. OR of getting false negative results was<br />
1.418 [1.107-1.816] and risk difference was 2.2% [0.1%-4.3%] (Q<br />
value=14.12 p=0.516 and I2=0).<br />
Conclusion: Successful sentinel node mapping is not decreased by<br />
prior surgical biopsy of the primary breast lesion. However, the false<br />
negative rate in this group of patients is slightly higher compared to<br />
those without previous biopsy. Despite this fact, the difference is low<br />
(2.2%) and is not clinically relevant. In our opinion prior biopsy of<br />
the primary breast lesions should not be considered as a contraindication<br />
for sentinel lymph node biopsy procedure.<br />
Keywords: Sentinel breast cancer, meta-analysis, core-needlebiopsy,<br />
excisional-biopsy<br />
52
3rd International Congress of of Nuclear Medicine & & 15th 15th Iranian Annual Annual Congress of<br />
Congress of Nuclear Medicine<br />
Shahid Beheshti Shahid Beheshti University University of Medical of Medical Sciences Sciences 19-21 19-21 May May 2011<br />
Sentinel node mapping in the prostate cancer: systematic<br />
review and meta-analysis of the literature<br />
Ramin Sadeghi 1 , Hassan Gholami 2 , Kamyar Tavakkoli Tabasi 3 , Asieh<br />
Sadat Fattahi Masoom 4<br />
1 Mash’had University of Medical Science, Nuclear Medicine Research Center<br />
2 Mash’had University of Medical Science, Education Management<br />
3 Mash’had University of Medical Science, Urology Department<br />
4 Mash’had University of Medical Science, General Surgery Department<br />
Aim: Sentinel node (SN) biopsy is becoming a standard procedure in<br />
the management of several malignancies. Several groups have<br />
evaluated the feasibility and value of this procedure in prostate<br />
cancer patients. In the current meta-analysis, we comprehensively<br />
and quantitatively summarized the results of these studies.<br />
Methods: Several databases including Medline, SCOPUS, Google<br />
Scholar, Ovid, Springer, and Science direct were systematically<br />
searched for the relevant studies regarding SL biopsy in the prostate<br />
cancer (prostate AND sentinel as search keywords). The outcomes of<br />
interest were sensitivity and detection rate of the procedure.<br />
Results: For detection rate and sensitivity 21 and 16 studies met the<br />
criteria of inclusion respectively. Pooled detection rate was 93.8%<br />
(95% CI 89-96.6%). Cochrane Q value was 216.077 (I2 = 89.81%<br />
and p < 0.001). Pooled sensitivity was 94% (95% CI 91-96%).<br />
Cochrane Q value was 14.12 (I2 = 0.0 and p = 0.516).<br />
Conclusion: SL biopsy can prevent unnecessary pelvic lymph node<br />
dissection in prostate cancer patients. This procedure is feasible with<br />
low false negative rate and high detection rate.<br />
Keywords: Prostate-cancer, sentinel, systematic-review, metaanalysis<br />
53
3rd International Congress 3rd International of Nuclear Congress Medicine of Nuclear & 15th Medicine Iranian Annual & 15th Iranian Congress Annual of<br />
Nuclear Congress Medicine of Nuclear Medicine<br />
Shahid Beheshti Shahid Beheshti University University of Medical Sciences of Medical 19-21 Sciences May 201119-21 May 2011<br />
99mTc-MIBI INFUSION VERSUS NITROGLYCERIN 99mTc-MIBI<br />
ON DETECTION OF MYOCARDIAL VIABILITY<br />
Shahram Dabiri Oskoei 1 , Babak Mahmoudian 2<br />
1 Tabriz University of Medical Science, Department of Nuclear Medicine<br />
2 Tabriz Gamma Scan Nuclear Medicine Center<br />
Objectives: Several studies have suggested that, rest 99mTc-MIBI<br />
underestimates the extent of viable myocardium. This study aimed to<br />
test whether 99mTc-MIBI infusion could increment the capacity of<br />
99mTc-MIBI to detect myocardial viability and to compare it with<br />
sublingual administration of nitroglycerine (TNG) before 99mTc-MIBI<br />
injection in the same sample.<br />
Method: Twenty patients (14 men, 6 women, mean age 51.5 ± 9.5<br />
years) with previous myocardial infarction (mean evolution 6.5 ± 4<br />
months) were submitted to myocardial perfusion scan with 99mTc-<br />
MIBI gated SPECT for evaluation of myocardial viability. Rest<br />
imaging, TNG 99mTc-MIBI scan and infusion of 99mTc-MIBI during<br />
30 minutes were performed in all patients. Acquisition was started 60<br />
minutes after starting of radiotracer infusion or injection. The uptake<br />
more than 50% of maximum activity on each segment of bull’s eye<br />
images was considered as viable tissue. Increased uptake more than<br />
5% in comparison to rest study was considered significant.<br />
Results: A total of 660 myocardial segments were analyzed, of which<br />
112(17%) showed viability on rest images. Viable tissue was<br />
observed in 135 segments (20.4%) on rest TNG99mTc-MIBI scan<br />
with significant increased uptake in 16 (2.4%) other segments. After<br />
99mTc-MIBI infusion, viability was seen on 132 segments (20%) and<br />
significant increased uptake in 18 (2.7%) other segments. All above<br />
mentioned segments were hypokinetic.<br />
Conclusion: Resting 99mTc-MIBI infusion imaging, with improved<br />
tracer delivery, may overcome some of the inadequacies of standard<br />
stress/rest 99mTc-MIBI imaging for assessing myocardial viability.<br />
The implication of this observation is that resting 99mTc-MIBI<br />
infusion scintigraphy can provide useful information when evaluating<br />
patients for the presence of hibernating myocardium. A prospective<br />
comparison of resting 99mTc-MIBI infusion scintigraphy with other<br />
noninvasive techniques which are used to identify viable myocardium<br />
may thus be warranted.<br />
Keywords: Myocardium, Perfusion, SPECT, MIBI, Infusion, Viability<br />
54
3rd International Congress of of Nuclear Medicine & & 15th 15th Iranian Annual Annual Congress of<br />
Congress of Nuclear Medicine<br />
Shahid Beheshti Shahid Beheshti University University of Medical of Medical Sciences Sciences 19-21 19-21 May May 2011<br />
Gated myocardial perfusion SPECT: patient position effect<br />
Vahid Reza Dabbagh Kakhki<br />
Mash’had University of Medical Science, Nuclear Medicine Research Center<br />
Objectives: Gated myocardial perfusion SPECT has traditionally been<br />
performed with the patient in the supine position. Prone position<br />
imaging is used to rule out of diaphragmatic attenuation. The main of<br />
this study was evaluation of patient position effect on left ventricular<br />
end-diastolic & end-systolic volumes (EDV & ESV) as well as left<br />
ventricular ejection fraction (LVEF) acquired on gated myocardial<br />
perfusion SPECT.<br />
Methods: Sixty patients (40 males and 20 females) with mean age:<br />
52.1±8.8 were studied. All patients underwent rest gated Tc99m-<br />
MIBI myocardial perfusion SPECT on both prone and supine positions.<br />
Gated images were analyzed by QGS software and EDV, ESV and<br />
LVEF were calculated for both supine and prone images.<br />
Results: EDV, ESV and stoke volume (SV) were significantly lower in<br />
prone positions, while no significant difference was noticed in LVEF<br />
between prone and supine positions. Heart rate (HR) was significantly<br />
lower on supine position as compared to the prone position (67.30 ±<br />
9.54 vs. 71.87 ± 9.56; P
3rd International Congress 3rd International of Nuclear Congress Medicine of Nuclear & 15th Medicine Iranian Annual & 15th Iranian Congress Annual of<br />
Nuclear Congress Medicine of Nuclear Medicine<br />
Shahid Beheshti Shahid Beheshti University University of Medical Sciences of Medical 19-21 Sciences May 201119-21 May 2011<br />
The association of Rate-Pressure Product (RPP) and<br />
myocardial perfusion imaging (MPI) findings; a preliminary<br />
study<br />
Majid Assadi 1 , Hamid Javadi 2 , Mohammad Reza Pourbehi 1 , Maryam<br />
Rayzan 1 , Mehdi Mogharrabi 3<br />
1 The Persian Gulf Nuclear Medicine Research Center<br />
2 Golestan Research Center of Gastroenterology and Hepatology (GRCGH)<br />
3 Golestan University of Medical Science, Department of Nuclear Medicine<br />
Introduction: The product of heart rate and systolic blood pressure,<br />
termed as Rate-Pressure Product (RPP), is a very reliable indicator of<br />
myocardial oxygen demand and is widely used clinically .The study<br />
was aimed to evaluate the association of RPP results with scan<br />
findings which is scare in the literature.<br />
Materials and methods: In total from 1250 patients who suspected<br />
to coronary artery disease (CAD) underwent gated SPECT imaging<br />
with dipyridamole , exercise and dobutamine stress, 497 cases with<br />
satisfied inclusion and exclusion criteria were included in this study.<br />
The difference between the RPP max and the basal RPP is known as<br />
the RPP reserve. The semi-quantitave analysis of MPI using gated<br />
software, as well as the demographic, risk factors of CAD and pretest<br />
likelihood of CAD using nomogram were also obtained.<br />
Results: In total, 497 cases including 426 patients with dipyridamole<br />
stress, 59 with exercise stress and 12 with dobutamine stress<br />
underwent myocardial perfusion imaging. In patients undertaking<br />
dipyridamole , there was a significant difference between HR at rest<br />
and at maximum; between systolic BP in rest and maximum ;<br />
between diastolic BP and between EF at rest and maximum. There<br />
was a significant correlation between sum stress score(SSS) and<br />
reserved RPP (r= -0.12, p value =0.00) which in dipyridamole<br />
patients was r=-0.18, p value=0.00). In addition, there was a<br />
significant association between reserved RPP and risk of CAD (p<br />
value=0.00). In the patients with dipyridamole stress , the EF change<br />
(odds ratio =0.92; 95% CI: 0.86-0.98; p = 0.01), reserve RPP (odds<br />
ratio =1.00; 95% CI: 1.00-1.00; p = 0.04), risk of CAD (odds ratio<br />
=5.80; 95% CI: 3.21-10.50; p = 0.00) and age (odds ratio =0.94;<br />
95% CI: 0.89-0.98; p = 0.01) were associated significantly with MPI<br />
results by using multiple logistic regressions. Multivariate linear<br />
analyses adjusting for main clinical risk factors revealed that age,<br />
SSS, risk of CAD, and sex were the independent determinants for<br />
prediction of reserve RPP across different models in the patients.<br />
Conclusion: The study demonstrated that RPP might become an<br />
appropriate indicator for optimal analysis of the dipyridamole stress<br />
MPI and it can help to nuclear medicine physicians for a favorable<br />
interpretation.<br />
Keywords: RPP, MPI, CAD<br />
56
3rd International Congress of of Nuclear Medicine & & 15th 15th Iranian Annual Annual Congress of<br />
Congress of Nuclear Medicine<br />
Shahid Beheshti Shahid Beheshti University University of Medical of Medical Sciences Sciences 19-21 19-21 May May 2011<br />
Silent myocardial ischemia in diabetic patients: screening,<br />
diagnosis and early anti-ischemic pharmacotherapy<br />
Mehrshad Abbasi 1 , Alireza Emami Ardakani 1 , Alireza Esteghamati 2 ,<br />
Babak Falahi 1 , Mohamad Eftekhari 1<br />
1 Tehran University of Medical Science, Department of Nuclear Medicine<br />
2 Tehran University of Medical Science, Endocrine and Metabolism Research<br />
Center<br />
Diabetes is considered as myocardial infarction (MI) equivalent for<br />
the risk of subsequent MI and cardiac mortality; shouldn't diabetic<br />
patients undergo the workup of post-MI subjects? The cardiovascular<br />
mortality rate and complications are similar between diabetic subjects<br />
with asymptomatic and symptomatic ischemia underscoring the value<br />
of screening programs. The current recommendations suggest an<br />
individualized approach to the diagnosis and therapy for silent<br />
myocardial ischemia in diabetic subjects, based on patient’s specific<br />
characteristics. The objective of this review is to evaluate the<br />
evidence based data pertaining to the benefits and limitations of<br />
screening, diagnosis and treatment of asymptomatic ischemia in<br />
diabetic subjects. The feasibility of discrimination between the high<br />
and low risk populations employing traditional and new risk factors,<br />
the role of exercise tolerance test and additional myocardial imaging<br />
or echocardiography, as well as alternative options including calcium<br />
score determination, and finally the decision to initiate early<br />
pharmacotherapy are discussed.<br />
Keywords: sillent ischemia, diabetes mellites, MPI<br />
57
3rd International Congress 3rd International of Nuclear Congress Medicine of Nuclear & 15th Medicine Iranian Annual & 15th Iranian Congress Annual of<br />
Nuclear Congress Medicine of Nuclear Medicine<br />
Shahid Beheshti Shahid Beheshti University University of Medical Sciences of Medical 19-21 Sciences May 201119-21 May 2011<br />
Different aspects of gated myocardial perfusion SPECT<br />
Vahid Reza Dabbagh Kakhki<br />
Nuclear Medicine Research Center, Mashhad University of Medical Sciences<br />
Myocardial single-photon emission computed tomography (SPECT)<br />
has been utilized as an important tool for optimal decision making in<br />
cardiology. Gated SPECT allows evaluation of myocardial perfusion<br />
imaging with subsequent analysis of regional wall motion and<br />
calculation of global & regional myocardial function. This integrated<br />
approach with simultaneous evaluation of myocardial perfusion and<br />
function, is clinically useful for the diagnosis, prognosis and follow-up<br />
of coronary artery disease. Available software algorithms for<br />
computation of left ventricular functional indices are: Quantitative<br />
Gated SPET (QGS, Cedars-Sinai Medical Center, Los Angeles,<br />
California, USA), Emory Cardiac Toolbox (ECTb, Emory University,<br />
Atlanta, Georgia, USA), 4D-MSPET (University of Michigan, Medical<br />
Center), layer of maximum counts (LMC), MultiDim (Sopha, Medical<br />
Vision International, Buc, France) and left ventricular global<br />
thickening fraction (LVGTF). Previous studies have compared these<br />
methods against cardiac magnetic resonance imaging (cMRI),<br />
echocardiography , gated blood pool SPET, contrast ventriculography<br />
,and simulated images. Each of the above methods has its own<br />
advantages and drawbacks in estimating the left ventricular volumes<br />
(LVV) and left ventricular ejection fraction (LVEF) . It has also been<br />
reported that the calculated LVEF and LVV can be affected by<br />
different patient populations, imaging protocols, use of different<br />
isotopes, time to imaging after stress, differences in the image<br />
matrix, zoom, prereconstruction filtering, heart size, extent and<br />
severity of perfusion defects, etc.<br />
Keywords: Gated myocardial perfusion SPECT<br />
58
3rd International Congress of of Nuclear Medicine & & 15th 15th Iranian Annual Annual Congress of<br />
Congress of Nuclear Medicine<br />
Shahid Beheshti Shahid Beheshti University University of Medical of Medical Sciences Sciences 19-21 19-21 May May 2011<br />
The effect of Methimazole on Thyroid gland uptake of<br />
technetium in hyperthyroid patients<br />
Farshid Gheisari, Alireza Mehdizadeh, Mehrosadat Alavi<br />
Shiraz University of Medical Science, Nuclear Medicine Department<br />
Abstract: The aim of this study was to investigate the effect of<br />
Methimazole on Technetium-99mreabsorbing by thyroid gland, it may<br />
be possible to perform thyroid scan when the patients are on<br />
Methimazole, this can be time saving and decrease the adverse effect<br />
of discontinuing Methimazole.<br />
Patients and methods: Among all the patients with<br />
hyperthyroidism who referred to Nuclear medicine department of<br />
Shiraz University of Medical Sciences, 50 Patients were randomly<br />
selected, we asked the patients who were on Methimazole, to<br />
discontinue the usage of all other drugs and keep exact thyroid diet<br />
for one week, after that thyroid scan was performed again. Revealed<br />
data was analyzed under supervision of statistical specialist with<br />
descriptive method on SPSS.<br />
Results: 34 patients were male (86%) and other were female. Mean<br />
age of the patients was 53.5 years (39-75). Although the region of<br />
interest (ROI)of thyroid was increase4d in the patients who used<br />
Methimazole before scan 398.72(SD:191.73)than the patients who<br />
discontinued Methimazole one week before scan 380.15(SD:112.49),<br />
but the difference wasn’t statistically significant . The ROI of<br />
peripheral tissue of the thyroid was decreased in the patients who<br />
used Methimazole before scan 26.44(SD:5.57), but the difference<br />
wasn’t statistically significant .<br />
Discussion: we demonstrated that Methimazole pretreatment<br />
doesn’t interfere with either the efficacy of ROI and reabsorbing of<br />
Technetium-99m in thyroid gland and peripheral tissues. A possible<br />
limitation of this study is the number of patients in the sample. In<br />
conclusion, it may be possible to perform thyroid scan when the<br />
patients are on the Methimazole, this can be time saving and<br />
decrease the adverse effect of discontinuing Methimazole.<br />
Keywords: Methimazole , Technetium -99m, Hyperthyroidism<br />
59
3rd International Congress 3rd International of Nuclear Congress Medicine of Nuclear & 15th Medicine Iranian Annual & 15th Iranian Congress Annual of<br />
Nuclear Congress Medicine of Nuclear Medicine<br />
Shahid Beheshti Shahid Beheshti University University of Medical Sciences of Medical 19-21 Sciences May 201119-21 May 2011<br />
Nasolacrimal Duct Obstruction as a Complication of Iodine-<br />
131 Therapy in Patients with Thyroid Cancer<br />
Armaghan Fard-Esfahani, Saeed Farzanefar, Babak Fallahi, Davood<br />
Beiki, Mohammad Eftekhari, Mohsen Saghari, Alireza Emami<br />
Ardekani, Mina Majdi<br />
Tehran University of Medical Sciences<br />
Aim: 131I has been widely used in treatment of differentiated thyroid<br />
carcinoma for almost 70 years. During this period many<br />
complications such as sialadenitis and lacrimal gland dysfunction<br />
have been established. This study argues a new complication<br />
asymptomatic or asymptomatic nasolacrimal duct obstruction.<br />
Materials and Methods: 81 patients (162 eyes) treated with more<br />
than 100 mCi 131I were categorized in 4 groups based on received<br />
cumulative dose and were evaluated in a historical cohort study. In<br />
addition 17 (34 eyes) age and sex matched persons were selected as<br />
control group. Using dacroscintigraphy, patients and control group<br />
were evaluated for partial or complete nasolacrimal duct obstruction.<br />
The data on different groups of patients were compared with the data<br />
of control group. Fishers exact and Mann-Whitney U tests were<br />
applied for analyses of categorical and numeric variables,<br />
respectively. The analyses were considered significant with p
3rd International Congress of of Nuclear Medicine & & 15th 15th Iranian Annual Annual Congress of<br />
Congress of Nuclear Medicine<br />
Shahid Beheshti Shahid Beheshti University University of Medical of Medical Sciences Sciences 19-21 19-21 May May 2011<br />
Evaluation of the therapeutic efficacy of treatment with<br />
olanzapine on regional cerebral blood flow measured by<br />
SPECT in patients with schizophrenia; correlating with the<br />
response to treatment<br />
Babak Fallahi 1 , Davood Beiki 1 , Seyed Mohammad Assadi 2 , Homayoun<br />
Amini 2 , Armaghan Fard-Esfahani 1 , Mohammad Eftekhari 1 , Mohsen<br />
Saghari 1 , Farzaneh Pooyafard 2<br />
1 Research Institute for Nuclear Medicine<br />
2 Psychiatry and Psychology Research Center<br />
Background: Some studies investigated the relations between<br />
regional cerebral blood flow (rCBF), psychopathology, positive and<br />
negative symptoms of schizophrenia. Dopamine D2 blocking typical<br />
antipsychotic drugs, such as haloperidol, are known to change the<br />
cerebral perfusion patterns of schizophrenic patients. The aim of this<br />
study was to evaluate the rCBF of the schizophrenic patients treated<br />
with atypical antipsychotic, Olanzapine, in a within-subject design.<br />
Methods: Twenty-one patients with schizophrenia participated in the<br />
study. Each subject was scanned and assessed according to PANSS<br />
and CGI in a medication-free state and after 4 weeks of 15 mg/day<br />
fixed dose Olanzapine treatment. Also a group of 12 cases without<br />
any history of neurological or psychological disorder was enrolled as a<br />
control group for comparing of the SPECT data. The changes in<br />
pattern of regional perfusion were evaluated between control and<br />
patient subjects and also in the patients group before and after<br />
treatment. The correlation between clinical improvement and rCBF<br />
changes after treatment was also analyzed.<br />
Results: In different patients, hyperperfusion (mainly in the inferior<br />
prefrontal and temporal regions) as well as hypoperfused patterns<br />
(mainly in the cerebellar, parietal and dorsolateral prefrontal regions)<br />
were found. Most of the positive symptoms were correlated with<br />
hyperperfusion in frontal and temporal regions and several negative<br />
symptoms were correlated with hypoperfusion in these areas. A<br />
correlation was found between some symptom improvement and<br />
rCBF changes after treatment with Olanzapine. The magnitude of<br />
increased rCBF before treatment may be considered as a predictor of<br />
clinical improvement in positive symptoms after treatment. However<br />
such a result was not met for negative and psychopathological<br />
symptoms.<br />
Conclusion: Hyperperfusion in the frontal and temporal regions is<br />
mostly correlated with the magnitude of positive symptoms before<br />
treatment and also with the degree of improvement in such<br />
symptoms after Olanzapine treatment. SPECT data may be valuable<br />
to predict the patients response to treatment with Olanzapine.<br />
Keywords: Olanzapine, SPECT Brain Perfusion, Schizophrenia<br />
61
3rd International Congress 3rd International of Nuclear Congress Medicine of Nuclear & 15th Medicine Iranian Annual & 15th Iranian Congress Annual of<br />
Nuclear Congress Medicine of Nuclear Medicine<br />
Shahid Beheshti Shahid Beheshti University University of Medical Sciences of Medical 19-21 Sciences May 201119-21 May 2011<br />
A novel scintigraphic agent, 99mTc-UBI 29-41, to detect<br />
osteomyelitis<br />
Majid Assadi 1 , Katayoun Vahdat 2 , Iraj Nabipour 3 , Mohammad Reza<br />
Sehhat 1 , Fahimeh Hadavand 2 , Hamid Javadi 4 , Alireza Tavakoli 5 ,<br />
Jamshid Saberifard 1 , Mohammad Reza Kalantarhormozi 3<br />
1 The Persian Gulf Nuclear Medicine Research Center<br />
2 Department of Infectious Diseases<br />
3 Department of Endocrine and Metabolic Diseases<br />
4 Golestan Research Center of Gastroenterology and Hepatology (GRCGH)<br />
5 Department of Orthopedic Surgery<br />
Objective: The discrimination of bacterial infections from sterile<br />
inflammatory processes is of great importance in the management of<br />
inflammation. Currently available techniques cannot decisively<br />
address this issue. In this respect, antimicrobial peptide 99m Tcubiquicidin<br />
(UBI) 29-41 scans have been showing interesting results.<br />
The aim of this study was to determine 99m Tc-UBI scan accuracy in<br />
the detection of osteomyelitis and to compare it with 99m Tc-MDP<br />
scan and magnetic resonance imaging (MRI).<br />
Methods: Twenty patients (mean age=48.90 years) with suspected<br />
osteomyelitis were included in this study. After evaluation of each<br />
patient through history taking, physical examination, appropriate<br />
laboratory tests, and other processes including bone probing, wound<br />
culture, and plain film radiography (PFR), MRIs, 99m Tc-UBI scans,<br />
and 99m Tc-MDP scans were performed. For quantitative analysis,<br />
the mean count of abnormal to normal region (A/N) was calculated<br />
for images acquired at 15, 30, 45, 60, 120, and 240 min to obtain<br />
the most favorable time for imaging. The final diagnosis of<br />
osteomyelitis was made clinically, laboratorically, and<br />
radiographically.<br />
Results: In total, osteomyelitis was detected in the 99m Tc-UBI<br />
scans of 17 patients indicating 100% accuracy, compared with an<br />
accuracy of 90% for osteomyelitis detected in 3-phase bone scans.<br />
The maximum mean A/N was observed at 15 min after intravenous<br />
injection [median 1.91, interquartile range (1.54-2.94)]. MRI was<br />
performed in 12 cases only, with 75% accuracy. In addition, the A/N<br />
ratios for the 99m Tc-UBI scans were not significantly different<br />
between patients with or without Staphylococcus aureus growth on<br />
wound cultures.<br />
Conclusions: For fast imaging with high accuracy, 99mTc-UBI 29-41<br />
is a suitable choice for the detection of osteomyelitis.<br />
Keywords: Osteomyelitis; UBI scan; MRI<br />
62
3rd International Congress of of Nuclear Medicine & & 15th 15th Iranian Annual Annual Congress of<br />
Congress of Nuclear Medicine<br />
Shahid Beheshti Shahid Beheshti University University of Medical of Medical Sciences Sciences 19-21 19-21 May May 2011<br />
THE EFFECT OF BARIUM SULFATE IN REDUCTION OF SUB<br />
DIAPHRAGMATIC ACTIVITY IN MYOCARDIAL PERFUSION<br />
IMAGING<br />
Alireza Mehdizadeh, Farshid Gheisari, Mehrosadat Alavi<br />
Shiraz University of Medical Sciences, Nuclear Medicine Department<br />
Background: The aim of this study was to investigate the effect of<br />
barium sulfate in reduction of sub-diaphragmatic activity in<br />
technetium 99m sestamibi myocardial perfusion scan.<br />
Methods: This study included 15 patients (6 male, 9 female)<br />
randomly selected from whom referred for 2 days rest-stress Tc-99m<br />
myocardial perfusion scan. All patients underwent stress phase of<br />
scan , after stress phase a planar static scan(for 5 min) from<br />
abdominal area of patients obtained, after that all patients were<br />
given 80 gr of barium sulfate , solved in 200 cc water , with 100 cc<br />
room temperature water and second planar static scan(for 5 min)<br />
obtained from them. The effect of barium sulfate on sub cardiac<br />
activity was evaluated both visually and quantitatively. After<br />
obtaining two planar static images, an area of about 1404 pixels<br />
(mean 1404.06 pixels) in left upper quadrant of abdomen, adjacent<br />
to inferior wall of heart in gastric area was selected in both images in<br />
same area of selection.<br />
Results: There was a significant reduction in the sub cardiac count<br />
per pixel in barium group compared to control group (p value <<br />
0.001).<br />
Conclusion: The findings indicate that filling of the stomach with<br />
barium sulfate, as a low price, safe and worldwide available oral<br />
contrast, resulted in an improvement in the image quality by<br />
decreasing the adjacent gut activity.<br />
Keywords: Myocardial perfusion, Barium sulfate, Sub-diaphragmatic<br />
63
3rd International Congress 3rd International of Nuclear Congress Medicine of Nuclear & 15th Medicine Iranian Annual & 15th Iranian Congress Annual of<br />
Nuclear Congress Medicine of Nuclear Medicine<br />
Shahid Beheshti Shahid Beheshti University University of Medical Sciences of Medical 19-21 Sciences May 201119-21 May 2011<br />
TREATMENT OF DIFFERENTIATED THYROID CARCINOMA,<br />
CONTROVERSIES AND CHALLENGES<br />
M. Eftekhri 1 , S. Farzanefar 2 , B. Fallahi 1 , A. Fard Esfahani 1 , D. Beiki 1 , J.<br />
Esmaili 2 , A. Emami Ardekani 1 , S. Izadyar 2 M. Saghari 1<br />
1 Research Institute for Nuclear Medicine, Tehran University Of Medical Sciences<br />
2 Vali Asr Hospital, Tehran University Of Medical Sciences<br />
Thyroid cancer is a common endocrine malignancy. Despite long term<br />
experience concerning diagnosis and treatment of differentiated<br />
thyroid carcinoma especially more than 70 years experience with I-<br />
131 therapy, still controversies exist regarding appropriate diagnosis,<br />
treatment methods and follow up. Growing advances in technology<br />
including molecular imaging and introduction of new methods for<br />
tumor detection and dosimetry help the caring physicians for optimal<br />
individualized therapy. Type of surgical approach, staging methods,<br />
benefits of I-131 ablation depending on tumor size, ablation dosage,<br />
optimal method for replacement therapy and follow up by serological<br />
and/or different imaging modalities still remain controversial. Other<br />
issues such as low ablative dose of I-131, follow up according to<br />
thyroglobulin level, and radioiodine whole body scan, long term side<br />
effects and possibility of second malignancies need well controlled<br />
studies and clarification. In this presentation these issues and our<br />
own experience at research institute for nuclear medicine Tehran<br />
University of Medical Sciences specially concerns regarding response<br />
versus adverse effects of I-131 are discussed.<br />
Keywords: DTC, Treatment, Radoiodine, Thyroglobulin<br />
64
3rd International Congress of of Nuclear Medicine & & 15th 15th Iranian Annual Annual Congress of<br />
Congress of Nuclear Medicine<br />
Shahid Beheshti Shahid Beheshti University University of Medical of Medical Sciences Sciences 19-21 19-21 May May 2011<br />
Radionuclide Cisternography In Diagnosis & Management of<br />
NPH<br />
Shahram Seifollahi Asl<br />
Arad Hospital<br />
Cerebrospinal fluid (CSF) flow & dynamic study using radionuclide<br />
cisternography has been used from 1964 to diagnosis a site of CSF<br />
leak to determine shunt patency & to diagnosis & management of<br />
communicating hydrocephalus & particularly normal pressure<br />
hydrocephalus (NPH). For the evaluation of the latter, CT & MRI<br />
primarily image anatomy & not CSF dynamic, although special<br />
sequences in MRI & gated MRI are being evaluated in assessing CSF<br />
flow. In current nuclear medicine practice, radionuclide<br />
cisternography is complementary to CT/MRI & can still play an<br />
important role because of the unique physiologic information it<br />
provides.<br />
This lecture will focus on normal physiologic finding of radionuclide<br />
cisternography & different patterns in some types of hydrocephalus<br />
particularly NPH & explain its role in diagnosis & management of the<br />
latter as a possible treatable type of dementia.<br />
65
3rd International Congress 3rd International of Nuclear Congress Medicine of Nuclear & 15th Medicine Iranian Annual & 15th Iranian Congress Annual of<br />
Nuclear Congress Medicine of Nuclear Medicine<br />
Shahid Beheshti Shahid Beheshti University University of Medical Sciences of Medical 19-21 Sciences May 201119-21 May 2011<br />
Normal Pressure Hydrocephalus and Dementia<br />
A. Shoja’ee<br />
NPH is a state of chronic hydrocephalus in which the CSF pressure is<br />
in physiologic range, but a slight pressure gradient persists between<br />
the ventricles and the brain. There is ventriculomegaly without a rise<br />
in intracranial pressure (ICT) as a result of insidious obstruction of<br />
the CSF circulation due to subarchnoid block. The NPH syndrome has<br />
continued to present many questions with regard to the most reliable<br />
diagnostic and prognostic factors. In addition the high rate of<br />
complications associated with shunting makes treatment highly<br />
controversial.<br />
In these topics the considered etiologic suggestions, the<br />
pathophysiologics points, the differential diagnosis, the new steps of<br />
clinical investigations, and method of managements are discussed.<br />
66
3rd International Congress of of Nuclear Medicine & & 15th 15th Iranian Annual Annual Congress of<br />
Congress of Nuclear Medicine<br />
Shahid Beheshti Shahid Beheshti University University of Medical of Medical Sciences Sciences 19-21 19-21 May May 2011<br />
The role of nuclear medicine in the diagnosis of infected joint<br />
prostheses<br />
K. Aryana<br />
Nuclear Medicine Department, Mashhad University of Medical Sciences<br />
Some complications of joint replacement surgery are easily<br />
diagnosed; however, differentiating infection from aseptic loosening<br />
is difficult because these entities are remarkably similar at clinical<br />
and histopathologic examination. Clinical signs and symptoms,<br />
laboratory tests, radiography, and joint aspiration are insensitive,<br />
nonspecic, or both. Cross-sectional imaging modalities are<br />
hampered by artifacts produced by the prosthetic devices<br />
themselves. Radionuclide imaging is not affected by the presence of<br />
metallic hardware and is therefore useful for evaluating the painful<br />
prosthesis. Bone scintigraphy is useful as a screening test, despite an<br />
accuracy of only 50%–70%, because normal results essentially<br />
exclude a prosthetic complication. The addition of gallium-67, a<br />
nonspecic inammation-imaging agent, improves the accuracy of<br />
bone scintigraphy to 70%– 80%. The accuracy of combined<br />
leukocyte-marrow imaging, 90%, is the highest among available<br />
radionuclide studies. Its success is due to the fact that leukocyte<br />
imaging is most sensitive for detection of neutrophil-mediated<br />
inammation . The success of leukocyte-marrow imaging is tempered<br />
by the limitations of in vitro labeling. In vivo labeling has been<br />
investigated, and a murine monoclonal antigranulocyte antibody<br />
appears promising. Ubiquicidin (UBI) 29–41 is a small synthetic<br />
antimicrobial cationic peptide that binds preferentially to the anionic<br />
present on microbial cell membrane at the site of infection is highly<br />
sensitive and specific for differentiating of infected prosthesis from<br />
loosening. Tc99m-ciprofloxacin (Infecton) has recently been<br />
established as a new radiopharmaceutical for infection imaging.<br />
Infecton has a sensitivity of 85%, specificity of 92%, and accuracy of<br />
88% in detecting orthopaedic infections compared with 78%, 100%,<br />
and 90% respectively for combined bone and gallium imaging. Some<br />
investigations have focused on uorodeoxyglucose imaging. Although<br />
this method is sensitive, specicity is a concern<br />
67
3rd International Congress 3rd International of Nuclear Congress Medicine of Nuclear & 15th Medicine Iranian Annual & 15th Iranian Congress Annual of<br />
Nuclear Congress Medicine of Nuclear Medicine<br />
Shahid Beheshti Shahid Beheshti University University of Medical Sciences of Medical 19-21 Sciences May 201119-21 May 2011<br />
Imaging Informatics & Nuclear Medicine<br />
Mansoor Fatehi<br />
Iranian Society of Radiology<br />
In a trend toward film-less medical practice, digital management of<br />
nuclear medicine images is becoming a major concern while there are<br />
few exceptional characteristics for handling nuclear medicine images<br />
compared to radiological ones. Specially after availability of PET/CT<br />
with its inherent data-overload, PACS is becoming part of any nuclear<br />
medicine department. Multiplanar and 3D reformatted images are<br />
frequently used in the practice of nuclear medicine. Image fusion is<br />
also a main area of research in nuclear medicine which relies on<br />
digital format of the images. Recently computer-aided diagnosis has<br />
become available in nuclear medicine as well. Electronic reporting<br />
options including structured reporting and voice recognition are other<br />
important areas of concern in imaging informatics for nuclear<br />
medicine<br />
departments.<br />
The purpose of this presentation is to introduce potential applications<br />
of imaging informatics in the practice of nuclear medicine and<br />
emphasize on specific differences between digital management of<br />
nuclear medicne images compared to radiological information.<br />
68
3rd International Congress of of Nuclear Medicine & & 15th 15th Iranian Annual Annual Congress of<br />
Congress of Nuclear Medicine<br />
Shahid Beheshti Shahid Beheshti University University of Medical of Medical Sciences Sciences 19-21 19-21 May May 2011<br />
Evidence Based Decision Making for Musculoskeletal Imaging:<br />
The Role of Scintigraphy<br />
Mansoor Fatehi<br />
Iranian Society of Radiology<br />
Currently, the most comprehensive resource for evidence-based<br />
imaging which means making the best decisions relying on sound<br />
research findings, are Appropriateness Criteria of American College of<br />
Radiology. Above 180 clinical conditions are defined where all<br />
potential imaging options are scored according to the literature by<br />
committees consisting of well-known experts of imaging and<br />
clinicians in that specific field. The scores are given from 1 to 9 where<br />
1 stands for always inappropriate and 9 stands for always appropriate<br />
imaging in each specific clinical condition.<br />
The purpose of this presentation is to overview selection criteria for<br />
imaging of musculoskeletal clinical conditions including scintigraphic<br />
studies. In this presentation we will explore where scintigraphic<br />
studies stand among other imaging options and the audience will be<br />
aware of the most appropriate imaging in each clinical condition if it<br />
is not a scintigraphic exam.<br />
69
3rd International Congress 3rd International of Nuclear Congress Medicine of Nuclear & 15th Medicine Iranian Annual & 15th Iranian Congress Annual of<br />
Nuclear Congress Medicine of Nuclear Medicine<br />
Shahid Beheshti Shahid Beheshti University University of Medical Sciences of Medical 19-21 Sciences May 201119-21 May 2011<br />
Update of V/Q Scan in Diagnosis of Pulmonary<br />
Thromboembolism<br />
Elahe Pirayesh<br />
Shahid Beheshti University of Medical Science, Shohada e Tajrish Hospital,<br />
Nuclear Medicine Department<br />
Perfusion-ventilation (V/Q) scintigraphy was introduced in 1964 and<br />
for several decades it was the only widely available method in<br />
imaging patients with suspected PE. The development of helical CT in<br />
the early 1990s provides a new means of imaging. Advanced<br />
technology of multidetector CT angiography (MDCTA) improved the<br />
ability of CT to depict small and subsegmental emboli. In view of<br />
increasing competition of CTA with V/Q scan, modernization of the<br />
conventional V/Q lung scan seems essential. V/Q SPECT as a mature<br />
technique has been shown to be obviously superior to planar V/Q in<br />
diagnosis of PTE. It is also associated a lower number of inconclusive<br />
reports; without limitations of CTA, including high radiation dose,<br />
pregnancy, renal failure and contrast allergy. Comparing MDCTA and<br />
V/Q scan also show equal sensitivity, specificity and accuracy of two<br />
techniques. So, many authors believe the enormous increase in the<br />
number of MDCTA must be reversed; not only because of<br />
unacceptably high radiation exposure, but also because of erroneous<br />
belief that it is a superior diagnostic tool as compared with V/Q<br />
SPECT imaging.<br />
SPECT/CT combines the high sensitivity of SPECT with the high<br />
specificity of CTPA and improves the diagnostic accuracy. SPECT/CT<br />
image fusion may be useful in cases of inconclusive CTPA imaging.<br />
Probabilistic interpretation of V/Q SPECT is also should be replaced by<br />
a holistic interpretation strategy on the basis of all relevant<br />
information about the patient.<br />
Keyword: perfusion ventilation scan, PTE, SPECT<br />
70
3rd International Congress of of Nuclear Medicine & & 15th 15th Iranian Annual Annual Congress of<br />
Congress of Nuclear Medicine<br />
Shahid Beheshti Shahid Beheshti University University of Medical of Medical Sciences Sciences 19-21 19-21 May May 2011<br />
Preliminary Imaging Studies of [61Cu] diacetyl-bis (N4-<br />
methylthiosemicarbazone)<br />
Amir Reza Jalilian, Hasan Yousefnia, Mohsen Kamali-dehghan,<br />
Sedigheh Moradkhani, Fatemeh Bolourinovin, Kamaleddin Shafaii,<br />
Gholamreza Aslani<br />
Nuclear science and technology research institute<br />
[61Cu] diacetyl-bis (N4-methylthiosemicarbazone) ([61Cu] ATSM) is<br />
a well-established hypoxia imaging tracer with simple production and<br />
significant specificity. In this work the accumulation of the tracer is<br />
studied in wild-type, necrotic and hypoxic fibrosarcoma tumors.<br />
[61Cu]ATSM was prepared using ATSM ligand and [61Cu]CuOAc<br />
followed by i.v. administration and imaging studies in wild-type rats<br />
and hypoxic fibrosarcoma-bearing mice.[61Cu]ATSM with high<br />
radiochemical purity (>99%, HPLC, RTLC) was injected to wild-type<br />
rats as well as hypoxic and necrotic fibrosarcoma-bearing mice<br />
followed by imaging up to 3 hours.[61Cu]ATSM was mainly<br />
accumulated in liver, as well as kidney and bladder and less but still<br />
significant in brain of wild-type rats. A significant and hypoxia-specific<br />
tumor/non tumor ratio in hypoxic models was observed by coincidence<br />
imaging 2 h post injection, while in necrotic and 12-week<br />
tumor-induced mice very slight tumor uptakes were detected.<br />
[61Cu]ATSM is a positron emission tomography (PET) radiotracer for<br />
selective tumor hypoxia imaging from necrotic and proliferative<br />
tumors.<br />
Keywords: [61Cu] ATSM, Hypoxia, Co-incidence imaging,<br />
Fibrosarcoma<br />
71
3rd International Congress 3rd International of Nuclear Congress Medicine of Nuclear & 15th Medicine Iranian Annual & 15th Iranian Congress Annual of<br />
Nuclear Congress Medicine of Nuclear Medicine<br />
Shahid Beheshti Shahid Beheshti University University of Medical Sciences of Medical 19-21 Sciences May 201119-21 May 2011<br />
Synthesis and Quality Control of 186Re-Sulphur Colloids as a<br />
Radiation Synovectomy Agent and its Biodistribution Studies<br />
in Rats<br />
M.R. Davarpanah, B.A. Kalantari, R. Nickzad, M. Ghannadi Maragheh,<br />
M. Erfani (Gandomkar), M. Mazidi, H. Mirfallah<br />
Nuclear Science and Technology Research Institute<br />
Introduction: One therapeutic approach to rheumatoid arthritis<br />
besides surgical removal is radiation synovectomy using betaemitting<br />
radionuclide to destroy the inflamed synovial tissue.<br />
Recently, rhenium radioisotopes have been paid attention more.<br />
186Re sulfur colloid is used for ablation of small and medium<br />
inflamed joints.<br />
Purpose: Our goal is 186Re sulfur colloid synthesis, fulfilling<br />
qualification control tests and biodistribution studies of this colloid.<br />
Methods: After 186Re sulfur colloid synthesis using acidic reduction<br />
of sodium thiosulfate in presence of perrhenate, below qualification<br />
control testes were implemented: a) Radiochemical purity: this factor<br />
was calculated with TLC (solvent: acetone) and measuring one third<br />
TLC paper activity (RF=1/3). b) Particle size: using optical<br />
microscope equipped with Motic Images plus 2.0 software we<br />
obtained a good estimation of particle size range. c) Toxicity studies:<br />
with inoculating synthesized sample in microorganism growth<br />
medium and successive studies this study was performed. d) In vitro<br />
stability: up to 5 days radiochemical purity and particle size were<br />
measured. In addition, animal studies were implemented with<br />
measuring activity of organs of rats been knees injected and killed<br />
within 4 days.<br />
Results: Qualification control tests showed a) radiochemical purity<br />
more than 99%, b) more than 95% colloids particles lied in the range<br />
of 1-5ï m, c) no toxicity and d) colloid was stable to 5 days out of<br />
living tissue. In addition, more than 90% of colloid activity was<br />
adsorbed in knee joints to four days.<br />
Conclusion: Because of a) gamma rays emitting, b) suitable half-life<br />
and beta energy and c) preventing leakage to other organs by<br />
particle size controlling 186Re sulfur colloid is a good alternative as a<br />
radiosynovectomy agent for small and medium joints.<br />
Keywords: 186Re-Sulfur Colloids, Radiation Synovectomy<br />
72
3rd International Congress of of Nuclear Medicine & & 15th 15th Iranian Annual Annual Congress of<br />
Congress of Nuclear Medicine<br />
Shahid Beheshti Shahid Beheshti University University of Medical of Medical Sciences Sciences 19-21 19-21 May May 2011<br />
Production and biodistribution studies of 64Cu-DOTAtrastuzumab<br />
as a diagnostic positron emitter<br />
radioimmunoconjugate for oncology molecular imaging<br />
Behrooz Alirezapour 1 , Amir Reza Jalilian 2 , Mohammad Javad Rasaee 1 ,<br />
Saeed Rajabifar 2 , Kamal Yavari 2 , Mohsen Kamalidehghan 2 , Fatemeh<br />
Bolourinovin 2 , Sedighe Moradkhani 2 , Hamid Zolata 2<br />
1 Tarbiat Modares University(TMU)<br />
2 Nuclear Science and Technology Research Institute (NSTRI)<br />
Introduction: Radiolabeled monoclonal antibodies have shown great<br />
promise for cancer diagnosis and therapy. Trastuzumab (trade name;<br />
Herceptin) is a humanized IgG1 monoclonal antibody directed against<br />
the extracellular domain of the Human Epidermal Growth Factor<br />
Receptor 2(HER2). HER 2 receptor is over expressed in 20-30% of<br />
the early-stage breast cancers and these patients may be candidates<br />
for Herceptin treatment. 64Cu (β= 17%, -β = 39%, EC = 43%) is an<br />
important emerging biomedical radionuclide that is suitable for<br />
labeling a wide range of radiopharmaceuticals for PET imaging. Its<br />
intermediate half-life (12.7 h) permits PET evaluation of slow<br />
biochemical pathways, such as protein and peptide interactions with<br />
cellular targets, and distribution to satellite imaging and therapy<br />
centers. In the present study, copper-64 labeled trastuzumab was<br />
prepared followed by the biodistribution studies in normal mice.<br />
Methods: Herceptin was conjugated with DOTA-NHS-ester<br />
(Macrocyclics), purified by molecular filtration, the average number of<br />
DOTA conjugated per mAb was calculated and total concentration<br />
was determined by spectrophotometrically. DOTA-Trastuzumab was<br />
labeled with 64Cu then Radiochemical purity, integrity of protein after<br />
radiolabeling and stability of 64Cu-DOTA-Trastuzumab were<br />
determined. The biodistribution study was performed in normal mice<br />
(64Cu-DOTA-Trastuzumab i.v., 30 ± 5.5 µCi, 2h, 6h, 12h,18h).<br />
Result: The radioimmunoconjugate was prepared with a<br />
radiochemical purity of 84% (RTLC). The average chelate to antibody<br />
ratio (c/a) for the conjugate used in this study was 5.8:1. The final<br />
compound was stable in presence of PBS at 37ºC and room<br />
temperature. The sample were showed to have similar patterns of<br />
migration in the gel electrophoresis.The accumulation of the<br />
radiolabeled antibody in lungs, liver, spleen and other tissues<br />
demonstrates a similar pattern to the other radiolabeled anti-HER2<br />
immunoconjugates.<br />
Conclusion: 64Cu-DOTA-Trastuzumab is a potential compound for<br />
molecular imaging of PET for diagnosis and treatment studies and<br />
follows up of HER2 expression in oncology.<br />
Keywords: 64Cu DOTA Trastuzumab, Radioimmunoconjugate<br />
Imaging<br />
73
3rd International Congress 3rd International of Nuclear Congress Medicine of Nuclear & 15th Medicine Iranian Annual & 15th Iranian Congress Annual of<br />
Nuclear Congress Medicine of Nuclear Medicine<br />
Shahid Beheshti Shahid Beheshti University University of Medical Sciences of Medical 19-21 Sciences May 201119-21 May 2011<br />
Production, quality control and biological evaluation of 177Lu-<br />
TTHMP as a possible bone palliation agent<br />
Hassan Yousefnia, Amir Reza Jalilian, Samaneh Zolghadri, Zohreh<br />
Naseri, Ali Bahrami-Samani, Mohammad Ghannadi Maragheh<br />
Nuclear Science and Technology Research Institute<br />
In this study, production, quality control and biodistribution studies of<br />
a newly developed therapeutic compound have been presented<br />
followed by imaging studies in wild-type rodents. In this study,<br />
177Lu-TTHMP complex was prepared successfully using synthesized<br />
TTHMP ligand and 177LuCl3. Lu-177 chloride was obtained by<br />
thermal neutron irradiation (4 x 1013 n.cm-2s-1) of natural Lu2O3<br />
samples. Radiochemical purity of 177Lu-TTHMP was checked by ITLC<br />
(>99%). Stability studies of the complex in the final preparation and<br />
in the presence of human serum were performed up to 72h. The<br />
biodistribution of 177Lu-TTHMP and 177LuCl3 in wild-type rats was<br />
checked in animal tissues up to 7 days. The produced 177Lu-TTHMP<br />
properties suggest a possible new bone palliative therapeutic to<br />
overcome the metastatic bone pains.<br />
Keywords: Lu-177, TTHMP, Radiopharmaceutical, Therapy,<br />
Biodistribution<br />
74
3rd International Congress of of Nuclear Medicine & & 15th 15th Iranian Annual Annual Congress of<br />
Congress of Nuclear Medicine<br />
Shahid Beheshti Shahid Beheshti University University of Medical of Medical Sciences Sciences 19-21 19-21 May May 2011<br />
Synthesis and evaluation of 99mTc-carbonyl phenyl piperazin<br />
dithiocarbamate as a 5-HT receptor imaging<br />
Mostafa Erfani(Gandomkar) 1 , Leila Hassanzadeh 2 , Seyed Esmaeil<br />
Sadat Ebrahimi 2 , Reza Najafi 1<br />
1 Nuclear Science Research School<br />
2 Department of Medicinal Chemistry<br />
Introduction: serotonin receptors are associated with a variety of<br />
neuropsychiatric disorder such as anxiety, depression, schizophrenia,<br />
and Alzheimer disease. There is a considerable interest in developing<br />
new 99mTc radiopharmaceuticals for imaging central neural system<br />
receptors by using single photon emission computer tomography. The<br />
goal of this study was to develop a novel 5-HT receptor imaging<br />
agent.<br />
Method: Phenyl piperazin dithiocarbamate was synthesized in the<br />
presence of potassium hydroxide. The desired structure was<br />
confirmed by IR and NMR analysis. 99mTc tricarbonyl precursor was<br />
prepared and the labeling conditions were optimized in the aspect of<br />
pH, reaction temperature, reaction time and the amount of ligand.<br />
The final complex was obtained with high yield following the optimal<br />
labeling procedure. The radiochemical purity of intermediate and final<br />
complex were evaluated by ITLC and HPLC methods. Stability in<br />
human serum, octanol/water partition coefficient and in vivo<br />
biodistribution study of labeled compound in rat were carried out.<br />
Results: Synthesized compound was labeled with 99mTc-tricarbonyl<br />
core in high yield (>%90 by HPLC). The labeled compound was a<br />
lipophilic complex, which was confirmed by octanol/water partition<br />
coefficient (P = 2.50). In vivo biodistribution indicated that this<br />
complex had moderate brain uptake (0.47 %ID/g at 5 min and 0.42<br />
%ID/g at 30 min). The labeled compound was stable up to 6h in<br />
saline.<br />
Conclusion: This result indicates that labeled complex has brain<br />
uptake and also has binding to receptor. Improvement of this<br />
compound needs further ligand modification to obtain an ideal brain<br />
receptor imaging agent.<br />
Keywords: carbonyl, 5-HT, imaging agent<br />
75
3rd International Congress 3rd International of Nuclear Congress Medicine of Nuclear & 15th Medicine Iranian Annual & 15th Iranian Congress Annual of<br />
Nuclear Congress Medicine of Nuclear Medicine<br />
Shahid Beheshti Shahid Beheshti University University of Medical Sciences of Medical 19-21 Sciences May 201119-21 May 2011<br />
Production and Labeling of Holmium-166 via DOTMP: A<br />
Promising Agent for Bone Marrow Ablation in Multiple<br />
Myeloma<br />
Reza Bagheri 1 , Ali Bahrami-Samani 2 , Mohammad Mazidi 2 , Amir Reza<br />
Jalilian 2 , Mohammad Ghannadi-Maragheh 2<br />
1 Faculty of Nuclear Engineering and Physics<br />
2 Radiopharmaceutical Research and Development Lab (RRDL)<br />
Introduction: Therapeutic radiopharmaceuticals are radiolabeled<br />
molecules to deliver sufficient doses of ionizing radiation to specific<br />
disease sites such as bone metastases, brain and liver tumors and<br />
bone marrows in multiple myeloma. Among some therapeutic<br />
radiopharmaceuticals, 166Ho - 1,4,7,10 tetraazacyclo dodecane<br />
1,4,7,10 tetraethylene phosphonic acid (166Ho-DOTMP) is used for<br />
delivering high doses to bone marrow.<br />
Methods: In this research production, quality control,<br />
pharmacokinetics and biodistribution studies of 166Ho-DOTMP with<br />
respect to its radiochemical and in-vivo biological characteristics have<br />
been presented. Holmium-166 was produced by irradiation of<br />
Holmium oxide (Ho2O3, purity > 99.8%) at a thermal neutron flux.<br />
This radionuclide was labeled at room temperature and<br />
Radiochemical purity of 166Ho-DOTMP was checked by ITLC.<br />
Results: 166Ho produced by irradiation of Holmium-165 oxide<br />
demonstrated high radionuclide purity. 166Ho-DOTMP complex was<br />
obtained in very high yields (radiochemical purity > 99%) under the<br />
reaction conditions employed. This complex exhibited excellent invitro<br />
stability at pH~7 when stored at room temperature and human<br />
serum.<br />
Conclusion: Wild tape rats were used for biodistribution and imaging<br />
studies of this agent. Biodistribution studies in rats showed favorable<br />
selective skeletal uptake with rapid clearance from blood along with<br />
insignificant accumulation of activity in any non-target organ or<br />
tissues. This warrants the detailed evaluation of the agent for bone<br />
marrow ablation in multiple myeloma by injection of high activity of<br />
radiopharmaceutical per kg of patient body.<br />
Keywords: 166Ho-DOTMP, Biodistribution, radiopharmaceutical,<br />
pharmacokinetics<br />
76
3rd International Congress of of Nuclear Medicine & & 15th 15th Iranian Annual Annual Congress of<br />
Congress of Nuclear Medicine<br />
Shahid Beheshti Shahid Beheshti University University of Medical of Medical Sciences Sciences 19-21 19-21 May May 2011<br />
In vivo tracking of 111In-Oxine Labeled Mesenchymal Stem<br />
Cells Following Infusion in Patients with Advanced Cirrhosis<br />
Sahar Mirpour 1 , Ali Gholamrezanezhad 1 , Mohammad Bagheri 2 , Mehdi<br />
Mohamadnejad 2 , Kamran Alimoghadam 3 , Reza Malekzadeh 2 , Mohsen<br />
Saghari 1 , Nader Ahmadin 1 , Maryam Bashtar 3<br />
1 Tehran University of Medical Science, Research Institute for Nuclear Medicine<br />
2 Tehran University of Medical Science, Digestive Diseases Research Center<br />
3 Tehran University of Medical Science, Department of Hematology<br />
Background: So far progress from the use of both in-vitro and invivo<br />
regenerative medicine models already offers hope for the use of<br />
stem-cells as powerful new therapeutic option for different human<br />
diseases. We initiated a pilot study on human to evaluate stem-cell<br />
bio-distribution after peripheral infusion of mesenchymal stem-cells<br />
(MSCs) in patients with cirrhosis.<br />
Methods: After three passages of MSCs, the first patient (F,62y/o)<br />
received a total of 270x106cells and the second one(M,17y/o) was<br />
infused with 290x106cells. In both patients only 50% of cells were<br />
labeled with 111In-Oxine.A specific activity of 0.67MBq/106 cells and<br />
0.71MBq/106 cells were maintained for the injected labeled cells of<br />
the first and second patients, respectively. The labeling-efficiency<br />
was 36.2% for the cells injected to the first patient and 38.8% for the<br />
second patient. Planar whole body acquisitions(anterior/posterior<br />
projections)were acquired immediately following infusion as well as at<br />
2h,4h,6h,24h,48h, 7th and 10th days after stem-cell infusion. The<br />
SPECT images were obtained at 24th hour post-infusion.<br />
Results: Immediately after I.V. infusion, the radioactivity (labeled-<br />
MSCs) was first observed to accumulate in the lungs, and gradually<br />
shifted to the liver and spleen during the following hours to days. On<br />
SPECT images of the 24th hour, the activity distribution was rather<br />
homogenous throughout the livers and enlarged spleens. Region of<br />
Interest(ROI)analysis in the first patient showed that the percentage<br />
of the homing of the cells into the liver (following decay and<br />
background correction and geometric mean calculation) to be 2.8%,<br />
4.1%,4.1%,4.3%,4.7%,12% and13.5% at 2h,4h,6h,24h,48h,7th and<br />
10th days. The respective values for the second patient were 0%,<br />
3.6%, 3.6%, 3.9%, 4%, 11% and 13%. The residual<br />
activities(labeled MSCs) in the spleen of first patient were<br />
2%,3%,3%,4%,5%,21% and 30% in the previously-mentioned time<br />
points and were 2.5%, 4%, 5%, 7%, 9%, 14% and 42%, for the<br />
second one, respectively.<br />
Conclusion: The infusion of stem cell throughout a peripheral vein is<br />
a safe and feasible alternative route of administration for possible<br />
regenerative treatment of patients with cirrhosis. Also, cell labeling<br />
with 111In-Oxine is a suitable method for following-up of cell<br />
distribution after infusion. Regarding the previous studies in noncirrhotic<br />
patients, the bio-distribution of MSCs in patients with liver<br />
cirrhosis is altered significantly (with decreased hepatic and almost<br />
77
3rd International Congress 3rd International of Nuclear Congress Medicine of Nuclear & 15th Medicine Iranian Annual & 15th Iranian Congress Annual of<br />
Nuclear Congress Medicine of Nuclear Medicine<br />
Shahid Beheshti Shahid Beheshti University University of Medical Sciences of Medical 19-21 Sciences May 201119-21 May 2011<br />
increased splenic homing) and hence, these alterations should be<br />
considered in predicting the therapeutic efficacy of stem cell infusion,<br />
when intravenous (systemic) route of administration is employed.<br />
Keywords: 111In-Oxine, Mesenchymal Stem Cell, Cirrhosis<br />
78
3rd International Congress of of Nuclear Medicine & & 15th 15th Iranian Annual Annual Congress of<br />
Congress of Nuclear Medicine<br />
Shahid Beheshti Shahid Beheshti University University of Medical of Medical Sciences Sciences 19-21 19-21 May May 2011<br />
Freeze-Dried cold Kit for Preparation of 99mTc-Ciprofloxacin<br />
as an Infection Imaging Agent<br />
Seyedeh Fatemeh Mirshojaei, Mostafa Erfani (Gandomkar), Mostafa<br />
Goudarzi<br />
Atomic Energy Organization of Iran<br />
Introduction: Radiolabeled antibiotics are being used for the specific<br />
diagnosis of infection by exploiting their specific binding properties to<br />
the bacterial components, thereby making it possible to differentiate<br />
infection from sterile lesions.99mTc-ciprofloxacin is the most widely<br />
used infection imaging agent. The aim of this work was to prepare a<br />
kit of 99mTc-ciprofloxacin with stability and biological activity<br />
preserved, able to identify a septic focous (E-coli) in the experimental<br />
infection model in mice.<br />
Methods: In this paper, different factors were investigated to make<br />
the ciprofloxacin kit. Kits were stored at the temperature of 4ºC<br />
under vacuum and evaluated for stability by estimating the<br />
radiochemical purity using instant thin layer chromatography (ITLC)<br />
following reconstitution with pertechnetate (99mTc) at regular<br />
intervals of time up to 75 days after their production date. The kit<br />
was reconstituted with 99mTc at room temperature and incubation<br />
time of 15 min. The kit stability and affinity to human serum was<br />
challenged for 24 hours and its in vitro binding to bacteria was<br />
assessed. Biodistribution and accumulation of labeled compound in<br />
staphylococcus aureus infected mice were studied using Scintigraphic<br />
methods and ex vivo counting. About 75% of the activity binds to the<br />
plasma proteins and the ratio of infected muscle to non-infected<br />
muscle is 3.2 and 1.8, 1h and 4 hours post injection.<br />
Results: Radiolabeling was performed in an easy way, and<br />
radiochemical purity was >90±4 %. The stability of radiolabeled<br />
antibiotic in human serum was 84.2% 1 h post incubation with<br />
human serum. In-vitro studies showed 75 % of radioactivity was<br />
bound to bacteria. After injection into mice with a bacterial infection,<br />
removing from the circulation occurred mainly by biliary-renal<br />
clearance and site of infection was rapidly detected within 30 min.<br />
Target to non-target muscle ratio was 3.23 ± 0.05 % at 30 min post<br />
injection.<br />
Conclusion: 99mTc-ciprofloxacin showed favorable radiochemical<br />
and biological characteristics which permitted detection of the<br />
infection with optimal visualization.<br />
Keywords: 99mTc-ciprofloxacin, infection imaging, kit preparation<br />
79
3rd International Congress 3rd International of Nuclear Congress Medicine of Nuclear & 15th Medicine Iranian Annual & 15th Iranian Congress Annual of<br />
Nuclear Congress Medicine of Nuclear Medicine<br />
Shahid Beheshti Shahid Beheshti University University of Medical Sciences of Medical 19-21 Sciences May 201119-21 May 2011<br />
Radiolabeled Affibody molecules as novel class of tumor<br />
targeted peptides for imaging and therapy<br />
Seyed Jalal Hosseinimehr 1 , Anna Orlova 2 , Vladimir Tolmachev 2 ,<br />
1 Department of Radiopharmacy<br />
2 Division of Biomedical Radiation Sciences, Uppsala, Sweden<br />
Affibody molecules are small, very stable, 58-amino acid residue<br />
proteins derived from one of the IgG-binding domains of<br />
staphylococcal protein A with the three-helix bundle structure.<br />
Affibody molecules with small size (7 kDa) have rapid tumor<br />
localization with fast clearance from nonspecific tissues. Affibody<br />
molecules can bind to HER2, IGF-1R and EGFR with high affinity. With<br />
these advantages, Affibody molecules are interesting as tumor<br />
targeted peptide for nuclear medicine. Another advantage of Affibody<br />
molecules is that they can be labeled with different radionuclides<br />
such as gamma- and beta- emitters for imaging and therapy.<br />
Recently, our research team prepared radiolabeled Affibody molecule<br />
for tumor imaging with 99mTc and 111In. These radiolabeled<br />
peptides showed excellent specific binding in vitro. Tumor bearing<br />
mice imaging showed a high contrast imaging with tumor localization.<br />
Affibody molecules can be labeled with beta emitters, such as 177Lu<br />
or 186Re, and used a therapeutic agents. Recently, we have evaluate<br />
a series of peptide-based chelators for 99mTc (and potentially for<br />
186/188 Re), which can be incorporated a C-orN-terminus of Affibody<br />
molecules. We have shown that modification of amino acids in such<br />
chelators enables modification of biodistribution of Affibody<br />
molecules.<br />
Keywords: Affibody, molecules imaging, 99mTc<br />
80
3rd International Congress of of Nuclear Medicine & & 15th 15th Iranian Annual Annual Congress of<br />
Congress of Nuclear Medicine<br />
Shahid Beheshti Shahid Beheshti University University of Medical of Medical Sciences Sciences 19-21 19-21 May May 2011<br />
Synthesis and labeling of a new bombesin analogue with 67Ga<br />
for imaging of BBN receptors<br />
Seyed Pezhman Shirmardi, Mostafa Erfani (Gandomkar), Mohammad<br />
Ghannadi Maragheh<br />
Nuclear Science & Technology Research Institute (NSTRI), Atomic Energy<br />
Organization of Iran<br />
Introduction: Bombesin (BBN) is a peptide showing high affinity for<br />
the gastrin releasing peptide receptor (GRPr). Tumors such as<br />
prostate, small cell lung cancer, breast, gastric and colon cancer are<br />
known to over express receptors to bombesin (BBN) and gastrin<br />
releasing peptide (GRP).<br />
Methods: The goal of this study was to evaluate a new 67Ga<br />
radiolabeled BBN analogue based upon the bifunctional chelating<br />
ligand DOTA which could be used as a tool for diagnosis of GRP<br />
receptor-positive tumors. DOTA-GABA-Bombesin (7-14) NH2 was<br />
synthesized using a standard Fmoc strategy. Labeling with 67Ga was<br />
performed at 95°C for 30 min in ammonium acetate buffer (pH =<br />
4.8). The stability of radiopeptide was examined in the presence of<br />
human serum at 37 °C up to 24 h. The receptor bound internalization<br />
and externalization rates were studied in GRP receptor expressing<br />
PC-3 cells. Biodistribution of radiopeptide was studied in mice.<br />
Results: labeling yield of >90% was obtained corresponding to a<br />
specific activity of 2.6 MBq/nmol. The radioligand showed a good and<br />
specific internalization into PC-3 cells (16.13 ± 0.71% at 4 h). After 4<br />
h a considerable amount of activity (52.42 ± 1.86%) was<br />
externalized. In animal biodistribution studies, a receptor-specific<br />
uptake of radioactivity was observed in GRP-receptor-positive organs.<br />
After 4 h, the uptake in mouse tumor and pancreas was 1.30 ±<br />
0.18% ID/g and 1.21 ± 0.13% ID/g respectively.<br />
Conclusion: These data show that [67Ga]-DOTA-GABA-Bombesin<br />
(7-14) NH2 is a specific radioligand for gastrin-releasing peptide<br />
receptor positive tumors and is a suitable candidate for clinical<br />
studies.<br />
Keywords: 67Ga Bombesin, synthesis, labeling<br />
81
3rd International Congress 3rd International of Nuclear Congress Medicine of Nuclear & 15th Medicine Iranian Annual & 15th Iranian Congress Annual of<br />
Nuclear Congress Medicine of Nuclear Medicine<br />
Shahid Beheshti Shahid Beheshti University University of Medical Sciences of Medical 19-21 Sciences May 201119-21 May 2011<br />
Production, Quality Control and Biological Evaluation of<br />
153Sm-TTHMP as a Possible Bone Palliation Agent<br />
Zohre Naseri 1 , Amir Reza Jalilian 2 , Ali Nemati Kharat 1<br />
1 University of Tehran, School of Chemistry<br />
2 Radiopharmaceutical Research and Development Lab (RRDL)<br />
Radionuclides have been used to treat skeletal diseases for decades.<br />
At present an array of radionuclides have been proposed for treating<br />
bone pain due to cancer. The most promising among these<br />
radionuclides is 153Sm. This radionuclide has favourable radition<br />
characteristics t1/2= 1.93d, βmax= 0.81 Mev(20%), 0.71 Mev<br />
(49%), 0.64 Mev (30%) and γ=103 Kev (30%) emission which is<br />
suitable for imaging purposes during therapy. Various bone palliative<br />
therapeutic agents have been developed for bone metastasis such as<br />
153Sm-EDTMP, widely used in the world. (EDTMP) has been proved<br />
to be a good therapeutic agent for the treatment of pain due to<br />
skeletal metastases and is now commercialized. In this study,<br />
production, quality control and biodistribution studies of a newly<br />
developed therapeutic compound have been presented followed by<br />
imaging studies in wild-type rodents. 153Sm-TTHMP was prepared<br />
starting 153Sm-SmCl3, prepared by neutron activation of an enriched<br />
152Sm sample (purity >98%), and in-house synthesized TTHMP in<br />
1h at 25ºC followed by stability tests, partition coefficient<br />
determination and biodistribution studies of in wild-type rodents<br />
using scarification. The radiolabeled Sm complex was prepared in<br />
high radiochemical purity (>99%, ITLC) and specific activity of 278<br />
GBq/mmol and demonstrated significant stability at 4, 25 and 37ºC<br />
(in presence of human serum). Initial biodistribution data showed<br />
significant bone accumulation of the tracer in 48h. The produced<br />
153Sm-TTHMP properties suggest an efficiently new bone palliative<br />
therapeutic agent in the country in order to overcome the metastatic<br />
bone pains.<br />
Keywords: Sm-153, TTHMP, Radiopharmaceutical, Therapy,<br />
Biodistribution, Imaging<br />
82
3rd International Congress of of Nuclear Medicine & & 15th 15th Iranian Annual Annual Congress of<br />
Congress of Nuclear Medicine<br />
Shahid Beheshti Shahid Beheshti University University of Medical of Medical Sciences Sciences 19-21 19-21 May May 2011<br />
Preparation and bio distribution of 99m Technetium-annexin V<br />
for in vivo detection of apoptosis<br />
Saeed Rajabifar, Hamidreza Zolata, Fateme Bolourinovin, Fariba<br />
Sadadi, Amir Reza Jalilian<br />
Nuclear Medicine group, Agricultural,Medicl and Industrial Research School,<br />
Nuclear Science and Technology Research Institute (NSTRI), Tehran, Iran.<br />
Introduction: Annexin V a human protein belongs to a class of Ca 2+<br />
-dependent binding proteins and has a high affinity for<br />
phosphotydilserine and can be used in determination of apoptosis in<br />
cells. Annexin V and its conjugates may be used to detect apoptotic<br />
cells significantly earlier than DNA- based assays. Labeled Annexin V<br />
using 99m Technetium may be useful in detection of apoptosis in vivo<br />
as well as effects of the drugs used for the therapy.<br />
Methods and material: For radiolabeling of Annexin V with<br />
99m technetium succinic dihydrazide, propylene diamine tetra acetic<br />
acid, tricine, nicotinic acid and stannous chloride at their best<br />
concentrations in 0.1 M hydro chloric acid were added to phosphate<br />
buffer at PH=8.5 and then 110 MBq 99m technetium eluted by normal<br />
saline and Annexin V were added to this mixture and heated at 90 oc<br />
for 10 minutes using stirrer at 1400 rpm. The radiochemical purity of<br />
99m technetium was determined by ascending Instant Thin Layer<br />
Chromatography (ITLC) with silica gel fiber glass sheet. Two solvents<br />
such as physiologic saline and acidified 85% ethanol were used and<br />
compared. The radiopharmaceutical prepared was administered<br />
through tail vein to experimental animals (n=5) and under anesthesia<br />
sacrificed for bio distribution studies at 1 and 3 hrs. Liver, kidney,<br />
heart, muscle, spleen, stomach, and intestine.<br />
Results: The radio chemical purity was found to be not less than<br />
90% and the ethanol solvent showed better results as compare to the<br />
normal saline. The serum stability studies showed the product is<br />
stable at least up to 1 hr. The highest percentage of injected dose<br />
per gram of organ (%ID/g) with the mean value were observed in<br />
liver 2.56, kidney 1.36, heart 0.53, stomach 0.39, spleen 0.37 and<br />
muscle 0.12 . Appreciable radio activity could be detected in the liver<br />
and kidneys until 3 hrs post injection of 99m technetium- Annexin V<br />
indicating radiopharmaceutical primarily excretion by hepatic and<br />
renal pathway. Stomach uptake is commonly assumed as a control of<br />
99m technetium labeled compounds stability in vivo assays, this tissue<br />
actively uptakes free 99m technetium which is a good indicator of<br />
radiochemical purity.<br />
Conclusion: 99m technetium-Annexin V is successfully labeled and the<br />
highest uptake was observed in liver and kidney. Stomach uptake of<br />
99mTc labeled Annexin was negligible ,confirming no contamination<br />
of free 99m technetium in the preparation.<br />
Keywords:AnnexinV,Apoptosis, 99m technetium-AnnexinV, Labeling<br />
83
3rd International Congress 3rd International of Nuclear Congress Medicine of Nuclear & 15th Medicine Iranian Annual & 15th Iranian Congress Annual of<br />
Nuclear Congress Medicine of Nuclear Medicine<br />
Shahid Beheshti Shahid Beheshti University University of Medical Sciences of Medical 19-21 Sciences May 201119-21 May 2011<br />
Estimation of Fan Beam Parameters by Parallel Beam<br />
Collimator in Wire Mesh Design<br />
Abdollah Khorshidi 1 , Mansour Ashoor 2<br />
1 Department of Physics<br />
2 Nuclear Science & Technology Research Institute<br />
Introduction: Collimation of the low energy photons, allowing<br />
detection of only those photons propagating in the appropriate<br />
direction, plays a key role to obtain a suitable map in the Single<br />
Photon Emission Computed Tomography (SPECT) imaging.<br />
Methods: In this study, for assessment of Fan Beam (FB) and<br />
Parallel Beam (PB) collimators responses various parameters have<br />
been compared based on the Geometric Efficiency (G), Geometric<br />
Resolution (Rc), Full Width at Half Maximum (FWHM) and Scatter and<br />
Penetration (S+P) components. Monte Carlo (MC) simulations were<br />
used for estimate the response of cubic hole collimators.<br />
Results: Calculations demonstrated FB Geometry efficiency was<br />
raised when angle of slant hole increased. In FB collimator, while<br />
distance between point source and collimator surface (z) became<br />
larger for a special angle, the Rc increased. But when hole angles<br />
were enlarged for a special distance, the Rc reduced. Simulations in<br />
wire mesh design indicated FB had the better resolution rather than<br />
PB with cubic holes. Simulated point source responses are relatively<br />
close to ADAC Company data. Moreover, whereas z increased the<br />
S+P amounts decreased for both collimators.<br />
Conclusion: The FB had the highest S+P and PB specified the lowest<br />
amount with 1.04 ratio in air at 10 cm distance. The closeness of the<br />
FB collimator responses demonstrated the cubic holes approximation<br />
is applicable to the MC modeling of converging collimators.<br />
Keywords: Fan Beam, Cube, FWHM, Penetration, Phantom<br />
84
3rd International Congress of of Nuclear Medicine & & 15th 15th Iranian Annual Annual Congress of<br />
Congress of Nuclear Medicine<br />
Shahid Beheshti Shahid Beheshti University University of Medical of Medical Sciences Sciences 19-21 19-21 May May 2011<br />
Paired organ internal dosimetry; should be treated jointly or<br />
separately?<br />
Ali Asghar Parach, Hossein Rajabi, Mohammad Ali Askari<br />
Tarbiat Modares University<br />
Purpose: The size, shape and the position of paired organs are<br />
different in abdomen. However, the counterpart organs are<br />
conventionally treated together for calculation of the SAF and S-<br />
values in radiation protection purposes. This study was performed to<br />
quantify the difference in treating paired organs separately or jointly<br />
together.<br />
Methods: Zubal phantom and GATE Monte Carlo package was used<br />
to calculate the SAF and S-value for the self-absorption and crossirradiation<br />
of the liverlung, kidney, adrenal glands (as paired organs)<br />
and liver, spleen stomach and pancreas (single organs). The activity<br />
was assumed uniformly distributed in the organs and simulation was<br />
performed for photons of 10-1000 keV and mono-energetic electrons<br />
of 350, 500, 690, 935, 1200 keV.<br />
Results: The results demonstrated that self-absorption of left and<br />
right organ is inversely dependent upon the mass of the organs.<br />
However, the cross-irradiations of counterpart organs are almost<br />
equal irrespective of the differences in the mass of the organs. The<br />
cross-irradiation from the left and right counterpart organs to other<br />
organs are different (4-24 times in Zubal phantom) depending on the<br />
photon energy and organs. The cross-irradiation from the single to<br />
paired organs is always different irrespective of activity<br />
concentration.<br />
Conclusion: The counterpart organs always receive different dose<br />
from single organs. Therefore, for protection and treatment planning<br />
purposes, these organs should be treated separately just like two<br />
separate organs.<br />
Keywords: Paired-Organ, Specific-Absorbed-Fraction, S-value,<br />
Zubal-phantom, GATE Monte-Carlo<br />
85
3rd International Congress 3rd International of Nuclear Congress Medicine of Nuclear & 15th Medicine Iranian Annual & 15th Iranian Congress Annual of<br />
Nuclear Congress Medicine of Nuclear Medicine<br />
Shahid Beheshti Shahid Beheshti University University of Medical Sciences of Medical 19-21 Sciences May 201119-21 May 2011<br />
Assessment of Radioactive Waste per Patient in a Nuclear<br />
Medicine Center<br />
Ali Jomehzadeh 1 , Mohammad Bagher Tavakoli 2 , Zahra Jomehzadeh 3<br />
1 Rafsanjan University of Medical Sciences<br />
2 Isfahan University of Medical Sciences<br />
3 Kerman University of Medical Sciences<br />
Introduction: During the last decades, radio-emitter materials have<br />
been rapidly used in nuclear medicine. Undoubtedly, several<br />
problems have been caused due to the application of unsealed radioemitter<br />
materials in nuclear medicine centers. Since, contamination<br />
to radio-drug in nuclear medicine centers causes health problems,<br />
and also, because of workers and patient's exposure reduction in<br />
nuclear medicine centers, informing of internal and external sources<br />
seems to be necessary. Therefore, in this study level of radioactive<br />
waste and radiation contamination per patient with respect to the<br />
contamination radiation sources in Isfahan Dey nuclear medicine<br />
center in Azar 1389 were measured.<br />
Materials & Methods: In this study, after initial studies of imaging<br />
devices, type and level of radio-drug and number of patients per day<br />
in Isfahan Dey nuclear medicine center, radiation contamination with<br />
respect to contamination sources has been investigated. To this end,<br />
all of radiation contamination sources (waste) including, injection<br />
siring, disposable glove, alcoholic cotton and vial have been<br />
determined and level of radiation contamination of each waste per<br />
patient, immediately after injection, has been measured using<br />
gamma counter (Dose Calibrator).<br />
Results: In this study, 38 and 15 patients have been checked up for<br />
heart and bone scans, respectively. Average radiation contamination<br />
of injection siring, alcoholic cotton, disposable glove and vial per<br />
patient were respectively 0.90±0.39, 0.02±0.03, 0.00 and 0.32±0.11<br />
millecurie for heart scan. Also, average radiation contamination of<br />
injection siring, alcoholic cotton, disposable glove and vial per patient<br />
were respectively 1.24±0.17, 0.03±0.05, 0.00 and 0.17±0.03<br />
millecurie for bone scan.<br />
Conclusion: According to the results, the average level of<br />
radioactive waste per patient for heart and bone scan was in the<br />
range of acceptable limitation and there are no necessary additional<br />
radiation protection criteria for wasting the radioactive wastes.<br />
Keywords: radioactive waste, nuclear medicine, heart scan, bone<br />
scan<br />
86
3rd International Congress of of Nuclear Medicine & & 15th 15th Iranian Annual Annual Congress of<br />
Congress of Nuclear Medicine<br />
Shahid Beheshti Shahid Beheshti University University of Medical of Medical Sciences Sciences 19-21 19-21 May May 2011<br />
Direct Additional Acceleration of Relativistic Electron and<br />
Generation of Electron irradiation by intense Short Laser Pulse<br />
Ammar Alani<br />
Islamic Azad University, Gilane gharb Branch, Gilane gharb, IRAN<br />
Electron irradiation uses electrons accelerated in a velocity close to<br />
the speed of light to destroy microorganisms, bacteria, viruses, or<br />
insects that might be present in the food (Cold pasteurization),<br />
sprout inhibition, delay of ripening, and increase of juice yield. Also<br />
used on non-food items, such as Sterilization of medical hardware,<br />
shrink-foils for food packaging, etc. Electron irradiation does not<br />
become radioactive, but in some cases there may be subtle chemical<br />
changes. In this paper investigate increase energy of relativistic<br />
electrons in intraction, by femtosecond laser pulse. for this purpose<br />
an intense short laser pulse with intensity I0=4.19E+020 w/cm2<br />
,wavelength λ=0.8µm, laser spot size W0=100µm, laser pulse time<br />
duration tp=100fs in the doughnut mode TEM*(0,1) for Capture and<br />
Acceleration Scenario(CAS) in vacuum and initial electron velocity<br />
0.7c has been employed. In order to we investigate the intensity<br />
electromagnetic field of femtosecond laser pulse using threedimensional<br />
test particle simulation and numerical analysis via Fourth<br />
order runge kutta formula and utilize Ponderomotive potential<br />
model(PPM) as the theoretical model for description elestron<br />
acceleration .then we scrutinize transverse and longitudinal<br />
ponderomotive force, electrons trajectory, history of the electrons<br />
energy, scattering angles and other variety of graphs. we abserve<br />
that ponderomotive force traps the electrons near the central axis of<br />
laser pulse and increase time intraction and energy exchange<br />
between pulse and elctrons as access electron energy from 0.58Mev<br />
to 2.35Gev in Optimal status then scattered. Finally, the acceleration<br />
problem for a bunch of electrons with 500,000 electrons was<br />
investigated. In our simulation results electrons confined and<br />
accelerated by using the TEM*(0,1) mode laser . The transvers<br />
ponderomotive scattering of the electrons is suppressed by the<br />
potential well of the high mode laser .<br />
Keywords: Electron irradiation, intense Short Laser Pulse<br />
87
3rd International Congress 3rd International of Nuclear Congress Medicine of Nuclear & 15th Medicine Iranian Annual & 15th Iranian Congress Annual of<br />
Nuclear Congress Medicine of Nuclear Medicine<br />
Shahid Beheshti Shahid Beheshti University University of Medical Sciences of Medical 19-21 Sciences May 201119-21 May 2011<br />
Is parentage error of bone Density determined by DEXA<br />
technique influenced by density?<br />
Azadeh Emami 1 , Hossein Ghadiri 1 , Mohammad Reza Ay 1 , Shahram<br />
Akhlaghpour 2 , Pardis Ghafarian 1 , Sima Taghizadeh 1<br />
1 Research Center for Science and Technology in Medicine<br />
2 Departments of Interventional Radiology<br />
Introduction: accurate performance assessment of bone mineral<br />
densitometry is crucial due to the fact a high level of exact estimation<br />
of bone situation is needed for correct diagnosis of patient with bone<br />
disease. Variation of parameters like percentage error which highly<br />
affect the densitometry results may induce some level of uncertainty<br />
in diagnosis procedure. So, determination of this variation and<br />
designing an algorithm for correction is necessary to assure<br />
examiners about measurement results.<br />
Method: In this study several phantoms consisting of soft tissueand<br />
bone-equivalent material was devised to accurately test bone<br />
densitometry systems. A Plexiglas cylindrical phantom was designed<br />
and constructed as a spine phantom to assess different bone<br />
densities. This phantom consists of two male-female separated parts<br />
which each part consists of two cylindrical shape vertebras .Four<br />
inserts in spine phantom with precisely wide range of K2HPO4<br />
simulate trabecular bone, and provide the basis for the accurately<br />
check of bone densitometry systems. Torso phantom is made up of<br />
polyethylene and designed in such a way that imitates the torso<br />
contour of human body and a hole in the low-middle part of it for<br />
inserting the spine phantom in.<br />
Results: The designed phantoms were used for performance<br />
assessment of Bone Mineral Measurement DEXA Technique. Data<br />
represents percentage error variation in DEXA in different densities.<br />
It is clear that there is a declining trend of percentage error in<br />
measured density versus true density values in DEXA technique.<br />
There is a linear regression equation plot between measured density<br />
and percentage error. The correlation coefficient and slope resulting<br />
from the regression analysis of the measured density versus<br />
percentage error by DEXA is calculated (slope:-0.32, intercept: 0.44).<br />
Conclusion: As it is shown, sensitivity varies by mineral density of<br />
spine results in an uncertainty in measurement procedure. The need<br />
for standardization and evaluation in bone mineral measurements has<br />
been recognized. A spine phantom was designed and produced to<br />
evaluate the percentage error variation in bone densitometry<br />
measurements. These assessments cover wide range of mineral<br />
density that simulated to cover different stages of bone situation. In<br />
this research it is demonstrated that the percentage error can be<br />
affected by spine density that may cause uncertain results.<br />
Keywords: DEXA, BMD, Phantom, Percentage error<br />
88
3rd International Congress of of Nuclear Medicine & & 15th 15th Iranian Annual Annual Congress of<br />
Congress of Nuclear Medicine<br />
Shahid Beheshti Shahid Beheshti University University of Medical of Medical Sciences Sciences 19-21 19-21 May May 2011<br />
Development of<br />
radioimmunotherapy<br />
153 Sm-DOTA-cetuximab for<br />
Kamal Yavari ٭1 , Mohammad Ghannadi Maragheh 1 , Reza Solhifam<br />
1 Radiobiomedical Laboratory (RBML), Nuclear Science and Technology Research<br />
Institute (NSTRI),<br />
2 Azad University, Chemistry department, Tabriz, Iran<br />
The monoclonal antibody cetuximab binds to EGFR and thus provides<br />
an opportunity to create both imaging and therapies that target this<br />
receptor. The potential of cetuximab as a radioimmunoconjugate was<br />
investigated and in vitro and in vivo quality control tests were<br />
performed as a first step in the production of a new<br />
radiopharmaceutical. Cetuximab solution first was dialyzed and<br />
concentrated by centrifugation using an Amicon Ultra-15 filter<br />
(Millipore, MWCO 30,000). Purified antibody was labeled with 153 Sm<br />
using the DOTA-NHS and radioimmunoconjugates were purified by<br />
using PD10 columns. Radiochemical purity and stability in buffer and<br />
human blood serum were determined using thin layer<br />
chromatography. Integrity of the radiolabeled complex was checked<br />
by SDS-PAGE. Preliminary biodistribution studies in normal mice<br />
model performed to determine radioimmunoconjugates distribution<br />
up to 72h. The radiochemical purity of the complex was 96±1.4%.<br />
The stabilities in phosphate buffer and in human blood serum at 96 h<br />
postpreparation were 94±2 % and 75±1%, respectively. All of the<br />
samples, controls and radiolabeled antibodies, showed a similar<br />
pattern of migration in the gel electrophoresis. Biodistribution of<br />
Lu 177 -cetuximab was evaluated in normal mice and the highest %ID/<br />
g was observed in the blood (15.2±1.3 at 24 hr) and the liver<br />
12.1±2.8 at 24 hr). Cetuximab is readily modified with the<br />
bifunctional acyclic chelate, DOTA-NHS. When labeled with 153 Sm its<br />
immunoreactivity is retained. The studies detailed above demonstrate<br />
the flexibility of cetuximab as a potentially useful<br />
radioimmunoconjugate for both imaging and therapeutic applications<br />
for the treatment and management of a spectrum of cancers.<br />
Key Words: Cetuximab, radiopharmaceuticals, 153 Sm, DOTA<br />
89
3rd International Congress 3rd International of Nuclear Congress Medicine of Nuclear & 15th Medicine Iranian Annual & 15th Iranian Congress Annual of<br />
Nuclear Congress Medicine of Nuclear Medicine<br />
Shahid Beheshti Shahid Beheshti University University of Medical Sciences of Medical 19-21 Sciences May 201119-21 May 2011<br />
Calculation of absorbed dose in human body produced by PET<br />
machine using MCNP code<br />
Masood Abdolahzade 1 , Atiyeh Moshayedi 2 , Hasan Yousefnia 3 , Yaser<br />
Kasesaz 3 , Davood Ghasemabadi 1 , Mohsen Shayeste 1<br />
1 Imam Hossein University<br />
2 Tehran Center Azad University<br />
3 Atomic Energy Organization of Iran<br />
In This paper the gamma absorbed dose in a simulated phantom of<br />
adult human body is calculated. The 0.5 MeV gamma rays are<br />
produced in positron annihilation process in PET device. A certain<br />
amount of F-FDG18 drag is injected in human body to positron<br />
emission by F-18 isotope and gamma production in organs ob body.<br />
The MCNP code is used for phantom and radiation simulation. The<br />
good results are obtained and compared with other works.<br />
Keywords: PET<br />
90
3rd International Congress of of Nuclear Medicine & & 15th 15th Iranian Annual Annual Congress of<br />
Congress of Nuclear Medicine<br />
Shahid Beheshti Shahid Beheshti University University of Medical of Medical Sciences Sciences 19-21 19-21 May May 2011<br />
Evaluation of single dose 99m Tc-MIBI as a myocardial imaging<br />
agent in clinical test<br />
G.A. Shabani, H.R. Khosrounejad, M. Farahani, F. Hajhasan Abbasi,<br />
M. Goudarzi, M.H. Talebi, M. Mazidi<br />
Radioisotope research group, NSTRI, Atomic Energy org. of Iran<br />
Introduction: 99m Tc-sestamibi (MIBI) is widely used in evaluation of<br />
myocardial perfusion abnormalities. The radiopharmaceutical 99m Tc-<br />
MIBI is a monovalent cation in which 99mTc is surround by six<br />
isonitril ligands. 99m Tc-sestamibi is prepared from a kit and required<br />
boiling to effect labeling. 99m Tc-MIBI diffuses passively out of the blood<br />
and apparently localizes in mitochondria on the basis of their<br />
negative electrical potentials.<br />
Materials and methods: in new formulation of 99m Tc-MIBI as a<br />
single dose, for one patient, we changed the formulation and reduced<br />
the amount of MIBI. Finally, the kit lyophilized and checked QC,<br />
biodistribution in mice, shelf life, sterility and pyrogeuicity test. For<br />
checking in clinical test, we sent to some nuclear medicine centers.<br />
Results: Radiolabelling was performed by ITLC chromatography and<br />
it was more than 95 percent up to 30 mCi of 99m Tc.<br />
Conclusion: this study demonstrated that the new formulation of<br />
99m Tc-MIBI as a single dose is a useful method for myocardial imaging<br />
of one patient in nuclear medicine centers.<br />
Keywords: MIBI, myocardial, radiopharmaceutical, 99m Tc<br />
91
3rd International Congress 3rd International of Nuclear Congress Medicine of Nuclear & 15th Medicine Iranian Annual & 15th Iranian Congress Annual of<br />
Nuclear Congress Medicine of Nuclear Medicine<br />
Shahid Beheshti Shahid Beheshti University University of Medical Sciences of Medical 19-21 Sciences May 201119-21 May 2011<br />
Assessment of the impact of applying attenuation correction<br />
on the accuracy activity recovery in Tc99m-ECD brain SPECT<br />
of healthy subject using Statistical Parametric Mapping<br />
Faeze Vedaei, Mohammadreza Ay 1 , Alireza Kamali Asl, Faraz Kalantari<br />
1 Department of Medical Physics and Biomedical Engineering<br />
Photon attenuation correction in tissues is the primary physical<br />
degrading factor limiting both visual qualitative interpretation and<br />
quantitative analysis capabilities of reconstructed Single Photon<br />
Emission Computed Tomography (SPECT) images. The aim of this<br />
present study was to investigate the effect of attenuation correction<br />
(AC) on the detection of activation area following statistical analysis<br />
with SPM. The study population consisted of 19 normal subjects (11<br />
male, 8 female, and age 30-40 years). SPECT images were<br />
reconstructed using filter back projection and attenuation correction<br />
was done by the Chang method. The SPECT imaging was obtained 20<br />
min after intravenous injecting of 740-1110 MBq (20-30 mCi) of<br />
Tc99m-ECD and were acquired on 128*128 matrices with a 20%<br />
symmetric window at 140 keV.This data is related to the Society of<br />
Nuclear Medicine of Toronto Hospital and is available on<br />
http://brainscans.indd.org.The data was standardized with respect to<br />
the Montreal Neurological Institute (MNI) atlas with a 12 parameter<br />
affine transformations. Images were then smoothed by a Gaussian<br />
filter of 10 mm FWHM. Significance differences between SPECT<br />
images were estimated at every voxel using t-statistics and is<br />
detected by using a voxel threshold at 6.45.P-value of 0.05 was used<br />
to significant criteria. The contrast comparing NAC to AC images<br />
suggest that regional brain perfusion activity increase in the<br />
cerebrum, parietal lobe, inferior parietal lobule(T score=12.88) and<br />
frontal lobe (T score=10.84), superior frontal gyrus(T score=8.56)<br />
and temporal lobe, superior temporal gyrus(T score=8.68) and<br />
decrease in the cerebrum, frontal lobe, sub-gyral(T score=16.18),<br />
frontal gyrus(T score=16.18), precentral gyrus(T score=7.69),<br />
parietal lobe, precuneus(T score=7.81), inferior parietal lobule(T<br />
score=7.81), angular gyrus(T score=9.82) and posterior lobe,<br />
declive, pyramis, uvula(T score=12.06) and occipital lobe,lingual<br />
gyrus, sub-gyal(T score=8.05) and limbic lobe, anterior cingulated(T<br />
score=9.72) and posterior cingulated (T score=7.91),<br />
parahippocampal gyrus(T score=7.91) before attenuation correction<br />
compare with attenuation correction. I have been concluded that<br />
applying attenuation correction in brain SPECT can effectively<br />
improve the accuracy of the detection of activation area.<br />
Keywords: SPM SPECT, attenuation correction, activation area<br />
92
3rd International Congress of of Nuclear Medicine & & 15th 15th Iranian Annual Annual Congress of<br />
Congress of Nuclear Medicine<br />
Shahid Beheshti Shahid Beheshti University University of Medical of Medical Sciences Sciences 19-21 19-21 May May 2011<br />
The effect of 3D resolution recovery in myocardial perfusion<br />
SPECT<br />
Faraz Kalantari 1 , Hossein Rajabi 1 , Mohsen Saghari 2 , Alireza Emami<br />
Ardakani 2<br />
1 Tarbiat Modares University, Department of Medical Physics<br />
3 Tehran University of Medical Science, Research Institute for Nuclear Medicine<br />
Introduction: Distance-dependent collimator-detector response<br />
(CDR) is one of the most important degrading factors in myocardial<br />
SPECT images. CDR is the main cause of resolution loss and partial<br />
volume effect in final reconstructed images. The primary assumption<br />
of conventional reconstruction algorithms is that projections are<br />
Radon transform of the object; however this model doesn’t consider<br />
the effect of non-ideal collimation. To correct for the effect of CDR<br />
accurately, CDR was modeled in iterative OSEM algorithm.<br />
Methods: Both simulated and real projections were used in this<br />
study. In simulation step, a point source of Tc-99m is modeled and<br />
placed in different distances from the face of collimator. SIMIND<br />
Monte Carlo simulator was used to create projections from this<br />
activity source. After finding suitable models, a digital torso phantom<br />
(NCAT) with a typical Tc99m-MIBI distribution and two small defects<br />
was used to validate the ability of the algorithm. In clinical step a<br />
point source of activity was prepared and used to find distance<br />
dependent CDRs. Projections of 10 patients (5 men and 5 women)<br />
who underwent myocardial SPECT were used to evaluate algorithm.<br />
Gaussian functions as function of distance were used to model CDR.<br />
The 3D collimator blurring was implemented into the forward and<br />
backprojection of OSEM (4 iterations, 8 subsets) to correct for its<br />
degrading effect. The FBP and iterative OSEM without compensation<br />
were also used in image reconstruction to compare our results with<br />
conventional methods.<br />
Results: Drastic improvements in both simulated and clinical image<br />
quality were found using the 3D OSEM and CDR model. In contrast to<br />
conventional OSEM, this algorithm is much more robust against noise<br />
when the number of iteration rises up.<br />
Conclusion: By using more suitable models for image formation it is<br />
possible to reconstruct images with much higher quantitative and<br />
qualitative accuracy which is essential in both diagnostic and image<br />
guided therapy procedures.<br />
Keywords: OSEM Resolution-recovery SPECT Modeling<br />
93
3rd International Congress 3rd International of Nuclear Congress Medicine of Nuclear & 15th Medicine Iranian Annual & 15th Iranian Congress Annual of<br />
Nuclear Congress Medicine of Nuclear Medicine<br />
Shahid Beheshti Shahid Beheshti University University of Medical Sciences of Medical 19-21 Sciences May 201119-21 May 2011<br />
Weighting Coefficient Studies for Compton Scattering Effect<br />
Compensation in SPECT Imaging Using Monte-Carlo<br />
Simulation<br />
Firouz Payervand, Mansour Ashoor, Ali Ramezani Moghaddam<br />
Nuclear Science & Technology Research Institute<br />
The aim of single photon emission computed tomography is to<br />
provide accurate images of the radionuclide distribution after<br />
injecting and to provide metabolic and physiologic functional data of<br />
some internal organs of the object being scanned. The inclusion of<br />
scatter radiation in the projections is one of the main sources of error<br />
in SPECT imaging.Tthe detection of scattered events affects the<br />
contrast, the signal to noise ratio and the resolution of the images. At<br />
the photon energies of interest in SPECT imaging, Compton scattering<br />
is the dominant mode of interaction. During Compton scattering, the<br />
photon is reduced in energy as well as deflected from its original<br />
path. Thus one can use energy loss and energy windowing to reduce<br />
the amount of scattered photons imaged. Several methods for the<br />
effects of scattered events have been proposed. The difference<br />
between methods is the way of estimating the scatter contribution.<br />
To modeling imaging systems or developing algorithms or evaluating<br />
and improving those methods, one can use Monte-Carlo simulation<br />
code. In this paper to evaluating and improving Energy Window<br />
Subtraction (EWS), MCNP code has been used and then scatter<br />
phenomena has been studied and the best weighting coefficient and<br />
the appropriate position and width of each energy window has been<br />
determined and quantitative parameters of image have been studied.<br />
Generally, with using the result of this paper and the mathematical<br />
modeling, one can eliminates scattering effects. Simulation results<br />
showed that by operating weighting coefficients we can improve<br />
quantitative parameters of image and provide suitable images with<br />
anatomical and physiological data of internal organs.<br />
Keywords: Compton scattering, Photo eak, SPECT, MCNP Code<br />
94
3rd International Congress of of Nuclear Medicine & & 15th 15th Iranian Annual Annual Congress of<br />
Congress of Nuclear Medicine<br />
Shahid Beheshti Shahid Beheshti University University of Medical of Medical Sciences Sciences 19-21 19-21 May May 2011<br />
Validation of Gate Monte Carlo simulation for bremsstrahlung<br />
planar imaging and assessment the energy window<br />
Hadi Ahangari 1 , Hosein Rajabi 1 , Saeed Farzanefar 2 , Mohammad<br />
Eftekhari 3<br />
1 Tarbiat Modares University<br />
2 Vali Asr Hospital<br />
3 Tehran University of Medical Science, Research Institute for Nuclear Medicine<br />
Introduction: Treatment in nuclear medicine base on beta emitter<br />
radioisotopes. Therapeutic radionuclides energy is outside the range<br />
of gamma camera imaging system sensitivity. Beta emitters interact<br />
with tissue and make bremsstrahlung ray that could contaminate the<br />
primary photon and hence could increase quantitative problem. In<br />
absence of gamma ray emission, bremsstrahlung ray could be used<br />
for imaging. GATE based on Geant4 is a general and very strong<br />
simulator. This simulator was used for nuclear medicine simulations.<br />
This package was already validated for several nuclear medicine<br />
studies. However, P-32 planar imaging has not validated with GATE<br />
yet.<br />
Materials & Methods: Imaging was performed with ADAC scanner<br />
equipped with VXGP collimators. A cylindrical shape bottle with 5 cm<br />
diameter and 20 cm height was filled with water (solution with 0.1<br />
mCi of phosphorus 32) as phantom at the center of the scanner. All<br />
the events were recorded. Also, this experiment simulated with GATE<br />
and given energy spectrum was validated. The simulation was<br />
repeated for this experiment without collimator.<br />
Results & Discussion: The simulation energy spectrums have a<br />
significant correlation with experiment energy spectrum. Detected<br />
counts in the image resultant of phantom and collimator<br />
bremsstrahlung ray. Thus, in the energy window, the spectrum of<br />
collimator bremsstrahlung should be considered. Collimator<br />
bremsstrahlung energy spectrum in the window below 100 keV is<br />
negligible.<br />
Keywords: GATE, Bremsstrahlung, Spectrum<br />
95
3rd International Congress 3rd International of Nuclear Congress Medicine of Nuclear & 15th Medicine Iranian Annual & 15th Iranian Congress Annual of<br />
Nuclear Congress Medicine of Nuclear Medicine<br />
Shahid Beheshti Shahid Beheshti University University of Medical Sciences of Medical 19-21 Sciences May 201119-21 May 2011<br />
Design and fabrication of imaging detector for medical<br />
application<br />
Hossein Zamani Zeinali 1 , Maryam Nazari 2 , Anita Alipoor 1<br />
1 Dosimetry and Radiation Monitoring Research Group. Agricultural, Medical and<br />
Industrial Research School, Nuclear Science and Technology Research Institute,<br />
AEOI, Karaj, Iran.<br />
2 Islamic Azad University of Tehran<br />
Introduction: An Imaging detector system, based on scintillation<br />
detectors, is designed. Fabricated and optimized for diagnostic<br />
radiology, industrial radiography, nuclear medicine and research<br />
application.<br />
Materials and methods: X radiation beam from a Siemens<br />
Stabilipan Orthovoltage unit, after passing through an object, which<br />
may be living sample or electronic device, produce a planar<br />
distribution of visible light on a GOS(Gd2O2S:Tb3+), that is the<br />
image of the object under examination. The image is displaced on a<br />
Cathode Ray Tube (CRT) by a Charged Coupled Camera (CCD)<br />
camera and is recorded digital by a video capture device. The image<br />
quality parameters, including contrast and resolution were<br />
determined by Inpatient Quality Indicator (IQI) tests. Imaging<br />
practices were carried out for different X ray tube voltages (kV) and<br />
Focal-spot Surface Distances (FSD). The data corresponding imaging<br />
quality parameters were then analyzed and plotted by MATLAB and<br />
Origin software.<br />
Results and discussion: The results for image quality parameters<br />
(contrast and resolution) for different x-ray tube voltages are fairly<br />
close to each other. Thus the imaging system has the capability to be<br />
used for different x-ray energies and radionuclide with relatively<br />
desired results. The study is considered to be an initiative for<br />
fabricating industrial fluoroscopy and radiation surveillance system in<br />
the country.<br />
Keywords: QC, Dose calibrators, Nuclear Medicine<br />
96
3rd International Congress of of Nuclear Medicine & & 15th 15th Iranian Annual Annual Congress of<br />
Congress of Nuclear Medicine<br />
Shahid Beheshti Shahid Beheshti University University of Medical of Medical Sciences Sciences 19-21 19-21 May May 2011<br />
An investigation of Iran's profile Nuclear Medicine centers in<br />
terms of Dose calibrator system<br />
Hossein Zamani Zeinali, Mostafa Ghafori, Anita Alipoor<br />
Dosimetry and Radiation Monitoring Research Group. Agricultural, Medical and<br />
Industrial Research School, Nuclear Science and Technology Research Institute,<br />
AEOI, Karaj, Iran<br />
Introduction: To investigate the status of the Nuclear Medicine<br />
centers in Iran for the performance of the dose calibrators, 100 out of<br />
130 centers providing nuclear medicine services in Iran were selected<br />
and inspected during 2008-2010.<br />
Materials and Methods: The QC test were performed using<br />
standardized radionuclides of Cs-137 and Ba-133 and calibrated dose<br />
calibrators type PTW curimentor 2 in which the nuclear medicine dose<br />
calibrators were calibrated against it. Besides the Cs-137 and Ba-133<br />
standard sources the nuclear medicine dose calibrators were<br />
calibrated for most commonly used radionuclides i.e. Tc-99m, I-131,<br />
Ga-67 and Tl-201 in the form of vials.<br />
Results: According to the obtained results in the study, 10 centers<br />
were found to be in unacceptable situation. Following this study, all<br />
the concerned nuclear medicine centers were informed about the<br />
results, and at the same time the replacement of some of the dose<br />
calibrator were requested.<br />
Keywords: QC, Dose calibrator, Iran.<br />
97
3rd International Congress 3rd International of Nuclear Congress Medicine of Nuclear & 15th Medicine Iranian Annual & 15th Iranian Congress Annual of<br />
Nuclear Congress Medicine of Nuclear Medicine<br />
Shahid Beheshti Shahid Beheshti University University of Medical Sciences of Medical 19-21 Sciences May 201119-21 May 2011<br />
Bone material decomposition by energy resolved CT:<br />
application in CT-based attenuation correction of PET data<br />
Hossien Ghadiri 1 , Mohammad Bagher Shiran 1 , Mohammad Reza Ay 1 ,<br />
Habib Zaidi 2 , Hamid Soltanian-Zadeh 3<br />
1 Department of Medical Physics and Biomedical Engineering<br />
2 Geneva Neuroscience Center<br />
3 CIPCE<br />
Introduction: Energy resolved CT (ERCT) could gain considerable<br />
improvements in its application, more likely in dual modality imaging<br />
systems like PET/CT, especially in terms of CT-based attenuation<br />
correction (AC). Utilizing ERCT would effectively improve<br />
determination of tissue types and consequently more accurate AC of<br />
PET data. The aim of this study was to develop a new approach in<br />
tissue determination by ERCT, especially bones, to improve PET<br />
image quality.<br />
Methods: The study was performed by using XCAT CT projector for<br />
simulation and patient images acquired from GE 64 slices scanner. X-<br />
ray spectrum divided to 5 bins: 20-40, 40-60, 60-80, 80-100, 100-<br />
120 KeV and for each bin an image was reconstructed. A matrix of<br />
data included a vector of LAC values was made which its elements<br />
related to corresponding pixels of all images. For each vector, using<br />
cubic spline algorithm, a curve was fitted and by tri-diagonal matrix<br />
algorithm the values of polynomials coefficients (PC) were extracted.<br />
Using a simple thresholding in map of PCs, 3 types of bones (i.e. rib<br />
cortical, spine cortical and trabeculars) were segmented and by<br />
utilizing appropriate scaling factor for each bone type, energy<br />
mapping was performed.<br />
Results: Conversion curve of current PET/CT systems suggest a<br />
0.40±0.1 factor to scale bone which leads to (9.0±3.0)% and<br />
(7.0±3.3)% relative error for cortical rib and trabeculars respectively.<br />
In contrast, utilizing bone segmentation method which is proposed in<br />
this study, gains errors of (2.1±0.3)%, (2.8±0.7)% and (2.3±0.9)%<br />
for cortical rib, cortical spine and trabeculars respectively. The linear<br />
correlation between PCs and amount of high atomic number materials<br />
in hydroxyapatite solutions concentration has a slope of 0.09 and 1.0<br />
intercept.<br />
Conclusion: This study suggested that an accurate segmentation of<br />
bones utilizing an ERCT could decrease the CT-based AC error and<br />
improve the image quality of PET systems.<br />
Keywords: Energy Resolved CT, PET Attenuation Correction<br />
98
3rd International Congress of of Nuclear Medicine & & 15th 15th Iranian Annual Annual Congress of<br />
Congress of Nuclear Medicine<br />
Shahid Beheshti Shahid Beheshti University University of Medical of Medical Sciences Sciences 19-21 19-21 May May 2011<br />
On The Protection Standards of Shielded Waste Containers in<br />
Five Nuclear Medicine Departments in Tehran<br />
Marzieh Goudarzi 1 , Shadi Davari 2<br />
1 Babol University of Medical Science<br />
2 Nuclear Medicine Department<br />
Since the shielded waste containers are a must for any facility that<br />
generates radioactive waste, all nuclear medicine departments need<br />
standard shielded waste containers to hold radioactive waste safely<br />
until disposal and to reduce radiation dose by appropriate designs to<br />
shield the personnel from the contents of the containers -even when<br />
their lids are open.<br />
Goal: We are attempting to discover whether the protection<br />
standards of shielded waste containers used in nuclear medicine<br />
departments of Tehran are within standard limits or not.<br />
Methods: Here, we present the quality assessment of shielded waste<br />
containers used in five nuclear medicine departments located in<br />
Tehran to evaluate the rate of protection standards applied for the<br />
mentioned containers by a Gayger Muller dose calibrator.<br />
Results: The study shows that shielded waste containers used in the<br />
5 mentioned departments are almost within standard limits but there<br />
can absolutely be some more ways to improve radiation protection<br />
procedures through developing shielded waste containers.<br />
Keywords: Shielded Waste Containers, Dose Calibrator, Radiation<br />
Protection<br />
99
3rd International Congress 3rd International of Nuclear Congress Medicine of Nuclear & 15th Medicine Iranian Annual & 15th Iranian Congress Annual of<br />
Nuclear Congress Medicine of Nuclear Medicine<br />
Shahid Beheshti Shahid Beheshti University University of Medical Sciences of Medical 19-21 Sciences May 201119-21 May 2011<br />
Semi-automated kidney region of interest selection method<br />
using the threshold technique in renography images<br />
Marzieh Rahmatpour 1 , Hosein Rajabi 2 , Farshid Babapour 1<br />
1 Islamic azad university, science and research branch<br />
2 Tarbiat modares university<br />
Introduction: In study of performance of kidneys in diagnosing<br />
kidney disorders, using renography images of nuclear medicine is<br />
among the most common methods. Dynamic imaging is made in two<br />
stages of perfusion and function. The function images are provided to<br />
study the function of kidneys such as refining and evacuation. By<br />
collecting the initial ROI frames, the kidneys are determined by<br />
operator and by coping it on the other frames, the renogram curve is<br />
drawn separately for the right and left kidneys. The renogram curve<br />
indicates changes of the kidney counting in each frame based on the<br />
time.<br />
Goal: Drawing the favorite region around the kidneys is manual<br />
which may reduce reliability in accuracy of the curve of kidneys<br />
activity. This error is due to unevenness of the medium defined by<br />
operator in different times and or due to selecting several operators.<br />
Through semi-automatic methods we can minimize the dependence<br />
of drawing error of the kidneys favorite environment to the operators.<br />
Numerous studies in this regard have been performed by threshold<br />
method which the notified results based on the maximum of kidneys<br />
count. Despite noise of nuclear medicine images, our method could<br />
decrease error.<br />
Methods: To automize selection of ROI in this research, thresholding<br />
method was used. Study on the real images including 19 dynamic<br />
images of different patients. The clinical images were categorized in<br />
two groups of images with different imaging protocols. Studies on<br />
two separate and simultaneous groups after normalizing was made<br />
and the appropriate threshold relations were gained by counting<br />
average.<br />
Results: In the thresholding method, the most suitable mood of<br />
studying thresholding after applying coefficient is normalizing the<br />
images. The correlation coefficient of threshold relation with average<br />
count is 0.95. With relation 1.03xmean count for the right and we<br />
gained 1.08xmean count for the left kidneys.<br />
Conclusion: The relationship between thresholds with counting<br />
average reduces the counting of noise error and by automatizing<br />
selection of ROI, in addition to reducing the error related to operator<br />
we can use this method for other renography images in variable<br />
maximum count.<br />
Keywords: Renography, Region of interest, Thresholding<br />
100
3rd International Congress of of Nuclear Medicine & & 15th 15th Iranian Annual Annual Congress of<br />
Congress of Nuclear Medicine<br />
Shahid Beheshti Shahid Beheshti University University of Medical of Medical Sciences Sciences 19-21 19-21 May May 2011<br />
Assessment two motion detection methods for patient<br />
motions in simulated and clinical renal dynamic imaging<br />
Mohamad Ali Tajik Mansoury 1 , Hossein Rajabi 1 , Ali Reza Emami<br />
Ardekani 3 , Saleh Salehi Zahabi 1<br />
1 Department of Medical Physics, Tarbiat Modares University<br />
2 Department of Nuclear Medicine, Tehran University of Medical Science<br />
Introduction: Considering the importance of renography in<br />
evaluating kidney function especially in children and hydronephrosis<br />
disease, motion is one of the limiting factors in this diagnostic<br />
method, however this motion may be not identified visually in image<br />
but will affected in quantitative assessment of renographic data and<br />
can lead to errors in clinical interpretation of results. The aim of this<br />
paper is assessment of two methods, the center of gravity and crosscorrelation,<br />
for motion detection in variety kind of predictable patient<br />
motion in renal dynamic imaging.<br />
Methods: In this study 4D NCAT phantom was used to generate a<br />
typical human torso and the SimSET Monte Carlo nuclear medicine<br />
(NM) simulator was used to generate phantoms images. Dynamic<br />
images were adjusted to construct 180 phantoms that each<br />
representing a 10 second duration. Here, kidneys in two sizes and<br />
two levels of kidney-to-background counts ratio and 32 types of<br />
predictable motion in different directions were simulated. Motion<br />
detection algorithms, center of gravity and cross-correlation, (were<br />
implemented in Matlab 7.1 environment) were used for motion<br />
determination in renal imaging data. and finally algorithms used for<br />
motion detection in 30 clinical images.<br />
Results: Data obtained from motion detection algorithms shows that<br />
the precision of motion detection in rotational motions was<br />
significantly (p-value < 0.03) better than cross-correlation method.<br />
Dissociation: Results show that two methods of center of gravity<br />
and cross-correlation were suitable for motion detection and<br />
correction in simulated and clinical renographic images and center of<br />
gravity algorithm have more precision than cross correlation method.<br />
Keywords: Renal-Dynamic-Imaging, Motion-Detection, Center Of<br />
Gravity, Cross-Correlation<br />
101
3rd International Congress 3rd International of Nuclear Congress Medicine of Nuclear & 15th Medicine Iranian Annual & 15th Iranian Congress Annual of<br />
Nuclear Congress Medicine of Nuclear Medicine<br />
Shahid Beheshti Shahid Beheshti University University of Medical Sciences of Medical 19-21 Sciences May 201119-21 May 2011<br />
Applying interpolated projections in cardiac SPECT and its<br />
effect on lesion detectability using Hotelling Trace<br />
Mohammad Ali Askari 1 , Hossein Rajabi 1 , Armaghan Fard Esfahani 2<br />
1 Department of Medical Physics, Tarbiat Modares University<br />
2 Tehran University of Medical Science, Research Institute for Nuclear Medicine<br />
Introduction: Myocardial SPECT imaging is usually performed<br />
acquiring 32 views in 180 degree with equal steps of 5.625 degrees.<br />
Mathematically, increasing the number of projections can increase<br />
the image quality and decrease reconstruction artifacts. But acquiring<br />
more projections requires spending more time or injection of more<br />
activity to the patients. An idea to improve the quality of the<br />
reconstructed images without acquiring extra projections is applying<br />
interpolated data between adjacent projections. The aim of present<br />
study was using Hotelling Trace method to investigate the lesion<br />
detectability in reconstructed images with interpolated projections.<br />
Methods: Such investigation cannot be performed on real patient's<br />
data. Therefore, data were simulated using NCAT digital phantom and<br />
SimSET Monte Carlo code. The imaging was performed as usual,<br />
acquiring 32 views from right anterior oblique to left posterior<br />
oblique. The data were interpolated to construct 5 images between<br />
adjacent projections convert it into 187 projections. The simulation<br />
was performed again acquiring 187 images as the reference. The<br />
conventional, interpolated and reference data set were reconstructed<br />
and compared for improvement and degradation in quality of final<br />
images. Four methods of interpolation used, linear, cosine, cubic and<br />
hermit. The above procedure was repeated for phantoms<br />
representing different types of heart disease, different cardiac size<br />
and different count densities. Then short-axis cuts were used for<br />
Hotelling Trace analysis. Comparing Hotelling J-number would show<br />
the best method for interpolation.<br />
Results: The results showed that linear interpolation technique<br />
produces better lesion detectability comparing to other interpolation<br />
methods tested. Results also confirmed that streak artifacts<br />
decreases, signal to noise ratio and contrast increased due to<br />
increasing the number of samples.<br />
Conclusion: These results indicate that lesion detectability and the<br />
physical properties of reconstructed images improve significantly<br />
using interpolation.<br />
Keywords: Myocardial SPECT, Reconstruction, Interpolation, Image<br />
Hotelling<br />
102
3rd International Congress of of Nuclear Medicine & & 15th 15th Iranian Annual Annual Congress of<br />
Congress of Nuclear Medicine<br />
Shahid Beheshti Shahid Beheshti University University of Medical of Medical Sciences Sciences 19-21 19-21 May May 2011<br />
Quantification of bremsstrahlung images with respect to postradioembolization<br />
liver dosimetry<br />
Mohammad Reza Teimoori Sichani 1 , Shahram Akhalghpoor 2 ,<br />
Mohammad Reza Ay 3 , Faraz Kalantari 3 , Mahasti Amoui 4<br />
1 Islamic Azad University<br />
2 Novin radiation medicine institute<br />
3 Medical Physics department<br />
4 Department of Nuclear Medicine, Shahid Beheshti University of Medical<br />
University<br />
Introduction: Evaluation of quantitative bremsstrahlung SPECT and<br />
planar images was done using phantom and patient study to calculate<br />
liver and tumor dose post radioembolization with colloidal<br />
Phosphorus-32.<br />
Material and methods: Bremsstrahlung SPECT and planar images<br />
from Jaszczak phantom and 10 patients under specific condition<br />
(MEGP collimator, Energy peak: 100keV±20%) were obtained. Due to<br />
low quality of bremsstrahlung images a method which used<br />
backscatter photons from external 99mTc sources was applied to<br />
determine body contour in SPECT images. Two small 99mTc sources<br />
on patient body were also used as landmarks. A computer program<br />
was written to calculate liver and tumor dose from raw SPECT data<br />
and CT images of patients. SPECT images were reconstructed using<br />
MLEM method. Registration of SPECT and CT images was done on a<br />
point-to-point basis using body contour and landmarks. Uniform and<br />
non-uniform attenuation maps were made from CT images. Then<br />
attenuation correction (AC) for SPECT images was done using 2<br />
different methods, conventional Chang’s method and during an<br />
iterative reconstruction method using expectation maximization (EM)<br />
algorithm. Evaluation of both AC methods was done using SIMIND<br />
MC simulation code. VOIs for each patient were defined by user and<br />
system calibration factor is calculated using a syringe containing<br />
known activity of 32P dissolved in water. Volume and activity within<br />
each VOI are calculated using attenuation corrected images and<br />
system calibration factor. Absorbed dose within each VOI is estimated<br />
using MIRD method. Also activity and dose within liver area were<br />
calculated from planar images using Conjugate View Method (CVM).<br />
Validation of suggested methods for bremsstrahlung planar and<br />
SPECT quantification was done by phantom study and delivered dose<br />
to tumor and liver of 10 patients were estimated.<br />
Results: Phantom study reveals the most accurate method for image<br />
quantification is using attenuation corrected SPECT images using EM<br />
method and according to patient study delivered dose to livers of<br />
80% of patients is below liver’s tolerance dose (40 Gy) while tumors<br />
receive great amount of dose.<br />
Conclusions: The study shows bremsstrahlung SPECT quantification<br />
is possible even without corrections for scatter and collimatordetector<br />
response and cumulated activity in each organ can be<br />
103
3rd International Congress 3rd International of Nuclear Congress Medicine of Nuclear & 15th Medicine Iranian Annual & 15th Iranian Congress Annual of<br />
Nuclear Congress Medicine of Nuclear Medicine<br />
Shahid Beheshti Shahid Beheshti University University of Medical Sciences of Medical 19-21 Sciences May 201119-21 May 2011<br />
calculated with the precision of ±4% while activity determination<br />
from planar images can be done with higher degree of uncertainty.<br />
Keywords: Bremsstrahlung Imaging, SPECT quantitation,<br />
Radioembolization<br />
104
3rd International Congress of of Nuclear Medicine & & 15th 15th Iranian Annual Annual Congress of<br />
Congress of Nuclear Medicine<br />
Shahid Beheshti Shahid Beheshti University University of Medical of Medical Sciences Sciences 19-21 19-21 May May 2011<br />
Dual isotope cardiac imaging using Tl-Tc cross-contamination<br />
correction by subtraction method<br />
Mohsen Kohanpour 1 , Hossein Rajabi 2 , Mohsen Beheshti 3 , Faraz<br />
Kalantari 2 , Majid Pouladian 1<br />
1 Islamic Azad University<br />
2 Department of Medical Physics, Tarbiat Modares University<br />
3 Paracelsus Medical University<br />
Introduction: Separate dual isotope, rest 201Tl-stress 99mTc, is a<br />
common protocol for heart imaging. Theoretically, this imaging<br />
protocol can perform simultaneously by defining different energy<br />
windows for each radionuclide. However, a potential limitation of<br />
simultaneous dual isotope SPECT imaging is contribution of scattered<br />
photons from technetium-99m and lead X-rays produced in the<br />
collimator into the thallium-201 energy window, referred to here as<br />
cross-contamination. The aim of this study is introducing a modified<br />
middle energy window method to compensate for this crosscontamination.<br />
Material and Methods: This investigation was performed in clinical<br />
study, that 30 men is gone for cardiac study. In simulation step, the<br />
most suitable functions by their ability to modeling crosscontamination<br />
were determined. To achieve this goal, Root Mean<br />
Square errors between our estimated and real cross-contamination<br />
for each view were used. SPECT images of patients who had<br />
angiographic data were acquired in different energy windows. In each<br />
step of this study, in addition to 201Tl and 99mTc windows centered<br />
at 77 keV and 140 keV respectively; a third window centered at 100<br />
keV is established. at each projection angle, the contaminant image<br />
to be subtracted from the image in the 201Tl window was estimated<br />
as a linear combination of a scatter-window (90-110 keV) image,<br />
convolved by a 2D modified exponential function, and the 99mTc<br />
photopeak image, convolved by a different Gaussian function. All of<br />
these images were compared by determining defect or left ventricle<br />
cavity to myocardium contrast.<br />
Results: Significant improvements in contrasts of simultaneous dual<br />
201Tl images were found in each step . Better results in comparison<br />
with other similar methods also were acquired by our suggested<br />
functions.<br />
Discussion and Conclusion: Our results showed contrast<br />
improvement, however many other parameters should be evaluated<br />
for clinical approaches. Simultaneous dual-isotope201Tl/99mTc<br />
myocardial imaging is seems feasible with 99mTc crosscontamination<br />
correction specific. There are many advantages by<br />
simultaneous dual isotope imaging. It halves imaging time and<br />
doubles patient throughput, improves scheduling flexibility, and<br />
reduces patient waiting time and discomfort. Identical rest/stress<br />
registration of images also makes motion or attenuation correction<br />
easy by physicist and image interpretation by physicians.<br />
105
3rd International Congress 3rd International of Nuclear Congress Medicine of Nuclear & 15th Medicine Iranian Annual & 15th Iranian Congress Annual of<br />
Nuclear Congress Medicine of Nuclear Medicine<br />
Shahid Beheshti Shahid Beheshti University University of Medical Sciences of Medical 19-21 Sciences May 201119-21 May 2011<br />
Keywords: dual-isotope, cardiac SPECT, cross-contamination,<br />
Thallium, Technetium<br />
106
3rd International Congress of of Nuclear Medicine & & 15th 15th Iranian Annual Annual Congress of<br />
Congress of Nuclear Medicine<br />
Shahid Beheshti Shahid Beheshti University University of Medical of Medical Sciences Sciences 19-21 19-21 May May 2011<br />
Synthesis and evaluation of [99mTc-HYNIC]-BOC-ATE as a<br />
new somatostatin analogue for receptor scintigraphy<br />
Mostafa Erfani(Gandomkar), Reza Najafi<br />
Nuclear Science Research School<br />
Introduction: Radiolabeled somatostatin analogues have been<br />
successfully used for targeted radiotherapy and imaging of<br />
somatostatin receptor (sstr) positive tumours. In an effort to make<br />
available radiolabeled analogues with a broader spectrum and able to<br />
target other sstr in addition to sstr2, [DOTA0, 1-Nal3]-octreotate has<br />
been recently developed. In this study the preclinical evaluation of<br />
Boc-Octreotate labeled with 99mTc using HYNIC chelator and<br />
ethylenediamine-N,N'-diacetic acid (EDDA) as a coligands is<br />
described.<br />
Methods: Peptide was synthesized on a solid phase following typical<br />
Fmoc/Boc protection strategies. Labeling with 99mTc was performed<br />
at 100 °C for 10 min using SnCl2 as reducing agent. Radiochemical<br />
analysis involved ITLC and HPLC methods. The internalization rate<br />
was studied in sstr2 expressing AR4-2J. Biodistribution was studied in<br />
rats.<br />
Results: [99mTc-EDDA-HYNIC]-Boc-ATE was prepared in high<br />
radiochemical yield and purity (>95%). The radiopeptide showed a<br />
fast and specific internalization into AR4-2J cells (15.17% ± 0.81% at<br />
4 h). In animal biodistribution studies a receptor-specific uptake of<br />
radioactivity was observed in sstr-positive organs like pancrase (1.83<br />
± 0.33 %ID/g).<br />
Conclusions: These data show that radioligand have a potential to<br />
target tumours with sstr2 and sstr3 expression, either alone or<br />
concomitantly with other subtypes. [99mTc-EDDA-HYNIC]-Boc-ATE<br />
might prove to be useful in the diagnostic imaging of tumours<br />
expressing sstr2 or additional receptor subtypes.<br />
Keywords: Somatostatin, 99mTc, Tumour<br />
107
3rd International Congress 3rd International of Nuclear Congress Medicine of Nuclear & 15th Medicine Iranian Annual & 15th Iranian Congress Annual of<br />
Nuclear Congress Medicine of Nuclear Medicine<br />
Shahid Beheshti Shahid Beheshti University University of Medical Sciences of Medical 19-21 Sciences May 201119-21 May 2011<br />
Assessment of the influence of crystal material and size on the<br />
performance of dual head small animal PET scanners<br />
Nafise Ghazanfari 1 , Mohammad Reza Ay 1 , Saeed Sarkar 1 , George<br />
Loudos 2<br />
1 Department of Medical Physics and Biomedical Engineering<br />
2 Department of Medical Instrument Technology<br />
Introduction: Small animal imaging is a significant tool at the<br />
disposition of biological researchers to use in non-invasive study of<br />
preclinical animal models. In the last two decades, commercialization<br />
of these technologies has significantly increased due to the<br />
specifications and ability of them. However, several groups try to<br />
develop high-resolution and high-sensitivity dual head systems,<br />
which are cost benefits and can satisfy requirement of basic PET<br />
studies. It is well known system performance significantly depend on<br />
different crystal factors such as material, size, thickness.<br />
Methods: In this study pixilated dual head animal PET scanner using<br />
GATE MC package was modeled. In order to assess the influence of<br />
crystal dimension on system performance numerous pixel size,<br />
ranging between 0.5—0.5 to 3.0—3.0 mm by increment of 0.5 mm<br />
and crystal materials BGO, LSO, and GSO was considered. For all<br />
measurements a point source with the activity 1 MBq was placed at<br />
the center of FOV.<br />
Results: According to the achieved result, by increasing pixel size<br />
sensitivity will be increased from %1 to %7 and percentage of mispositioned<br />
events will be decreased between the range %76 to % 45<br />
and spatial resolution in different designs will be lost from 0.6 to 2.6<br />
mm. But by increment of crystal length from 10 mm to 15 mm,<br />
sensitivity enhance from %2 to %6, percentage of mis-positioned<br />
events increased from % 89 to % 59 and also spatial resolution<br />
changed from 0.6 to 3.5 mm.<br />
Conclusion: The simulation illustrated that BGO based scanners<br />
have higher sensitivity than equivalent size of LSO and GSO and also<br />
less registration of mis-position events. The results of the evaluation<br />
demonstrate to achieve proper dimension of crystal size, can be said,<br />
considering pixel size 2 mm, crystal thickness 10 mm could provide<br />
the best situation to get better system performance.<br />
Keywords: small animal PET, DHC, GATE<br />
108
3rd International Congress of of Nuclear Medicine & & 15th 15th Iranian Annual Annual Congress of<br />
Congress of Nuclear Medicine<br />
Shahid Beheshti Shahid Beheshti University University of Medical of Medical Sciences Sciences 19-21 19-21 May May 2011<br />
STUDY ON NEW NON-RADIOACTIVE FDG-like MAGNETIC<br />
NANOMATERIALS FOR DIAGNOSIS, MARKING AND<br />
TREATMENT OF MALIGNANT TUMORS<br />
Nicolae Verga 1 , Jenica Neamtu 2 , Dariush Sardari 3<br />
1 Carol Davila Univ- Romania<br />
2 ICPE-CA - Romania<br />
3 Islamic Azad University<br />
Introduction: PET-CT imaging is a valuable method to detect<br />
malignant neoplasia of either primary or metastatic types. There are<br />
always the technical possibilities of implementing PET-CT but no MRI<br />
and CT scanners, which is why we have invented a nanogranular<br />
magnetic compound on whose surface was fixed 2-deoxy-D-glucose.<br />
After the diagnosis of malignancy it is necessary for tumor marking to<br />
track its evolution under treatment. There are currently implanted<br />
invasive fiduciary markers. Hyperthermia therapy is another method<br />
that increases efficiency in radiotherapy and chemotherapy. Our<br />
compound nanogranular meets all these three qualities.<br />
Scope and aims: In this paper are presented some results regarding<br />
the effect of a colloidal solution of magnetite-saccharide nanosystem<br />
on both normal and tumor cells. For this purpose we chose a cell<br />
culture with high sensitivity to glucose. The cells have been grown in<br />
order to obtain two cell cultures with different response to the<br />
dynamics of glucose metabolism. We supposed that the tumor cells<br />
alike will absorb significant amount of magneto-saccharidic<br />
nanocomposite.<br />
Methods: Both cultures were exposed to the same colloidal solution<br />
of a magnetite-saccharide nanosystem. Sample of colloidal solution of<br />
magneto-saccharidic nanocomposite is ferromagnetic at room<br />
temperature behavior: saturation magnetization of 20 emu / g, the<br />
saturation magnetic field (SA) of 3500 Oe, coercivity (HC) of 100 Oe.<br />
We will also present the specific experimental device for modeling the<br />
arterial system and target tissue. Findings Results are analyzed<br />
before and after exposure to the solution of composite regarding the<br />
number of cells (toxicity), the ferromagnetic behavior culture medium<br />
of the two cell types, and magnetic resonance imaging diagnostic in<br />
T1 and T2 of both two cell culture.<br />
Results: Small quantity of magnetite-saccharide nanosystem has<br />
been produce and examined. Due to small amount of material, the<br />
results are not conclusive enough. We consider it necessary to<br />
produce a larger amount of magneto-saccharide nanocomposite.<br />
Complementary experiments are to carried out both to bi-cellular<br />
model and experimental animal with cancer.<br />
Keywords: Malignancy, Nanomgnetism, PET/CT Diagnostic<br />
109
3rd International Congress 3rd International of Nuclear Congress Medicine of Nuclear & 15th Medicine Iranian Annual & 15th Iranian Congress Annual of<br />
Nuclear Congress Medicine of Nuclear Medicine<br />
Shahid Beheshti Shahid Beheshti University University of Medical Sciences of Medical 19-21 Sciences May 201119-21 May 2011<br />
Correction of contrast agent induced artifacts in CT-based<br />
attenuation correction of cardiac PET data using a semiautomated<br />
segmentation algorithm<br />
Pardis Ghafarian 1 , Mohammad Reza Ay 2 , Javad Hassani Bidgholi 2<br />
1 NRITLD<br />
2 Research Center for Science and Technology in Medicine<br />
Introduction: With the advent of 64-slice CT subsystems combined<br />
with PET scanners, full clinical cardiac protocols are possible including<br />
CTA and calcium score imaging as an adjunct to myocardial viability<br />
and perfusion examination. The propagation of CT artifacts into PET<br />
images due to CT image contaminated with high density intravenous<br />
contrast agent during CTA is one of the main reasons that force the<br />
physicians to take two different CT for the purpose of CTA and CTAC.<br />
In this study, we developed a semi-automated algorithm for<br />
segmentation and classification of regions containing contrast<br />
medium to correct for artifacts in CTAC using the segmented contrast<br />
correction (SCC) algorithm in order to reduce patient dose during full<br />
cardiac assessment.<br />
Methods: The study was performed using 12 patients including CTA<br />
and perfusion/viability examinations acquired on the Biograph TP 64<br />
PET/CT scanners. After segmentation of contrast agent in myocardial<br />
wall and chamber the values replaced with correct value based on<br />
SCC algorithm and then the µ-map generated using both CTA and the<br />
CT images acquired for the purpose of CTAC.<br />
Results: After correction of CTA for all patients and generation of<br />
their µ-map based on CTAC method for both corrected CTA and<br />
ACCT it was showed that the percentage absolute relative difference<br />
between the generated µ-map from ACCT and CTA before and after<br />
correction was 8.8±3.9 and 1.3±1.2 for myocardium wall and<br />
15.5±4.7 and 0.3±0.2 for left ventricle chamber, respectively.<br />
However the percentage absolute relative differences between the CT<br />
numbers of the same regions were 340.7±193.8, 21.4±18.6,<br />
599.7±215.6 and 10.7±11.3, respectively. The preliminary results of<br />
this study showed that corrected CTA can be used for CTAC of cardiac<br />
PET data.<br />
Conclusion: This feasibility study suggested the potential to<br />
eliminate the ACCT scan that normally used for attenuation<br />
correction, thus allowing reduction of patient dose during full cardiac<br />
assessment.<br />
Keywords: CTAC, PET, Contrast Agent, CTA<br />
110
3rd International Congress of of Nuclear Medicine & & 15th 15th Iranian Annual Annual Congress of<br />
Congress of Nuclear Medicine<br />
Shahid Beheshti Shahid Beheshti University University of Medical of Medical Sciences Sciences 19-21 19-21 May May 2011<br />
Estimation of Human Effective Absorbed Dose of 67Ga-DTPA-<br />
Gonadorelin Based On Biodistribution Rat Data<br />
Saeed Shanehsazzadeh, Afsaneh Lahooti<br />
Department of Biomedical Physics and Engineering<br />
Background: In this investigation, we estimated the effective<br />
absorbed dose to human organs, following i.v. administration of<br />
67Ga-labeled gonadorelin -one of the gonadotropin releasing<br />
hormone (GnRH) agonists- using biodistribution data from injected<br />
normal rats.<br />
Methods: Four rats were sacrificed at exact time intervals (0.25, 0.5,<br />
1, 2, 4, 24 and 48 hour post injections) and the percentage of<br />
injected dose per gram of each organ was measured by direct<br />
counting from rat data. The Medical Internal Radiation Dose (MIRD)<br />
formulation was applied to extrapolate from rat to human and to<br />
project the absorbed radiation dose for various organs in the human.<br />
Results: From rat data we estimate that a 185-MBq injection of<br />
67Ga-cDTPA-GnRH into the human might resulted in an estimated<br />
absorbed dose of 5.26 mGy to the whole body and the highest<br />
effective absorbed dose was in lung with 2.73 mSv and the organs<br />
received the next highest doses were the bladder wall 1.59 mSv, liver<br />
0.80 mSv and Bone marrow 0.52 mSv.<br />
Conclusion: The biodistribution of 67Ga-cDTPA-GnRH in rats showed<br />
high breast uptake and low muscle and blood uptake. These results<br />
suggest that it should be possible to perform early imaging of the<br />
breast anomalies and GnRH receptors indicating potential malignant<br />
lesions.<br />
Keywords: Absorbed dose, GnRH, Biodistribution<br />
111
3rd International Congress 3rd International of Nuclear Congress Medicine of Nuclear & 15th Medicine Iranian Annual & 15th Iranian Congress Annual of<br />
Nuclear Congress Medicine of Nuclear Medicine<br />
Shahid Beheshti Shahid Beheshti University University of Medical Sciences of Medical 19-21 Sciences May 201119-21 May 2011<br />
Patient and Staff Dose Optimization in Nuclear Medicine<br />
Diagnosis Methods<br />
Sajad Abedi<br />
The implementation of the Basic Safety Standards (BSS) Directive<br />
96/29 on the protection of workers and general population against<br />
the danger arising from ionizing radiation [1] and the Directive 97/43<br />
on health protection of individuals against dangers of ionizing<br />
radiation in relation to medical exposure, known as the Medical<br />
Exposure Directive (MED) [2], they started in Poland some years ago<br />
with the Polish Atomic Law [3] and executive orders published by the<br />
Polish Government and Polish Health Minister [4]. Poland’s<br />
Government has applied for several years transitory period to<br />
complete implementation of the Directive 97/43/EURATOM because<br />
of the technical, organizing and economical problems related with this<br />
procedure. The most important task has arisen to prepare procedures<br />
according with the current state of knowledge in the area of Quality<br />
Assurance (QA) and Quality Control (QC) of medical equipment using<br />
ionizing radiation in diagnosis. QA and QC in X-ray diagnosis<br />
equipment started to be introduced since several years ago and<br />
nowadays they are put in common practice in almost every X-ray<br />
laboratory in Poland. As result, the nuclear medicine departments<br />
must follow the new legislation which has imposed also obligatory<br />
necessity of regular Quality Assurance and Quality Control of<br />
equipment and procedures for preparing and using<br />
radiopharmaceuticals. In this paper the QA and QC procedure<br />
elaborated for the nuclear medicine department has been presented.<br />
Keywords: 97/43/EURATOM, Staff Dose Optimization, Diagnosis<br />
Methods<br />
112
3rd International Congress of of Nuclear Medicine & & 15th 15th Iranian Annual Annual Congress of<br />
Congress of Nuclear Medicine<br />
Shahid Beheshti Shahid Beheshti University University of Medical of Medical Sciences Sciences 19-21 19-21 May May 2011<br />
Therapeutic applications and dosimetry of<br />
radiopharmaceuticals with the help of compartmental analysis<br />
Sajad Abedi<br />
The successful application of radiopharmaceuticals requires a patientspecific<br />
optimization of the activity to be administered, in order to<br />
deliver the desired therapeutic dose to the target organ while saving<br />
the healthy tissues. For a therapy specifically tailored on the<br />
characteristics of the patient, the correct knowledge of the<br />
morphology of the regions of interest, of the fractional uptake and of<br />
the related kinetics is necessary. Compartmental analysis is a<br />
modeling tool used to describe a system as a series of units<br />
(compartments), where the quantities of interests (variables of state,<br />
Qi) can be considered to behave in a uniform and homogeneous<br />
way.The examples presented have shown that compartmental<br />
models, although still excessively demanding for being used in the<br />
daily routine in nuclear medicine departments, can be a valuable tool<br />
in preliminary studies to provide better, individualized dosimeter for<br />
the patient, to improve and optimize the time schedule for data<br />
measurements, to improve and optimize the modality of drug<br />
administration and to improve the understanding of the underlying<br />
pharmacokinetics and pharmacodynamics.<br />
Keywords: Compartmental analysis, Therapeutic compartments<br />
D120<br />
113
3rd International Congress 3rd International of Nuclear Congress Medicine of Nuclear & 15th Medicine Iranian Annual & 15th Iranian Congress Annual of<br />
Nuclear Congress Medicine of Nuclear Medicine<br />
Shahid Beheshti Shahid Beheshti University University of Medical Sciences of Medical 19-21 Sciences May 201119-21 May 2011<br />
Development of Ho-166 chitosan for radiosynovectomy<br />
Samaneh Zolghadri, Amir Reza Jalilian, Hasan Yousefnia, Ali Bahrami-<br />
Samani, Simindokht Shirvani-Arani, Mohammad Ghannadi-Maragheh<br />
Nuclear Science and Technology Research Institute<br />
Chitosan (CHITO), a natural and biodegradable polysaccharide with<br />
wide range applications in bio-pharmaceutics, agriculture and water<br />
treatment purposes, is an excellent molecule for intra-cavital therapy.<br />
In this research, 166Ho-CHITO complex production is described in<br />
details, followed by determination of complex radiochemical purity,<br />
stability and biodistribution (after intra-articular injection) in wildtype<br />
male rats. Finally a Ho-166 based chitosan kit for ultimate<br />
radiosynovectomy applications in the country was developed.<br />
Production of 166Ho was performed at the Tehran Research Reactor<br />
(TRR) using natHo (n, gamma)166Ho nuclear reaction. 166Ho-<br />
Holmium chitosan complex was prepared and Radiochemical purity<br />
was determined using ITLC. The stability of prepared 166Ho-holmium<br />
chitosan complex was checked up to 48 hours after preparation. The<br />
distribution of injected dose in rat organs up to 144 h after intraarticular<br />
injection of 166Ho-holmium chitosan complex (60 µCi/100ul)<br />
solution was determined for control studies. labeling yield increased<br />
with increasing chitosan concentration and reached above 98% when<br />
the concentration reached 35 mg/3 ml. The highest labeling yield was<br />
achieved at pH=2.8-3.2 while decreased beyond this range. The<br />
labeling yield of 99% was achieved after 30 minutes. The effect of<br />
absence and presence of ascorbic acid (at various concentrations) as<br />
a complex stabilizer were also studied. A kit formulation was<br />
developed for the in-situ preparation of the radiopharmaceutical in<br />
remote clinical centers.<br />
Keywords: chitosan, holmium, biodistribution, labeling<br />
114
3rd International Congress of of Nuclear Medicine & & 15th 15th Iranian Annual Annual Congress of<br />
Congress of Nuclear Medicine<br />
Shahid Beheshti Shahid Beheshti University University of Medical of Medical Sciences Sciences 19-21 19-21 May May 2011<br />
Evaluation of hand dose and internal dose of workers in<br />
selected nuclear medicine centers of Iran<br />
Seyed Mehdi Hosseini Pooya 1 , Tahereh Orouji 2 , Jila Karimi Diba 3 ,<br />
Mansour Jafarizadeh 3<br />
1 National Radiation Protection Department<br />
2 Radiation Application Research school, Nuclear Science & Technology Research<br />
Institute (NSTRI)<br />
3 Agriculture, Medicine and Industry Research school, Nuclear Science &<br />
Technology Research Institute (NSTRI)<br />
Abstract: The Annual hand dose of nuclear medicine personnel who<br />
directly deal with the injection of radionuclides to the patients have<br />
been measured using TLD finger dosimeters and statistically<br />
evaluated. This task related monitoring has been carried out in 8<br />
diagnostic nuclear medicine centers during the years 2006 to 2010 in<br />
Iran. The results show that the maximum equivalent hand dose is<br />
about 270 mSv and showing a decreasing trend by a factor of around<br />
5 to about 55 mSv value during 2006 to 2010. As well in spite of<br />
increased number of workers during 2006 to 2010, the average hand<br />
dose has been decreased from 17 mSv in 2006 to 8.46mSv in 2010.<br />
Also the internal dose due to the inhalation of 131I have been<br />
measured for workers in two volunteer therapeutic nuclear medicine<br />
centers (with high load of patients) and the results did not show any<br />
significant internal contamination for the majority of them. The<br />
maximum contamination has been measured to be 70 kBq which can<br />
make a maximum committed effective dose of 0.764 mSv. It can be<br />
concluded that by observing the radiation protection principles and<br />
using appropriate radiation protection equipments, the hand<br />
equivalent dose and committed effective dose extremities could be<br />
kept less than the annual limits of 500 mSv and 20 mSv respectively.<br />
Keywords: nuclear medicine, committed dose, internal<br />
contamination, finger dosimetry<br />
115
3rd International Congress 3rd International of Nuclear Congress Medicine of Nuclear & 15th Medicine Iranian Annual & 15th Iranian Congress Annual of<br />
Nuclear Congress Medicine of Nuclear Medicine<br />
Shahid Beheshti Shahid Beheshti University University of Medical Sciences of Medical 19-21 Sciences May 201119-21 May 2011<br />
Radiolabeling of Cefepime and its evaluation as an infection<br />
imaging agent<br />
Seyedeh Fatemeh Mirshojaei, Mostafa Erfani (Gandomkar),<br />
Mohammad Hossein Talebi, Seyed Mohammad Mazidi<br />
AEOI<br />
Introduction: Contrary to conventional imaging techniques like CT<br />
and MRI, scintigraphic imaging is based on physiological and<br />
biochemical alterations resulting from inflammatory and infectious<br />
processes. A new proposal is based on the use of radiolabeled<br />
antibiotics. They are used as specific infection imaging because of<br />
their affinity to bind with bacteria. Antibiotics localize in the infectious<br />
focus, where they are frequently taken up and metabolized by<br />
microorganisms. The majority of the various antibiotics studied so far<br />
are those of the quinolones group. Recently, a new<br />
radiopharmaceutical, 99mTc-ciprofloxacin (Infecton), has been<br />
developed. Cefepime a third-generation cephalosporin antibiotic used<br />
to treat bacterial infections was investigated to label with 99mTc.<br />
Methods: labeling of Ceftazidime with 99mTc was performed by<br />
using sodium dithionite as reducing agent. Labeling was performed at<br />
100 ºC for 10 min and radiochemical analysis involved ITLC and HPLC<br />
methods. The stability of labeled antibiotic was checked in the<br />
presence of human serum at 37ºC up to 24 h.<br />
Results: This study aimed to investigate the labeling condition of<br />
cefepime, a third generation cephalosporin. The radiolabeling yield as<br />
measured by chromatographic method was 86.7±2%. The labeling<br />
of 99mTc-cefotaxime was optimal in the following reaction mixture:<br />
Cefepime (2.5 mg in 200 µl distilled water), 7.25 mg of Na2S2O4 in<br />
200 µl NaHCO3 0.5%, pH: 8.5-9, reaction time: 10 min and reaction<br />
temperature: 100ºC. 86.7±2%. Bacterial binding assay was<br />
performed with S. aureus and the in vivo distribution was studied in<br />
mice. Images showed minimal accumulation in non-target tissues,<br />
with an average target/non-target ratio of 1.88±0.28.<br />
Conclusion: Reaction was easygoing within a very short time which<br />
makes it a good radiopharmaceutical for clinical usage in nuclear<br />
medicine laboratories. The radiotracer demonstrated excellent<br />
radiochemical stability even up to 24 h post labeling. This antibiotic<br />
showed an improvement in excretion pathway from liver to kidney<br />
followed by an accumulation of radioactivity in infected areas.<br />
Keywords: Cefepime, Radiolabeling, Infection detection,<br />
Biodistribution<br />
116
3rd International Congress of of Nuclear Medicine & & 15th 15th Iranian Annual Annual Congress of<br />
Congress of Nuclear Medicine<br />
Shahid Beheshti Shahid Beheshti University University of Medical of Medical Sciences Sciences 19-21 19-21 May May 2011<br />
Attenuation Correction in SPECT, using Inverse Monte Carlo<br />
Methodduring Image reconstruction, A Simulation Study<br />
Shahla Ahmadi 1 , Hossein Rajabi 2 , Farshid babapour 1 , Faraz Kalantari 2<br />
1 Department of Medical Radiation Engineering<br />
2 Department of Medical Physics, Tarbiat Modares University<br />
Material and Methods: List mode output of SIMIND Monte Carlo<br />
simulator was used to find the relation between activity distribution<br />
and pixel values in projections. MLEM iterative reconstruction method<br />
then was used to reconstruct activity distribution from projections.<br />
Attenuation free projections were also simulates. Reconstructed<br />
images from these projections were used as our reference image. Our<br />
suggested attenuation correction method was evaluated using three<br />
different phantom configurations: uniform activity and uniform<br />
attenuation phantom, non-uniform activity and non-uniform<br />
attenuation phantom and NCAT torso phantom. The mean pixel<br />
values and fit between profiles were used as quantitative parameters.<br />
Results: Images free from the attenuation related artifact were<br />
reconstructed by our suggested method. A significant increase in<br />
pixel values was found after attenuation correction. Better fit<br />
between profiles of our corrected images and our reference images<br />
were also found for all phantom configurations.<br />
Conclusion: Using Monte Carlo it is possible to find the most precise<br />
relation between activity distribution and its projections. Therefore it<br />
is possible to create mathematical projections with the effect of<br />
attenuation. This helps to have more realistic comparison between<br />
mathematical and real projections that is necessary step for image<br />
reconstruction using MLEM. This results in images with much better<br />
quantitative accuracy, at the cost of computation time and memory.<br />
Keywords: MLEM, Reconstruction, Attenuation correction,<br />
117
3rd International Congress 3rd International of Nuclear Congress Medicine of Nuclear & 15th Medicine Iranian Annual & 15th Iranian Congress Annual of<br />
Nuclear Congress Medicine of Nuclear Medicine<br />
Shahid Beheshti Shahid Beheshti University University of Medical Sciences of Medical 19-21 Sciences May 201119-21 May 2011<br />
Production of colloidal radiopharmaceutical 90Y<br />
Hydroxyapatite for radiosynovectomy uses<br />
Sima Attar Nosrati, Mohamad Reza Davarpanah, Hoseinali<br />
Khoshhosn, Mohsen Harati<br />
NSTRI<br />
Introduction: Radiosynovectomy is a well-accepted therapeutic<br />
procedure in inflammatory joint diseases. There are several<br />
radionuclides available for this treatment, However, Yttrium-90 (90Y)<br />
is often believed to be among the most useful of the radionuclides<br />
that have been considered for therapeutic applications in large joints.<br />
90Y has a half-life of 64.1 h and emits beta rays of high energy<br />
(Eβmax=2.3 MeV), with no accompanying gamma-rays.<br />
Hydroxyapatite (HA) [Ca10(PO4)6(OH)2] is the natural mineral<br />
constituent of bone matrix and can be synthesized in the desired<br />
particle size range. HA particles get converted to Ca2+ and PO43-<br />
ions by natural metabolic process and eliminated over a period of 6<br />
weeks.<br />
Purpose: The present study describes the production of 90Y-HA<br />
colloidal radiopharmaceutical and its characterization including the<br />
size distribution profile of the particles, radiochemical purity,<br />
radionuclidic purity, stability and biodistribution studies.<br />
Method: For the preparation of 90Y labeled HA particles, 40 mg of<br />
HA particles added to a 2ml conical vial, 0.8 ml of saline solution, the<br />
suspension was stirred for 5 minutes at room temperature. 100 μL of<br />
90YCl3 solution (~370 MBq of 90Y) was added and the mixture was<br />
shaken for 1 h at room temperature and the radiolabeled particles<br />
were then separated from free 90Y activity by centrifugation. The<br />
radiolabeled particles were resuspended in 2 ml saline, shaken for<br />
few minutes and centrifuged to determine the labeling efficiency.<br />
Results: The radiolabelling yield was 98% and the radiochemical<br />
purity of the labelled product was 97%. Particle size distribution of<br />
the product was 2-10 μm. Stability studies in vitro showed that 90Y-<br />
HA particles were stable in saline as well as at least 3 days).<br />
Biodistribution experiments in rats showed good localization of the<br />
particles in the synovium of the knee joint.<br />
Conclusion: HA particles labeled with 90Y can be prepared with high<br />
labeling efficiency for radiosynovectomy applications. The 90Y-HA<br />
particles prepared are stable and the method is convenient for<br />
routine production of this radiopharmaceutical.<br />
Keywords: Colloide, Radiopharmaceutical, Radiosynovectomy, 90Y-<br />
HA, Hydroxyapatite<br />
118
3rd International Congress of of Nuclear Medicine & & 15th 15th Iranian Annual Annual Congress of<br />
Congress of Nuclear Medicine<br />
Shahid Beheshti Shahid Beheshti University University of Medical of Medical Sciences Sciences 19-21 19-21 May May 2011<br />
Poster Presentations<br />
119
3rd International Congress 3rd International of Nuclear Congress Medicine of Nuclear & 15th Medicine Iranian Annual & 15th Iranian Congress Annual of<br />
Nuclear Congress Medicine of Nuclear Medicine<br />
Shahid Beheshti Shahid Beheshti University University of Medical Sciences of Medical 19-21 Sciences May 201119-21 May 2011<br />
Effect of Restricted Sea foods on 99m Technetium Thyroid<br />
Scintigraphy: A Neglectful Issue in Routine Practice<br />
Hamid Javadi 1 , Mehdi Mogharrabi 2 , Isa Neshandar Asli 3 , Sara<br />
Jalallat 1 , Iraj Nabipour 4 , Majid Assadi 5<br />
1 Golestan Research Center of Gastroenterology and Hepatology (GRCGH)<br />
2 Golestan University of Medical Science, Department of Nuclear Medicine<br />
3 Shahid Beheshti University of Medical Science, Department of Nuclear Medicine<br />
4 The Persian Gulf Marine-Medicine Biotechnology Research Center<br />
5 The Persian Gulf Nuclear Medicine Research center<br />
Introduction: Although patients are recommended to avoid sea food<br />
and iodine-containing medications prior to I-131 scanning, the<br />
efficacy of this approach for Tc 99m-pertechnetate thyroid<br />
scintigraphy is not well addressed in the literature. We evaluated a<br />
self-managed, outpatient, restricted iodine diet (RID) designed to<br />
reduce total body iodine (TBI) in preparation for such scan.<br />
Methods: Thirty-nine subjects (30 females and 9 males; age: 14-54<br />
years) with poor visualization of thyroid gland on Tc99mpertechnetate<br />
thyroid scintigraphy were called to carry out the<br />
repeated scan after going on a RID for at least two weeks prior to the<br />
second scintigraphy. The semiquantitative analysis in 8 regions of<br />
interest (ROIs) was accomplished using Wilcoxon signed rank test.<br />
Results: Thirty-six subjects had better quality scintigraphy images in<br />
post RID thyroid scan, assessed by two nuclear medicine physicians<br />
with full agreement. There was a statistically significant difference in<br />
two regions of right and left thyroid lobes (ROI 5, 6) with increased<br />
count rates in the post RID projections (p
3rd International Congress of of Nuclear Medicine & & 15th 15th Iranian Annual Annual Congress of<br />
Congress of Nuclear Medicine<br />
Shahid Beheshti Shahid Beheshti University University of Medical of Medical Sciences Sciences 19-21 19-21 May May 2011<br />
Statistical Evaluation of Pulmonary Embolism with Lung<br />
Ventilation-Perfusion Scan<br />
Esmael Gharepapagh¹, Arman Salarifar 2<br />
1 Tabriz University of Medical Sciences, Department of Nuclear Medicine<br />
2 Tabriz University of Medical Sciences<br />
Background: Pulmonary embolism (PE) is a common fatal disease,<br />
therefore, the accurate and prompt diagnosis is very important. The<br />
aim of this study is evaluation of lung perfusion-ventilation scan with<br />
relative radiodrugs including 99mTc-MAA and radioaerosols as a noninvasive<br />
and readily available methods with acceptable sensitivity and<br />
specificity in the diagnosis of PE.<br />
Materials and Methods: In this study 149 patients with respiratory<br />
problems, who had referred to the nuclear medicine department of<br />
Tabriz Imam Hospital, from October 2005 to November 2006, were<br />
studied. The perfusion scans performed after iv. injection of 99mTc-<br />
MAA,and the ventilation scans performed after inhalation of 99mTc-<br />
DTPA aerosol on the routine views of lungs. The resulting images<br />
were evaluated by nuclear medicine specilalist regarding the<br />
probabilities of PE. The relationship of sex, age, clinical presentations,<br />
risk factors, previous cardio-pulmonary disorders and chest X-Rays of<br />
the patients, with high and low probability of PE were also evaluated.<br />
This study’s subjects were consisting of 78 men and 71 women who<br />
were examined based on taking their medical history, studying their<br />
medical files and evaluating their related documents.<br />
Results: In the present study, it was discovered that the number of<br />
involved men with PE was higher than women (P < 0.005), as the<br />
patients get older, the incidence of PE becomes higher (P = 0.005),<br />
there was a direct connection between the probability of PE and<br />
having clinical presentations of their illness(P = 0.005).It was also<br />
apparent that the existence of cardio-pulmonary disorders, having an<br />
abnormal CXR and the lack of a risk factor, were all accompanied<br />
with low probability of PE, but the presence or absence of risk factors<br />
showed no meaningful difference for the high probability of PE (P =<br />
0.232).<br />
Conclusion: The lung perfusion-ventilation scan is recommended as<br />
an acceptable method in the early diagnosis of PE and also evaluation<br />
of prevalence and affecting factors of disease.<br />
Key words: Lung perfusion-ventilation scan, pulmonary embolism<br />
121
3rd International Congress 3rd International of Nuclear Congress Medicine of Nuclear & 15th Medicine Iranian Annual & 15th Iranian Congress Annual of<br />
Nuclear Congress Medicine of Nuclear Medicine<br />
Shahid Beheshti Shahid Beheshti University University of Medical Sciences of Medical 19-21 Sciences May 201119-21 May 2011<br />
Brain SPECT in patients with history of unsuccessful suicide<br />
Fariba Saddadi, Reza Shokouhizadeh<br />
AIM: Brain scintigraphy is a helpful method to evaluate psychiatric<br />
patients and the aim of this study to assess depressive patients who<br />
attempted suicide to find any significant changes in their cerebral<br />
flow.<br />
Material and Methods: 14 patients who attempted unsuccessful<br />
suicide were enrolled and underwent brain SPECT study. The mean<br />
time of scan from suicide was 6 months. SPECT imaging was<br />
performed as standard protocol using Philips ADAC with LEAP<br />
collimator to find rCBF changes.<br />
Results: There is almost reduced rCBF in frontal cortex in all 14<br />
patients. Which 10/14 shows perfusion deficits in left frontal lobe and<br />
4/14 with sever depression show bilateral deficits throughout the<br />
frontal lobes, fronto-parietal and temporo-parietal cortex as well.<br />
Conclusions: We found that brain scintigraphy can helpful in<br />
management of depressive patients and via close monitoring of<br />
cerebral flow with doing periodically scans it can also help in<br />
prevention of suicide.<br />
Keywords: Brain SPECT, Suicide<br />
122
3rd International Congress of of Nuclear Medicine & & 15th 15th Iranian Annual Annual Congress of<br />
Congress of Nuclear Medicine<br />
Shahid Beheshti Shahid Beheshti University University of Medical of Medical Sciences Sciences 19-21 19-21 May May 2011<br />
Hybride Imaging in Thyroid Cancer<br />
Mehrossadat Alavi, Farshid Gheisari<br />
Shiraz University of Medical Sciences<br />
Whole-body scintigraphy (WBS) performed after radioiodine ablation<br />
or therapy has the ability to detect new or additional metastases in<br />
10-25% of cases, alter staging in 10%, and affect further<br />
management in 9-15% of patients. Radioiodine-avid metastases can<br />
be small and may occur in regions with distorted anatomy after<br />
surgery. SPECT/CT will improve the ability for their correct<br />
localization. On post-therapeutic WBS, the high activity contained in<br />
residual thyroid tissue often hampers cervical N-staging, a limitation<br />
that is overcome with SPECT/CT. SPECT/CT is expected to improve<br />
the diagnostic accuracy of WBS and therefore to have a significant<br />
effect on patient management. The majority of radioiodine-avid foci<br />
were correctly classified as benign or malignant by hybrid imaging.<br />
SPECT/CT was found to change the therapeutic procedure in 25% of<br />
patients. In There is currently no well-established role for 18Ffluorodeoxyglucose<br />
(FDG) PET/CT for routine diagnosis and follow-up<br />
of patients with differentiated thyroid carcinoma. 18F-FDG PET/CT is<br />
currently recommended for patients with differentiated thyroid cancer<br />
who have elevated thyroglobulin levels and negative radioiodine WBS<br />
post-therapy.<br />
Keywords: Hybrid imaging, Thyroid cancer, SPECT-CT<br />
123
3rd International Congress 3rd International of Nuclear Congress Medicine of Nuclear & 15th Medicine Iranian Annual & 15th Iranian Congress Annual of<br />
Nuclear Congress Medicine of Nuclear Medicine<br />
Shahid Beheshti Shahid Beheshti University University of Medical Sciences of Medical 19-21 Sciences May 201119-21 May 2011<br />
Radiolabeling of ceftriaxone with 99mTc for detecting site of<br />
infection in mouse model<br />
Akram Fazli, Gholamreza Ahmadi, Mojtaba Salouti, Shahrzad<br />
Mirshojaei<br />
Introduction: Although our understanding of microorganisms has<br />
advanced significantly and antimicrobial therapy has become<br />
increasingly available, infection remains a major cause of patient<br />
morbidity and mortality. The use of radiopharmaceuticals for<br />
diagnosis of infection is increasing due to their ability to distinguish<br />
between septic and aseptic inflammation.<br />
Aims: The aim of this work was, labeling of ceftriaxone (a<br />
cephalosporin antibiotic) with 99mTc for Staphylococcus aureus<br />
infection diagnosis in nuclear medicine.<br />
Methods: Radiolabeling of ceftriaxone was carried out by adding<br />
99mTc to ceftriaxone (1.5 µCi to 1 mg) in the presence of<br />
SnCl2.2H2O at PH 5.5. The radiolabeling yield and radiochemical<br />
purity of product was evaluated with ITLC. The mice were induced<br />
infection intramusculary with Staphylococcus aureus and strile<br />
inflammations with turpentine oil. The biodistribiotion and<br />
scintigraphy imaging were performed at 1, 4 and 16h post injection.<br />
Results: Radiochemical yield of product was 94±5% with a good<br />
stability in room temperature and human serum. The biodistribution<br />
and scintigraphic imaging studies showed the specific localization of<br />
99mTc-ceftriaxone at the site of infection in relation to inflamated leg<br />
and other organs with high sensivity.<br />
Conclutions: One may consider 99mTc-ceftriaxone as a promissing<br />
candidate for Staphylococcus aureus infection diagnosis in nuclear<br />
medicine.<br />
Keywords: Radiolabeling, Infection, Biodistribution, Scintigraphy<br />
124
3rd International Congress of of Nuclear Medicine & & 15th 15th Iranian Annual Annual Congress of<br />
Congress of Nuclear Medicine<br />
Shahid Beheshti Shahid Beheshti University University of Medical of Medical Sciences Sciences 19-21 19-21 May May 2011<br />
Correlation of circulating omentin-1 with bone mineral density<br />
in multiple sclerosis: the crosstalk between bone and adipose<br />
tissue<br />
Majid Assadi 1 , Hooman Salimipour 2 , Samad Akbarzadeh 3 , Zahra<br />
Samani 1 , Reza Nemati 2 , Seyed Mojtaba Jafari 4 , Mohammad<br />
Seyedabadi 1 , Iraj Nabipour 4<br />
1 The Persian Gulf Nuclear Medicine Research Center<br />
2 Department of Neurology<br />
3 Department of Biochemistry<br />
4 Department of Endocrine and Metabolic Diseases<br />
Introduction: Adipose tissue-derived adipokines play important<br />
roles in inflammatory and autoimmunediseases. Although the<br />
relationship of adipokines with chondrocyte function and the skeleton<br />
have been investigated, the role of novel adipokines (e.g., omentin-1<br />
and vaspin) in osteoimmunology remains to be elucidated. Patients<br />
with multiple sclerosis (MS) are at increased risk of osteoporosis and<br />
fractures.<br />
Methods: In order to investigate circulating levels of these novel<br />
adipokines in relation to bone health in MS, 35 ambulatory MS<br />
patients with elapsingremitting courses were compared with 38<br />
healthy age- and sex-matched healthy controls. Bone mineral density<br />
(BMD) was determined for the lumbar spine (L2-L4) and the proximal<br />
femur using dual-energy x-ray absorptiometry. Circulating omentin-<br />
1, vaspin, osteocalcin, osteopontin, osteoprotegerin, the receptor<br />
activator of nuclear factor-ĸB ligand, matrix metalloproteinase 9, and<br />
C-reactive protein were evaluated by highly specific enzyme-linked<br />
immunosorbent assay methods.<br />
Results: There was no significant difference between the two groups<br />
regarding bone-related cytokines, adipocytokines, and the BMD<br />
measurements of patients with MS and the healthy controls.<br />
However, age- and body mass index- adjusted circulating omentin-1<br />
levels were positively correlated with BMD at the femoral neck (r=<br />
0.44, p=0.017), total hip (r=0.41, p=0.027), osteopontin (r=0.44,<br />
p=0.031) and osteocalcin (r=0.47, p=0.012) in MS patients. No<br />
correlations were found between vaspin, biochemical, and BMD<br />
measures in both groups.<br />
Conclusion: Elevated omentin-1 serum levels are correlated with<br />
BMD at the femoral neck and the serum levels of osteocalcin and<br />
osteopontin in MS patients. Therefore, there is crosstalk between<br />
adipose tissue and bone in MS as an autoimmune disorder.<br />
Keywords: Multiple sclerosis, Bone mineral density, Omentin-1<br />
125
3rd International Congress 3rd International of Nuclear Congress Medicine of Nuclear & 15th Medicine Iranian Annual & 15th Iranian Congress Annual of<br />
Nuclear Congress Medicine of Nuclear Medicine<br />
Shahid Beheshti Shahid Beheshti University University of Medical Sciences of Medical 19-21 Sciences May 201119-21 May 2011<br />
Functional anatomical cardiac imaging: PET/CT molecular<br />
imaging<br />
Mehrshad Abbasi 1 , Alireza Emami 1 , Salam Heydarinejad 2 , Babak<br />
Falahi 1 , Mohammad Eftekhari 1<br />
1 Tehran University of Medical Sciences, Department of Nuclear Medicine<br />
3 Endocrine and Metabolism Research Center<br />
Comparable with the pure anatomical findings of the CT, the<br />
functional PET/CT imaging provides two additional advantages over<br />
the SPECT technique: attenuation correction and corresponding<br />
feasibility of absolute measurements. In cardiology, the absolute<br />
measures of myocardial blood flow and the myocardial flow reserve<br />
joint with the metabolic imaging can be used for noninvasive<br />
evaluation of sub-clinical as well as more advanced clinical<br />
abnormalities in the coronary function, tissue viability of the<br />
myocardium, left ventricular dysfunction and the response to<br />
therapy. The co-registration of PET/CT biological and morphological<br />
data with the higher accuracy for detection of trivial or balanced<br />
perfusion abnormalities and better assessment of the extent and<br />
severity of pathology would probably limit the number of superfluous<br />
invasive procedures in future. In this review the diversity of the usual<br />
tracers as well as endothelial and metabolic molecular markers<br />
(targeting apoptosis, inflammation, remodeling, and above all,<br />
reporter genes) with their current and possible forthcoming clinical<br />
applications are discussed.<br />
Keywords: PET, Molecular imaging, CAD<br />
126
3rd International Congress of of Nuclear Medicine & & 15th 15th Iranian Annual Annual Congress of<br />
Congress of Nuclear Medicine<br />
Shahid Beheshti Shahid Beheshti University University of Medical of Medical Sciences Sciences 19-21 19-21 May May 2011<br />
Overview of the lymph edema caused by radiation<br />
Mohamadreza Chahkandi 1 , Sanaz Amirian 2 , Amene Yalodbardan 3<br />
1 Mash’had University of Medical Sciences<br />
2 Islamic Azad University-Young Research Club-Mashhad Brunch<br />
3 Emdad Hospital-Mashhad University of Medical Sciences<br />
Radiotherapy in the treatment of many diseases such as cancers is<br />
used. In the meantime problems such as arm swelling caused by<br />
swelling of lymph organs, which may in some cases after<br />
radiotherapy, especially radiotherapy due to breast cancer that is<br />
done is very common. In this review article The causes and<br />
treatment of this complication will.<br />
Intoduction & Conclusion: high-energy X-rays in breast cancer are<br />
used to destroy cancer cells. Side effects that may result from<br />
damage to tissues near the tumor, but usually they can be controlled.<br />
In external radiation, radiation to the tumor carefully shining and<br />
shining from the surrounding healthy tissue, can be avoided. In<br />
internal radiation therapy or brakyatrapy, radioactive material<br />
directly into the breast is placed. After a lumpectomy, breast<br />
irradiation under fully placed. After mastectomy, the chest may also<br />
be irradiated. In some cases, the lymph nodes that area are probably<br />
irradiated. Lymphedema or swelling of lymph hands and arms, and<br />
one of the most common complications of breast cancer is about 30<br />
percent of patients with this condition involves. This condition for<br />
protein-rich fluid in the subcutaneous tissue comes into existence.<br />
Patients following mastectomy, radiotherapy and axillary lymph<br />
glands discharge after surgery due to impaired lymphatic drain upper<br />
extremity on the affected side of 10 to 49 percent in the risk of<br />
lymphedema are. Effective methods for controlling edema lymph to<br />
mobilize fluid accumulated as a first step in treatment and to mobilize<br />
fluid lymph tissue, subcutaneous methods such as using Stynhay<br />
genocidal _ exercise because the exercise by moving fluid nodes of<br />
total it being a place prevents and reduces edema and improve organ<br />
function is affected Vlavh this exercise heart rate and blood flow can<br />
increase lymphatic flow Dhddr result is also higher. hack such a fluid<br />
pump using maneuvers performed by hand or pump pressure can<br />
also be useful.<br />
Keywords: Lymphedema, radioactive material, breast cancer,<br />
Radiotherapy<br />
127
3rd International Congress 3rd International of Nuclear Congress Medicine of Nuclear & 15th Medicine Iranian Annual & 15th Iranian Congress Annual of<br />
Nuclear Congress Medicine of Nuclear Medicine<br />
Shahid Beheshti Shahid Beheshti University University of Medical Sciences of Medical 19-21 Sciences May 201119-21 May 2011<br />
Radiosynovectomy: A noble treatment for joint diseases<br />
Mohammad Qodsi Rad, Nasim Norouzbeigi<br />
Mashhad University of Medical Science, Imam Reza Hospital<br />
Introduction: Joint disorders are relatively common in any society<br />
and radiosynovectomy is an reliable and effective treatment for joints<br />
diseases like rheumatoid arthritis and hemophilic artheropathy.<br />
Aims: This study aims to review latest achievements in the field of<br />
radiosynovectomy.<br />
Methods: Two important data base PUBMED and SCOPUS as well as<br />
the Cochrane library was searched for latest articles about<br />
radiosynovectomy.<br />
Results: Three radionuclides are in current use: 90Y-silicate/citrate,<br />
186Re-sulfide, and 169Ercitrate. 90Y emits a beta particle with a<br />
maximum energy of 2.27 MeV, a mean energy of 0.935 MeV and an<br />
average soft tissue range of 3.6 mm. The physical half-life is 2.7<br />
days. 186Re emits a beta particle with a maximum energy of 1.07<br />
MeV, a mean energy of 0.349 MeV, an average soft tissue range of<br />
1.1 mm and the physical half-life is 3.7 days. 169Er emits a beta<br />
particle with a maximum energy of 0.34 MeV, a mean energy of<br />
0.099 MeV and an average soft tissue range of 0.3 mm. The physical<br />
half-life is 9.4 days. It is generally accepted that Y90 is an ideal<br />
radioisotope agent for treating knees. For medium sized joints as<br />
elbows, ankles or shoulders. Because of rational level of local energy<br />
capacity and limited tissue penetration, Re186 seems to be as an<br />
ideal isotope for medium-sized joints. 169Er citrate colloid is suitable<br />
for metacarpophalangeal, metatarsophalangeal and digital<br />
interphalangeal joints. The subjectively estimated success rates for<br />
the small, medium-sized, and large joints were 89% (215/242), 86%<br />
(112/130), and 79% (41/52), and for RA and OA 89% (280/313) and<br />
79% (88/111). The scintigraphically determined response rates for<br />
small and medium-sized joints were 81% (86/106) and 69% (35/51).<br />
Conclusion: Regarding cost and effectiveness it is highly<br />
recommended to use radiosynovectomy specially in hemophilic<br />
arthropathy (level 1b of recommendation) and hemophilic<br />
artheropathy (level 2a of recommendation).<br />
Keywords: radiosynovectomy, rheumatoid arthritis, hemophilic<br />
artheropathy<br />
128
3rd International Congress of of Nuclear Medicine & & 15th 15th Iranian Annual Annual Congress of<br />
Congress of Nuclear Medicine<br />
Shahid Beheshti Shahid Beheshti University University of Medical of Medical Sciences Sciences 19-21 19-21 May May 2011<br />
Rate Dependent Left Bundle Branch Block: The Pattern of<br />
Myocardial Perfusion SPECT<br />
Sahar Mirpour, Ali Gholamrezanezhad<br />
Tehran University of Medical Science, Research Institute for Nuclear Medicine<br />
Introduction: We report myocardial perfusion SPECT pattern in four<br />
subsequent patients with rate dependent left bundle branch block<br />
(LBBB).<br />
Methods: All patients were tested for baseline and serial heart rate,<br />
blood pressure, and electrocardiogram recordings. The exercise<br />
treadmill tests (ETT) tests were carried out under the strict<br />
supervision of a cardiologist, a nuclear medicine physician and close<br />
availability of an expert cardio-pulmonary resuscitation team and<br />
cardiac care unit within just few seconds. Maximal stress test (at<br />
least 85% of calculated heart rate, even following development of<br />
LBBB) was achieved in all three patients according to standard Bruce<br />
protocol. No adverse cardiac events were noted and all ETT stress<br />
protocols terminated completely and safely.<br />
Results: Three females and one male (aged 48, 63 and 67 years)<br />
were studied. None of the patients had history of typical chest pain<br />
and all were suffered from atypical chest pain or dyspnea on<br />
exertion. Myocardial perfusion SPECT imaging showed no evidence of<br />
reversible perfusion defects. The only patient with past history of<br />
exercise induced LBBB showed nonreversible perfusion defects in the<br />
septal and anteroseptal regions and mild LV cavity dilatation.<br />
Conclusion: The limited number of patients enrolled in our study<br />
does not allow us to draw a definite conclusion. Despite the presence<br />
of false positive defects in myocardial perfusion SPECT in patients<br />
with sustained LBBB, it seems that rate dependent or exercisedinduced<br />
LBBB has not shown such a pattern, unlike we expect. Maybe<br />
it can be possible to continue ETT as the stress protocol for those<br />
patients undergoing myocardial perfusion scintigraphy and<br />
developing rate dependent LBBB.<br />
Keywords: Rate Dependent LBBB<br />
129
3rd International Congress 3rd International of Nuclear Congress Medicine of Nuclear & 15th Medicine Iranian Annual & 15th Iranian Congress Annual of<br />
Nuclear Congress Medicine of Nuclear Medicine<br />
Shahid Beheshti Shahid Beheshti University University of Medical Sciences of Medical 19-21 Sciences May 201119-21 May 2011<br />
How Ictal Brain Perfusion SPECT-CT help for determining<br />
treatment plan of patient?<br />
Seyed Mahdi Modarresi 1 , Kazem Shiroodi 2<br />
1 Baqiyatallah Medical Sciences University<br />
2 Khatam-al-Anbia Hospital<br />
Introduction: It is well known that ictal brain perfusion SPECT can<br />
determine the seizure onset zone with high accuracy especially in<br />
temporal lobe. Unfortunately performing ictal SPECT needs a<br />
complicated logistics and few nuclear medicine departments have<br />
access to such facilities.<br />
Objects: For the first time in Iran we performed both interictal and<br />
ictal SPECT-CT in several patients at Khatam-al-Anbia hospital<br />
nuclear medicine department that is equipped with SPECT-CT (GE-<br />
Infinia- Hawkeye4). Our object was setting up this procedure and<br />
training the personnel and technicians of both nuclear medicine and<br />
epilepsy departments.<br />
Findings: In the following section we present two cases that ictal<br />
SPECT-CT can be helpful to determine treatment plan. In a male 22<br />
years old patient that had history of brain surgery for<br />
hypocampectomy without improving seizure attacks the brain<br />
perfusion study shows another onset zone at contralateral side. In<br />
another female 33 year old patient the study showed a definite<br />
seizure onset zone in left temporal lobe.<br />
Conclusion: Because ictal brain perfusion SPECT-CT can help for<br />
determining treatment plan of patient it should not be ignored and<br />
setting up this procedure is easy and practical.<br />
Keywords: Ictal, Interictal, SPECT-CT, ECD Radioisotope<br />
130
3rd International Congress of of Nuclear Medicine & & 15th 15th Iranian Annual Annual Congress of<br />
Congress of Nuclear Medicine<br />
Shahid Beheshti Shahid Beheshti University University of Medical of Medical Sciences Sciences 19-21 19-21 May May 2011<br />
DETECTION OF PITUITARY ADENOMA BY 68Ga-DOTATATE<br />
PET/CT<br />
Sudabeh Sobhani, Ozlem Nuriye Kucuk, Elgin Ozkan, Erkan Ibis<br />
Ankara University, Turkey<br />
PURPOSE: 68Ga-Peptide PET/CT is a sensitive and specific imaging<br />
in diagnose of neuroendocrine tumors . In this case we performed<br />
68Ga-DOTATATE PET/CT scan for detecting pituitary adenoma.<br />
METHOD: In a 66 year-old man referred to the hospital for routine<br />
medical assessment, was detected increased T3,T4 and TSH levels.<br />
The sella MRI showed an 5x3mm adenoma in the left half of<br />
hypophyseal fossa. This patient was referred to nuclear medicine<br />
department for 68Ga-DOTATATE PET/CT imaging and the scan<br />
detected focal 68Ga-DOTATATE uptake in the pituitary gland location.<br />
RESULTS AND CONCLUSION: Pituitary adenomas are suspected if<br />
there are hyperthyroidism and/or galactorrhea symptoms and it’s<br />
usually used MRI for detection of this adenoma. According to<br />
guidelines, 68Ga-Peptide PET/CT can be helpful in the detection of<br />
pituitary adenomas, but there is no literature or case report about<br />
using this imaging to find the pituitary adenomas. In this case we<br />
reported intense 68Ga-DOTATATE uptake in the location of adenoma.<br />
According to this case we can use 68Ga-Peptide PET/CT to detect<br />
pituitary adenomas, also taking whole body scan beside the scan of<br />
interest region.<br />
Keywords: Pituitary adenoma, PET/CT, Sella MRI<br />
131
3rd International Congress 3rd International of Nuclear Congress Medicine of Nuclear & 15th Medicine Iranian Annual & 15th Iranian Congress Annual of<br />
Nuclear Congress Medicine of Nuclear Medicine<br />
Shahid Beheshti Shahid Beheshti University University of Medical Sciences of Medical 19-21 Sciences May 201119-21 May 2011<br />
Evaluation of different pattern bone metastasis from breast,<br />
lung, prostate and gastrointestinal cancers in whole body<br />
bone scans<br />
Vahid Reza Dabbagh Kakhki, Kazem Anvari, Ramin Sadeghi,<br />
Anooshesadat Mahmoudian<br />
Mashhad University of Medical Science, Nuclear Medicine Research Center<br />
Introduction: Bone metastasis is one of the important and disabling<br />
side effects of cancers, so immediate diagnosis can improve the<br />
quantity and quality of patient's life and prevent from disabling<br />
factors. Metastatic patterns of different cancers may be helpful for<br />
physicians to follow up the existence of bone metastasis. These kinds<br />
of researches were done in different countries and races, therefore,<br />
we decided to evaluate bone metastasis of variable cancers in<br />
Nuclear Medical Center of Imam Reza hospital in Mashhad.<br />
Materials & Methods: In this descriptive cross sectional study we<br />
assessed bone metastasis in lung. GI, prostate and breast cancers<br />
among patients referred to Imam Reza hospital to do bone scan.<br />
Bone scan procedure includes three steps: 1- Injection of 2mc TC99-<br />
MDP 2- Whole body bone scan (Ant and post view) 3- According to<br />
check list watch includes location, number intensity, bone metastasis<br />
is reported in both genders with different ages.<br />
Results: 160 patients were studied (113 male and 47 female) with a<br />
mean age of 55.66±14.08 years. The prevalence of breast, prostate,<br />
GI and lung cancers among these patients were 107, 32, 13 and 8,<br />
respectively. Metastasis was found in 58 patients.<br />
Conclusion: The most prevalent locations of metastasis are: ribs,<br />
lumbar vertebrae, thoracic vertebrae, sternum and pelvis,<br />
respectively. High frequency of bone metastatic lesions is seen in ribs<br />
and lumbar vertebrae.<br />
Keywords: Bone Scan, Bone metastasis<br />
132
3rd International Congress of of Nuclear Medicine & & 15th 15th Iranian Annual Annual Congress of<br />
Congress of Nuclear Medicine<br />
Shahid Beheshti Shahid Beheshti University University of Medical of Medical Sciences Sciences 19-21 19-21 May May 2011<br />
Recent developments in RPC Technology for PET Detector<br />
Akbar Anvari, Doman Arefan, Alireza Kamali-asl<br />
Department of Radiation Medicine<br />
Introduction: In this study, small animal positron emission<br />
tomography system based on the resistive plate chamber technology<br />
is briefly reviewed. RPC invented in 1980, experimental and<br />
theoretical studies of it are still under development. RPCs are<br />
gaseous parallel plate detectors with good spatial and time resolution<br />
and high efficiency. They operating at atmospheric pressure with<br />
non-flammable gases and they made with glass and metal electrodes<br />
that separated by precision spacers.<br />
Methods: The system is composed of two counting heads, able to<br />
measure the photon interaction point in two dimensions, the<br />
transaxial dimension and the Depth of Interaction. Each head<br />
composed of 16 single-gap RPC detectors capable of detecting the<br />
photon interaction point in the transaxial plane.<br />
Results: The yields of prototype RPC-PET reconstructed 22Na pointsource<br />
reported, spatial resolution of 0:6 mm FWHM without parallax<br />
error and time resolution below 50 ps σ with efficiencies 99% for<br />
minimum ionizing particles.<br />
Conclusions: RPC technology to be very appropriate for used in<br />
small animal PET systems, providing a very high spatial resolution<br />
and efficiency with accurate TOF at a low cost.<br />
Keywords: RPC, PET, TOF<br />
133
3rd International Congress 3rd International of Nuclear Congress Medicine of Nuclear & 15th Medicine Iranian Annual & 15th Iranian Congress Annual of<br />
Nuclear Congress Medicine of Nuclear Medicine<br />
Shahid Beheshti Shahid Beheshti University University of Medical Sciences of Medical 19-21 Sciences May 201119-21 May 2011<br />
Biological studies of samarium-153 bleomycin complex in<br />
human breast cancer murine xenografts for therapeutic<br />
applications<br />
Ali Bahrami-Samani, Amir Reza Jalilian, Mohammad Mazidi,<br />
Mohammad Ghannadi-Maragheh<br />
Radiopharmaceutical Research and Development Lab (RRDL)<br />
Introduction: Bleomycins are tumor seeking antibiotics that are<br />
widely used in cancer chemotherapy produced by the bacterium<br />
Streptomyces verticullus. Bleomycin as well as other compounds such<br />
as doxorubicin, methotrextate, dactinomycin, cisplatin is an<br />
important chemotherapeutic agent while possesses no bone marrow<br />
depression. It is believed that bleomycin antibiotics interfere with<br />
DNA as false nucleotides, assuming the dithiazole moiety acts like a<br />
purine base.<br />
Methods: In this work, a potential therapeutic DNA targeting agent,<br />
153Sm-bleomycin complex (153Sm-BLM), was developed and the<br />
tumor accumulation studies were performed using single photon<br />
emission computed tomography (SPECT) and scarification studies.<br />
153Sm-BLM was prepared at optimized conditions (room<br />
temperature, 4-8 h, 0.1 mg bleomycin for 740-3700 MBq 153SmCl3,<br />
radiochemical purity over 98%, HPLC, specific activity = 55<br />
TBq/mmol).<br />
Results: 153Sm-BLM was administered into human breast cancer<br />
murine xenografts and the biodistribution and imaging studies were<br />
performed up to 48h. 153Sm-BLM demonstrated superior tumor<br />
accumulation properties in contrast with the other radiolabeled<br />
bleomycins with tumor:blood ratios of 41, 72 and 182 at 4, 24 and<br />
48 h respectively and tumor:muscle ratios of 23, 33 and >1490 at 4,<br />
24 and 48 h respectively while administered intravenously. The<br />
SPECT images also demonstrated the obvious tumor uptake at the<br />
chest region of the breast-tumor bearing mice.<br />
Conclusion: These initial experiments demonstrate significant<br />
accumulation of 153Sm-BLM in tumor tissues. 153Sm-BLM is a<br />
potential therapeutic compound and our experiments on this<br />
compound have shown satisfactory quality, and stability suitable for<br />
future therapeutic studies.<br />
Keywords: Bleomycin, Sm-153, breast cancer-xenograft,<br />
Biodistribution, SPECT<br />
134
3rd International Congress of of Nuclear Medicine & & 15th 15th Iranian Annual Annual Congress of<br />
Congress of Nuclear Medicine<br />
Shahid Beheshti Shahid Beheshti University University of Medical of Medical Sciences Sciences 19-21 19-21 May May 2011<br />
Development of radiogallium ethylenecysteamine cysteine<br />
complex as a possible renal imaging agent<br />
Amir Reza Jalilian, Hassan Yousefnia, Samaneh Zolghadri,<br />
Mohammad Khoshdel, Fatemeh Bolourinovin, Ali Rahiminejad<br />
Nuclear Science and Technology Research Institute<br />
The interesting physical properties and availability of gallium-67<br />
make it an interesting nuclide for radiopharmaceutical research. The<br />
mono-carboxylic derivative of EC, i.e., ECC has only been reported as<br />
99mTc complex [12] use in renal imaging. Since there was no report<br />
of any radiogallium radiolabeled ethylenecysteamine cysteine (ECC)<br />
in the literature, in this study we developed a new radiogallium-ECC<br />
complex demonstrating significant urinary excretion like that of the<br />
homolog Tc-99m compound (99mTc-ECC) for future 68Ga-homolog<br />
development.[67Ga]-ethylenecysteamine cysteine ([67Ga]ECC)was<br />
prepared using freshly prepared [67Ga]GaCl3 and<br />
ethylenecysteamine cysteine (ECC) for 30 min at 90C (radiochemical<br />
purity &97 ± 0.88% ITLC, specific activity: 210 ± 5 GBq/mM).<br />
Stability of the complex was checked in human serum for 24 h at 37<br />
C. Partition coefficient of the tracer in octanol:saline mixture was<br />
determined (log P; 0.8). The biodistribution of the radiolabeled<br />
compound in vital organs of wild-type rats were compared with that<br />
of free Ga3? cation up to 48 h. Initial biodistribution results showed<br />
significant kidney excretion of the tracer comparable to that of<br />
homologous 99mTc compound.<br />
Keywords: 7Ga-complexation, Ethylenecysteamine cysteine,<br />
Biodistribution, Renal agent<br />
135
3rd International Congress 3rd International of Nuclear Congress Medicine of Nuclear & 15th Medicine Iranian Annual & 15th Iranian Congress Annual of<br />
Nuclear Congress Medicine of Nuclear Medicine<br />
Shahid Beheshti Shahid Beheshti University University of Medical Sciences of Medical 19-21 Sciences May 201119-21 May 2011<br />
Preparation, quality control and biodistribution studies of<br />
[61Cu]-oxinate for PET tumor imaging<br />
Amir Reza Jalilian 1 , Samaneh Zolghadri 1 , Reza Faghihi 2 , Hassan<br />
Yousefnia 1 , Javad Garousi 1 , Kamaledin Shafaii 1<br />
1 Nuclear Science and Technology Research Institute<br />
2 Shiraz University<br />
Targeting apoptosis is an interesting issue in molecular imaging and<br />
various modalities have been presented. However recent experiences<br />
in nuclear pharmacy demonstrated the application of small tracer<br />
molecules is more desired. This work was conducted for production of<br />
a radiolabeled copper complex, i.e. 61Cu-oxinate as a potential PET<br />
tracer for apoptosis imaging in oncology. Cu-61 was prepared from<br />
natural zinc target irradiation by 22 MeV protons (150 uA) via nuclear<br />
reaction with a yield of 3.33 mCi/µAh. In order to obtain the best<br />
labeling method optimization reactions were performed for pH,<br />
temperature and concentration followed by solid phase extraction.<br />
Biodistribution of the tracer was studied in wild-type and<br />
fibrosarcoma bearing mice. At the optimized conditions, radio-thinlayer<br />
chromatography (RTLC) and HPLC showed radiochemical<br />
purities of 99.99% and 97% respectively (with a minimum specific<br />
activity of 16 Ci/mM). Biodistribution of the tracer in fibrosarcoma<br />
bearing mice demonstrated significant tumor uptake after 3h.<br />
Tumor:blood and tumor:muscle ratios were 2.0 and 6.0 respectively<br />
at 3 h.<br />
Keywords: Cu-61, oxine, PET, Fibrosarcoma<br />
136
3rd International Congress of of Nuclear Medicine & & 15th 15th Iranian Annual Annual Congress of<br />
Congress of Nuclear Medicine<br />
Shahid Beheshti Shahid Beheshti University University of Medical of Medical Sciences Sciences 19-21 19-21 May May 2011<br />
Evaluation of difference between pure positron emitter and<br />
non-pure positron emitter in three gamma PET imaging<br />
Amir Hakimi, Dariush Sardari<br />
Department of Nuclear Engineering<br />
Introduction and Purpose: PET is a technique for measuring the<br />
concentrations of positron-emitting radioisotopes within the body by<br />
registering the emitted annihilation radiation. At present, the basic<br />
process employed in PET is the annihilation of the emitted positron an<br />
electron that results in two almost co-linear gamma-photons<br />
travelling in opposite directions, each with 511 keV energy. Recently<br />
it has been shown, that extra information could also be obtained in<br />
PET by registering the annihilations into three photons. In spite of the<br />
relative rareness of positron annihilation into three photons, it may<br />
still be exploited to develop a new imaging modality. Although the<br />
rate of 3gamma decays is small, the positioning information<br />
conveyed by a single event is much larger than in the case of two<br />
gamma, so the total information gained from three gamma may be<br />
significant.<br />
Material and Methods: Three high resolution detectors arranged in<br />
a plane forming angels of about 120° with respect to each other to<br />
form a primitive 3-gamma scanner. Each detector generates pulse,<br />
which passes to a time pick-off units. Using non-pure positron emitter<br />
such as 22Na, cause increasing the probability of random coincidence<br />
while the level of background would be much lower for a pure<br />
positron emitter, e.g., 18F.<br />
Results: Three gamma imaging would provide information not only<br />
about the local concentration of radionuclide, but also, by virtue of<br />
chemical interactions of Positronium, the local chemical environment<br />
in tissue. Using pure positron emitter according to energy and time<br />
window will drop up the proportion of true 3gamma-counts. Random<br />
triple coincidences can also arise due to a single 2gamma-annihilation<br />
when one of the 5ll keV photons is Compton scattered from one<br />
detector into one of two others, the third one begin hit by the nuclear<br />
photon of non-pure positron emitter, partially detected.<br />
Keywords: Three gamma, PET, Random coincidence<br />
137
3rd International Congress 3rd International of Nuclear Congress Medicine of Nuclear & 15th Medicine Iranian Annual & 15th Iranian Congress Annual of<br />
Nuclear Congress Medicine of Nuclear Medicine<br />
Shahid Beheshti Shahid Beheshti University University of Medical Sciences of Medical 19-21 Sciences May 201119-21 May 2011<br />
Preparation, quality control and biodistribution studies of<br />
[61Cu]-doxorubicin for PET tumor imaging<br />
Amir Reza Jalilian 1 , Hassan Yousefnia 1 , Reza Faghihi 2 , Mehdi<br />
Akhlaghi 1 , Hassan Zandi 1<br />
1 Nuclear Science and Technology Research Institute<br />
2 Shiraz University<br />
This work was conducted for radiolabeling of an anticancer antibiotic,<br />
i.e. doxorubicin with Cu-61 for production of possible tracer used in<br />
PET oncology. Cu-61 was prepared from natural zinc target<br />
irradiation by 22 MeV protons (150 A) via nuclear reaction with a<br />
yield of 3.33 mCi/µAh. In order to obtain the best labeling method<br />
optimization reactions were performed for pH, temperature and<br />
concentration. Biodistribution of the tracer was studied in normal and<br />
fibrosarcoma bearing mice. At the optimized conditions, ITLC showed<br />
radiochemical purity more than 97% with a specific activity of 0.06<br />
Ci/mM. This was kept unchanged even with presence of human<br />
serum as well as room temperature for 5h. Biodistribution of the<br />
tracer in fibrosarcoma bearing mice demonstrated significant tumor<br />
uptake after 2h. This tracer can be used in the detection of various<br />
tumors responding to doxorubicin chemotherapy using PET scan<br />
and/or determination of tumor therapy response to doxorubicin<br />
chemotherapy.<br />
Keywords: Copper-61, Doxorubicin, Radiolabeling, Biodistribution<br />
138
3rd International Congress of of Nuclear Medicine & & 15th 15th Iranian Annual Annual Congress of<br />
Congress of Nuclear Medicine<br />
Shahid Beheshti Shahid Beheshti University University of Medical of Medical Sciences Sciences 19-21 19-21 May May 2011<br />
Development of 153Sm-[Tris (1,10 Phenanthroline) Samarium<br />
(III)]trithiocyanate complex as a therapeutic agent<br />
Amir Reza Jalilian 1 , Amir Hakimi 2 , Simindokht Shirvani-Arani 1 ,<br />
Mohammad Ghannadi-Maragheh 1<br />
1 Radiopharmaceutical Research and Development Lab (RRDL)<br />
2 Department of Nuclear Engineering<br />
In this work, 153Sm-[Tris(1,10-phenanthroline) Samarium(III)]<br />
trithiocyanate (153Sm-TPTTC) was developed for possible therapeutic<br />
properties. The cold compound, i.e. natSm-TPTTC was prepared and<br />
characterized by IR, UV and 1H NMR spectroscopy. 153Sm-TPTTC<br />
was prepared starting 153Sm-SmCl3, prepared by neutron activation<br />
of an enriched 152Sm sample (purity >98%), in 1h at 25ï‚°C.<br />
Stability tests, partition coefficient determination and biodistribution<br />
studies of the complex in wild-type rats were also determined. The<br />
radiolabeled complex was prepared in high radiochemical purity<br />
(>99% precipitation method) and specific activity of 278 GBq/mmol<br />
and demonstrated significant stability at 4, 25 and 37ï‚°C (in<br />
presence of human serum). Hepatotoxicity of the cold compound was<br />
also checked by serum enzyme measurements after rat<br />
administration. Initial biodistribution data showed significant bone<br />
accumulation of the tracer in 48h. The produced 153Sm- TPTTC<br />
properties suggest an efficiently new liver accumulating therapeutic<br />
agent in order to overcome possible liver malignancies with the<br />
lowest toxicity.<br />
Keywords: Therapy Biodistribution Phenanthroline Sm-153<br />
139
3rd International Congress 3rd International of Nuclear Congress Medicine of Nuclear & 15th Medicine Iranian Annual & 15th Iranian Congress Annual of<br />
Nuclear Congress Medicine of Nuclear Medicine<br />
Shahid Beheshti Shahid Beheshti University University of Medical Sciences of Medical 19-21 Sciences May 201119-21 May 2011<br />
The development of radiogallium-acetylacetonate bis<br />
(thiosemicarbazone) complex for tumour imaging<br />
Amirreza jalilian, Hassan yousefnia, Javad Garousi, Aytak Novinrouz,<br />
Amir Rajamand, Kamaledin Shafaii<br />
Nuclear Science and Technology Research Institute<br />
Various radiometal complexes have been developed for tumor<br />
imaging, especially Ga-68 tracer. In this work, the development of a<br />
radiogallium bis (thiosemicarbazone) complex has been<br />
reported.[67Ga] acetylacetonate bis (thio-semicarbazone)complex<br />
([67Ga]AATS) was prepared starting with [67Ga]Gallium acetate and<br />
freshly prepared acetylacetonate bis (thiosemicarbazone) (AATS) for<br />
30 min at 90∞C. The partition co-efficient and stability of the tracer<br />
was determined in final solution (25C) and the presence of human<br />
serum (37C) for up to 24 hours. The biodistribution of the labeled<br />
compound in wild-type and fibrosarcoma-bearing rodents were<br />
determined for up to 72 hours. The radiolabelled Ga complex was<br />
prepared to a high radiochemical purity (> 97%, HPLC) followed by<br />
initial biodistribution data with the significant tumour accumulation of<br />
the tracer at two hours, which is far higher than free Ga-67 cation,<br />
while the compound wash-out is significantly faster. The abovementioned<br />
pharmacokinetic properties suggest an interesting<br />
radiogallium complex prepared by the PET Ga radioisotope, 68Ga, in<br />
accordance with the physical half life, for use in fibrosarcoma<br />
tumours and possibly in other malignancies.<br />
Keywords: Gallium-67, acetyl acetone bis (thiosemicarbazonate),<br />
biodistribution, fibrosarcoma<br />
140
3rd International Congress of of Nuclear Medicine & & 15th 15th Iranian Annual Annual Congress of<br />
Congress of Nuclear Medicine<br />
Shahid Beheshti Shahid Beheshti University University of Medical of Medical Sciences Sciences 19-21 19-21 May May 2011<br />
Preparation, Quality control studies of [90Y]-DOTA-Cetuximab<br />
for radioimmunotherapy<br />
Ariandokht Vakili 1 , Simindokht Shirvani-Arani 2 , Dariush Sardari 1 , Ali<br />
Bahrami-Samani 2 , Mohamad Ghanadi-Maragheh 2<br />
1 Islamic Azad university<br />
2 Radiopharmaceutical Research and Development Lab (RRDL)<br />
Introduction: Yttrium-90 is a useful radionuclide for<br />
radioimmunotherapy (RIT), due to its energetic beta emissions<br />
(Emax=2.3 MeV), ready availability at moderate cost and absence of<br />
γ emissions, allowing outpatient RIT. Its half-life of 64 hr is<br />
comparable to the uptake and residence time of many antibodies on<br />
the tumor. The anti-epidermal growth factor receptor (anti-EGFR)<br />
antibody Cetuximab is clinically approved for the treatment of EGFRexpressing<br />
metastatic colorectal cancer and advanced head and neck<br />
cancer. The overall goal of this study was to develop the<br />
radioimmunoconjugation of monoclonal anti-EGFR with 90Y as a<br />
potential tracer for radioimmunotherapy(RIT).<br />
Methods: Cetuximab was successively labeled with [90Y] chloride<br />
(185MBq) 5mCi after conjugation with macrocyclic bifunctional<br />
chelating agent , 1,4,7,10-tetraazacyclododecane-N,N,N,N-tetraacetic<br />
acid mono-(N-hydroxysuccinimidyl) ester (DOTA-NHS). Conjugated<br />
Cetuximab was obtained by the addition of 1ml of Cetuximab<br />
pharmaceutical solution (2mg/1ml , in phosphate buffer pH=8) to a<br />
glass tube pre-coated with DOTA-NHS at 25°C with continuous mild<br />
stirring for 15h. Y-90 chloride was obtained by thermal neutron flux<br />
(4 — 1013 n.cm-2.s-1) of a natural Y2O3 sample, dissolved in acidic<br />
media. Radiolabeling was completed in 24 hours by the addition of<br />
DOTA-NHS-Cetuximab conjugate at 37°C. The stability of<br />
radiolabeled was studied in human serum. For biological evaluation<br />
we carried out the cell binding assay.<br />
Results: Radiochemical purity of 92% (using ITLC) was obtained for<br />
final radioimmunoconjugate (Specific activity = 440-480 MBq/mg).<br />
The final isotonic 90Y-Cetuximab complex was checked by gel<br />
electrophoresis for protein integrity retention. Stability of radiolabeled<br />
protein in presence of human serum was tested at 37°C for up to<br />
24h. A high binding affinity was determind for the<br />
radioimmunoconjugate (90Y-DOTA-NHS-Cetuximab) in comparison to<br />
radiolabeled bifunctional chelating agent(90Y-DOTA).<br />
Conclusion: This study demonstrated that 90Y-DOTA-NHS-<br />
Cetuximab is a potential compound for the treatment of EGFRexpressing<br />
cancers. The experiments on animal models should be<br />
performed for this radioimmunoconjugate before human use.<br />
Keywords: Radiopharmaceutical, Yttrium-90, Cetuximab,Targetted<br />
Therapy<br />
141
3rd International Congress 3rd International of Nuclear Congress Medicine of Nuclear & 15th Medicine Iranian Annual & 15th Iranian Congress Annual of<br />
Nuclear Congress Medicine of Nuclear Medicine<br />
Shahid Beheshti Shahid Beheshti University University of Medical Sciences of Medical 19-21 Sciences May 201119-21 May 2011<br />
Synthesis and biodistribution studies of 67Ga-DOTAtrastuzumab<br />
as a diagnostic radioimmunoconjugate for<br />
oncology imaging by SPECT<br />
Behrooz Alirezapour 1 , Amir Reza Jalilian 1 , Mohammad javad Rasaee 2 ,<br />
Saeed Rajabifar 1 , Kamal Yavari 1 , Javad Mohammadnejad 1 ,<br />
Mohammad Reza Aboudzadeh 1 , Fatemeh Bolourinovin 1 , Sedigheh<br />
Moradkhani 1 , Mojtaba Fathi 2<br />
1 Nuclear Science and Technology Research Institute (NSTRI)<br />
2 Tarbiat Modares University(TMU)<br />
Introduction: Radiolabeled monoclonal antibodies have shown great<br />
promise for cancer diagnosis and therapy. Trastuzumab (trade name;<br />
Herceptin) is a humanized IgG1 monoclonal antibody directed against<br />
the extracellular domain of the Human Epidermal Growth Factor<br />
Receptor 2(HER2). HER 2 receptor is over expressed in 20-30% of<br />
the early-stage breast cancers and these patients may be candidates<br />
for Herceptin treatment. we attempted to label trastuzumab with<br />
radioactive gallium(67Ga) 67Ga is cyclotron produced, decays by<br />
electron capture (EC) with t1/2 = 77.9h accompanied with γ-rays,<br />
mainly 93, 184 and 296 keV, and is suitable for SPECT imaging. In<br />
the present study, 67Ga labeled trastuzumab was prepared followed<br />
by the biodistribution studies in normal mice.<br />
Methods: Herceptin was conjugated with DOTA-NHS-ester<br />
(Macrocyclics), purified by molecular filtration, the average number of<br />
DOTA conjugated per mAb was calculated and total concentration<br />
was determined by spectrophotometrically. DOTA-Trastuzumab was<br />
labeled with 67Ga then Radiochemical purity, integrity of protein after<br />
radiolabeling and stability of 67Ga -DOTA-Trastuzumab were<br />
determined. The biodistribution studies was performed in normal rats<br />
(67Ga -DOTA-Trastuzumab i.v., 75 ± 5.5 µCi, 30min, 2h, 4h, 24h,<br />
48h, 72h).<br />
Result: The radioimmunoconjugate was prepared with a<br />
radiochemical purity of 88% (RTLC). The average chelate to antibody<br />
ratio(c/a) for the conjugate used in this study was 5.8:1. The final<br />
compound was stable in presence of PBS at 37ºC and room<br />
temperature.The sample were showed to have similar patterns of<br />
migration in the gel electrophoresis.The accumulation of the<br />
radiolabeled antibody in lungs, liver, spleen and other tissues<br />
demonstrates a similar pattern to the other radiolabeled anti-HER2<br />
immunoconjugates.<br />
Conclusion: 67Ga-DOTA-Trastuzumab is potentially good probe for<br />
diagnosis and treatment studies of HER2 expression in oncology by<br />
SPECT.<br />
Keywords: 67Ga DOTA, Radioimmunoconjugate, Trastuzumab,<br />
HER2<br />
142
3rd International Congress of of Nuclear Medicine & & 15th 15th Iranian Annual Annual Congress of<br />
Congress of Nuclear Medicine<br />
Shahid Beheshti Shahid Beheshti University University of Medical of Medical Sciences Sciences 19-21 19-21 May May 2011<br />
Calculation of relative dose of human body produced by fusion<br />
neutrons using MCNP code<br />
Masoode Abdolahzade 1 , Masome Nonbede 2 , Yaser kasesaz 3 , Amir<br />
Moslehi 3 , Davoode Gasemabadi 1 , Mohsen Shayeste 1<br />
1 Imam Hossein University<br />
2 Tehran Center Azad University<br />
3 Atomic Energy Organization of Tehran<br />
In this paper a simulated phantom of adult human body using Monte<br />
Carlo method and MCNP code, is used for the neutron effective dose<br />
equivalent calculation. The plasma focus device emits neutrons with<br />
2.45 MeV energy in D-D fusion reactions. Effective dose equivalent is<br />
calculated in four geometry, AP, PA, LLAT, RLAT, for some organs by<br />
the weight coefficients of radiation and the tissue weight factor<br />
reported by ICRP. The results are compared by the occupational<br />
exposures effective dose equivalent recommended by ICRP.<br />
Keywords: Neutron emission, Dosimetery, Phantom, CodeMCNP<br />
Simulation<br />
143
3rd International Congress 3rd International of Nuclear Congress Medicine of Nuclear & 15th Medicine Iranian Annual & 15th Iranian Congress Annual of<br />
Nuclear Congress Medicine of Nuclear Medicine<br />
Shahid Beheshti Shahid Beheshti University University of Medical Sciences of Medical 19-21 Sciences May 201119-21 May 2011<br />
Biological and Dosimetry Studies of Three Radiolabeled of<br />
Rituximab for Human Based on Distribution Data in Rats<br />
Edalat Radfar 1 , Amir Reza Jalilian 1 , Ariandokht Vakili 2 , Ali Bahrami-<br />
Samani 1 , Hassan Yousefnia 1 , Simindokht Shirvani-Arani 1 , Mohammad<br />
Ghannadi-Maragheh 1<br />
1 Radiopharmaceutical Research & Development Laboratory (RRDL)<br />
2 Islamic Azad University<br />
Introduction: Rituximab binds with human B-lymphocate-restricted<br />
differentiation antigen: CD20. Many beta emitters such as I-131, Y-<br />
90, Sm-153 and Lu-177 were widely used in antibody labeling for<br />
radioimmunotherapy (RIT).<br />
Purpose: In the present article, preparation and biodistribution of<br />
177Lu, 153Sm and 90Y labeled rituximabs have been studied and<br />
followed by calculation of preliminary dosimetry for human based on<br />
distribution data in rats by acceptable approximations.<br />
Method: Radiolabeled compound was prepared according to the<br />
methods previously given in the literature and their QCs and stability<br />
testing was run completely. 177Lu-DOTA-rituximab, 90Y-DOTArituximab<br />
and 153Sm-DOTA-rituximab were administered to normal<br />
rats separately (10-15 rats). The animals were killed at the exact<br />
time and the specific activities of different organs were measured by<br />
using an HPGe detector (for 177Lu and 153Sm) and a beta scintillator<br />
detector (for 90Y). The following equation was used to extrapolate<br />
biodistribution data of radiolabeled from rats to humans: %ID/g<br />
human organ = %ID/g animal organ * k k= Body mass animal/ Body<br />
mass human Absorbed dose rate of each organ was calculated in<br />
determined time by MIRD method with linear approximation in<br />
measurement of activities.<br />
Result: Absorption and biodistribution of radiolabeled in organs of<br />
rats were determined by measuring %ID/g at different times. The<br />
uptakes were observed in limited organs such as liver, spleen and<br />
lungs and less in kidneys, bone and blood.<br />
Discussion: Dose rate estimate was calculated for 1.5 times more<br />
than effective half-life of each radiolabeled. The results showed that<br />
the high absorbed dose is in liver, lungs and spleen; and absorbed<br />
dose of other organs is low as acceptable level values.<br />
Keywords: Lu-177 Radiolabeled Rituximab, Biodistribution,<br />
Dosimetry, MIRD<br />
144
3rd International Congress of of Nuclear Medicine & & 15th 15th Iranian Annual Annual Congress of<br />
Congress of Nuclear Medicine<br />
Shahid Beheshti Shahid Beheshti University University of Medical of Medical Sciences Sciences 19-21 19-21 May May 2011<br />
Comparative Assessment of Different Energy Mapping<br />
Methods in CT-Based Attenuation Correction in PET/CT<br />
Systems Using Whole Body XCAT Phantom<br />
Elham Soleimani, Mohammad Reza Ay, Majid Pouladian<br />
Introduction: This paper presents the result of assessing different<br />
attenuation correction methods for PET data according to CT data<br />
(CTAC). These methods are intended for use with a combined PET/CT<br />
scanner. We discuss five possible methods of energy mapping from<br />
the CT energies to the required 511keV. CT images are obtained<br />
using a computerized whole body phantom, 4DXCAT, which is<br />
simulation of physically and anatomically of human body.<br />
Materials and methods: The aim of this study is to compare<br />
different energy-mapping techniques: scaling, segmentation, hybrid,<br />
bilinear calibration curve and dual energy approach through<br />
attenuation map generated from CT data through XCAT phantom.<br />
The CT images acquired from XCAT phantom are applied to generate<br />
µ-maps in 511keV. Then these generated µ-maps are compared to<br />
the image acquired from XCAT phantom in 511keV as the gold<br />
standard image. For comparing methods we use three ways:<br />
Assessing different ROIs, correlation coefficients and difference<br />
images for comparing pixel by pixel.<br />
Results and Discussion: Nearly all energy-mapping methods shown<br />
similar results in soft tissues. A noticeable relative difference is seen<br />
in lung tissues in Segmentation method which refers to the variability<br />
in densities. Also a bias in bone in the same method, which is due to<br />
the extended borders of the segments. In Scaling results for different<br />
tissues are acceptable beside bone as it has a high photoelectric<br />
ratio. Hybrid and Bilinear are somehow good. Dual Energy reports the<br />
best results.<br />
Keywords: attenuation correction, PET/CT, XCAT Phantom<br />
145
3rd International Congress 3rd International of Nuclear Congress Medicine of Nuclear & 15th Medicine Iranian Annual & 15th Iranian Congress Annual of<br />
Nuclear Congress Medicine of Nuclear Medicine<br />
Shahid Beheshti Shahid Beheshti University University of Medical Sciences of Medical 19-21 Sciences May 201119-21 May 2011<br />
Evaluation of<br />
153 Sm-EDTMP as a therapeutic<br />
radiopharmaceutical for bone pain palliation in clinical test<br />
G.A. Shabani, H.R. Khosrounejad, F. Hajhasan Abbasi, M. Farahani,<br />
M. Goudarzi, Y.H. Tavakoli, M.H. Talebi<br />
Radioisotope research group, NSTRI, Atomic Energy org. of Iran,<br />
Introduction: Owing to its favorable decay characteristic of<br />
153 Sm[t 12 =46.27h, Eβ (max) =810 KeV and Eγ=103KeV] and EDTMP<br />
(Ethylene diamine tetra methylene phosphonate as a ligands, is one<br />
of the most widely used as therapeutic radiopharmaceutical for bone<br />
pain palliation. Also it was approved by FDA in 1997.<br />
Methods: Enriched 152 Sm target was irradiated by thermal neutron<br />
flux in Tehran research reactor then dissolved in acidic media; EDTMP<br />
was dissolved in DDW. After labelling, the QC and RCP were done by<br />
ITLC chromatography.<br />
Results: Radiochemical purity of 153 Sm-EDTMP was more than 98<br />
percent at RT. Biodistribution in rat was the same the other<br />
references.<br />
Conclusion: More than 20 patients received our produced 153 Sm-<br />
EDTMP as a bone pain palliation.<br />
Keywords: 153 Sm, Bone Pain palliation, EDTMP<br />
146
3rd International Congress of of Nuclear Medicine & & 15th 15th Iranian Annual Annual Congress of<br />
Congress of Nuclear Medicine<br />
Shahid Beheshti Shahid Beheshti University University of Medical of Medical Sciences Sciences 19-21 19-21 May May 2011<br />
Photon scatter and penetration in parallel hole collimator in<br />
preclinical Gamma Camera: A Monte Carlo study<br />
Farzaneh Adibpour 1 , Mohammad Reza Ay 1 , Saeed Sarkar 1 , George<br />
Loudos 2<br />
1 Department of Medical Physics and Biomedical Engineering<br />
2 Department of Medical Instrument Technology<br />
Introduction: Parallel hole SPECT is rapidly obtaining popularity for<br />
preclinical imaging using gamma-emitting molecules. Scatter and<br />
septal penetration degrade contrast and quantitative accuracy in<br />
SPECT. The magnitude of penetrated and scattered photons depends<br />
on the photon’s energy, object under study and collimator design<br />
parameters. The main goal of this study is to quantify the effects of<br />
penetration and scatter as function of collimator thickness and septa<br />
with parallel hole collimator (made of lead).<br />
Methods: In this study, GATE was applied for accurate modeling of<br />
collimator. In order to separate the contribution of scatter and<br />
penetration components, we simulated Tc-99m and I-131 point<br />
sources in air,5cm away from the detector surface. To evaluate<br />
penetration and scatter in collimator, three different classes are<br />
considered in order to classify the registered events. In first category<br />
there are photons which were registered within the crystal under<br />
which the source has been located. This group is called true photons.<br />
In the second group, penetration occurs when the photon without any<br />
interaction with collimator, are detected in another crystal. Third<br />
category belongs to photons incident which experience one or more<br />
scatter interaction in collimator and finally were registered in another<br />
crystal.<br />
Result: Simulation results demonstrated that in case of Tc-99m point<br />
source with collimator thickness of 10mm only approximately 18% of<br />
the photons detected resulted from both penetration and scatter<br />
while this ratio will increase to 85% for I-131.By increasing collimator<br />
thickness fraction of photons undergo penetration and scattering<br />
decrease particularly for collimator thickness above 25mm(for<br />
140keV photons).The results also indicate, increasing collimator septa<br />
from 0.1 to 0.4 leads to 8% decrease in penetration and scatter in<br />
our desired energy window.<br />
Conclusion: The current assessment of septal penetration and septal<br />
scatter in parallel hole collimator not only provides a deeper<br />
understanding of their respective contributions but is also aimed to<br />
be utilized for optimization of collimator design in high resolution<br />
preclinical imaging.<br />
Keywords: septal penetration, septal scatter, parallel hole collimator<br />
147
3rd International Congress 3rd International of Nuclear Congress Medicine of Nuclear & 15th Medicine Iranian Annual & 15th Iranian Congress Annual of<br />
Nuclear Congress Medicine of Nuclear Medicine<br />
Shahid Beheshti Shahid Beheshti University University of Medical Sciences of Medical 19-21 Sciences May 201119-21 May 2011<br />
Formulation and quality control of<br />
diagnostic of MCT and tumor agent<br />
99m Tc-DMSA(V) as a<br />
G.A. Shabani, H.R. Khosrounejad, M. Farahani, F. Hajhasan Abbasi,<br />
M. Goudarzi, M.H. Talebi, M.H. Mir Falah<br />
Radioisotope research group, NSTRI, Atomic Energy org. of Iran<br />
Introduction: 99m Tc-DMS(V) is a tumor seeking agent that is known<br />
for its ability to detect medullary Thyroid carcinoma (MTC), soft<br />
tissue tumors, lung cancer, metastatic disease and brain tumors.<br />
Medullary thyroid carcinoma (MTC) is a rare thyroid cancer secreting<br />
calcitonin which is the most sensitive and specific marker for MTC.<br />
This type of thyroid cancer is able to metastasize to different body<br />
areas including regional lymph nodes, lung, liver and bone.<br />
Materials and methods: in this study and new formulation for<br />
preparation of 99m Tc-DMS(V) complex, we changed the formulation in<br />
two steps.<br />
Results: radiochemical purity of<br />
99m Tc-DMS(V) complex was<br />
performed by ITLC chromatography at various amount of<br />
Pertechnetate up to 100 mCi and it was more than 95 percent.<br />
Conclusion: Our study showed that the new kit formulation was<br />
stable at Ref up to one year.<br />
Keywords: MTC, DMS(V), 99m Tc<br />
148
3rd International Congress of of Nuclear Medicine & & 15th 15th Iranian Annual Annual Congress of<br />
Congress of Nuclear Medicine<br />
Shahid Beheshti Shahid Beheshti University University of Medical of Medical Sciences Sciences 19-21 19-21 May May 2011<br />
Preparation and quality control of lutetium-177 bleomycin as<br />
a possible therapeutic agent<br />
Hassan Yousefnia, Amir Reza Jalilian, Samaneh Zolghadri, Ali<br />
Bahrami-Samani, Simindokht Shirvani-Arani, Mohammad Ghannadi-<br />
Maragheh<br />
Nuclear Science and Technology Research Institute<br />
Bleomycins are tumor seeking antibiotics that are widely used in<br />
cancer chemotherapy .It is believed that bleomycin antibiotics<br />
interfere with DNA as false nucleotides, assuming the dithiazole<br />
moiety acts like a purine base .It has been shown that labeling of<br />
bleomycin with bi/trivalent radioisotopes can produce<br />
pharmacologically active compounds carrying a diagnostic and/or<br />
therapeutic radioisotope depending on the decay type.Due to<br />
interesting therapeutic properties of 177Lu and antineoblastic<br />
antibiotic, bleomycin (BLM), 177Lu-bleomycin (177Lu-BLM) was<br />
developed as a possible therapeutic compound. Lu-177 of 2.6-3<br />
GBq/mg specific activity was obtained by irradiation of a natural<br />
Lu2O3 sample with a thermal neutron flux of 4x1013 n.cm-2.s-1. The<br />
product was converted into chloride form which was further used for<br />
labeling of BLM. In optimized conditions a radiochemical purity of<br />
98% was obtained for 177Lu-BLM shown by instant thin-layer<br />
chromatography (ITLC) (specific activity, 740 GBq/mmole).<br />
Biodistribution studies of Lu-177 chloride and 177Lu-BLM were<br />
performed in wild-type rats. The accumulation of the radiolabeled<br />
compound in lungs, liver and spleen demonstrates a pattern similar<br />
to the other radiolabeled bleomycins. Lu-BLM is a possible<br />
therapeutic agent in human malignancies and the efficacy of the<br />
compound should be tested in various tumor-bearing models.<br />
Keywords: bleomycin, Lu-177, biodistribution, radiolabeling<br />
149
3rd International Congress 3rd International of Nuclear Congress Medicine of Nuclear & 15th Medicine Iranian Annual & 15th Iranian Congress Annual of<br />
Nuclear Congress Medicine of Nuclear Medicine<br />
Shahid Beheshti Shahid Beheshti University University of Medical Sciences of Medical 19-21 Sciences May 201119-21 May 2011<br />
Preparation and quality control of 177Lu-[tris(1,10-<br />
phenanthroline) lutetium(III)] complex for therapy<br />
Hassan Yousefnia, Amir Reza Jalilian, Samaneh Zolghadri, Ali<br />
Bahrami-Samani, Mohammad Ghannadi-Maragheh<br />
Nuclear Science and Technology Research Institute<br />
The 177Lu-[tris(1,10-phenanthroline)lutetium(III)]complex (177Lu-<br />
PQ3) was prepared successfully with high radiochemical purity<br />
(>99%). Lu-177 chloride was obtained by thermal neutron flux (4<br />
× 1013 n.cm-2.s-1) of natural Lu2(NO3)3 sample, dissolved in<br />
acidic media. The radiochemical yield was checked by measuring of<br />
radiochemical purity of 177Lu-PQ complex by ITLC ( 10mM DTPA,<br />
pH.5, as mobile phase). The final complex solution was injected<br />
intravenously to wild-type male rats and biodistribution of the<br />
complex was checked up to 48 h. the dose limiting organs were<br />
shown to be reticuluendothelial system. The bidsitribution of the<br />
labeled compounds in tumor-bearing animals is under investigation.<br />
Keywords: Lutetium-177, 1,10-Phenanthroquinone, Biodistribution<br />
150
3rd International Congress of of Nuclear Medicine & & 15th 15th Iranian Annual Annual Congress of<br />
Congress of Nuclear Medicine<br />
Shahid Beheshti Shahid Beheshti University University of Medical of Medical Sciences Sciences 19-21 19-21 May May 2011<br />
Development of 177Lu-phytate complex for radiosynovectomy<br />
Hassan Yousefnia, Amir Reza Jalilian, Samaneh Zolghadri, Ali<br />
Bahrami-Samani, Mohammad Mazidi, Mohammad Ghannadi<br />
Maragheh<br />
Nuclear Science and Technology Research Institute<br />
Lu-177 of 2.6-3 GBq/mg specific activity was obtained by irradiation<br />
of natural Lu2O3 sample with thermal neutron flux of 4—1013 n.cm-<br />
2.s-1. The product was converted into chloride form which was<br />
further used for labeling of 177Lu-phytate complex successfully with<br />
high radiochemical purity (>99.9 %, ITLC, MeOH: H2O: acetic acid,<br />
4: 4: 2, as mobile phase). The complex stability and viscosity were<br />
checked in the final solution up to 7 days. The prepared complex<br />
solution (100 µCi/100 µl) was injected intra-articularly to male rat<br />
knee joint. Leakage of radioactivity from injection site and its<br />
distribution in organs were investigated up to 7 days. Approximately,<br />
all injected dose has remained in injection site 7 days after injection.<br />
The complex was proved to be a feasible agent for cavital<br />
radiotherapy in oncology and rheumatology.<br />
Keywords: phytate, radiosynovectomy, lutetium-177, biodistribution<br />
151
3rd International Congress 3rd International of Nuclear Congress Medicine of Nuclear & 15th Medicine Iranian Annual & 15th Iranian Congress Annual of<br />
Nuclear Congress Medicine of Nuclear Medicine<br />
Shahid Beheshti Shahid Beheshti University University of Medical Sciences of Medical 19-21 Sciences May 201119-21 May 2011<br />
Development of [177Lu]-Tetra phenyl porphyrin complexes as<br />
possible imaging agents<br />
Hassan Yousefnia 1 , Amir Reza Jalilian 1 , Samaneh Zolghadri 1 , Yousef<br />
Fazaeli 2 , Ali Bahrami Samani 1 , Mohammad Ghannadi-Maragheh 1<br />
1 Nuclear Science and Technology Research Institute<br />
2 Agriculture, Medicine and Industry Research School<br />
Due to interesting therapeutic properties of 177Lu and tumor avidity<br />
of tetraphenyl porphyrins (TPPs), 177Lu-tetraphenyl porphyrin<br />
(177Lu-TPP) was developed as a possible therapeutic compound. Lu-<br />
177 of 2.6-3 GBq/mg specific activity was obtained by irradiation of<br />
natural Lu2O3 sample with thermal neutron flux of 4—1013 n.cm-<br />
2.s-1. [17Lu]labeled tetraphenyl porphyrin ([177Lu]-TPP) was<br />
prepared using freshly prepared [177Lu]-LuCl3 and tetraphenyl<br />
porphyrin (TPPH2) for 30-60 min at 25°C (radiochemical purity:<br />
>97±1% ITLC, >98±0.5 % HPLC, specific activity: 13-14<br />
GBq/mmol). Stability of the complex was checked in final formulation<br />
and human serum for 24 h. The partition coefficient was calculated<br />
for the compound (log P. 1.89). The biodistribution of the labeled<br />
compound in vital organs of wild-type rats was studied using<br />
scarification studies and SPECT imaging up to 24 h. A detailed<br />
comparative pharmacokinetic study performed for 177Lu cation and<br />
[177Lu]-TPP. The complex is mostly washed out from the circulation<br />
through kidneys and can be an interesting tumor imaging/targeting<br />
agent due to low liver uptake and rapid excretion through the urinary<br />
tract.<br />
Keywords: 177Lu, tetra phenyl prophyrin, biodistribution<br />
152
3rd International Congress of of Nuclear Medicine & & 15th 15th Iranian Annual Annual Congress of<br />
Congress of Nuclear Medicine<br />
Shahid Beheshti Shahid Beheshti University University of Medical of Medical Sciences Sciences 19-21 19-21 May May 2011<br />
Production, quality control and biological evaluation of 177Lu-<br />
1,2-propylene di-amino tetra(methy1enephosphonicAcid) as a<br />
possible bone palliation agent<br />
Hassan Yousefnia, Amir Reza Jalilian, Samaneh Zolghadri, Zohreh<br />
Naseri, Ali Bahrami-Samani, Mohammad Ghannadi Maragheh<br />
Nuclear Science and Technology Research Institute<br />
In this study, production, quality control and biodistribution studies of<br />
a newly developed therapeutic compound have been presented<br />
followed by imaging studies in wild-type rodents. In this study,<br />
177Lu-1,2-propylene di-amino tetra(methy1enephosphonicAcid)<br />
(PDTMP) complex was prepared successfully using synthesized<br />
PDTMP ligand and 177LuCl3. Lu-177 chloride was obtained by<br />
thermal neutron irradiation (4—1013 n.cm-2s-1) of natural Lu2O3<br />
samples. Radiochemical purity of 177Lu-PDTMP was checked by ITLC<br />
(>99%). Stability studies of the complex in the final preparation and<br />
in the presence of human serum were performed up to 72h. The<br />
biodistribution of 177Lu-PDTMP and 177LuCl3 in wild-type rats was<br />
checked in animal tissues up to 7 days. The produced 177Lu-PDTMP<br />
properties suggest a possible new bone palliative therapeutic to<br />
overcome the metastatic bone pains.<br />
Keywords: Lu-177, PDTMP, Radiopharmaceutical, Therapy,<br />
Biodistribution<br />
153
3rd International Congress 3rd International of Nuclear Congress Medicine of Nuclear & 15th Medicine Iranian Annual & 15th Iranian Congress Annual of<br />
Nuclear Congress Medicine of Nuclear Medicine<br />
Shahid Beheshti Shahid Beheshti University University of Medical Sciences of Medical 19-21 Sciences May 201119-21 May 2011<br />
Effect of usual lead apron in decreasing dose rate in nuclear<br />
medicine departments<br />
Hassan Gheshlaghi, Seid-mohammad Haeri, Karim Ghazikhanlou Sani<br />
Hamadan University of Medical Sciences<br />
Introduction: In a busy nuclear medicine department personnel<br />
exposure to radiation is inevitable during patient positioning and<br />
radiotracer preparation. There is controversy regarding usage of<br />
usual lead aprons with respect to penetrating gamma rays used in<br />
nuclear medicine departments as well as production of characteristic<br />
lead x-ray from aprons .This study tries to evaluate the effect of 0.5<br />
mm lead apron on dose reduction.<br />
Methods and materials: We used three point sources usual<br />
radioisotopes used in nuclear medicine departments (99mTc, 201Tl<br />
and 131I) and a single head LFOV gamma camera (SMV, DSX) was<br />
used for counting purposes. The count rate for each source was about<br />
20 Kcount/sec in air and in a brain water phantom. All point sources<br />
were placed at a distance of 3 meters, parallel to the center of the<br />
detector. The collimator was removed and imaging was performed for<br />
1 min with and without lead apron on the detector. Lead apron<br />
covered all field of view of the detector. Each imaging was repeated 3<br />
times and mean count was obtained for each radioisotope.<br />
Result: The measurement and comparison of count rates<br />
(count/min) for each source in different conditions (with and without<br />
apron source in air and in water phantom) showed that count rates<br />
were reduced in air about 77.3%, 84.2% and 40.8% for 99mTc,<br />
201Tl and 131I respectively. The reduction in count rates when<br />
sources placed in brain water phantom were 83.5%, 87% and 53.7%<br />
for the same isotope respectively. As the main source of radiation for<br />
personnel is from scattered photon and with respect to about 83% of<br />
count rate reduction using lead aprons for 99mTc, it is expected that<br />
wearing lead apron significantly decrease dose rate.<br />
Conclusion: Our study showed that lead aprons significantly<br />
decrease count rate and it is expected to reduce dose rate as well.<br />
We recommend wearing apron in NM departments especially at the<br />
time of injection and any times that need to be near the patient for<br />
long times.<br />
Keywords: Nuclear medicine, Dose, Radioisotope, Gamma camera<br />
154
3rd International Congress of of Nuclear Medicine & & 15th 15th Iranian Annual Annual Congress of<br />
Congress of Nuclear Medicine<br />
Shahid Beheshti Shahid Beheshti University University of Medical of Medical Sciences Sciences 19-21 19-21 May May 2011<br />
Development of 177Lu-DOTA-Trastuzumab for<br />
radioimmunotherapy<br />
Hassan Yousefnia, Amir Reza Jalilian, Samaneh Zolghadri, Ali<br />
Bahrami-Samani, Mohammad Ghannadi-Maragheh<br />
Nuclear Science and Technology Research Institute<br />
Trastuzumab was successively labeled with 177Lu-lutetium chloride.<br />
Lu-177 chloride was obtained by thermal neutron flux (4— 013 n.cm-<br />
2.s-1) of natural Lu2O3 sample with a specific activity of 2.6-3<br />
GBq/mg. The macrocyclic bifunctional chelating agent, N-<br />
succinimidyl-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic<br />
acid (DOTA-NHS) was prepared at 25°C using DOTA, N-hydroxy<br />
succinimide (NHS) in CH2Cl2. DOTA-Trastuzumab was obtained by<br />
the addition of 1 ml of a Trastuzumab pharmaceutical solution (5<br />
mg/ml, in phosphate buffer, pH=7.8) to a glass tube pre-coated with<br />
DOTA-NHS (0.01-0.1 mg) at 25°C with continuous mild stirring for 15<br />
h. Radiolabeling was performed at 37°C in 24h. Radio-thin layer<br />
chromatography showed an overall radiochemical purity of >98% at<br />
optimized conditions (specific activity=444 MBq/mg, labeling efficacy;<br />
82%). The final isotonic 177Lu-DOTA-Trastuzumab complex was<br />
checked by gel electrophoresis for structure integrity control. Radio-<br />
TLC was performed to ensure that only one species was present after<br />
filtration through a 0.22 µm filter. Preliminary biodistribution studies<br />
in normal rats were carried out to determine complex distribution of<br />
the radioimmunoconjugate up to 168h. The biodistribution data were<br />
in accordance with other antiCD20 radioimmunoconjugates already<br />
reported.<br />
Keywords: radioimmunotherapy, 177-Lu, trastuzumab<br />
155
3rd International Congress 3rd International of Nuclear Congress Medicine of Nuclear & 15th Medicine Iranian Annual & 15th Iranian Congress Annual of<br />
Nuclear Congress Medicine of Nuclear Medicine<br />
Shahid Beheshti Shahid Beheshti University University of Medical Sciences of Medical 19-21 Sciences May 201119-21 May 2011<br />
Design and fabrication of imaging detector for medical<br />
application<br />
Hossein Zamani Zeinali 1 , Maryam Nazari 2 , Anita Alipoor 1<br />
1 Agricultural, Medical and Industrial Research School, Nuclear Science and<br />
Technology Research Institute, AEOI, Karaj, Iran.<br />
2 Islamic Azad University of Tehran<br />
Introduction: An Imaging detector system, based on scintillation<br />
detectors, is designed. Fabricated and optimized for diagnostic<br />
radiology, industrial radiography, nuclear medicine and research<br />
application.<br />
Materials and methods: X radiation beam from a Siemens<br />
Stabilipan Orthovoltage unit, after passing through an object, which<br />
may be living sample or electronic device, produce a planar<br />
distribution of visible light on a GOS(Gd2O2S:Tb3+), that is the<br />
image of the object under examination. The image is displaced on a<br />
Cathode Ray Tube (CRT) by a Charged Coupled Camera (CCD)<br />
camera and is recorded digital by a video capture device. The image<br />
quality parameters, including contrast and resolution were<br />
determined by Inpatient Quality Indicator (IQI) tests. Imaging<br />
practices were carried out for different X ray tube voltages (kV) and<br />
Focal-spot Surface Distances (FSD). The data corresponding imaging<br />
quality parameters were then analyzed and plotted by MATLAB and<br />
Origin software.<br />
Results and discussion: The results for image quality parameters<br />
(contrast and resolution) for different X ray tube voltages are fairly<br />
close to each other. Thus the imaging system has the capability to be<br />
used for different X ray energies and radionuclide with relatively<br />
desired results. The study is considered to be an initiative for<br />
fabricating industrial fluoroscopy and radiation surveillance system in<br />
the country.<br />
Keywords: QC, Dose calibrators, Nuclear Medicine<br />
156
3rd International Congress of of Nuclear Medicine & & 15th 15th Iranian Annual Annual Congress of<br />
Congress of Nuclear Medicine<br />
Shahid Beheshti Shahid Beheshti University University of Medical of Medical Sciences Sciences 19-21 19-21 May May 2011<br />
Legal requirements in the operation of laboratory rays<br />
Jamal Salehizahaby<br />
lawyer<br />
Discussion: Performing any activity in connection with the<br />
construction, establishment, start-up, operation, knock-up and<br />
charging any unit in which the work is done with radiation, requires<br />
getting a profession license in the relevant unit and the employment<br />
license in the Atomic Energy Organization of Iran. All those persons in<br />
terms of their job duties are in connection with the radiation sources,<br />
should notify the Atomic Energy Organization of any event,<br />
disruption, defect or changes related to radiation sources, which<br />
increases the possibility of potential radiation hazards to people and<br />
also radiation accidents and human suspicious radiation; Designating<br />
the persons to work, which as a result of medical experiments<br />
verified by the "Organization", working with the radiation is harmful<br />
for their health, is prohibited in these labs; also by comply with all<br />
the regulations, standards, by-laws and radiation protection<br />
guidelines, those labs should forecast, supply and implement all<br />
necessary protective measures and equipment in accordance with<br />
related regulations; and should avoid in unnecessary radiation; in the<br />
area of their occupational activities, they should provide the facilities<br />
for the supervision and inspection of the "Organization" and put the<br />
required information and documents in its option. Before and after<br />
the recruitment and periodically during employment or in emergency<br />
circumstances, the laboratory employees should be checked up by<br />
medical required tests and specialized examinations. Conclusion:<br />
Scientifically, there is no doubt about the losses caused by the<br />
radiation of medical diagnostic laboratories on the human; because of<br />
the losses caused by radiation, in the legal perspective, the radiation<br />
using is prohibited principally; unless in a case which medical need so<br />
appropriate, and in such cases the physician should compare the<br />
losses resulting from the operation of the radiation to losses from the<br />
disease; in cases which the interests of radiation operation prevail, he<br />
can exploit; otherwise he would not be allowed to use; also when<br />
using the radiation is necessary, he will suffice as much as necessary<br />
and no more.<br />
Keywords: Laboratory, human, ray, loss, law.<br />
157
3rd International Congress 3rd International of Nuclear Congress Medicine of Nuclear & 15th Medicine Iranian Annual & 15th Iranian Congress Annual of<br />
Nuclear Congress Medicine of Nuclear Medicine<br />
Shahid Beheshti Shahid Beheshti University University of Medical Sciences of Medical 19-21 Sciences May 201119-21 May 2011<br />
Simulation of Msgc using two methods: Monte carlo and Finite<br />
difference method<br />
Kokab moosavi<br />
Nuclear Science and Technology Research Institute<br />
Micro Strip Gas Chambers (MSGCs) are suited for the application in<br />
modern experiments of high energy physics because of their good<br />
spatial resolution and their high rate capability. In this work msgc<br />
was simulated by using two methods: Monte Carlo and Finite<br />
Difference Method. The electric field variations versus different anode<br />
and cathode widths and cathode to anode distance studied and at<br />
least the number of particles entered on anode and the deposited<br />
energy in the region of electric field lines were calculated. This<br />
chamber could be useful in medical imaging systems because of<br />
excellent position resolution.<br />
Keywords: MSGC, simulation, electric field<br />
158
3rd International Congress of of Nuclear Medicine & & 15th 15th Iranian Annual Annual Congress of<br />
Congress of Nuclear Medicine<br />
Shahid Beheshti Shahid Beheshti University University of Medical of Medical Sciences Sciences 19-21 19-21 May May 2011<br />
Development of an in vivo radionuclide generator by labeling<br />
Bleomycin with 191Os<br />
Leila Moghaddam-Banaem 1 , Amir Reza Jalilian 1 , Mina Jamreh 2 ,<br />
Nafiseh Salek 2 , Mojtaba Shamsaee 2<br />
1 Radiopharmaceutical Research and Development Lab (RRDL)<br />
2 Faculty of Nuclear Engineering and Physics-AmirKabir Technical University<br />
Bleomycin (BLM) has been labeled with various radioisotopes and<br />
widely used in therapy and diagnosis. 191Osmium is a parent<br />
radionuclide with 15.4d half-life and decays by beta emission to<br />
191mIridium which is a radionuclide with 4.96s half-life. It decays by<br />
isometric transition to stable 191Ir, emitting a 129-keV gamma<br />
photon. In this study BLM was labeled with 191Os-hexachloro-osmate<br />
and its distribution and stability in mice was determined. The<br />
complex was obtained at the pH=2 in normal saline at 90°C in 60<br />
minutes. Radio-TLC showed an overall radiochemical yield of 95-97%<br />
(radiochemical purity >97%). The biodistribution studies for 191Os<br />
and 191Os -BLM were carried out in mice up to 15d. Liver and spleen<br />
uptake increased 24-48 hours after administration of 191Os-BLM.<br />
Lung uptake increased after 48 hours. Twenty four hours after<br />
administration, the radioactivity of the bladder and kidney increased<br />
and remained constant. This research introduces 191Os-BLM in<br />
therapeutic studies as an in-vivo generator for therapy because of<br />
beta emissions and also for localization and dosimetry study in<br />
relevant organs by gamma emission of the daughter radio-nuclide.<br />
Keywords: 191Osmium-Bleomycin, Labeling, Biodistribution<br />
159
3rd International Congress 3rd International of Nuclear Congress Medicine of Nuclear & 15th Medicine Iranian Annual & 15th Iranian Congress Annual of<br />
Nuclear Congress Medicine of Nuclear Medicine<br />
Shahid Beheshti Shahid Beheshti University University of Medical Sciences of Medical 19-21 Sciences May 201119-21 May 2011<br />
Production of Os191/Ir191m generator by Tehran Research<br />
Reactor<br />
Leila Moghaddam-Banaem 1 , Amir Reza Jalilian 1 , Nafiseh Salek 2 , Mina<br />
Jamreh 2 , Mojtaba Shamsaee 2<br />
1 Radiopharmaceutical Research and Development Lab (RRDL)<br />
2 Faculty of Nuclear Engineering and Physics-AmirKabir Technical University<br />
In this research production of 191Os/191mIr generator was<br />
investigated. 191Osmium is a parent radionuclide with 15.4d half-life<br />
and 191mIridium is daughter radionuclide with 4.96s half-life. It<br />
decays by isometric transition to stable 191Ir, emitting a 129-keV<br />
gamma photon. In addition, iridium x-rays at about 65 keV are<br />
emitted, as a result of internal conversion, from the 129-keV excited<br />
state. The half-life of 191Os (15.4 days) is sufficiently long to<br />
facilitate transportation, generator construction, quality control, and<br />
clinical use. 191mIr is recently has been used as an angiography<br />
radionuclide. One major use of this technique is in the evaluation of<br />
children with congenital heart disease. The information obtained with<br />
radio-angiography is of importance in the diagnosis and management<br />
of these patients and, at times, can take the place of a cardiac<br />
catheterization. In this work, 191Os-hexachloro-osmate was obtained<br />
by thermal neutron flux (4—1013 n.cm-2.s-1) of natural osmium<br />
oxide sample followed by fusion with KOH and KNO3 in acidic media.<br />
One of the important radionuclide impurities is 192Ir that produced<br />
with 191Os in reactor. Separation this impurity from 191Os is<br />
developed by a new performance in this research and the total<br />
recovery yield of 191Os is about %99 and the total time required for<br />
completion the procedure is about 2h. This method improved the<br />
yield and the time of performance in comparison with the published<br />
literatures. Then 191Os is loaded on an anion-exchange column and<br />
191mIr eluted with normal saline. Each elution is 1 ml of 0.9% saline<br />
at pH 1. The yield of generator was assessed for two weeks. 191mIr<br />
yield is 8 to 11% and 191Os breakthrough is 0.001 to 0.005%.<br />
Keywords: Radiopharmaceutical, Gnerator 191Os/191Ir<br />
160
3rd International Congress of of Nuclear Medicine & & 15th 15th Iranian Annual Annual Congress of<br />
Congress of Nuclear Medicine<br />
Shahid Beheshti Shahid Beheshti University University of Medical of Medical Sciences Sciences 19-21 19-21 May May 2011<br />
Preparation and evaluation of 166Ho-DTPA for medical<br />
applications<br />
H. Salehi, M. Gourani, H. Farahani, M. Zoghi, M. Mazidi, S. Shaybani<br />
Radioisotope research Group, Science & Technology Nuclear Center (NSTRI)<br />
Atomic Energy Organization of IRAN (AEOI)<br />
Introduction: Radiopharmaceuticals are now increasingly used for<br />
therapy of cancer, palliation of pain caused due to bone metastasis<br />
and for the treatment of rheumatoid arthritis. 166Ho, with its<br />
favorable radiation characteristics of t1/2 26.8 h and β 1.85 and 1.75<br />
MeV is decayed to stable daughter. It also emits an 80.5 Kev<br />
gamma-ray (6.2%) and thus is imaginable by conventional<br />
techniques.<br />
Purposes: Irradiating 165Ho(n,γ)166Ho 2- Labeling 166HoCl3-<br />
DTPA(diethylentriaminepentaacetic acid).<br />
Investigation Methods: Holmium oxide (Ho2O3, purity >99.9%, 1-<br />
3 mg target mass) was irradiated in a thermal neutron flux 5—1013<br />
n.cm-2.s-1 in the TRR reactor. Irradiated target is dissolved in 20%<br />
HCl, evaporated to dryness. 166Ho should be labeled by DTPA kit as<br />
a complex (DTPA: 166HoCl3) with a same molecular weight (1:1) and<br />
pH~ 7-8 at room temperature in 30 min.<br />
Results: The purity of radionuclide was checked by a multichannel<br />
analyzer coupled with HPGe detector and measured in curimeter dose<br />
calibrator. The radiochemical purity of the DTPA:166HoCl3 was<br />
determined by paper chromatography and 0.9% saline as solvent.<br />
Radiochemical purity of the DTPA:166HoCl3 was 99 %. Gamma<br />
spectrometry of the 166Ho didn't show gamma peaks for any other<br />
radionuclide other than 166Ho.<br />
CONCLUTION: Results of this investigation indicate that<br />
166HoCl3:DTPA kit proposed as a suitable choice for the<br />
endovascular radionuclide therapy (EVRT) technique of liquid filled,<br />
low pressure balloon angioplasty. In a study using mice >85% of the<br />
injected dose was cleared into the urine within 30 min post-injection,<br />
with insignificant retention in any major tissues. The studies show<br />
that the 166Ho-DTPA complex could be an alternative to the more<br />
expensive and difficult to access 188Re based products for EVRT, and<br />
provide adequate uniform radiation dose for the arterial vessel wall<br />
under treatment.<br />
Keywords: ho-166 DTPA Irradiation angioplasty<br />
161
3rd International Congress 3rd International of Nuclear Congress Medicine of Nuclear & 15th Medicine Iranian Annual & 15th Iranian Congress Annual of<br />
Nuclear Congress Medicine of Nuclear Medicine<br />
Shahid Beheshti Shahid Beheshti University University of Medical Sciences of Medical 19-21 Sciences May 201119-21 May 2011<br />
Radiolabeled annexin V imaging: a useful technique for<br />
determining apoptosis in multiple sclerosis<br />
Majid Assadi 1 , Reza Nemati 2 , Iraj Nabipour 1 , Hooman Salimipour 2 ,<br />
Abdullatif Amini 1<br />
1 The Persian Gulf Nuclear Medicine Research Center<br />
2 Department of Neurology<br />
Multiple sclerosis (MS) is an inflammatory disease of the central<br />
nervous system (CNS) that involves myelin, oligodendrocytes and<br />
axons and culminates in consecutive neuronal death and progressive<br />
neurologic disability. Based on magnetic resonance imaging (MRI),<br />
neuroaxonal loss in MS results in brain atrophy and has a strong<br />
correlation with neurological disability. The newer MR imaging tools<br />
seem to be sensitive biomarkers for measuring the pathogenetic<br />
processes associated with disease activity and progression. However,<br />
it has been difficult to predict the prognosis of MS patients<br />
undergoing an exacerbation from the cross-sectional area of the<br />
contrast-enhanced lesions seen on MRI (or with FLARE MRI). The<br />
edema assocaited with MS lesions creates confusion between changes<br />
in extracellular fluid space and damage to the neuronal elements.<br />
Annexin V has a high affinity for phosphatidylserine (PS) that<br />
presents on the outer surface of the plasma membrane early on<br />
during the onset of apoptosis. Radiolabeled annexin V imaging may<br />
reveal the initiation and degree of neuronal apoptosis. It is our<br />
expectation that annexin will pass through the blood-brain-barrier at<br />
the site of new lesions and localize at the site of stressed or damaged<br />
neurons. The extent of localization should be proportional to the<br />
extent of damage to the cellular elements of the brain. Thus, we<br />
expect a much better correlation of annexin imaging to prognosis.<br />
Based on this model, it might be good to image as soon as possible<br />
after clinical presentation of an exacerbation to determine the extent<br />
of neuronal involvement and then to do a follow up study about 14<br />
days post treatment to determine response to therapeutic<br />
intervention. Such studies should provide specific information on<br />
severity and prognosis of the and on individual response to<br />
treatment. We hypothesize that radiolabeled annexin V imaging is a<br />
useful modality in the determination of apoptosis in MS and can<br />
assess and monitor the effectiveness of neuroprotective and<br />
immunomodulatory therapies on the clinical course of MS. It would<br />
be productive to study MS patients with Tc-99m annexin V imaging.<br />
Unfortunately, this cold kit is unavailable for human use in the world.<br />
Keywords: Multiple sclerosis , phosphatidylserine<br />
162
3rd International Congress of of Nuclear Medicine & & 15th 15th Iranian Annual Annual Congress of<br />
Congress of Nuclear Medicine<br />
Shahid Beheshti Shahid Beheshti University University of Medical of Medical Sciences Sciences 19-21 19-21 May May 2011<br />
Comparison between Neutron Flux and Spectrum in North<br />
Beam Tubes of Tehran Research Reactor by MCNP4C Code for<br />
BNCT<br />
Majid Zamani, Hossein Khalafi, Yaser Kasesaz, Mohsen Shayesteh<br />
In order to investigate the possibility of using the T.R.R beam tubes<br />
in BNCT, it is necessary to select the best one from three north beam<br />
tubes. This beam tube should have more flux and better spectrum<br />
compare to others. So, after simulation of the last configuration of<br />
reactor’s core (NO.55) by MCNP4C code, the neutron flux and<br />
spectrum were calculated at the start, middle, and end of each three<br />
north beam tubes (B1, B2, B3). Because of the relation between<br />
these parameters and the state of core, this calculation has been<br />
done in three different situations of reactor’s core: BOC, MOC and<br />
EOC. The analyses of results showed that the neutron spectrum is<br />
almost the same in all of the beam tubes, but the neutron flux in<br />
northwest beam tube is better than the others .so, this beam tube is<br />
more proper to be used in BNCT.<br />
Keywords: BNCT, Reactor, MCNP4C, Tubeon Flux<br />
163
3rd International Congress 3rd International of Nuclear Congress Medicine of Nuclear & 15th Medicine Iranian Annual & 15th Iranian Congress Annual of<br />
Nuclear Congress Medicine of Nuclear Medicine<br />
Shahid Beheshti Shahid Beheshti University University of Medical Sciences of Medical 19-21 Sciences May 201119-21 May 2011<br />
Successful implementation of Electronic Medical Records in<br />
research settings: Diabetes and Cardiovascular Surgery<br />
Mohammad Kia<br />
All aspects of modern medical practice are greatly influenced by<br />
technology advancements. New advancements for handling of<br />
Medical Records failed to get popular and still handling of medical<br />
data uses inefficient traditional paper based approach. Employing of<br />
new diagnostic and therapeutic technologies culminates in dramatic<br />
rising in diversity, quantity and quality of medical data which can not<br />
be handled in an old style. Different demanding disciplines (such as:<br />
National and local health policies, prerequisites of Scientific Bodies,<br />
Insurances, Consumer expectations etc.) and new requirements (e.g.<br />
Research needs, early diagnostic and therapeutic intervention etc.)<br />
call for qualified information and worsens the shortages of paper<br />
based works. Presuming computers can solve the riddle but good<br />
planning and proper insight should be considered. Implementation of<br />
Electronic Medical Record (EMR) at various levels (National registries,<br />
Medical Research Centers and clinics) aligned with national and local<br />
health systems' objectives can play a significant role on quality and<br />
quantity of services and researches. Implementation of EMR in Iran in<br />
both private and governmental sectors is not prioritized due to some<br />
systemic flaws such as: Lack of strategic planning for producing and<br />
consuming of medical data. Considering EMR as cost and not as an<br />
investment. Decision makers suffer from lack of EMR insight.<br />
Investing on scientific show offs instead of infrastructures. Caring<br />
about quantitative indices of processes instead of qualitative ones,<br />
etc. Unsuccessful EMR implementation is common due to the same<br />
managerial and workflow mistakes and role of employing well known<br />
methodologies and best practices on successful EMR implementation<br />
is inevitable. In this article we are going to elaborate learned<br />
experiences of implementing of Hakim Diabetes EMR and Nuclear<br />
Medicine EMR in different clinical and research settings across the<br />
Country.<br />
Keywords: Electronic Medical Record<br />
164
3rd International Congress of of Nuclear Medicine & & 15th 15th Iranian Annual Annual Congress of<br />
Congress of Nuclear Medicine<br />
Shahid Beheshti Shahid Beheshti University University of Medical of Medical Sciences Sciences 19-21 19-21 May May 2011<br />
Dosimetry of a new 192Ir PDR brachytherapy source<br />
Mohammad Reza Javanshir 1 , Shahab Sheibani 1 , Behrooz Ghozati 2 ,<br />
Hosein Poorbeygi 1 , Farzam kabiri 2<br />
1 AEOI Nuclear Science and Technology Research Institute<br />
2 Shahid Beheshti University<br />
The PDR brachytherapy source, has got application in some cases of<br />
cancer treatment. According to the AAPM ,determining of the<br />
dosimetry parameters of a new source , should be done by a qualified<br />
group. In this research , we study the functions related to the<br />
dosimetry of Ir 192 brachytherapy source , which includes 3mm<br />
length and 140mci activity , using experiment measurements in<br />
water equivalent phantom. The value of dose were measured using<br />
TLD dosimeter (LiF-100) with putting in to holes which were<br />
embedded in a Plexiglas phantom .The result of anisotropy function,<br />
the radial dose function and the dose rate constant with less than 5%<br />
error indicate that the new Ir192 PDR source is applicable in<br />
radiotherapy.<br />
Keywords: Brachytherapy, PDR, anisotropy, radial dose<br />
165
3rd International Congress 3rd International of Nuclear Congress Medicine of Nuclear & 15th Medicine Iranian Annual & 15th Iranian Congress Annual of<br />
Nuclear Congress Medicine of Nuclear Medicine<br />
Shahid Beheshti Shahid Beheshti University University of Medical Sciences of Medical 19-21 Sciences May 201119-21 May 2011<br />
A new bombesin kit labeled with 99mTc for breast cancer<br />
imaging<br />
Mostafa Erfani (Gandomkar), Seyed Pejman Shirmardi<br />
Nuclear Science Research School<br />
Introduction: Tumors such as prostate, small cell lung<br />
cancer,breast, gastric and colon cancer are known to over express<br />
receptors to bombesin (BBN). In this study, a new bombesin<br />
analogue was labeled with 99mTc via HYNIC and tricine/EDDA as<br />
coligands and investigated further.<br />
Methods: HYNIC-GABA-Bombesin (7-14) NH2 was synthesized using<br />
a standard Fmoc strategy. Labeling with 99mTc was performed at<br />
100 C for 10 min and radiochemical analysis involved ITLC and HPLC<br />
methods. The stability of radiopeptide was checked in the presence of<br />
humane serum at 37C up to 24 h. The receptor bound internalization<br />
and externalization rates were studied in GRP receptor expressing<br />
PC-3 cells. Biodistribution of radiopeptide was studied in mice.<br />
Results: Labeling yield of 98% was obtained corresponding to a<br />
specific activity of 2.6 MBq/nmol. Peptide conjugate showed good<br />
stability in the presence of human serum. The radioligand showed<br />
high and specific internalization into PC-3 cells (14.63±0.41% at 4<br />
h). In biodistribution studies, a receptor-specific uptake was observed<br />
in GRP-receptor-positive organs so that after 4 h the uptakes in<br />
mouse pancreas was 1.2±0.13% ID/g.<br />
Conclusion: The prepared conjugate showed high accumulation in<br />
pancreas as a positive GRP receptor targeted tissue followed by<br />
excretion via the kidney. These promising characteristics make our<br />
new designed labeled peptide conjugate as a very suitable candidate<br />
for diagnostic of malignant tumors.<br />
Keywords: Radiolabeling, Bombesin, 99mTc, Tumor<br />
166
3rd International Congress of of Nuclear Medicine & & 15th 15th Iranian Annual Annual Congress of<br />
Congress of Nuclear Medicine<br />
Shahid Beheshti Shahid Beheshti University University of Medical of Medical Sciences Sciences 19-21 19-21 May May 2011<br />
Preparation and labeling of a Bombesin analogueWith 99mTc<br />
for imaging of GRP receptors<br />
Mostafa Erfani(Gandomkar), Seyed Pezhman Shirmardi, Mohammad<br />
Ghannadi Maragheh<br />
Nuclear Science Research School, Nuclear Science & Technology Research<br />
Institute (NSTRI), Atomic Energy Organization of Iran<br />
Introduction: It has been shown that some primary human tumors<br />
and their metastases, including prostate and breast tumors, overexpress<br />
gastrin-releasing peptide (GRP) receptors. Bombesin is a<br />
neuropeptide with a high affinity for these GRP receptors. The<br />
purpose of this study was to prepare and evaluate the characteristics<br />
of a new Bombesin analogue, [6-hydrazinopyridine-3-carboxylic acid<br />
(HYNIC)]-GABA-Bombesin (7-14) NH2 designed for the labeling with<br />
99mTc using tricine and EDDA as coligand.<br />
Methods: Synthesis was performed on a solid phase using a<br />
standard Fmoc strategy and HYNIC precursor coupled at the N-<br />
terminus. Purified peptide conjugate was labeled with 99mTc at<br />
100°C for 10 min. Radiochemical analysis involved ITLC and highperformance<br />
liquid chromatography methods. Peptide conjugate<br />
stability and affinity to human serum was challenged for 24 hours.<br />
The internalization rate was studied in GRP receptor expressing PC-3<br />
cells. Biodistribution of radiopeptide was studied in rats.<br />
Results: Radiolabeling was performed at high specific activities, and<br />
radiochemical purity was >98%. The stability of radiolabeled peptide<br />
in human serum was excellent. In vitro studies showed >14% of<br />
activity was specific internalized into PC-3 cells up to 4 h. After<br />
injection into rat biodistribution data showed a rapid blood clearance,<br />
with renal excretion and specific binding towards GRP receptorpositive<br />
tissues such as pancreas (1.15±0.19% ID/g after 4 h).<br />
Conclusion: [99mTc-HYNIC]-GABA-Bombesin (7-14) NH2 showed<br />
favorable radiochemical and biological characteristics which make our<br />
new designed labeled peptide conjugate as a very suitable candidate<br />
for diagnostic of malignant tumors.<br />
Keywords: 99mTc Bombesin, Synthesis, Labeling<br />
167
3rd International Congress 3rd International of Nuclear Congress Medicine of Nuclear & 15th Medicine Iranian Annual & 15th Iranian Congress Annual of<br />
Nuclear Congress Medicine of Nuclear Medicine<br />
Shahid Beheshti Shahid Beheshti University University of Medical Sciences of Medical 19-21 Sciences May 201119-21 May 2011<br />
Isolation and labeling of a toxic fraction from Iranian<br />
Mesobuthus eupeus venom<br />
Mostafa Erfani(Gandomkar), Seyed Pezhman Shirmardi, Mohammad<br />
Ghannadi Maragheh<br />
Nuclear Science Research School, Nuclear Science & Technology Research<br />
Institute (NSTRI), Atomic Energy Organization of Iran<br />
Introduction: In this study, Preparation, purification and evaluation<br />
of biological distribution for venom of Iranian Mesobuthus eupeus<br />
labeled with 99mTc has been performed. Its venom has different<br />
toxin same the other scorpions which affect on ion channels.<br />
Material and Methods: For studying of these toxins, the venom was<br />
purified during 3 stages gel chromatography, anion resin and cation<br />
resin respectively. The fractions were identified with UV spectroscopy<br />
and collected with Fraction collector. The fractions were injected to 2<br />
normal mice and the toxic fraction with killing effect was selected for<br />
next stage. For toxic fraction labeling with 99mTc has been done and<br />
biological distribution was obtained in normal mice.<br />
Results: High labeling yield (97%) was achieved using stannous<br />
chloride (SnCl2) and sodium borohydride (NaBH4) as reducing<br />
agents. In biodistribution study, excretion via kidney and liver were<br />
distinguished as a major excretion pathway.<br />
Conclusion: In this study, we have shown an approach toward<br />
preparation and purification of a toxic fraction from venom of<br />
Mesobuthus eupeus. The radiolabeling of its toxic fractions with<br />
99mTc could help to investigate the biological effects.<br />
Keywords: Mesobuthus venom purification labeling<br />
168
3rd International Congress of of Nuclear Medicine & & 15th 15th Iranian Annual Annual Congress of<br />
Congress of Nuclear Medicine<br />
Shahid Beheshti Shahid Beheshti University University of Medical of Medical Sciences Sciences 19-21 19-21 May May 2011<br />
Preparation and evaluation of a neuropeptide Y analogue for<br />
diagnosis of breast tumors<br />
Mostafa Erfani(Gandomkar), Mohammad Mazidi, Mostafa Goudarzi,<br />
Nuclear Science Research School, Nuclear Science & Technology Research<br />
Institute (NSTRI), Atomic Energy Organization of Iran<br />
Introduction: Over expression of selected peptide receptors in<br />
human tumors has been shown to represent clinically relevant targets<br />
for cancer diagnosis and therapy. The aim of this work was to<br />
investigate Neuropeptide Y (NPY) as a new radiopharmaceutical for<br />
diagnosis of breast cancer.<br />
Methods: A neuropeptide Y analogues with Y1 receptor preference<br />
and agonistic properties was synthesized by solid phase method.<br />
After conjugation with HYNIC labeling with 99mTc was performed.<br />
For labeled peptide, yield of labeling, stability in human serum,<br />
receptor binding in cell surface with internalization in SK-N-MC cells,<br />
and biodistribution in normal rat were determined.<br />
Results: Peptide was synthesized and labeled with more than 95%<br />
purity. Radiolabeled peptide was stable in human serum and<br />
specifically binds and internalized in the cells with Y1 receptor (4h =<br />
22%). A rapid clearance from blood pool and urinary with<br />
hepatobiliary excretion were observed.<br />
Conclusion: Our results showed that this peptide can be considerate<br />
as a candidate for diagnosis of breast tumors.<br />
Keywords: Neuropeptide Y, HYNIC, 99mTc, Tumor<br />
169
3rd International Congress 3rd International of Nuclear Congress Medicine of Nuclear & 15th Medicine Iranian Annual & 15th Iranian Congress Annual of<br />
Nuclear Congress Medicine of Nuclear Medicine<br />
Shahid Beheshti Shahid Beheshti University University of Medical Sciences of Medical 19-21 Sciences May 201119-21 May 2011<br />
Preparation and evaluation of 99mTc-cefotaxime for infection<br />
imaging<br />
Mostafa Erfani (Gandomkar), Fatameh Mirshojaei<br />
Nuclear Science Research School, Nuclear Science & Technology Research<br />
Institute (NSTRI), Atomic Energy Organization of Iran<br />
Introduction: A wide range of radiopharmaceuticals have been<br />
proposed to visualize infection and inflammation scintigraphically.<br />
The use of radiolabeled antibiotics is fast emerging as a promising<br />
diagnostic test for the detection of infective lesions. Second and third<br />
generation cephalosporines, including cefuroxime and ceftizoxime<br />
have been labeled with 99mTc. In this study we describe the<br />
optimum condition for radiolabeling of cefotaxime with the most<br />
widely used imaging radionuclide, 99mTc.<br />
Method: The radiolabeling was performed by the sodium dithionite<br />
as the reducing agent. The labeling yield and radiochemical purity<br />
were determined by thin layer chromatography. The affinity of the<br />
labeled antibiotic to human serum proteins was examined by mixing<br />
1 mL of labeled cefotaxime with activity between 5 and 20 mCi to 1<br />
mL of human serum in a vial. Binding of 99mTc-cefotaxime to<br />
bacteria was assessed in S. aureus suspention. Animal biodistribution<br />
was evaluated in mice with infectious thigh muscle.<br />
Result: The maximum radiolabeling yield was 92±2% and was stable<br />
for up to 12 h. This antibiotic showed an improvement in excretion<br />
pathway from the liver to the kidney followed by an accumulation of<br />
radioactivity in infected areas. Images showed minimal accumulation<br />
in non-target tissues, with an average target/non-target ration of<br />
2.89±0.58%.<br />
Conclusion: The promising characteristics make our new radiotracer<br />
a very suitable candidate for diagnostic of infectious foci in nuclear<br />
medicine<br />
Keywords: 99mTc, Cefotaxime, Infection imaging<br />
170
3rd International Congress of of Nuclear Medicine & & 15th 15th Iranian Annual Annual Congress of<br />
Congress of Nuclear Medicine<br />
Shahid Beheshti Shahid Beheshti University University of Medical of Medical Sciences Sciences 19-21 19-21 May May 2011<br />
B10 distribution in adult rat’s brain<br />
Nasrin Baghban Khojasteh, Ali Pazirandeh, Behnam Jameie<br />
Islamic Azad University<br />
Background: Boron Neutron Capture Therapy is a tumor specific<br />
modality to treat some hard to cure cancers such glioblastoma<br />
multiform and melanoma. It is based on the reaction of 10B atoms<br />
absorbed in the tumor and thermal neutrons. The exact mechanism,<br />
absorption rate and distribution of boron in different areas of brain<br />
are still unknown. In order to find the distribution of 10B in different<br />
regions of brain the present study was done.<br />
Material and Methods: Adult Wistar female rats were used; animals<br />
were divided into two groups including control and trial. Trial group<br />
received two single intraperitoneal shots of 1 ml of neutral boron<br />
compound. Three hours later, the animals were sacrificed and the<br />
brains were removed and three coronal sections of 20μm thickness of<br />
forebrain, midbrain and brainstem were prepared by using freezing<br />
microtome. The sections were sandwiched between two pieces of<br />
polycarbonates and irradiated with thermal neutrons and then<br />
etched. Alpha tracks were detected and studied by optical<br />
microscopy. The plots of 10B distribution in three regions of brain<br />
were obtained, compared and analyzed statistically.<br />
Results: We found significant differences in 10B distribution among<br />
forebrain, midbrain and brainstem with the highest concentration in<br />
the midbrain.<br />
Conclusion: Based on our findings the concentration of 10B in<br />
midbrain may help therapists use more effective treatment planning,<br />
including neutron flux level and irradiation time.<br />
Keywords: BNCT, Rat brain, Boron distribution<br />
171
3rd International Congress 3rd International of Nuclear Congress Medicine of Nuclear & 15th Medicine Iranian Annual & 15th Iranian Congress Annual of<br />
Nuclear Congress Medicine of Nuclear Medicine<br />
Shahid Beheshti Shahid Beheshti University University of Medical Sciences of Medical 19-21 Sciences May 201119-21 May 2011<br />
Research of exposure rate of urinary tract and gonads of<br />
nuclear medicine patients during kidney scan with Tc-99m-Ec<br />
with the use of TLD-100h and comparison with VMC method<br />
Navideh Aghaei Amirkhizi, Sepideh Hekmat, Elham Shahhoseini,<br />
Farhad Manouchehri, Mohaddeseh Naderi<br />
In kidney diseases that are reported widely in our country, in order to<br />
evaluation and diagnostic of physiological situation of kidney and<br />
bladder, nuclear medicine method is the first priority among other<br />
diagnostic methods. In this research, exposure rate of urinary tract<br />
and gonad of selected patients were measured in kidney scan with<br />
Tc-99m-Ec with the use of TLD-100h and skin surface doses were<br />
studied during imaging time. In general, skin surface doses were<br />
measured and the results were compared with Visual Mont<br />
Carlo(VMC) method. The final results show, skin and total dose have<br />
been lower than annual dose limits.<br />
Keywords: TLD, Urinary tract, VMC<br />
172
3rd International Congress of of Nuclear Medicine & & 15th 15th Iranian Annual Annual Congress of<br />
Congress of Nuclear Medicine<br />
Shahid Beheshti Shahid Beheshti University University of Medical of Medical Sciences Sciences 19-21 19-21 May May 2011<br />
The calculation of absorbed dose due to 131I-Chlorotoxin in<br />
liver using monte carlo method<br />
Rohollah Adeli, Seyed Pezhman Shirmardi, Mostafa Erfani<br />
(Gandomkar), Mohammad Ghannadi-Maragheh<br />
Nuclear Science & Technology Research Institute (NSTRI), Atomic Energy<br />
Organization of Iran<br />
Introduction: Chlorotoxin is a peptide derived from the venom of<br />
the scorpion Leiurus Quinquestriatus. It can bind with mmp2<br />
receptors on glioma cells. In this research,we used Monte carlo<br />
method to calculate the absorbed dose in organ of interest.this<br />
method is a useful tool to transport of particles and absorbed dose<br />
calcululation.<br />
Methods: The peptide was synthesized by standard Fmoc solidphase<br />
synthesis on Rink amide MBHA resin with substitution of 0.69<br />
mmol/g. Labeling of product was performed by chloramine-T method.<br />
Peptide (40 µg) was dissolved in PBS buffer (50 µl, 0.25 M, pH=7.5)<br />
then was added to a solution of 200 µci Na131I (in 0.1 N NaOH),<br />
followed by 50 µl chloramine-T (4 mg/ml in PBS 0.05 M, pH=7.5).<br />
For ex vivo counting mice were sacrificed after 1, 4 and 24 h and<br />
various organs were dissected, weighed and counted for radioactivity.<br />
The obtained data from organs was used in Monte Carlo method<br />
(MCNP code) to calculate the tissues dose according to MIRD<br />
principles.<br />
Results: Our results suggest that, this labeled chlorotoxin derivative<br />
might be useful in determining tumor extent and also tumor therapy<br />
of gliomas or possibly other cancers. The overall radiolabeling<br />
efficiency was about 80% at a specific activity of 0.740 GBq/mol. The<br />
liver of mouse was assumed as target organ. The sum of gamma and<br />
beta particles dose emitted by 131I were used to calculate total<br />
absorbed dose to liver. The results show that the delivered dose to<br />
liver was very small and 98% of total dose is due to beta particles.<br />
Conclusion: In this study, we have shown a synthetic approach<br />
toward preparation of a chemically and metabolically stable<br />
chlorotoxin derivative. Iodine-131 radiolabeling of these novel<br />
conjugate was performed in order to assess the most optimum<br />
conditions for radiolabeling and potential usage in clinical<br />
applications. We calculated the absorbed dose in liver using Monte<br />
Carlo method (MCNP code). Liver as a target organ absorbed very<br />
small dose as mentioned above.<br />
Keywords: Chlorotoxin 131I, Monte Carlo, Dosimetry, MIRD<br />
173
3rd International Congress 3rd International of Nuclear Congress Medicine of Nuclear & 15th Medicine Iranian Annual & 15th Iranian Congress Annual of<br />
Nuclear Congress Medicine of Nuclear Medicine<br />
Shahid Beheshti Shahid Beheshti University University of Medical Sciences of Medical 19-21 Sciences May 201119-21 May 2011<br />
Production and quality control of 99mTechnetium-IgG-hynic<br />
for infection imaging in experimental rats<br />
Saeed Rajabifar, Amir Reza Jalilian, Mahdie Ghafori, Sedighe<br />
Moradkhani, Fariba Sadadi<br />
Introduction: Over the last decades several radiopharmaceuticals<br />
have been developed for the detection of infection and inflammation<br />
some have found their way into clinical practice and routinely used<br />
for evaluation of infectious and inflammatory diseases. Human<br />
gamma globulin can be labelled by direct or indirect method of<br />
radiotracer incorporated in protein molecule. In this indirect method<br />
hydrazino nicotinic acid or hynic is used which saves the structure<br />
and biological activity of the protein. Infection is induced by<br />
inoculation of S.aureus in one thigh and inflammation by turpentine<br />
in another.<br />
Methods and material: Immuno globulin is mixed with s-hynic and<br />
IgG-hynic is developed using slide- A lyzer and stored at -20 oC<br />
which can be used at least for six months and then sn-tricine kit is<br />
prepared which is used for 99mTc labelling. Efficiency of 99mTc-IgGhynic<br />
labelling at pH 6.4 was very much dependent on ligand (hynic)<br />
and coligand (tricine) presence in the reaction mixture. Wistar rats<br />
(n=5) were used for bio distribution as well as imaging studies.<br />
Result: Radiochemical purity was found to be more than 90% in the<br />
kits prepared. Serum stability study showed no decomposition of<br />
99mTechnetium from the complex. The bio distribution studies<br />
showed the highest percentage ID/organ in Blood, Liver and Kidney<br />
respectively and the imaging studies revealed the site of infection in<br />
the thigh as compared to the inflamed thigh using turpentine.<br />
Conclusion: A human gamma globulin was successfully labelled<br />
through hynic to 99mTechnetium by indirect method with high<br />
radiochemical purity and differentiation in infected and inflamed thigh<br />
by imaging studies which is a good imaging property.<br />
Keywords: IgG-Hyni, Infection, Inflammation, 99mTechnetium<br />
174
3rd International Congress of of Nuclear Medicine & & 15th 15th Iranian Annual Annual Congress of<br />
Congress of Nuclear Medicine<br />
Shahid Beheshti Shahid Beheshti University University of Medical of Medical Sciences Sciences 19-21 19-21 May May 2011<br />
Development of holmium-166 bleomycin as a possible<br />
therapeutic complex<br />
Samaneh Zolghadri, Amir Reza Jalilian, Hassan Yousefnia, Ali<br />
Bahrami-Samani, Simindokht Shirvani-Arani, Mohammad Ghannadi-<br />
Maragheh<br />
Nuclear Science and Technology Research Institute<br />
Due to interesting therapeutic properties of 166Ho and the<br />
antineoblastic antibiotic, bleomycin (BLM), 166Ho-bleomycin (166Ho-<br />
BLM) was developed as a possible therapeutic compound. Ho-166<br />
chloride was obtained by thermal neutron irradiation (1—1013 n.cm-<br />
2.s-1) of natural Ho2(NO3)3 samples (Specific activity = 3-5<br />
GBq/mg), dissolved in acidic media. At optimized conditions (room<br />
temperature, 12 h, 0.15-0.3 mg bleomycin for 74 MBq 166HoCl3) a<br />
radiochemical purity of 94-97% was obtained as shown by ITLC and<br />
HPLC (Specific activity, 700-740 GBq/mmol). Biodistribution studies<br />
of Ho-166 chloride and 166Ho-BLM were performed in wild-type rats.<br />
The accumulation of the radiolabeled compound in lungs, liver and<br />
spleen demonstrates a similar pattern to the other radiolabeled<br />
bleomycins.<br />
Keywords: Bleomycin, Ho-166, Biodistribution, Radiolabeling<br />
175
3rd International Congress 3rd International of Nuclear Congress Medicine of Nuclear & 15th Medicine Iranian Annual & 15th Iranian Congress Annual of<br />
Nuclear Congress Medicine of Nuclear Medicine<br />
Shahid Beheshti Shahid Beheshti University University of Medical Sciences of Medical 19-21 Sciences May 201119-21 May 2011<br />
Production, quality control and biological evaluation of 166Ho-<br />
PDTMP as a possible bone palliation agent<br />
Samaneh Zolghadri, Amir Reza Jalilian, Hassan Yousefnia, Zohreh<br />
Naseri, Ali Bahrami-Samani, Mohammad Ghannadi-Maragheh<br />
Nuclear Science and Technology Research Institute<br />
In this study, 166Ho-1,2-propylene di-amino tetra<br />
(methy1enephosphonic Acid) (166Ho-PDTMP) complex was prepared<br />
successfully using an in-house synthesized EDTMP ligand and<br />
166HoCl3. Ho-166 chloride was obtained by thermal neutron<br />
irradiation (1—1013 n.cm-2.s-1) of natural Ho(NO3)3 samples<br />
(Specific activity = 3-5 GBq/mg), dissolved in acidic media.<br />
Radiochemical purity of 166Ho-PDTMP was checked by ITLC (>99%).<br />
Stability studies of the complex in the final preparation and in the<br />
presence of human serum were performed up to 72h. The<br />
biodistribution of 166Ho-PDTMP and 166HoCl3 in wild-type rats was<br />
checked in animal tissues up to 48h. The produced 166Ho-PDTMP<br />
properties suggest a possible new bone palliative therapeutic to<br />
overcome the metastatic bone pains.<br />
Keywords: 166Ho, PDTMP, Radiopharmaceutical, Therapy,<br />
Biodistribution<br />
176
3rd International Congress of of Nuclear Medicine & & 15th 15th Iranian Annual Annual Congress of<br />
Congress of Nuclear Medicine<br />
Shahid Beheshti Shahid Beheshti University University of Medical of Medical Sciences Sciences 19-21 19-21 May May 2011<br />
Development of 166Ho-phytate complex for radiosynovectomy<br />
Samaneh Zolghadri, Akbar Anvari, Amir Reza Jalilian, Hasan<br />
Yousefnia, Ali Bahrami-Samani, Mohammad Ghannadi-Maragheh<br />
Nuclear Science and Technology Research Institute<br />
66Ho-chloride was obtained by bombardment of natural Ho(NO3)3,<br />
dissolved in acidic media using thermal neutron flux (4-5 — 1013<br />
n.cm-2.s-1). 166Ho-holmium chloride (185 MBq) was used for<br />
preparation of 166Ho-phytate complex successfully with high<br />
radiochemical purity (>99.9 %, ITLC, MeOH: H2O: acetic acid, 4: 4:<br />
2, as mobile phase). The complex stability and viscosity were<br />
checked in the final solution up to 2 days. The prepared complex<br />
solution (60 µCi/100 µl) was injected intra-articularly to male rat<br />
knee joint. Leakage of radioactivity from injection site and its<br />
distribution in organs were investigated up to 2 days. Approximately,<br />
all injected dose has remained in injection site 2days after injection.<br />
The complex was proved to be a feasible agent for cavital<br />
radiotherapy in oncology and rheumatology.<br />
Keywords: phytate, radiosynovectomy, holmium-166,<br />
biodistribution, SPECT<br />
177
3rd International Congress 3rd International of Nuclear Congress Medicine of Nuclear & 15th Medicine Iranian Annual & 15th Iranian Congress Annual of<br />
Nuclear Congress Medicine of Nuclear Medicine<br />
Shahid Beheshti Shahid Beheshti University University of Medical Sciences of Medical 19-21 Sciences May 201119-21 May 2011<br />
Synthesis and quality control of magnetic nanoparticles<br />
labeled 177Lu as a radiopharmaceutical agent for targeted<br />
cancer therapy<br />
Samira Rasaneh 1 , Hossein Rajabi 2 , Fariba Johari Daha 1 , Shahab<br />
Sheybani 1<br />
1 Nuclear Science and Technology Research Institute<br />
2 Tarbiat Modares University<br />
Introduction: Magnetic nanoparticles are good candidates used for<br />
the targeted drug delivery. They can be concentrated on a desired<br />
region, reducing collateral effects and improving the efficiency of<br />
therapy. In this paper we synthesized iron oxide nanoparticles as<br />
magnetic nanoparticles and labeled with 177Lutetium to produce a<br />
new radiopharmaceutical agent for targeted cancer therapy.<br />
Material and methods: Lutetium-177 was produced by bombarding<br />
176Lu2O3 at a flux of 2.6—1014 n.Cm-2.S-1 for 10 days. Iron oxide<br />
nanoparticles were prepared using co-precipitation method. 177Luiron<br />
oxide nanoparticles was synthesized and all the quality control<br />
tests such as labeling yield, nanoparticle hydrodynamic and core size,<br />
stability up to 10 days, magnetization and cell toxicity was<br />
determined.<br />
Results: The good results of quality control tests indicated that<br />
177Lu-iron oxide nanoparticles could be used for further investigation<br />
as a radiopharmaceutical agent in mice bearing tumor. The mean<br />
hydrodynamic size of the nanoparticles was 170±30 nm and the<br />
average core size was 120±25 nm. The Labeling yield was calculated<br />
61±2%. On the average 86±5% of 177lu-iron oxide nanoparticles<br />
were stable in up to 10 days and no meaning changes were seen in<br />
nanoparticles size. This conjugation showed very good cytotoxcicity<br />
on cancer cells.<br />
Conclusion: We can conclude that 177Lu-iron oxide nanoparticles<br />
may be considered for further evaluation as a new<br />
radiopharmaceutical agent for targeted cancer therapy that needs<br />
more investigations.<br />
Keywords: magneticnanoparticles, 177Lutetium, drugdelivery,<br />
targetedcancertherapy<br />
178
3rd International Congress of of Nuclear Medicine & & 15th 15th Iranian Annual Annual Congress of<br />
Congress of Nuclear Medicine<br />
Shahid Beheshti Shahid Beheshti University University of Medical of Medical Sciences Sciences 19-21 19-21 May May 2011<br />
Biodistribution study of 177Lu- iron oxide nanoparticles in<br />
mice under an external magnetic field<br />
Samira Rasaneh 1 , Fariba Johari Daha 1 , Shahab Sheybani 1 , Shahram<br />
Akhlaghpoor 2<br />
1 Nuclear Science and Technology Research Institute<br />
2 Departments of Interventional Radiology<br />
Introduction: This study explored the possibility of utilizing iron<br />
oxide nanoparticles as a 177Lu delivery vehicle under an external<br />
magnetic field. In this study the biodistribution of 177Lu-iron oxide<br />
nanoparticles in mice with and without of an external magnetic field<br />
was considered.<br />
Material and methods: 177Lu-iron oxide nanoparticles were<br />
synthesized and all the quality control tests was performed. For the<br />
biodistribution study, female mice(n=24) were used. Before injection<br />
of 177Lu-iron oxide nanoparticles, an external magnetic field<br />
(magnetic flux density of 0.6 T) was positioned on the right feet of<br />
the mice, and it would persist in existence for 72 h. The mice were<br />
killed at 24, 48 and 72 h post-administration, tissues were removed<br />
and considered for 177Lu activities and iron concentration. This<br />
procedure was repeated without external magnetic field.<br />
Results: Comparison of the biodistribution results showed that<br />
177Lu-iron oxide nanoparticles accumulated in the right feet of the<br />
mice more than other organs under the external magnetic field. The<br />
results indicated that the distribution of 177Lu-iron oxide<br />
nanoparticles was different with and without using magnetic field.<br />
Conclusion: The good biodistribution results accented that 177Luiron<br />
oxide nanoparticles may be considered for further evaluation as<br />
a new radiopharmaceutical agent for targeted cancer therapy that<br />
needs more investigations.<br />
Keywords: ironoxidenanoparticles, 177Lutetium, biodistribution,<br />
drugdelivery, cancertargetedtherapy<br />
179
3rd International Congress 3rd International of Nuclear Congress Medicine of Nuclear & 15th Medicine Iranian Annual & 15th Iranian Congress Annual of<br />
Nuclear Congress Medicine of Nuclear Medicine<br />
Shahid Beheshti Shahid Beheshti University University of Medical Sciences of Medical 19-21 Sciences May 201119-21 May 2011<br />
Evaluation and quality control of Radiolabeled Streptokinase<br />
for dignostic purposes<br />
Sayyede Fateme Mirazizi, Amir Reza Jalilian, Hossein Sadeghpour<br />
Introduction: Cardiovascular diseases are major cause of morbidity<br />
and mortality in developing and developed countries. Rapid diagnosis<br />
of the thrombosis can be an essential step in management of the<br />
stroke people.<br />
Methods: Streptokinase was successively labeled with gallium<br />
chloride using cyclic DTPA-dianhydrid. In this work a recently<br />
developed radiolabeled streptokinase tracer was evaluated in an<br />
animal thrombotic model using SPECT imaging and biodictribution<br />
studies. Produced [67Ga]-Streptokinase was checked by RTLC, HPLC<br />
and SDS-PAGE experiments to check the tracer integrity/purity. The<br />
biodistribution studies were performed in femoral vein thrombotic<br />
rats (up to 12h) using tissue counting and preliminary SPECT studies<br />
respectively (up to 3 h- 48 h).<br />
Results: [67Ga]-Streptokinase prepared with suitable radiochemical<br />
purity (HPLC >95%, RTLC >99%) was administered to FeCl3 induced<br />
thrombotic rats and the percentage of injected dose per gram of<br />
tissue (ID/g%) and SPECT images demonstrated the specific binding<br />
of the tracer in thrombotic clots located in heart and aortic 2-3 hours<br />
post injection.<br />
Conclusion: [67Ga]-DTPA-SPK can be a suitable probe for imaging<br />
of thrombosis in cardiovascular diseases .Further studies use of Ga-<br />
68 labeled SPK can result in a superior labeled compound due to<br />
positron emission properties for PET studies as well as appropriate<br />
physical half live.<br />
Keywords: Streptokinase, Gallium-67, Thrombosis, SPECT,<br />
biodistribution<br />
180
3rd International Congress of of Nuclear Medicine & & 15th 15th Iranian Annual Annual Congress of<br />
Congress of Nuclear Medicine<br />
Shahid Beheshti Shahid Beheshti University University of Medical of Medical Sciences Sciences 19-21 19-21 May May 2011<br />
Radioprotective agents prevent genotoxicity induced by<br />
ionizing radiation in nuclear medicine practice<br />
Seyed Jalal Hosseinimehr<br />
Department of Radiopharmacy<br />
Ionizing radiation passing through living tissues induces damage,<br />
these damage are caused directly or indirectly with producing free<br />
radicals and toxic agents. Interaction of free radicals with critical<br />
macromolecules such as DNA is leading to genotoxicity and then<br />
mutation and carcinogenesis. In nuclear medicine practice, personnel<br />
and patients expose to ionizing radiation through radiopharmaceutical<br />
preparation and administration. Although, gamma irradiation<br />
produced by radiopharmaceuticals is not high level, it can induce<br />
genotoxicity. There are several compounds were evaluated for<br />
protection against genotoxicity induced by external or internal<br />
irradiation on culture human lymphocytes in our laboratory. These<br />
compounds are mainly natural origin products. Radioprotective<br />
effects of Hawthorn, Zataria extracts and hesperidin were<br />
investigated against genotoxicity induced by external gamma<br />
irradiation in vitro cultured human lymphocytes, they have good<br />
radioprotection. In other study, we showed that hesperidin protected<br />
significantly, DNA damage induced by gamma irradiation produced by<br />
99mT-MIBI in lymphocytes. These results showed that natural<br />
products could be candidate as radioprotective agents in internal and<br />
external genotoxicity induced by ionizing radiation.<br />
Keywords: Radioprotective, natural product, gamma iradiation,<br />
genotoxicity<br />
181
3rd International Congress 3rd International of Nuclear Congress Medicine of Nuclear & 15th Medicine Iranian Annual & 15th Iranian Congress Annual of<br />
Nuclear Congress Medicine of Nuclear Medicine<br />
Shahid Beheshti Shahid Beheshti University University of Medical Sciences of Medical 19-21 Sciences May 201119-21 May 2011<br />
Preparation and biodistribution study of a chlorotoxin<br />
derivative peptide labeled with 131-iodine for tumor therapy<br />
Seyed Pezhman Shirmardi, Mostafa Erfani (Gandomkar), Mohammad<br />
Ghannadi Maragheh<br />
Nuclear Sciences and Technology Research Institute, Tehran, Iran<br />
Introduction: Chlorotoxin is a 36-amino acid peptide found in the<br />
venom of the Leiurus quinquestriatus which blocks small-conductance<br />
chloride channels. Chlorotoxin binds preferentially to glioma cells that<br />
allow development of new methods for the treatment and diagnosis<br />
of several types of cancer. Due to this a chlorotoxin derivative was<br />
labeled with 131I and investigated further.<br />
Methods: A chlorotoxin derivative was synthesized on a solid phase<br />
using a standard Fmoc strategy. Labeling with iodine-131 was<br />
performed through chloramine-T method and radiochemical analysis<br />
involved sephadex G-25 and HPLC methods. The stability of<br />
radiopeptide was checked in the presence of PBS and human serum<br />
at 37°C up to 24 h. The biodistribution was studied in mice. Results:<br />
The chemical purity of synthesized peptide as assessed by analytical<br />
RP-HPLC was 95%. Labeling of peptide resulted in a radiochemical<br />
yield of 80% with radiochemical purity of > 95% with specific activity<br />
of 0.740 GBq/μmol. Results of In vitro studies demonstrated<br />
acceptable stability of compound in human serum and PBS solution.<br />
Biodistribution data showed moderate blood clearance, with<br />
concentration of radioactivity in the kidneys, liver, intestine and<br />
stomach.<br />
Keywords: cancer, peptide, 131I labeling, Chlorotoxin<br />
182
3rd International Congress of of Nuclear Medicine & & 15th 15th Iranian Annual Annual Congress of<br />
Congress of Nuclear Medicine<br />
Shahid Beheshti Shahid Beheshti University University of Medical of Medical Sciences Sciences 19-21 19-21 May May 2011<br />
Synthesis, Radiolabeling and Biological Evaluation of [67Ga]-<br />
5,10,15,20-tetrakis(pentafluorophenyl) porphyrin complex as<br />
an imaging agent<br />
Seyed Yousef Fazaeli 1 , Amir Reza Jalilian 1 , Mostafa M. Amini 2 , Abbas<br />
Majdabadi 1 , Ali Rahiminejad 1 , Fatemeh Bolourinovin 1 , Sedigheh<br />
Moradkhani 1<br />
1 Nuclear Science and Technology Research Institute (NSTRI)<br />
2 Department of Chemistry<br />
INTRODUCTION: Porphyrins appeal large attention because of their<br />
impersonation in the human body, ability to accumulate in many<br />
kinds of cancer cells, as well as magnetic and optical properties.<br />
Radiolabeled porphyrins have been developed for the therapeutic<br />
purposes such as, 109Pd-protoporphyrins , 109Pd-porphyrins [1],<br />
and 188Re-porphyrin [2]. In continuation of our previous work [3] ,<br />
we report, synthesis, radiolabeling, partition coefficient, quality<br />
control and biodistribution studies (using: SPECT and scarification) of<br />
67Ga-F20P in wild-type rats. METHODS [67Ga] labeled 5,10,15,20-<br />
tetrakis(pentafluorophenyl) porphyrin ([67Ga]-F20P) was prepared<br />
using freshly prepared [67Ga]GaCl3 and 5,10,15,20-tetrakis<br />
(pentafluorophenyl)porphyrin (F20PH2) for 50 min at 25°C<br />
(radiochemical purity: >97% ITLC, >98% HPLC, specific activity: 13-<br />
14 GBq/mmol). Stability of the complex was checked in final<br />
formulation and human serum for 24 h. The partition coefficient was<br />
calculated for the compound (log P=0.58). The biodistribution of the<br />
labeled compound in vital organs of wild-type and tumor bearing rats<br />
was studied using scarification studies and SPECT imaging up to 24 h.<br />
A detailed comparative pharmacokinetic study performed for 67Ga<br />
cation and [67Ga]-F20P. Results Total labeling and formulation of<br />
[67Ga]- F20P took about 30-60 min (RCP >97% ITLC, >98% HPLC,<br />
specific activity: 13-14 GBq/mmol). The complex was stable in final<br />
formulation and human serum at least for 24 h. At the pH.7, the logP<br />
was 0.58. The biodistribution of the labeled compound in vital organs<br />
of wild-type rats was studied using scarification studies and SPECT<br />
imaging up to 24 h. The complex is mostly washed out from the<br />
circulation through liver and kidneys and can be an interesting tumor<br />
imaging/targeting agent due to high tumor uptake and rapid<br />
excretion through the urinary tract. Conclusion It is suggested that<br />
67Ga-F20P could be a possible SPECT tracer, however considering<br />
the fast wash-out, the short half life gallium-68 can be a suitable<br />
candidate for tumor imaging applications and future 68Ga-PET<br />
studies and less imposed radiation doses to patients.<br />
References: 1. R.A. Fawwaz , F. Frye , W.D. Loughman, W.<br />
Hemphill, Survival of skin homografts in dogs injected with 109Pdprotoporphyrin.<br />
J Nucl Med 15 (1974) 997-1002. 2. H.D. Sarma, T.<br />
Das, S. Banerjee, M. Venkatesh, P.B. Vidyasagar, K.P. Mishra.<br />
Biologic evaluation of a novel 188Re-labeled porphyrin in mice tumor<br />
model. Cancer Biother Radiopharm 25 (2010) 47-54. 3.Yousef<br />
183
3rd International Congress 3rd International of Nuclear Congress Medicine of Nuclear & 15th Medicine Iranian Annual & 15th Iranian Congress Annual of<br />
Nuclear Congress Medicine of Nuclear Medicine<br />
Shahid Beheshti Shahid Beheshti University University of Medical Sciences of Medical 19-21 Sciences May 201119-21 May 2011<br />
Fazaeli, Amir. R. Jalilian, Mostafa .M. Amini, J. Radioanal. Nucl.<br />
Chem, 288 (2011) ,17-24<br />
Keywords: [67Ga]- 5,10,15,20-tetrakis(pentafluorophenyl)<br />
porphyrin , imaging agent<br />
184
3rd International Congress of of Nuclear Medicine & & 15th 15th Iranian Annual Annual Congress of<br />
Congress of Nuclear Medicine<br />
Shahid Beheshti Shahid Beheshti University University of Medical of Medical Sciences Sciences 19-21 19-21 May May 2011<br />
Production, quality control and imaging of 64Cu-ATSM in<br />
healthy rabbits for clinical applications<br />
Seyed Yousef Fazaeli, Amir Reza Jalilian, Mohsen Kamali-Dehghan,<br />
Fateme Bolourinovin, Sedigheh Moradkhani, Gholamreza Aslani, Ali<br />
Rahiminejad, Mohammad Ghannadi-Maragheh<br />
Nuclear Science and Technology Research Institute (NSTRI)<br />
INTRODUCTION: [64Cu]diacetyl-bis(N4-methylthiosemicarbazone)<br />
([64Cu]ATSM) is a well-established hypoxia imaging tracer with<br />
reproducible production and significant specifity. In this work the high<br />
yield production and quality control as well as imaging studies in<br />
healthy rabbits is reported.<br />
METHODS: Copper-64 produced via the 68Zn(p, n)64Cu nuclear<br />
reaction (30 MeV protons at 180 µA) was used for the preparation of<br />
[64Cu]diacetyl-bis(N4-methylthiosemicarbazone)([64Cu]ATSM).<br />
Followed by quality control and administration to healthy rats as well<br />
as healthy rabbits for biodistribution and imaging studies respectively<br />
Results 64Cu2+ (500 mCi, separation yield> 95%, radionuclide<br />
purity>96%) was used for [64Cu]ATSM production (radiochemical<br />
purity>99%, specific activity of 300 Ci/mmol) followed by<br />
administration to healthy rabbits and coincidence imaging<br />
demonstrating uptake in liver, kidney and bowel as shown by other<br />
reports in various rodents and human. Conclusion Copper-64 in the<br />
form of 64Cu2+ (500 mCi, separation yield> 95%, radionuclide<br />
purity>96%) was used for [64Cu]ATSM production (radiochemical<br />
purity>99%, specific activity of 300 Ci/mmol) in 10 min. No other<br />
labeled by-products were observed upon RTLC/HPLC analysis of the<br />
final preparations after solid phase extraction (SPE) purification. The<br />
radio-labeled complex was stable in aqueous solutions for at least 12<br />
hours and no significant amount of other radioactive species were<br />
detected by RTLC 12 hours after labeling. The biodistribution of the<br />
tracer in normal rats up to 210 min demonstrated similar<br />
biodistribution to the other reports for [64Cu]ATSM. Intravenous<br />
administration of the tracer to healthy rabbits and coincidence<br />
imaging demonstrated uptake in liver, kidney and bowel as shown by<br />
other reports in various rodents and human. [64Cu]ATSM, is PET<br />
radiotracer with a long half life, and the high yield, large scale<br />
production and stability of this radiopharmaceutical make it a<br />
accessible diagnostic agent for clinical trial initiation in the country.<br />
Keywords: [64Cu]ATSM, Rabbits, biodistribution, coincidence<br />
imaging<br />
185
3rd International Congress 3rd International of Nuclear Congress Medicine of Nuclear & 15th Medicine Iranian Annual & 15th Iranian Congress Annual of<br />
Nuclear Congress Medicine of Nuclear Medicine<br />
Shahid Beheshti Shahid Beheshti University University of Medical Sciences of Medical 19-21 Sciences May 201119-21 May 2011<br />
Synthesis, Radiolabeling and Biological Evaluation of [67Ga]-<br />
maltolate complex as an imaging agent<br />
Seyed Yousef Fazaeli 1 , Amir Reza Jalilian 1 , Mostafa M. Amini 2 , Abbas<br />
Majdabadi 1 , Ali Rahiminejad 1 , Fatemeh Bolourinovin 1 , Mehraban<br />
Pouladi 1<br />
1 Nuclear Science and Technology Research Institute (NSTRI)<br />
2 Department of Chemistry<br />
INTRODUCTION: The interesting physical properties and availability<br />
of gallium-67 make it an interesting nuclide for radiopharmaceutical<br />
research [1] recently. Studies of gallium maltolate as a potential<br />
treatment for liver cancer and gastrointestinal cancers has been done<br />
[2]. Gallium maltolate is stable in aqueous solutions between about<br />
pH 5 and 8, and it has significant solubility in both water and lipids.In<br />
this work we report, synthesis, radiolabeling, partition coefficient,<br />
quality control and biodistribution studies (using SPECT and<br />
scarification) of 67Ga-maltolate in Swiss mice.The time/activity<br />
diagrams for the labeled compound in vital organs have been plotted<br />
compared to gallium cation. METHODS [67Ga] labeled 3-hydroxy-2-<br />
methyl-4H-pyran-4-onate ([67Ga]- maltolate) was prepared using<br />
freshly prepared [67Ga]GaCl3 and 3-hydroxy-2-methyl-4H-pyran-4-<br />
onate in a sodium salt form for 25 min at 40°C (radiochemical purity:<br />
>96% ITLC, >98% HPLC, specific activity: 13-17 GBq/mmol).<br />
Stability of the complex was checked in final formulation and human<br />
serum for 24 h. The partition coefficient was calculated for the<br />
compound (log P=0.40). The biodistribution of the labeled compound<br />
in vital organs of Swiss mice studied using scarification studies and<br />
SPECT imaging up to 24 h. A detailed comparative pharmacokinetic<br />
study performed for 67Ga cation and [67Ga]-maltolate. Results Total<br />
labeling and formulation of [67Ga]-maltolate took about 30 min. The<br />
complex was stable in final formulation and human serum at least for<br />
24 h. At the pH.7, the logP was 0.4. The biodistribution of the labeled<br />
compound in vital organs of Swiss mice was studied using<br />
scarification studies and SPECT imaging up to 24 h. Conclusion It is<br />
suggested that [67Ga]-maltolate could be a possible SPECT tracer,<br />
however considering the fast wash-out and the short half life gallium-<br />
68, [67Ga]-maltolate can be a suitable candidate for tumor imaging<br />
applications and future 68Ga-PET studies and less use and therefore<br />
less imposed radiation doses to patients.<br />
References: 1. R.B. Firestone, In: Table of isotopes. 8th edition,<br />
John Wiley and Sons, p.1447, New York, (1996). 2. C.R. Chitambar,<br />
"Development of Gallium Compounds for Treatment of Lymphoma:<br />
Gallium Maltolate. J. Pharmacol. Exp. Ther. (2007) 322.<br />
Keywords: ([67Ga]- maltolate), imaging agents, biodistribution<br />
186
3rd International Congress of of Nuclear Medicine & & 15th 15th Iranian Annual Annual Congress of<br />
Congress of Nuclear Medicine<br />
Shahid Beheshti Shahid Beheshti University University of Medical of Medical Sciences Sciences 19-21 19-21 May May 2011<br />
Preparation and biological evaluation of radiogallium-labeled<br />
folate-embedded superparamagnetic nanoparticles in<br />
fibrosarcoma-bearing rat<br />
Seyydeh Leila Hosseini Salekdeh 1 , Amir Reza Jalilian 2 , Morteza<br />
Mahmoudi 3 , Hassan Yousefnia 2 , Majid Pouladian 1<br />
1 Nuclear Engineering Departmant<br />
2 Radiopharmaceutical Research and Development Lab (RRDL)<br />
3 Institute for Nanoscience and Nanotechnology<br />
The development of a large variety of colloidal dispersions of super<br />
paramagnetic iron oxide nanoparticles (SPION) has added a<br />
supplementary function to nanomaterials, their magnetic properties,<br />
which led to a range of new biological and biomedical (diagnostic and<br />
treatment) applications. The interesting biological activity of folic acid<br />
as well as amphiphilic properties of this important hematopoietic<br />
vitamin was considered to be a multi-purposes functional additive to<br />
SPION core. Superparamagnetic iron oxide nanoparticles (SPION)<br />
embedded by folic acid (SPION-folate) were prepared by a modified<br />
co-precipitation method. The structure, size, morphology, magnetic<br />
property and relaxivity of the SPION-folate were characterized<br />
systematically by means of XRD, VSM, HRSEM and TEM and the<br />
interaction between folate and iron oxide (Fe3O4) was characterized<br />
by FT-IR. The particle size was shown to be ≈ 5-10 nm. Stability of<br />
67Ga-SPION-folate in final preparation was determined by storing the<br />
final solution at 25C for 4 days and performing frequent ITLC<br />
analysis to determine radiochemical purity. Biocompatibility of the<br />
compound was investigated using an MTT assay followed by stability<br />
tests and tumor accumulation studies in fibrosarcoma-bearing mice<br />
after subcutaneous (s.c.) application. [67Ga]-SPION-folate<br />
(radiochemical purity> 96%, RTLC method) was evaluated in<br />
fibrosarcoma-bearing rat after subcutaneous injection. All values<br />
were expressed as mean ± standard deviation (mean ± SD) and the<br />
data were compared using student T test. Statistical significance was<br />
defined as P
3rd International Congress 3rd International of Nuclear Congress Medicine of Nuclear & 15th Medicine Iranian Annual & 15th Iranian Congress Annual of<br />
Nuclear Congress Medicine of Nuclear Medicine<br />
Shahid Beheshti Shahid Beheshti University University of Medical Sciences of Medical 19-21 Sciences May 201119-21 May 2011<br />
Development of 165Dy-chitosan for radio-synovectomy<br />
Simindokht Shirvani-Arani, Ali Bahrami-Samani, Amir Reza Jalilian,<br />
Mohammad Ghannadi-Maragheh<br />
Radiopharmaceutical Research and Development Laboratory (RRDL)<br />
Introduction: Radioactive chitosan complexes are new internal<br />
radiation therapeutic agents; they exist in solution state in acidic pH<br />
and in gel state in pH of the human body. Therefore they do not leak<br />
from the lesion. In addition radioactive chitosan complex is a natural<br />
biocompatible and biodegradable product which can be excreted after<br />
decay. In this research the 165Dy-chitosan complex (165Dy-Chit)<br />
was prepared successfully with high radiochemical purity (>99%) in<br />
diluted acetic acid solution.<br />
Methods: 165Dy was produced by thermal neutron bombardment on<br />
natural Dy (NO3)3 at the Tehran Research Reactor (TRR) for a period<br />
of 6 hours at a flux of 3-4—1013 neutrons/cm2.s. The preparation of<br />
165Dy-Chit was performed with regard to the optimized situation<br />
reported by shin et al in which complexation gradually increased with<br />
increase in ligand concentration and reached to almost 100% at a<br />
value of 35mg of chitosan in 4 ml acetic acid (pH. 3). Radiochemical<br />
purity was determined using ITLC.<br />
Results: The 165Dy-Chit complex was prepared with high<br />
radiochemical yield (>99 %) in the optimized condition; 35mg/3ml of<br />
chitosan concentration in diluted acetic acid solution (pH=3). The<br />
prepared complex was stable in the final solution at room<br />
temperature, 37ºC and presence of human serum, and can be used<br />
even 24 hours after preparation. The retention in the injected rabbit<br />
knee joint was observed after passing three half lives of radionuclide.<br />
Conclusion: The short half-life of 165Dy (2.3 h) suggests minimal<br />
exposure of non-target organs by reduction of leakage. Numerous<br />
reports have shown the efficacy and safety of 165Dy for the<br />
treatment of chronic synovitis. These studies indicate that 165Dy-Chit<br />
shows promising features and warrants further investigation for<br />
development as a cost-effective agent for radiosynovectomy. It is<br />
ready to be used for therapeutic applications in the country.<br />
Keywords: 165Dy Chitosan, radiosynovectomy<br />
188
3rd International Congress of of Nuclear Medicine & & 15th 15th Iranian Annual Annual Congress of<br />
Congress of Nuclear Medicine<br />
Shahid Beheshti Shahid Beheshti University University of Medical of Medical Sciences Sciences 19-21 19-21 May May 2011<br />
Study of radioprotection effects of some bis-<br />
Thiosemicarbazone compounds<br />
Zahra Mehdipour, Amir Reza Jalilian 1 , Alireza Shirazi<br />
1 Radiopharmaceutical Research and Development Laboratory (RRDL)<br />
ATSM, PTSM and GTS are bis- thiosemicarbazone ligands used in the<br />
preparation of copper radiopharmaceuticals. According to the<br />
theoretical studies, these ligands possess radical scavenging<br />
properties due to the presence of NH, SH functional groups, leading<br />
to radioprotection effects. In this work, radiaprotective effect of the<br />
compounds at various doses (20, 40 and 80 μg) and two time<br />
intervals injections prior to Co-60 gamma radiation (40 min, 7.5 Gy)<br />
have been studied compared to control experiments. The survival of<br />
the animals was recorded in one month post irradiation. At the next<br />
step, the hepatotoxicity of the effective compounds at the exact<br />
protective doses (ATSM, 80 μg and GTS, 20 μg) were checked by the<br />
determination of ALT and AST enzyme concentrations in the rat sera<br />
7 days after injection. ATSM at the effective radioprotection doses<br />
demonstrate no significant increase in SGPT and SGOT serum levels<br />
demonstrating no hepatotoxicity compared to the control, while a 30-<br />
40% of increase in enzymes was observed for GTS even 7 days postinjection.<br />
Due to the similar moles of injections in both cases, ATSM<br />
is definitely a better candidate for future radioprotection studies.<br />
Keywords: ATSM, PTSM, GTS, radioprotection, ALT, AST<br />
189
3rd International Congress 3rd International of Nuclear Congress Medicine of Nuclear & 15th Medicine Iranian Annual & 15th Iranian Congress Annual of<br />
Nuclear Congress Medicine of Nuclear Medicine<br />
Shahid Beheshti Shahid Beheshti University University of Medical Sciences of Medical 19-21 Sciences May 201119-21 May 2011<br />
The influence of misalignment between PET and CT images on<br />
the accuracy of CT-based attenuation correction in thorax<br />
imaging: a simulation study<br />
Zahra Anvari 1 , Mohammad Reza Ay 1 , Babak Fallahi 2<br />
1 Department of Medical Physics and Biomedical Engineering<br />
2 Research Institute for Nuclear Medicine<br />
Purpose: The accuracy of activity recovery from PET images is<br />
affected by respiratory motion especially in lung imaging. Moreover,<br />
Misregistration between PET and CT images in PET/CT imaging<br />
significantly influences the quantification of PET images due to the<br />
CT-based attenuation correction process. The aim of this study was to<br />
evaluate the impact of misregistration between PET and CT images<br />
on the accuracy of CTAC.<br />
Methods: Using 4-dimensional extended Cardiac Torso (XCAT)<br />
phantom, 4 lesions with 10 mm diameter and specified activity were<br />
defined in different locations of lung. To investigate the impact of<br />
respiratory motion on CT-based attenuation correction of PET images,<br />
first static PET images were generated as reference. Then the<br />
average PET data was acquired in 10 phases of a respiratory cycle.<br />
Two CT image sets were generated. One, obtained at end expiration<br />
called EE-CT, and another was the average of one respiratory period<br />
called Ave-CT. As phantom images are ideal, first PET sinograms<br />
were attenuated with the corresponding CT images using STIR<br />
(Software for Tomographic Image Reconstruction) code. Attenuation<br />
correction of PET sinograms was performed with EE-CT and Ave-CT.<br />
After adding poisson noise to sinograms, PET images were<br />
reconstructed using OSEM algorithm with 4 subsets and 24<br />
subiterations followed by a 4 mm Gaussian filter. The attenuation<br />
corrected PET images were compared with the static images.<br />
Results: For upper lesions with 11mm diaphragm motion amplitude,<br />
Standardized Uptake Values (SUVmax) underestimation was not<br />
significantly different between Ave-CTAC and EE-CTAC. However, for<br />
middle and lower lesions with 16 mm motion, errors were 25 % and<br />
61% respectively for Ave-CTAC rather than 62% and 73% for EE-<br />
CTAC.<br />
Conclusion: Respiratory motion complicates lung tumor<br />
quantification. Using Ave-CT for attenuation correction can yield<br />
smaller mismatch errors than EE-CT. Our study suggests that<br />
mismatched attenuation correction can be partly compensated by<br />
using Ave-CT for attenuation correction.<br />
Keywords: PET/CT, attenuation correction, respiratory, STIR, XCAT<br />
190
3rd International Congress of of Nuclear Medicine & & 15th 15th Iranian Annual Annual Congress of<br />
Congress of Nuclear Medicine<br />
Shahid Beheshti Shahid Beheshti University University of Medical of Medical Sciences Sciences 19-21 19-21 May May 2011<br />
Determination of neutron flux of Esfahan ZPR in different level<br />
of energy by MCNP cod for investigate of BNCT<br />
Zahra Eslami 1 , Feridoun Payami 2 , Behzad Timuri 2<br />
1 Payamnoor university Tehran<br />
2 Nuclear science and technology research institute reactor and accelerator<br />
research and development school (Esfahan)<br />
Introduction: Relating to deaths caused by cancers, we have tried<br />
to investigate the type of the cancers, and common method used for<br />
their treatments. Then we have evaluated the advantage and<br />
disadvantage of different methods, in regarding with the type of<br />
cancers, aiming to proof, that BNCT (boron neutron capture therapy )<br />
method can be the most appropriate methods for treatment of cancer<br />
in comparison with the other methods available. Now of days,<br />
advanced method of BNCT use a thermal (E n < 0.5 eV), or<br />
epithermal (0.5 eV < E n < 10 keV), neutron beam in conjunction<br />
with tumor- targeting boron compound for irradiation of glioblastoma<br />
and metastatic melanomas.<br />
Methods: In conjunction with, a systematic Mont carlo N-particle<br />
(MCNP) investigation of the different level of energy for neutron in<br />
ZPR (Zero Power Reactor) has been performed.<br />
Results: We did calculated with MCNP code, on neutron flux in ZPR,<br />
for different level of energies, and to complete the work, we<br />
compared the results with neutron flux requirements in BNCT cancer<br />
treatments.<br />
Conclusion: we believe that in future, BNCT can pursue its way as<br />
one of the safest, and fastest method of brain cancers treatment, and<br />
We hope that in the near future, an appropriate (bed) will be<br />
established, for research and development of this methods in our<br />
country, so that this method can become vastly available to those<br />
patients, who are hopelessly seeking, a safer methods of brain cancer<br />
treatment.<br />
Keywords: BNCT, neutron flux, cancer therapy<br />
191
3rd International Congress 3rd International of Nuclear Congress Medicine of Nuclear & 15th Medicine Iranian Annual & 15th Iranian Congress Annual of<br />
Nuclear Congress Medicine of Nuclear Medicine<br />
Shahid Beheshti Shahid Beheshti University University of Medical Sciences of Medical 19-21 Sciences May 201119-21 May 2011<br />
192
3rd International Congress of of Nuclear Medicine & & 15th 15th Iranian Annual Annual Congress of<br />
Congress of Nuclear Medicine<br />
Shahid Beheshti Shahid Beheshti University University of Medical of Medical Sciences Sciences 19-21 19-21 May May 2011<br />
Index<br />
A<br />
Abbasi K. 23<br />
Abbasi M. 57, 126<br />
Abdolahzade M. 90, 143<br />
Abedi S. 112, 113<br />
Aboudzadeh M.R. 142<br />
Adeli R. 173<br />
Adibpour F. 147<br />
Aghaei Amirkhizi N. 172<br />
Ahangari H. 95<br />
Ahmadi G.R. 124<br />
Ahmadi Sh. 117<br />
Ahmadin N. 77<br />
Akbari M. 26<br />
Akbarzadeh S. 125<br />
Akhlaghi M. 138<br />
Akhlaghpour Sh. 88, 103, 179<br />
Alani A. 87<br />
Alavi M. 28, 59, 63, 123<br />
Alipoor A. 96, 97, 156<br />
Alirezapour B. 73, 142<br />
Amini A. 162<br />
Amini H. 61<br />
Amini M.M. 183, 186<br />
Amirian S. 127<br />
Amoui M. 26, 103<br />
Anvari A. 133<br />
Anvari K. 132, 177<br />
Anvari Z. 190<br />
Arbabi M. 30<br />
Arefan D. 133<br />
Arjmand Shabestari A. 28, 29<br />
Aryana K. 51, 67<br />
Asadi M. 52<br />
Ashoor M. 84, 94<br />
Askari M.A. 85, 102<br />
Aslani G.R. 71, 185<br />
Assadi M. 56, 62, 120, 125, 162<br />
Assadi S.M. 61<br />
Attar Nosrati S. 118<br />
Ay M.R. 22, 25, 33, 88, 92, 98, 103, 108, 110,<br />
145, 147, 190<br />
B<br />
Babaei M.H. 22, 24, 31, 36<br />
Babapour F. 100, 117<br />
Baghban Khojasteh N. 171<br />
Bagheri M. 27<br />
Bagheri M. 77<br />
Bagheri R. 76<br />
Bahrami Samani A. 74, 76, 114, 134, 141, 144, 149, 150,<br />
151, 152, 153, 155, 175, 176, 177, 188<br />
Bakhshandepour G.R. 30<br />
193
3rd International Congress 3rd International of Nuclear Congress Medicine of Nuclear & 15th Medicine Iranian Annual & 15th Iranian Congress Annual of<br />
Nuclear Congress Medicine of Nuclear Medicine<br />
Shahid Beheshti Shahid Beheshti University University of Medical Sciences of Medical 19-21 Sciences May 201119-21 May 2011<br />
Bashtar M. 77<br />
Beheshti M. 105<br />
Beyki D. 22, 24, 31, 39, 42, 60, 61, 64,<br />
Bijan B. 21, 26<br />
Bolourinovin F. 71, 73, 83, 135, 142, 183, 185, 186<br />
Bombardieri E. 21, 23, 26, 28<br />
Bouzarjomehri F. 25<br />
C<br />
Chahkandi M.R. 127<br />
D<br />
Dabbagh Kakhki V.R. 29, 32, 49, 55, 58, 132<br />
Dabiri Oskoei Sh. 54<br />
Davari Sh. 99<br />
Davarpanah M.R. 72, 118<br />
Derakhshan S. 32<br />
E<br />
Eftekhari M. 23, 57, 60, 61, 64, 95, 126<br />
Elahi F. 26<br />
Emami A. 88<br />
Emami Ardakani A.R. 57, 60, 64, 93, 101, 126<br />
Erfani(Gandomkar) M. 22, 25, 40, 47, 72, 75, 79, 81, 107,<br />
116, 166, 167, 168, 169, 170, 173, 182<br />
Eslami Z. 191<br />
Esmaili J. 64<br />
Esteghamati A.R. 57<br />
F<br />
Faghihi R. 136, 138<br />
Fallahi B. 57, 60, 61, 64, 126, 190<br />
Fani Pakdel A. 52<br />
Farahani H. 161<br />
Farahani M. 91, 146, 148<br />
Fard Esfahani A. 28, 60, 61, 64, 102<br />
Farsad M. 21, 23, 28, 35<br />
Farzanefar S. 60, 64, 95<br />
Fatehi M. 68, 69<br />
Fathi M. 142<br />
Fattahi Masoom A.S. 53<br />
Fazaeli Y. 152, 183, 185, 186<br />
Fazli A. 124<br />
G<br />
Gannadi Maragheh M. 72, 74, 76, 81, 89, 114, 134, 139, 141,<br />
144, 149, 150, 151, 152, 153, 155,<br />
167, 168, 173, 175, 176, 177, 182,<br />
185, 188<br />
Garousi J. 136, 140<br />
Gasemabadi D. 143<br />
Ghadiri H. 32, 88, 98<br />
Ghadiri P. 88<br />
Ghafarian P. 110<br />
Ghafori M. 174<br />
Ghafori M. 97<br />
194
3rd International Congress of of Nuclear Medicine & & 15th 15th Iranian Annual Annual Congress of<br />
Congress of Nuclear Medicine<br />
Shahid Beheshti Shahid Beheshti University University of Medical of Medical Sciences Sciences 19-21 19-21 May May 2011<br />
Gharepapagh E. 121<br />
Ghasemabadi D. 90<br />
Ghazanfari N. 108<br />
Ghazikhanlou Sani K. 154<br />
Gheisari F. 59, 63, 123<br />
Gheshlaghi H. 154<br />
Gholami H. 52, 53,<br />
Gholamrezanezhad A. 77, 129<br />
Ghozati B. 165<br />
Giannopoulou Ch. 23, 29, 41<br />
Goudarzi M. 99<br />
Goudarzi M. 79, 91, 146, 148, 169<br />
Gourani M. 161<br />
H<br />
Hadavand F. 62<br />
Haeri M. 154<br />
Hajhasan Abbasi F. 91, 146, 148<br />
Hakimi A. 137, 139<br />
Harati M. 118<br />
Hassani Bidgoli J. 110<br />
Hassanzadeh L. 75<br />
Hedayati A. 28<br />
Hekmat S. 22, 27, 36, 172<br />
Heydarinejad S. 126<br />
Hosseini R. 27<br />
Hosseini Pooya M. 115<br />
Hosseini Salekdeh L. 187<br />
Hosseinimehr J. 25, 31, 80, 181<br />
I<br />
Ibis E. 131<br />
Izadyar S. 64<br />
J<br />
Jafari M. 125<br />
Jafarizadeh M. 115<br />
Jalallat S. 120<br />
Jalilian A.R. 22, 24, 31, 33, 37, 43, 71, 73, 74, 76 ,<br />
82, 83, 114, 134, 135, 136, 138, 139,<br />
140, 142, 144, 149, 150, 151, 152,<br />
153, 155, 159, 160, 174, 175, 176,<br />
177, 180, 183, 185, 186, 187, 188, 189<br />
Jameie B. 171<br />
Jamreh M. 159, 160<br />
Jangjoo A. 26<br />
Javadi H. 56, 62, 120<br />
Javan H. 52<br />
Javanshir M.R. 165<br />
Johari Daha F. 22, 44, 178, 179<br />
Jomehzadeh A. 86<br />
Jomehzadeh Z. 86<br />
K<br />
Kabiri F. 165<br />
Kalantarhormozi M.R. 62<br />
195
3rd International Congress 3rd International of Nuclear Congress Medicine of Nuclear & 15th Medicine Iranian Annual & 15th Iranian Congress Annual of<br />
Nuclear Congress Medicine of Nuclear Medicine<br />
Shahid Beheshti Shahid Beheshti University University of Medical Sciences of Medical 19-21 Sciences May 201119-21 May 2011<br />
Kalantari B.A. 72<br />
Kalantari F. 92, 93, 103, 105, 117<br />
Kamali Asl A.R. 92, 133<br />
Kamali Dehghan M. 71, 73, 185<br />
Kardan M. 28<br />
Karimi Diba J. 115<br />
Kasesaz Y. 90, 143, 163<br />
Khalafi H. 163<br />
Khorshidi A. 84<br />
Khoshdel M. 135<br />
Khoshhosn H.A. 118<br />
Khosravi H. 31, 33<br />
Khosrounejad H.R. 91, 146, 148<br />
Kia M. 164<br />
Kohanpour M. 105<br />
Kucuk O.N. 131<br />
L<br />
Lahooti A. 111<br />
Loudos G. 108, 147<br />
M<br />
Mahdavi R. 25<br />
Mahmoudi M. 187<br />
Mahmoudian A. 132<br />
Mahmoudian B. 54<br />
Maghsoodi R. 27<br />
Majdabadi A.<br />
183, a86<br />
Majdi M. 60<br />
Malek H. 29<br />
Malekzadeh M. 23<br />
Malekzadeh R. 77<br />
Manouchehri F. 172<br />
Mazidi M. 72, 76, 91, 116, 134, 151, 161, 169<br />
Mehdipour Z. 189<br />
Mehdizadeh A.R. 59, 63<br />
Mifallah H. 72<br />
Mir Falah M.H. 148<br />
Mirazizi F. 180<br />
Mirpour S. 77, 129<br />
Mirshojaei F. 79, 116, 170<br />
Mirshojaei Sh. 124<br />
Mishra K.P. 23, 28, 31, 38<br />
Modarresi M. 130<br />
Moghaddam Banaem L. 159, 160<br />
Mogharrabi M. 56, 120<br />
Mohajeri M.R. 28<br />
Mohamadnejad J. 142<br />
Mohamadnejad M. 77<br />
Momen’nejhad M. 28, 31<br />
Moosavi H. 24<br />
Moosavi K. 158<br />
Moradkhani S. 71, 73, 142, 174, 183, 185<br />
Moshayedi A. 90<br />
Moslehi A. 143<br />
Mousavi Z. 49<br />
196
3rd International Congress of of Nuclear Medicine & & 15th 15th Iranian Annual Annual Congress of<br />
Congress of Nuclear Medicine<br />
Shahid Beheshti Shahid Beheshti University University of Medical of Medical Sciences Sciences 19-21 19-21 May May 2011<br />
Movahed M. 22<br />
Mozdarani H. 23, 28<br />
N<br />
Nabipour I. 62, 120, 125, 162<br />
Naderi M. 172<br />
Najafi R. 31, 75, 107<br />
Naseri Z. 74, 82, 153, 176<br />
Nasrollahi A. 22<br />
Nazari M. 96, 156<br />
Neamtu J. 109<br />
Nemati Kharat A. 82<br />
Nemati R. 125, 162<br />
Neshandar Asli I. 120<br />
Nikzad R. 72<br />
Nonbede M. 143<br />
Norouzbeigi N. 128<br />
Novinrouz A. 140<br />
Nouroozian M. 25, 30<br />
O<br />
Orlova A. 80<br />
Orouji T. 115<br />
Ozdan E. 131<br />
P<br />
Parach A.S. 85<br />
Payami F. 191<br />
Payervand F. 94<br />
Pazirandeh A. 171<br />
Pirayesh E. 70<br />
Poorbeygi H. 165<br />
Pooyafard F. 61<br />
Pouladi M. 186<br />
Pouladian M. 105, 145, 187<br />
Pouraliakbar H.R. 29<br />
Pourbehi M.R. 56<br />
Q<br />
Qodsi Rad M. 128<br />
R<br />
Radfar E. 144<br />
Rahiminejad A. 135, 183, 185, 186<br />
Rahimzadeh N. 22<br />
Rahmatpour M. 100<br />
Rahmim A. 21, 22, 24<br />
Rajabi H. 25, 32, 85, 93, 95, 100, 101, 102, 105,<br />
117, 178<br />
Rajabifar S. 73, 83, 142, 174<br />
Rajamand A. 140<br />
Ramezani Moghaddam A. 94<br />
Rasaee M.J. 73, 142<br />
Rasaneh S. 178, 179<br />
Rayzan M. 56<br />
197
3rd International Congress 3rd International of Nuclear Congress Medicine of Nuclear & 15th Medicine Iranian Annual & 15th Iranian Congress Annual of<br />
Nuclear Congress Medicine of Nuclear Medicine<br />
Shahid Beheshti Shahid Beheshti University University of Medical Sciences of Medical 19-21 Sciences May 201119-21 May 2011<br />
S<br />
Saberifard J. 62<br />
Sadadi F. 83, 122, 174<br />
Sadat Ebrahimi E. 75<br />
Sadeghi R. 21, 26, 32, 49, 52, 53, 132<br />
Sadeghpour H. 180<br />
Saghari M. 60, 61, 64, 77, 93<br />
Salarifar A. 121<br />
Salehi H. 161<br />
Salehi N. 23, 41<br />
Salehi Zahabi S. 101<br />
Salehizahaby J. 157<br />
Salek N. 159, 160<br />
Salimi H. 27<br />
Salimipour H. 125, 162<br />
Salouti M. 124<br />
Samani Z. 125<br />
Samiee F. 26<br />
San’ati H.R. 29<br />
Sardari D. 109, 137, 141<br />
Sarkar S. 108, 147<br />
Sarvghadi F. 28<br />
Sedaghat F. 25, 30, 33, 45, 46<br />
Sehhat M.R. 62<br />
Seifollahi Asl Sh. 30, 65<br />
Seyedabadi M. 125<br />
Shabani G.A. 91, 146, 148<br />
Shabestani Monfared A. 24, 28, 31, 33<br />
Shafaii K. 71, 136, 140<br />
Shafiei B. 27, 28, 32<br />
Shahhoseini E. 172<br />
Shahhoseini S. 31<br />
Shamsaee M. 159, 160<br />
Shanehsazzadeh S. 111<br />
Shaybani S. 161<br />
Shayeste M. 90, 143, 163<br />
Sheibani Sh. 165<br />
Sheybani Sh. 178, 179<br />
Shirazi A.R. 189<br />
Shirin M.B. 98<br />
Shirmardi P. 81, 166, 167, 168, 173, 182<br />
Shiroodi K. 130<br />
Shirvani-Arani S. 114, 139, 141, 144, 149, 175, 188<br />
Shojaee A. 30, 66<br />
Shokouhizadeh R. 122<br />
Singh B. 23, 31<br />
Sobhani S. 131<br />
Soleimani E. 145<br />
Solhifam R. 89<br />
Soltani-Zadeh H. 98<br />
Soni P.S. 22, 24, 25<br />
T<br />
Tabeie F. 24, 33<br />
Taghizadeh S. 88<br />
Tajik Mansouri M.A. 101<br />
198
3rd International Congress of of Nuclear Medicine & & 15th 15th Iranian Annual Annual Congress of<br />
Congress of Nuclear Medicine<br />
Shahid Beheshti Shahid Beheshti University University of Medical of Medical Sciences Sciences 19-21 19-21 May May 2011<br />
Talebi M.H. 91, 116, 146, 148<br />
Tavakoli A.R. 62<br />
Tavakoli M.B. 86<br />
Tavakoli Tabasi K. 53<br />
Tavakoli Y.H. 146<br />
Teimoori Sichani M.R. 103<br />
Timuri B. 191<br />
Tolmachev V. 80<br />
V<br />
Vahdat K. 62<br />
Vakili A. 141, 144<br />
Vedaei F 92<br />
Verga N. 109<br />
Y<br />
Yalodbardan A. 127<br />
Yavari K. 73, 89, 142<br />
Yousefnia H. 71, 74, 90, 114, 135, 136, 138, 140,<br />
144, 149, 150, 151, 152, 153, 155,<br />
175, 176, 177, 187<br />
Z<br />
Zaidi H. 98<br />
Zakavi R. 23, 28, 49<br />
Zamani M. 163<br />
Zamani Zeinali H. 96, 97, 156<br />
Zandi H. 138<br />
Zoghi M. 161<br />
Zolata H. 73, 83<br />
Zolghadri S. 74, 114, 135, 136, 149, 150, 151, 152,<br />
153, 155, 175, 176, 177<br />
199
3rd International Congress 3rd International of Nuclear Congress Medicine of Nuclear & 15th Medicine Iranian Annual & 15th Iranian Congress Annual of<br />
Nuclear Congress Medicine of Nuclear Medicine<br />
Shahid Beheshti Shahid Beheshti University University of Medical Sciences of Medical 19-21 Sciences May 201119-21 May 2011<br />
Note<br />
200